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Poorly controlled diabetes is common among the majority of youth with type 1 
diabetes and can lead to adverse health outcomes at an early age. There is a need to 
change this to minimise the risk of negative long-term consequences. The onset of 
complications from diabetes can be prevented or delayed with good management as 
demonstrated by blood glucose being kept close to or within the normal range. Diabetes 
control is challenging for young people due to a combination of physiological and 
psychological factors.
Diabetes control needs to be monitored both at an individual level and also at a 
population level, in order to optimise health outcomes and provide important information 
for health service provision. There are gaps in knowledge relating to the current level of 
diabetes control at a population level and of the epidemiological characteristics of youth 
with type 1 diabetes in the Canterbury region in New Zealand. There has been no 
research of this nature in the Canterbury region since 2003. There are also gaps in 
knowledge and a lack of national and international research that investigates 
psychosocial characteristics of youth with type 1 diabetes and the impact these may have 
on diabetes control. There is a potentially promising intervention, namely, Motivational 
Interviewing (MI), that although previous research investigating it with diabetes has 
shown some promise, methodological problems have limited the conclusions that can be 
drawn. This thesis, within the New Zealand context, addresses some of these gaps and 
adds to the body of knowledge of research concerning diabetes control and youth with 
type 1 diabetes, and investigates MI intervention for youth with poorly controlled 
diabetes.
The thesis encompasses three studies. The first study is an audit that provides up-
to-date information on epidemiological characteristics and clinical outcomes for the 
youth population with type 1 diabetes residing in the Canterbury region. The second 
xiv
study is a cross-sectional study that investigates the relationship between glycaemic 
control and key psychosocial characteristics: illness beliefs, self-efficacy, and quality of 
life in youth with type 1 diabetes in Canterbury. The third study is a longitudinal study 
that investigates the efficacy of MI as an intervention for youth with poorly controlled 
type 1 diabetes, and explores its impact on diabetes outcomes using statistical and 
clinical analyses.
The first study showed that from 2003 to 2010 the prevalence of adolescents and 
young adults with type 1 diabetes in Canterbury has increased; there is therefore an 
increased demand on health resources. In addition, in 2010 glycaemic control at a 
population level was in the poorly controlled diabetes range and this had remained 
unchanged since 2003. This suggests the need for more intensive interventions. The 
second study found that poor diabetes control in youth with type 1 diabetes is influenced 
by a number of factors, including negative views on diabetes, lower perceived personal 
control, higher diabetes-related concerns, and lower levels of worry about complications. 
These findings provide a new understanding of the importance of balancing worries 
about diabetes complications and the perception of diabetes as a threatening condition. 
The third study showed that the MI intervention was generally successful in improving 
diabetes outcomes – clinical, psychosocial, and behavioural changes were observed. 
Statistically and clinically significant positive changes were found across multiple 
variables: glycated haemoglobin (HbA1c), glycaemic variability, adherence, and 
psychosocial functioning.
Taken together, the findings of the three studies indicate that majority of youth 
with type 1 diabetes in the Canterbury region had poor glycaemic control, which 
suggests that additional interventions may be required to improve management of their 
condition, especially interventions targeting psychosocial functioning (e.g., illness 
perceptions) and diabetes self-management. Motivational Interviewing may be a viable 
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CHAPTER 1: INTRODUCTION 
Overview of the Thesis
The current research aims to contribute to the research on improving diabetes 
outcomes for youth with type 1 diabetes. The target age range in this thesis is 15-24 
years old; this age group is referred to as youth and is differentiated from childhood 
(0-14 years old) and adulthood (25-64 years old) for diabetes groups (Alberti & 
Zimmet, 2011; UNESCO, 2014; United Nations, 2013). The study cohort is from the 
Canterbury region in New Zealand. The thesis starts with an overview of diabetes, 
then moves to an overview of type 1 diabetes and its management. The thesis 
comprises three main studies, the first two studies describe and investigate specific 
characteristics of the target population, and the third study trials an intervention for 
youth with poorly controlled type 1 diabetes. 
In brief, the first study is an audit to provide up-to-date information on
epidemiological characteristics and clinical outcomes for the youth population who 
have type 1 diabetes, and who reside in the Canterbury region in New Zealand. The 
second study is a cross-sectional study of specific diabetes-related psychosocial 
factors and their relationship to diabetes control. The third study is a longitudinal 
study that investigates the efficacy of Motivational Interviewing (MI) as an 
intervention for youth with poorly controlled type 1 diabetes. 
The current study had the support of the Canterbury District Health Board 
(CDHB) Diabetes Centre facilitated by the Diabetes Centre Manager, in consultation 
with relevant CDHB staff. Approvals for relevant parts of the study were granted by the 
Upper South B Regional Ethics Committee (URB/10/EXP/048), the University of 
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Canterbury Human Ethics Committee (HEC 2010/183), Te Komiti Whakarite 
(CDHB Research Consultation with Māori), and the University of Canterbury Māori 
Research Advisory Group. Appendix 1.1 contains the invitation letters, information 
sheets, and consent forms. In addition, permission was sought from, and given by the 
authors of the questionnaires used in this study. 
The three studies of this thesis (i.e., audit, psychosocial evaluation, and MI 
intervention) are presented in separate chapters. Each chapter provides a review of 
the literature on theoretical and empirical knowledge related to the subject of the 
study, the aims and significance of the study, the methodological basis of the study, 
analysis of data, interpretation of the results, and discussion. A summary of key 
findings, conclusions, recommendations, and future directions follow these chapters 
to conclude the thesis. The present chapter provides an overview and background on 
type 1 diabetes and its management.  
Diabetes Mellitus 
Diabetes mellitus is a complex metabolic disorder that is associated with 
abnormalities in controlling blood glucose levels (Alberti & Zimmet, 2011; Amiel, 
2011). The regulation of blood glucose is vital for health and proper functioning of 
the body and brain. The blood glucose regulation process involves transporting 
glucose from the blood into cells in the body so it can be used for energy – this is the 
main action of insulin, a hormone that is produced in the pancreas (Hanas, 2007; 
Heller, 2011). Diabetes is caused by the body failing to produce insulin to regulate 
the blood. 
The classification of diabetes types is based on the diagnosis of insulin 
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secretion and action and its impact on blood glucose levels (Alberti & Zimmet, 
2011). Three of the main classifications are: type 1 diabetes, in which insulin 
secretion is critically defective as a result of the destruction of the insulin releasing 
cells in the pancreas; type 2 diabetes, in which there is abnormal insulin secretion, or 
abnormal insulin action, or both; and gestational diabetes, which occurs during 
pregnancy due to glucose intolerance, arising from an insufficient production of 
insulin during pregnancy (Alberti & Zimmet, 2011). The former two types are 
chronic conditions, whereas the latter type is temporary and may resolve after 
pregnancy (Alberti & Zimmet, 2011). 
At present, although there is no cure for chronic diabetes conditions, ongoing 
treatment using medications and diabetes self-management is essential to avoid or 
prevent diabetes-related complications such as heart and kidney diseases (Atkinson 
& Eisenbarth, 2001). Diabetes management is a complicated process, and is 
influenced by many factors, including physiological, psychological, behavioural, and 
social factors (Delamater, de Wit, McDarby, Malik, & Acerini, 2014; Madsen, 
Roisman, & Collins, 2002; Moran et al., 2002). In addition to the individual patient’s 
diabetes-management challenges, there are challenges for the health system 
(International Diabetes Federation, 2013; Ministry of Health, 2014). These include 
planning and accessibility of resources, such as medication, equipment, and access to 
appropriately trained health care professionals. Despite advanced medical treatments 
and modern health initiatives, poor diabetes control is common and persistent 
amongst individuals with diabetes (Nam, Chesla, Stotts, Kroon, & Janson, 2011). 
This has costly consequences and places a heavy burden on health systems at a 
global level (International Diabetes Federation, 2013). 
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Diabetes has become an increasing burden on health systems because of its 
complexity and rapidly increasing incidence rate (International Diabetes Federation, 
2013; Sicree, Shaw, & Zimmet, 2009). The incidence rate and prevalence of diabetes 
is increasing nationally and internationally (Onkamo, Vaananen, Karvonen, & 
Tuomilehto, 1999; Wild, Roglic, Green, Sicree, & King, 2004; Willis et al., 2002). 
The incidence rate represents the rate of occurrence of new presentations of a disease 
during a particular period of time (Boniol & Heanue, 2007; Boyle & Parkin, 1991). 
The prevalence quantifies the proportion of patients with a certain condition in 
relevance to the entire population at a given time (Boniol & Heanue, 2007; Boyle & 
Parkin, 1991). This disorder is a global epidemic (International Diabetes Federation, 
2013; Unwin, 2011; Whiting, Guariguata, Weil, & Shaw, 2011). Globally, it is 
estimated that more than 387 million people have diabetes and this estimation is 
likely to markedly increase by 2035 (International Diabetes Federation, 2013, 2014).
In New Zealand, the estimated national prevalence of diagnosed cases of 
diabetes in 2013 was 243,125, with an increase of 7.2% from 2005 (Jo & Drury, 
2015; Ministry of Health, 2015). The estimated prevalence by district health board 
(DHB) domicile is 275,000–290,000 by end of 2015 (Ministry of Health, 2014). 
Diabetes is a major and increasing cause of premature death and disability in New 
Zealand and its prevalence is substantial, making it a top health priority for the New 
Zealand government (Jo & Drury, 2015; Ministry of Health, 2014). Health 
organisations worldwide, including those in New Zealand, have been investigating 
and implementing strategies to reduce the incidence and impact of diabetes (Diabetes 
Research Institute, n.d.; Ministry of Health, 2014).
Research on diabetes is needed to inform health professionals and those 
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involved in the care of patients to reduce the impact of diabetes and achieve optimal 
diabetes outcomes (Diabetes Research Institute, n.d.; Fonseca, Kirkman, Darsow, & 
Ratner, 2012). Research into the following components is required: epidemiological 
characteristics (e.g., prevalence and incidence rates), evaluation of clinical outcomes 
at a population level (e.g., diabetes control biomarkers levels), influential 
psychosocial factors (e.g., assessment of treatment barriers and illness perceptions), 
and effective interventions (e.g., educational, psychological, and behavioural 
interventions) (Diabetes Research Institute, n.d.; International Diabetes Federation, 
2013; Ministry of Health, 2014). Research into diabetes needs to consider the type of 
diabetes to be studied, clinical aspects of that type, the target groups, and diabetes 
management for the type of diabetes being studied (Fonseca et al., 2012). Type 1 
diabetes, a prevalent condition in young people, was selected for the current study. 
Type 1 diabetes in Young People 
Type 1 diabetes is a serious condition that has a peak onset in childhood and 
adolescence (Alberti & Zimmet, 2011). Although type 1 diabetes can develop at any 
age, it is prevalent in those younger than 26 years old (Scott et al., 2006). The 
morbidity and mortality rates in young people diagnosed with diabetes are higher 
than the rates for those without diabetes (Borch-Johnsen, 1989; Laing et al., 1999a, 
1999b). Diagnosis at an early age (< 15 years old), compared to diagnosis in 
adulthood, increases the risk for developing complications from diabetes (Harvey & 
Allagoa, 2004). Furthermore, during youth, negative or positive behaviours related to 
diabetes management develop, and these may have a critical impact on future 
diabetes management and health outcomes (Wysocki, Hough, Ward, & Green, 1992). 
Youth are vulnerable for sustained poorly controlled diabetes, and global studies 
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have shown that the majority of youth do not meet recommended clinical targets and 
may need more intensive interventions (Anderson et al., 2014; Daneman & 
Hamilton, 2001; Holl et al., 2003; Mortensen & Hougaard, 1997; Tan, Shafiee, Wu, 
Rizal, & Rey, 2005). This is discussed in the following sections. 
Management of type 1 diabetes in young people is challenging and is 
influenced by developmental factors that include biological and psychological 
changes, particularly during adolescence years when diabetes control often 
deteriorates (Borus & Laffel, 2010; Hamilton & Daneman, 2002; Pinhas-Hamiel et 
al., 2014). The physiological aspects include pubertal and hormonal changes which 
are accompanied by increased biological requirements for insulin (Borus & Laffel, 
2010). Psychological aspects include emotional distress, developing self-identity, and 
seeking autonomy (Borus & Laffel, 2010; Helgeson, Escobar, Siminerio, & Becker, 
2010; Lerman-Garber et al., 2003; McCallister, 2006). 
Type 1 Diabetes
Type 1 diabetes is an autoimmune disease that is identified by a deficiency in 
insulin because of the destruction of insulin-secreting cells (beta-cells) in the 
pancreas, which are attacked by the body’s immune system (Amiel, 2011). The body 
mistakenly identifies these cells as foreign and, as a consequence, attacks and isolates 
them, in a process that inhibits insulin production (Amiel, 2011). The precise 
mechanisms underlying type 1 diabetes are still not fully understood, and these as 
well as the risk factors for the development of type 1 diabetes are still the subject of 
research (Atkinson & Eisenbarth, 2001; Xie, Chang, & Zhou, 2014). Some potential 
risk factors for type 1 diabetes that have been identified are: genetic, environmental, 
hormonal, or a combination of these. There are genetic markers that confer increased 
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risk for type1 diabetes; for example, when a member of a family has type 1 diabetes 
other members of that family may be susceptible to developing it (Savage & Bain, 
2011; Xie et al., 2014). Nonetheless, not having the high risk genes does not preclude 
the development of type 1 diabetes. Environmental factors also play a role in the 
development of type 1 diabetes; however, it is still unclear as to what exactly these 
factors are, or what combinations increase the risk for developing diabetes (Knip et 
al., 2005; Xie et al., 2014). Possible environmental causes include viruses, cold 
weather and cow milk proteins (Knip et al., 2005). Hormones, such as growth and 
stress hormones, are factors that may inhibit the action of insulin and this can also 
lead to the development of diabetes (Hanas, 2007; Knip et al., 2005). The rapid 
growth at early puberty increases the risk for developing type 1 diabetes when beta-
cells come under stress to produce more insulin because growth hormones hinder 
insulin action (Chowdhury, 2015). The onset of diabetes can be triggered by 
defective beta-cells, which are put under pressure because of highly demanding 
physiological changes (Knip et al., 2005). In addition, psychological stress, which 
increases the secretion of the cortisol hormone may obstruct insulin action (American 
Diabetes Association, 2008; Hägglöf, Blom, Dahlquist, Lönnberg, & Sahlin, 1991; 
Hanas, 2007).
Lack of insulin secretion into the blood stream causes abnormalities in 
glucose concentration levels (American Diabetes Association, 2014; Atkinson & 
Eisenbarth, 2001). This can negatively impact on a person’s physical and cognitive 
functioning (Kodl & Seaquist, 2008). Individuals with type 1 diabetes may 
experience symptoms such as excessive thirst and extreme hunger, fatigue, increased 
urination, unexplained weight loss, mood swings, abdominal pain, nausea, vomiting, 
blurred vision, skin infections, and poor concentration and performance (Hanas, 
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2007). These symptoms may indicate a diagnosis of diabetes, which can be 
confirmed using clinical biomarkers that are tested and analysed at a medical 
laboratory. 
The diagnosis of type 1 diabetes involves analysing results from specific 
glucose tests that may include: fasting blood glucose, random (non-fasting) blood 
glucose, oral glucose tolerance, and haemoglobin A1c (HbA1c) tests (Alberti & 
Zimmet, 2011; American Diabetes Association, 2014). The fasting blood glucose test 
measures the blood glucose level in a person who has not eaten for several hours. A 
random blood glucose test, as the name suggests, is a blood sample taken at a random 
time (regardless of when they have eaten last) to measure the blood glucose level. 
The oral glucose tolerance test involves several blood tests taken to measure how the 
body reacts to glucose (glucose tolerance); a blood test precedes an oral intake of 
glucose followed by several tests at fixed intervals within a two hour time frame. The 
HbA1c assay measures the average blood glucose levels over the preceding 2-3 
months by measuring the amount of glucose attached to haemoglobin in red blood 
cells. This is also referred to as glycated haemoglobin (Hanas, John, & International 
HbA1c Consensus Committee, 2014). Each test has clinical cut-off levels which can 
indicate whether an individual has a pre-diabetic condition or diabetes. A 
combination of tests may be required to confirm a diagnosis. There are international 
guidelines for the diagnosis criteria which have been well-documented (American 
Diabetes Association, 2014; World Health Organization, 2011).
Glycated Haemoglobin  
Haemoglobin A1c is considered the gold-standard to monitor the progress of 
the diabetes condition, the effectiveness of treatment, and the risk for developing 
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diabetes-related complications (Bruns, 2007; Hanas et al., 2014). The measurement 
and reporting of HbA1c has been standardised worldwide (Little et al., 2001; 
Weykamp et al., 2008). A commonly used standardised reference system is sourced 
from the National Glycohemoglobin Standardization Program (NGSP) protocol, 
whereby the reporting of the HbA1c level is depicted in a percentage unit 
(percentage of glycated haemoglobin) with at most one decimal place (e.g., HbA1c = 
7.5%) (Little et al., 2001). More recently, an updated system was implemented by the 
International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), 
which uses the mmol/mol units with no decimal places (e.g., HbA1c = 55 mmol/mol)
(Mosca et al., 2007). Specific equations can be used to convert values between the 
NGSP and IFCC systems (NZSSD, 2011). Globally, IFCC is a recommended system 
for reporting HbA1c, and this has replaced the NGSP system in many countries, 
including New Zealand (Mosca et al., 2007). The HbA1c laboratory data was 
formally changed in New Zealand in late 2011 to report HbA1c in the IFCC units 
(Florkowski & Crooke, 2010; Florkowski, Crooke, & Reed, 2014; NZSSD, 2009a, 
2011). In the current study, the IFCC unit is used; however, original units used in the 
reviewed literature will be reported. 
The New Zealand Society for the Study of Diabetes (NZSSD), which is the 
national advisory body on scientific and clinical diabetes care and standards in New 
Zealand, has provided guidelines for individual targets for HbA1c (see Table 1.1)
(NZSSD, 2009b). There are also international guidelines that specify HbA1c targets 
for youth. The International Society for Pediatric and Adolescent Diabetes (ISPAD) 
recommends an HbA1c less than 7.5% (58 mmol/mol) for those aged 13-19, and a 
lower level (7%; 53 mmol/mol) for adults (ISPAD & International Diabetes 
Federation, 2011). The above guidelines are generic targets and recommendations 
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may vary across individuals. The NZSSD standards for HbA1c levels and 
classifications are used for the current study. In Table 1.1, it can be noted that in 
addition to the classification of diabetes control levels there are indications for the 
risk of developing diabetes-related complications. There are two types of diabetes-
related complications: short-term and long-term. These are presented in greater detail 
in following sections. 
Table 1.1




< 50 Excellent control; increased risk of hypoglycaemia if on insulin/sulphonylureas
50-54 Very good control; some risk of hypoglycaemia if on insulin/sulphonylureas
55-64
May be appropriate and acceptable in many individuals but higher than ideal 
from clinical trial evidence.
Microvascular complication risk increases exponentially above around 
55mmol/mol
65-79 Suboptimal glycaemic control. Consider more intensive treatment.
Microvascular complication risk increases exponentially above around 
55mmol/mol
80-99 Poor glycaemic control. More intensive treatment recommended.
Microvascular complication risk increases exponentially above around 55
> 100 Very poor glycaemic control. Warrants immediate action
The recommended HbA1c targets, as stated earlier, can be achieved through a 
complicated management process that addresses issues associated with the diabetes 
condition including insulin deficiency and unregulated blood glucose (Hanas, 2007). 
This complex process requires the involvement of a multidisciplinary team 
(including physicians, dietitians, diabetes nurses, psychologists, and diabetes 
educators), and the individual who has diabetes and their family. Many aspects are 
taken into consideration in this process, such as comorbidity, psychological status, 
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and an individual’s age and lifestyle; thus, treatment plans differ amongst individuals 
(McNabb, 1997). 
Management of Type 1 Diabetes
Diabetes management refers to the process of controlling blood glucose by 
means of restoring carbohydrate metabolism to a near normal state (Hanas, 2010). 
Diabetes management aims to address abnormalities in the glucose concentration 
levels in the blood because of the defective insulin-secretion (Hanas, 2010). Diabetes 
management also refers to dealing with high and low blood glucose levels in the 
short term to be able to meet the long term goals recommended for diabetes control 
(Hanas, 2010). 
Diabetes management is not a straightforward task and involves a system of 
medical, behavioural, and psychosocial processes, which include diabetes self-
management tasks, and diabetes-oriented lifestyle adjustments (Borus & Laffel, 
2010; Hanas, 2010; Reed, 2014). These are part of a daily regimen, which 
incorporate four main components: blood glucose monitoring, insulin mediation, 
diet, and exercise (Hanas, 2007; Reed, 2014). 
There are generic guidelines that address these components for type 1 
diabetes (CDHB, 2015; Diabetes New Zealand, 2014; Reed, 2014). As an example, 
diabetes self-management includes adjusting insulin medication according to specific 
dietary intakes. Individuals with type 1 diabetes are expected to adjust their insulin 
dosage to suit their carbohydrate intake shortly after meal time or snack (e.g., within 
15 minutes), with a prospect of a three meals per day and at least one snack. Ideally, 
the insulin dosage would be enough to cover the number of units counted from the 
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carbohydrates they eat (1 unit = 15 grams of carbohydrates). In addition, they are 
advised to have regular exercise (at least three times per week) to help break down
the glucose in the blood, and also to coordinate medication and monitor blood 
glucose levels to avoid immediate complications from having low blood glucose 
levels. 
Adherence to recommendations for the diabetes self-management has been 
shown to have a positive impact on diabetes outcomes (Asche, LaFleur, & Conner, 
2011; Hood, Peterson, Rohan, & Drotar, 2009). Adherence refers to the level of 
engagement to the recommended diabetes self-management behaviours and lifestyle 
adjustments (e.g., blood glucose monitoring and insulin dose adjustments) 
(Delamater, 2006). Measurement of adherence mostly involves using self-report 
measures (e.g., log diaries, adherence recall interviews, and scales such as the Self-
Care Inventory). Blood glucose monitoring adherence, however, can be measured 
more objectively (rather than merely by self-report) by means of downloading blood 
glucose readings from blood glucose monitors (Budde, 2009). 
Self-monitoring of blood glucose (SMOBG) is an essential component of 
diabetes self-management (Hanas, 2010; Rewers et al., 2014). This provides instant 
feedback on current blood glucose levels which individuals with type 1 diabetes can 
use to inform their daily management of blood glucose levels. Research has reported 
significant correlations between frequent SMOBG and lower and improved HbA1c 
(e.g., Anderson et al., 2014; Rewers et al., 2014; Ziegler et al., 2011). Furthermore, 
SMOBG can be used to evaluate glycaemic variability and this is also associated 
with changes in HbA1c and the risk for complications; this is discussed shortly. 
A portable blood glucose monitoring device is usually recommended so that 
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individuals with diabetes can check their glucose levels as part of their daily self-
management routine (Hanas, 2010). There is a range of blood glucose readings, also 
referred to as the practically observed range, which many blood glucose monitoring 
devices can display. This range includes blood glucose readings from 1.1 to 33.3 
mmol/L (Kovatchev, Cox, Kumar, Gonder-Frederick, & Clarke, 2003). Clinical 
studies recommend classifications for blood glucose levels to differentiate low or 
high blood glucose values that may lead to severe hypoglycaemia or hyperglycaemia. 
These are: normal blood glucose (euglycaemia), 3.9-10 mmol/L; low blood glucose 
(hypoglycaemia), 1.1 < blood glucose < 3.9 mmol/L; and high blood glucose
(hyperglycaemia), 10 < blood glucose < 33.3 mmol/L (DCCT Research Group, 1993; 
Robeva et al., 2007). Values that are less than 2.2 mmol/L are considered to be 
extreme hypoglycaemia, and those that exceed 22.2 mmol/L are considered to be 
evidence of extreme hyperglycaemia (Kovatchev et al., 2003). 
Blood glucose values outside of the euglycaemia range can have negative 
consequences and result in a person experiencing various diabetes-related symptoms 
or complications (Shaw & Cummings, 2012). These symptoms and complications 
can range from unpleasant to acute depending on the extent and severity of changes 
in blood glucose concentration (Amiel, 2011; Choudhary & Amiel, 2011; Clarke, 
Jones, Rewers, Dunger, & Klingensmith, 2009; Wass & Owen, 2014). Change in 
blood glucose concentration in a given time is referred to as glycaemic excursion. 
Glycaemic excursions contribute to forming a profile of blood glucose fluctuations or 
glycaemic variability (GV) (Krishna, Kota, & Modi, 2013). 
Reducing GV has the potential to contribute to improved diabetes control and 
to reduce the risk of complications (DeVries, 2013; Krishna et al., 2013). The HbA1c 
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measures glycaemic control using an averaged value over a considerable time period; 
however, it does not capture GV of intra-day and inter-day data found in a blood 
glucose profile (Dailey, 2007; Tylee & Trence, 2012). The evaluation of GV 
provides information on the quality of blood glucose profiles and may account for 
the frequency and level of hypoglycaemia and hyperglycaemia excursions (i.e., mild, 
moderate, or severe excursions) (Dailey, 2007; Kovatchev, Otto, Cox, Gonder-
Frederick, & Clarke, 2006; Kovatchev, Straume, Cox, & Farhy, 2000). In simple 
words, GV measures the quality of blood glucose fluctuations and extent of peaks 
and nadirs in glycaemic excursions (Tylee & Trence, 2012). Methods for measuring 
GV are presented in Chapter 4. 
Diabetes Complications 
Poorly controlled diabetes may result in a range of complications, including
physiological damage and cognitive dysfunction (Choudhary & Amiel, 2011; 
Donaghue, Chiarelli, Trotta, Allgrove, & Dahl-Jorgensen, 2009; Nathan, 1993; Wass 
& Owen, 2014). There are short-term and long-term complications linked to poorly 
controlled diabetes. Hypoglycaemia and hyperglycaemia are two forms of short-term 
complications, and may lead to the development of other severe conditions. 
Untreated or persistent hypoglycaemia and hyperglycaemia increase the risk of 
developing critical complications that can be life threating (e.g., coma and death) or 
long-lasting (e.g., heart and kidney diseases) (Nathan, 1993). Thus, preventing or 
avoiding short-term complications can minimise the risk of critical and long-term 
complications (Nathan et al., 2009). 
Long-term diabetes complications include the development of microvascular 
and macrovascular diseases (Donaghue et al., 2009). The former affects smaller 
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blood vessels leading to nephropathy (kidney disease), neuropathy (nerve damage), 
and retinopathy (eye disease). The latter affects larger blood vessels and leads to 
cardiovascular diseases, such as circulation disorders and heart failure. Clinical trials 
have shown that tight control of diabetes reduces the risk for complications (DCCT 
Research Group, 1993, 2002; Fullerton et al., 2014; Nordwall et al., 2015). To 
achieve tight control typically involves intensive medical treatment, frequent 
monitoring of blood glucose, and strict adherence to recommendations of diabetes 
self-management (e.g., insulin mediation, diet, and exercise). The intensive medical 
regime may involve taking frequent insulin medications, which may include at least 
three insulin injections per day corresponding to meal or snack consumption. Insulin 
injections are an attempt to mimic insulin secretion from the pancreas and so achieve 
blood glucose levels that are within the healthy range in non-diabetic individuals. 
There is, however, a risk of experiencing severe hypoglycaemia associated with the 
intensive and tight control in the attempt to achieve lower HbA1c (DCCT Research 
Group, 1997; Fowler, 2008; Havlin & Cryer, 1988). Nevertheless, safely reaching 
recommended HbA1c values, through the tight daily management and blood glucose 
control, has been shown to reduce microvascular and macrovascular complications to 
a significant extent (DCCT Research Group, 1993, 2002).
A large controlled clinical trial of 1,441 subjects (aged 13-39) with type 1 
diabetes showed that a reduction of 1% in HbA1c (i.e., 11 mmol/mol) significantly 
reduced the risk for diabetes complications of retinopathy, nephropathy, neuropathy, 
and cardiovascular conditions (DCCT Research Group, 1993, 1996). A related study 
showed that the risk of complications can be potentially eliminated if long-term 
HbA1c is maintained below 60 mmol/mol (Nordwall et al., 2015). This study found 
that none of the participants (aged under 35) with long-term HbA1c below 60 
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mmol/mol developed retinopathy or nephropathy, when followed up over a 20 year 
period. In contrast, 51% of those with poorly controlled diabetes (long-term HbA1c 
of 80 mmol/mol) developed retinopathy and chronic nephropathy. It is therefore 
crucial for people with type 1 diabetes to maintain good diabetes control, and
reductions in HbA1c for those with HbA1c above recommended levels can 
contribute to a substantial decrease in the risk for long-lasting complications. This is 
not as simple as it seems and, as noted earlier, is influenced by a number of factors, 
especially for those in the youth developmental stage. 
Poor Diabetes Control in Youth
Poor diabetes control is common for the majority of adolescents and young 
adults and there is a global documentation of this (Anderson et al., 2014; Daneman & 
Hamilton, 2001; Holl et al., 2003; Mortensen & Hougaard, 1997). The largest 
international, contemporary, study found that the majority of young people (8-25 
year olds) with type 1 diabetes were not meeting recommended glucose control 
targets (Anderson et al., 2014; Laffel et al., 2014). This cross-sectional and 
observational study recruited nearly 6000 participants from 20 countries (Europe, 
USA, Latin America, Middle East, Africa, and India). The study found nearly three-
quarters (72%) of the young people had HbA1c above the recommended level, with 
higher percentages in the age groups 13-25 year olds. The overall HbA1c means for 
adolescents aged 13-18 (n = 2854) and young adults aged 19-25 (n = 1382) were 
8.6% and 8.4%, respectively. Only, about a third (29%) of the adolescents and a fifth 
(19%) of young adults met the recommended targets, with one in five having an 
HbA1c that was extremely high (≥10%). These results are consistent with findings 
from previous global audits that found the majority of youth with type 1 diabetes did 
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not meet targets for HbA1c and presented an overall HbA1c average that was above 
8% (e.g., Holl et al., 2003; Mortensen & Hougaard, 1997). 
Key findings from the above study suggested that targets for heathy diabetes 
control may be achieved by improving behavioural and psychosocial aspects related 
to diabetes management (Anderson et al., 2014; Laffel et al., 2014). Factors that were 
found to be associated with achieving target HbA1c, as identified in multivariate 
analysis, included: monitoring blood glucose at least three times a day, carbohydrate 
counting, regular exercise, no history of diabetic ketoacidosis in the previous 3 
months, diabetes related family conflict, and an absence of financial burden related to 
diabetes management. Moreover, the study found that better quality of life for young 
people is significantly associated with better diabetes control. The findings suggest 
that whilst the majority of youth with type 1 diabetes are not meeting the HbA1c 
targets, diabetes control can be improved and the impact of diabetes can be reduced 
(Anderson et al., 2014; Laffel et al., 2014). Control of diabetes in youth with type 1 
diabetes can be achieved by targeting the factors that can be modified and so help 
youth meet the recommended HbA1c targets (Anderson et al., 2014; Laffel et al., 
2014; Svoren, Butler, Levine, Anderson, & Laffel, 2003).  
The current status of diabetes management can be generally summarised by a 
statement by Nam et al. (2011) in his systematic review of barriers to diabetes 
management: “despite significant advances in diagnosis and treatment, the 
persistence of inadequate metabolic control continues. Poor glycemic control may be 
reflected by both the failure of diabetes self-management by patients as well as 
inadequate intervention strategies by clinicians” (p. 1).
This chapter provided an overview of diabetes mellitus and diabetes 
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management particularly in youth with type 1 diabetes, all relevant as background to 
the three studies in this thesis. Diabetes is a complex metabolic disorder that is 
becoming a global epidemic. Type 1 diabetes is prevalent in those younger than 26 
years old (Scott et al., 2006) and although it cannot be cured, it can be managed so 
that blood glucose levels are maintained within the healthy range in non-diabetic 
individuals. Diabetes management is not a straightforward task and involves 
engagement in multiple diabetes self-management behaviours and diabetes-oriented 
lifestyle adjustments (Hanas, 2007). Management of type 1 diabetes in young people 
is challenging and is influenced by developmental factors that include physiological 
and psychological changes, particularly during adolescence years when diabetes 
control often deteriorates (Borus & Laffel, 2010; Hamilton & Daneman, 2002; 
Pinhas-Hamiel et al., 2014). 
The next chapter presents an audit of the demographics, prevalence of type 1 




Youth with type 1 diabetes: an audit of the 
demographics, prevalence of type 1 
diabetes, and glycaemic control for youth 




This chapter presents the first study in the thesis, which is an audit of the 
demographics, prevalence, and diabetes control of youth (15-24 year olds) with type 
1 diabetes in the CDHB catchment area, and an exploration of changes in the 
prevalence and diabetes control outcomes. This study was published in the New 
Zealand Medical Journal (Obaid, Britt, Wallace-Bell, & Johnson-Elsmore, 2012a), 
and presented at the 36th Annual Scientific Meeting the New Zealand Society for the 
Study of Diabetes (Obaid, Britt, Wallace-Bell, & Johnson-Elsmore, 2012b, 2012c). 
The following is a review of literature relevant to the current study.  
Youth with Type 1 Diabetes in Canterbury
The incidence rate of children and adolescents (0-19 years) with type 1 
diabetes over a period of 30 years was previously investigated in the Canterbury 
region (Willis et al., 2002). The study by Willis et al. (2002) analysed the number of 
newly diagnosed cases from 1970 to 1999 as to whether there were any changes in 
the incidence rates over time. The analysis involved collating data obtained from 
clinical registers, including the Canterbury Register of Insulin Treated Persons 
(Brown & Scott, 1988). Records of hospital admissions, and inpatient and outpatient 
clinics were also accessed. Secondary sources of information included General 
Practitioner (GP) records, community-based surveys, and direct contact with patients 
and their families. The study reported that 100% of individuals with type 1 diabetes 
were identified with no missing cases. 
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The incidence of type 1 diabetes for those younger than 20 years in 
Canterbury was found to have significantly increased over time, with a 3.4-fold 
increase in the number of type 1 diabetes presentations between 1970 and 1999 
(Willis et al., 2002). The increase in age-gender specific incidence rate of type 1 
diabetes over time was statistically significant in females and males 0-14 years old, 
with the exception for females aged 0-4 years. In contrast, the change in rate of new 
presentations of type 1 diabetes in both age-gender groups in adolescents (15-19 
years old) with time was not significant (Willis et al., 2002). For children less than 12 
years of age, the number of males exceeded the number of females with type 1 
diabetes over the entire period (i.e., from 1970 to 1999). From 1990-1999 it was 
observed that the difference between number of males and females with type 1 
diabetes was consistent across all ages after 5 years of age, in which males always 
exceeded females (Willis et al., 2002). Ethnicity was not considered for analyses, 
because of the small number of non-European presentations of type 1 diabetes in 
Canterbury. The total number of incident cases in this study was 474 (256 males, and 
218 females), with the lowest incidence rate (2.40 per 100,000 person-years) 
recorded in 1970 and the highest incidence rate (26.59 per 100,000 person-years) 
recorded in 1998. The dramatic increase in incidence rate of type 1 observed from 
1970 to 1999, Figure 2.1, follows a global trend of rapidly increasing presentations of 
type 1 diabetes (Willis et al., 2002).
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Figure 2.1. The incidence of type 1 diabetes in children and adolescents, aged < 
20 years, in Canterbury, New Zealand, 1970-2000 (- - - 95% CI); source: Willis et 
al. (2002, p. 639).
The prevalence of type 1 diabetes in children and young adults (0-24 year 
olds) in the CDHB region was investigated in 2003 (Wu et al., 2005). The CDHB 
catchment area was defined to include the city of Christchurch, the town of 
Ashburton, and rural areas around North Canterbury. Records of children and young 
adults were obtained from clinical and research registers of CDHB diabetes services. 
The study database was cross-checked for completeness; checks were carried out on 
records retrospectively with a back date of two and a half year since the start of the 
study. The records were obtained from the Christchurch Hospital, Ashburton 
Diabetes Clinic, and community-focused diabetes services.
This study reported an estimated prevalence of 227 per 100,000 population 
for young people with type 1 diabetes in the CDHB catchment area (Wu et al., 2005). 
The study found a total of 353 young people with diagnoses of diabetes in the 
Canterbury region, with 330 individuals diagnosed with type 1 diabetes. Of those 
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individuals with type 1 diabetes, 168 (51%) were males and 307 (93%) were of 
European descent. Stratified data of age-specific European New Zealanders with type 
1 diabetes showed that the majority were adolescents (15-19 years old) and young 
adults (20-24 years old); n = 92 (30%) and 95 (31%), respectively. That is, of the 
total number of European New Zealanders with type 1 in the CDBH catchment area, 
61% were youth. This suggests that those who are potentially vulnerable to 
deterioration in metabolic control constitute more than half of the young CDBH 
population with type 1 diabetes. 
Diabetes control, as measured by HbA1c, was investigated in the Canterbury 
region at a population level. Lunt et al. (2002) reported HbA1c results for the CDHB 
population of adolescents and youth (13-20 years old) with type 1 diabetes, N = 118. 
These individuals had diabetes of at least one year’s duration (referred to as 
established diabetes), and were identified from a clinical database of the Christchurch 
Diabetes Centre, which services the CDHB catchment area. The identified list was 
rechecked using an independent population-based research register; the reported data 
represented the entire diabetic population in Canterbury for the target age range. The 
overall average HbA1c was higher than the recommended target, falling in the poor 
glycaemic control category, which is associated with a higher risk for developing 
long-term diabetes complications. Females (mean HbA1c = 10.2%) had significantly 
worse diabetes control than males (mean HbA1c = 9.5%), p = 0.042. The study 
recommended that effective ways of delivering young adults diabetes services in 
Canterbury and New Zealand be explored (Lunt et al., 2002). 
A further study was conducted to evaluate diabetes control at a population 
level in Canterbury, following changes in the delivery of diabetes health services, 
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between 2001 and 2005 (Lunt, Kendall, Moore, Soule, & Cole, 2006). Changes to 
the delivery of health services included: designating a minimum of four specialist 
visits per annum for those aged 13-18 years old (e.g., specialist doctors and nurse 
visits), forming links between the clinic and the community through a diabetes youth 
field worker with nursing qualification, scheduling a weekly meeting for the 
multidisciplinary team staff, assigning case management for selected patients,
providing funded insulin treatment for selected patients, and putting greater emphasis 
on carbohydrates counting (Lunt et al., 2006). These changes were in addition to the 
services already in place in 2001, such as the inclusion of clinical psychology 
services and blood glucose meter downloading at the Diabetes Centre. 
The data comprised HbA1c results recorded in 2001 (N = 119), 2003 (N = 
147), and 2005 (N = 142) for youth residing in the CDHB catchment area who had 
diabetes for more than a year (Lunt et al., 2006). The mean HbA1c was 9.8%, 9.8%, 
and 9.1%; respectively, for the years 2001, 2003, and 2005. There was no change in 
HbA1c from 2001 to 2003, and only in 2001 did females have significantly higher 
HbA1c (p = 0.035) than males. A statistically significant improvement (p = 0.03) in 
HbA1c was observed from the year 2001 to 2005. The overall results, however, still 
showed higher mean HbA1c levels than the recommended level (i.e., >55 
mmol/mol). In 2005, only 12% of patients achieved the recommended HbA1c target. 
Thus, despite implementing changes to the diabetes services that aimed to improve 
glycaemic control that followed on from the findings of the 2001 audit (Lunt et al., 
2002), only small changes were observed in diabetes control from 2001 to 2005 
(Lunt et al., 2006). The results also suggested that mean HbA1c levels remained 
mostly in the suboptimal to poor diabetes control category.
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Since these studies, there have been no further studies of the prevalence and 
diabetes control of youth with type 1 diabetes in Canterbury. Thus there is a seven 
year gap in knowledge, which is critical because it could be used to inform the 
planning and delivery of diabetes health services to youth with type 1 diabetes. Given 
the significant short and long term consequences of poorly controlled type 1 diabetes, 
it is imperative that there is regular ongoing evaluation of the prevalence and 
diabetes control of youth with type 1 diabetes. The following aims were formulated 
as part of the current study to bridge some of the gaps in knowledge and to provide 
up-to-date information which can inform health service providers:    
a) Describe the demographics of youth (15-24 year olds) with type 1 
diabetes in the CDHB catchment area and to compare this data with 
previous research (Wu et al., 2005). 
b) Estimate the prevalence of youth with type 1 diabetes in the CDHB 
catchment area. 
c) Investigate whether there has been an increase in the prevalence of 
youth with type 1 diabetes residing within the CDHB catchment area.
d) Describe diabetes control outcomes and its classifications according to 
the HbA1c targets of NZSSD (2009b). 
e) Investigate whether there has been any change in diabetes control, as 
measured by the mean value of HbA1c, from 2001 (Lunt et al., 2002)
to 2010 for youth (aged 15 to 20 years) who reside in the CDHB 
catchment area, and for whom data are available. 
Based on the previous research, it was hypothesised that the majority of youth 
with type 1 diabetes residing in the CDHB would be of European descent, with males 
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out numbering females. It was also hypothesised that there would be an observed 
increase in the prevalence of type 1 diabetes in youth. Furthermore it was 
hypothesised that the diabetes control, as measured by HbA1c, would have improved 
at a population level from 2001 to 2010, but that the mean HbA1c would still not be 
within the healthy range (i.e., less than 55 mmol/mol). 
Method
The study comprised two main parts that describe and investigate changes in 
prevalence and diabetes control. The following outlines the procedures for data 
collection, prevalence estimation, and diabetes control assessment. 
The information was collated for youth with type 1 diabetes aged between 15 
and 24 years, who resided within the CDHB catchment area. This included 
Christchurch, the town of Ashburton, and Northern rural Canterbury. The current 
study identified youth residing in the CDHB catchment area based on an anchor date 
of 1 November 2010. This date was chosen to align with the previous study’s anchor 
date, 1 November 2003, which yielded a seven-year gap between the two studies 
(Wu et al., 2005). The search and inclusion criteria (i.e., valid entries) used in the 
earlier study by Wu et al. (2005) were followed. Thus, those newly diagnosed 
diabetes and with secondary or type 2 diabetes were excluded from the study – only 
entries of youth with established type 1 diabetes were included.  
The CDHB records were searched in multiple electronic and physical 
sources. The electronic data sources included the CDHB inpatient and outpatient 
lists, the Diabetes Youth Canterbury database, and records from the previous study 
(Wu et al., 2005). The data collected comprised descriptive information and 
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demographic characteristics of the youth. This included gender, ethnicity, age, 
residential area deprivation level, diabetes duration, and the most recent HbA1c 
record. Age data were divided into two age bands (15-19 years and 20-24 years), 
which represented adolescents and young adults. This division was consistent with 
the census age categories obtained from Statistics New Zealand (the New Zealand’s 
national statistical department) and allowed comparison with Wu et al. (2005). 
Missing data-point entries were updated by searching the physical files held at the 
CDHB Diabetes Centre based on the National Health Index (NHI), and contacting 
the individual youth’s GP. The collated data were entered in raw format and then 
analysed using Microsoft Excel 2007 and IBM Statistical Package for Social 
Sciences (IBM SPSS 19).
Prevalence 
The prevalence of youth with type 1 diabetes was estimated, and then this 
was compared to the results of the previous audit conducted in the CDHB in 2003, by
Wu et al. (2005). In the current research, the prevalence calculation was based on the 
2006 census data (Statistics New Zealand, 2007), whereas the 2003 prevalence 
calculation was based on the 2001 census data (Wu et al., 2005). Prior to comparing 
the results of the two studies, the studies populations were checked for adequate 
comparability. This is because of changes made to some aspects of the 2006 census 
in comparison to the 2001 census, and two main issues were considered that were of 
relevance to the current study. The first issue was to base the prevalence calculation 
on populations drawn from the same source. This was ensured by using the same 
source from the Statistics New Zealand records to find the total number of the target 
population residing in the CDHB for each of the years 2001 and 2006; these were 
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drawn from statistics specific to DHBs (Statistics New Zealand, 2002, 2007). The 
second issue was related to a difference in the data collection and classification of 
ethnicity in 2001 compared to the 2006 census. For example, in the 2001 census data 
the New Zealander entry was grouped with the European entry; however, in 2006 a 
separate classification under other ethnicities was created to include the New 
Zealander entries. This issue was remedied by adding the total number of the New 
Zealander subcategory in the 2006 census data to the total number of the European 
category, thus making the 2001 and 2006 census population totals comparable to 
each other. 
A further consideration was taken into account in comparing the estimated 
prevalence over time, which was to eliminate a potential confounding effect from 
different population compositions (Boniol & Heanue, 2007; Boyle & Parkin, 1991; 
Naing, 2000). Changes in prevalence from 2003 to 2010 were assessed using 
standardised prevalence rather than crude prevalence. Crude prevalence presents a 
measure of the entire population and does not account for the composition of 
subgroups within that population, whereas standardised prevalence eliminates the 
influence of the different makeup of subgroups when comparing prevalences from 
two populations (Boniol & Heanue, 2007; Boyle & Parkin, 1991; Naing, 2000). 
The standardisation procedure is as follows, and in Appendix 2.1 are the 
relevant equations. Age-specific prevalence in each year was calculated based on the 
number of observed cases in the total population in each age stratum (Statistics New 
Zealand, 2002, 2007). Age-standardised prevalence was then estimated by 
calculating weighted averages of the age-specific prevalence, using 2010 as a 
reference year. This was to account for differences in population compositions from 
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2003 to 2010 and to provide a reliable estimate for evaluating change in prevalence 
over time (Boniol & Heanue, 2007; Boyle & Parkin, 1991).  
The change in prevalence was statistically evaluated by calculating an age-
standardised prevalence ratio (ASPR), also referred to as a standardised morbidity 
ratio (SMR), which is the ratio of the 2010 age-standardised prevalence to that of the 
year 2003 (Boniol & Heanue, 2007; Boyle & Parkin, 1991). The 95% confidence 
interval (CI) was calculated to assess whether there was a statistically significant 
difference between the prevalence from 2003 to 2010. A statistically significant 
difference is said to exist if the ASPR is significantly different from unity (i.e., the CI 
does not include one), which is equivalent to zero in a standard 95% CI of the 
difference between means (Boniol & Heanue, 2007; Boyle & Parkin, 1991). 
Diabetes control 
In the second part of the audit study, the data collected above were used to 
describe the population of youth with type 1 diabetes in terms of their diabetes 
control, as measured by HbA1c. This included finding the percentage of people with 
particular HbA1c levels in each category of diabetes control classifications (e.g., 
excellent, acceptable, and poor), and the category of diabetes control for the overall 
mean. A comparison of current diabetes control with the study by Lunt et al. (2002)
was conducted. It is of note, however, that the age range in the earlier study was 13 
to 20 years old, which did not match the age range for the current study and 
therefore, a sub-group (15-20 years old) was used to compare matching groups’
results for the designated years. 
An independent-samples t-test was carried out assuming that the variability in 
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2001 was the same as that observed in 2010, because no variability measures were 
reported in the 2001 audit (Lunt et al., 2002). The 2001 audit reported the number of 
youth entries, and HbA1c mean values, but did not report the SD for the population 
HbA1c. In order for the two groups to be compared using a t-test requires a mean, 
SD, and a total number of entries for each of the groups; the same SD, obtained from 
the current study, was assumed for both groups. The aim of the comparison, as 
previously mentioned, was to investigate if there had been any change in diabetes 
control, as measured by the mean value of HbA1c, from 2001 to 2010 for youth 
(aged 15 to 20 years) residing in the CDHB catchment area. An independent-samples 
t-test was also used to identify whether in 2010 there was a statistically significant 
difference in mean HbA1c values between females and males. This was explored
because there had been a significant difference in diabetes control between females 
and males in the 2001 study (Lunt et al., 2002). 
Results
Prevalence 
The number of youth with type 1 diabetes residing within the CDHB 
catchment area on the anchor date 1 November 2010 was 248. The demographics of 
these youth are depicted in Table 2.1.  
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Table 2.1
Demographics of youth with type 1 diabetes, who are residing within the CDHB 
catchment area in 2010
n %
Gender Female 120 48.4%
Male 128 51.6%
Age Groups* (years) (15-19) 131 52.8%
(20-24) 117 47.2%
Ethnicity European 227 91.5%
Maori 9 3.6%
Pacific Peoples 3 1.2%
Other 9 3.6%
Diabetes duration** between 1 and 5 55 22.2%
(years) between 6 and 10 82 33.1%
between 11 and 15 68 27.4%
between 16 and 20 33 13.3%
more than 20 10 4.0%
Deprivation quintiles*** 1 77 31.2%





* Mean age was 19.2 years old (SD = 2.6 years); 
** Mean length of diagnosis was 10 years (SD =5.4 years; minimum = 0.9 year (11 months); 
maximum=22 years); 
*** (Statistics New Zealand, 2011).
The percentage of females and males were 48.4% (n = 120) and 51.6%, (n = 
128) respectively. The majority (91.5%; n = 227) of youth with type 1 diabetes were 
European New Zealanders. The percentage of 15-19 year olds (adolescents) was 
52.8% (n = 131), and 20-24 year olds (young adults) was 47.2% (n = 117). The 
diabetes’ duration ranged from 11 months to 22 years, with one third (33.1%) in the 
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6-10 year duration range. About a third (31.2%) of youth with type 1 diabetes resided 
in the least deprived socioeconomic area (quintile 1).
Based on the total number of youth with type 1 diabetes residing within the 
CDHB catchment area in 2010, the prevalence was calculated using the 2006 census 
data. The majority (91.5%; n = 227) of youth with type 1 in Canterbury were 
European new Zealanders and data in this ethnic group were stratified by age. The 
two age bands were 15-19 years and 20-24 years, which correspond to the census age 
categories, and were also presented in the previous audit (Wu et al., 2005). The 
results are depicted in Table 2.2, which shows age-specific and age-standardised 
prevalences for both 2010 and 2003 (Wu et al., 2005). Table 2.3 shows the 
percentage of changes from 2003 to 2010 in the number of cases and prevalence of 
youth with type 1 diabetes, and the general youth population. 
Table 2.2
Prevalence of European New Zealanders with type 1 diabetes (stratified by age) residing in the CDHB 
catchment area in 2010 and 2003
Year 15-19 years 20-24 year % of 
difference
ASP+
2010 Cases 126 101 22.0
Prevalence per 100,000 443 406 8.7 426
(95% CI) (366 to 520) (327 to 485) - (370 to 481)
Population* 28,452 24,891 13.4
2003 Cases ** 92 95 3.2
Prevalence per 100,000 369 394 6.6 380
(95% CI) (294 to 444) (315 to 473) - (326 to 435)
Population *** 24,951 24,126 3.4
Note. + Age-standardised prevalence; 
* (Statistics New Zealand, 2007); 
** (Wu et al., 2005); 
*** (Statistics New Zealand, 2002).
34
Table 2.3
Percentages of increase from 2003 to 2010 in the cases and prevalence of European New 
Zealanders with type 1 diabetes, and the general population
15-19 years 20-24 years
Cases with type 1 diabetes 37.0% 6.3%
Prevalence of type 1 diabetes 20.0% 3.0%
General youth population * 14.0% 3.2%
Note. * Inclusive of all youth with or without diabetes
The age-specific data shows that there had been an increase in the number of 
the adolescents and young adults with type 1 diabetes over time (Table 2.2-3), with a 
37% and 6.3% increase in the crude number of cases, respectively. There was a 
prevalence increase of 74 per 100,000 (20%) in adolescents (15-19 year olds), and 12 
per 100,000 (3%) in young adults (20-24 year olds) with type 1 diabetes. These age-
specific increases, however, were not statistically significant in each age group. 
The age-standardised prevalence per 100,000 was estimated by calculating 
the weighted average of the age-specific prevalence using the year 2010 as a 
reference year (see Appendix 2.1). From 2003 to 2010 there was an increase of 46 
per 100,000 (12%) in the age-standardised prevalence. The ratio of the 2010 to 2003 
age-standardised prevalence was used to calculate the ASPR. The ASPR was found 
to be 1.19 (95% CI: 0.910 to 1.429). The CI includes figure one, which indicates that 
the difference in prevalence over time was not statistically significant. 
In Table 2.3 it can also be seen that there was an increase in the general 
population of youth from 2003 to 2010, which may have contributed to inflation in 
the crude diabetes prevalence in 2010. In the adolescents’ age band there was an 
increase of 14%, whereas there was only a 3.2% increase in the general young adult
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total population.  In addition, the number of adolescents (15-19 year olds) with type 1 
diabetes exceeded the number of young adults (20-24 year olds) with type 1 diabetes 
by 22% in 2010 (Table 2.2). This is in contrast to the findings of the Wu et al. (2005)
study, where the number of young adults with type 1 diabetes was slightly (3.2%) 
larger.  
Diabetes Control
The overall mean HbA1c was 82 mmol/mol (SD = 22 mmol/mol), which fell 
into the category of poor diabetes control. The majority of youth (93.2%; n = 229) 
had HbA1c levels that exceeded the recommended range (i.e., > 55 mmol/mol), with 
more than half of this percentage falling in the poor to extremely poor diabetes 
control. The observed classifications (Table 2.4) suggest that the majority (77%; n = 
190) of individuals with type 1 diabetes in Canterbury may require more intensive 
treatment, with nearly a third requiring urgent interventions or immediate action
(NZSSD, 2009b).
Table 2.4
Mean HbA1c and diabetes control range for youth (15-24 year olds) with type 1 
diabetes in the CDHB catchment area in 2010
 HbA1c (mmol/mol)
Range+ n % M SD Minimum Maximum
< 50 7 2.8% 41 4 34 45
50-54 10 4.1% 52 1 50 54
55-64 39 15.9% 60 3 55 64
65-79 72 29.3% 72 5 65 79
80-99 59 24.0% 88 5 80 99
>100 59 24.0% 114 13 100 146
Note. +NZSSD (2009) diabetes control range
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The data of the current study for the age range 15-20, Table 2.5, were 
compared to that of the 2001 audit, Table 2.6 (Lunt et al., 2002). The t-test showed 
no statistically significant difference (p = 0.75) between the two results. The mean 
HbA1c had neither significantly deteriorated, nor improved since 2001. The mean 
HbA1c in 2010 was 85 mmol/mol. This exceeded the recommended HbA1c target, 
and fell in the poor diabetes control category, suggesting that more intensive 
intervention was required. The gender specific data analysis showed that in 2010 (as 
it had been in 2001) females had statistically significantly worse (p = 0.04) diabetes 
control than males, with a mean HbA1c 88 and 81 mmol/mol, respectively. 
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Table 2.5
Mean HbA1c according to gender and age for youth (15-20 years) with type 1 diabetes residing in the 
CDHB catchment area in 2010  
Female Male




15 16 88 (21) 10 74 (18)
16 15 81(23) 13 76(15)
17 11 87(29) 10 84(15)
18 7 104(28) 17 88(27)
19 18 89(19) 14 77(18)
20 11 85(24) 15 87(20)
Total 78 88(23) 79 81(19)
M HbA1c (N =157) = 85 mmol/mol; SD = 22 mmol/mol
Table 2.6
Mean HbA1c according to gender and age for youth (15-20 years) with type 1 diabetes residing in the 
CDHB catchment area in 2001 (Lunt et al., 2002)
Female Male




15 5 76 5 73
16 9 96 10 83
17 7 101 8 87
18 9 86 7 80
19 7 88 12 83
20 5 81 7 64
Total 42 88 49 78
M HbA1c (N = 91) = 83 mmol/mol, SD was not reported
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Discussion 
Type 1 diabetes is a chronic illness that is associated with multiple 
challenges. In addition to the individual’s diabetes-management challenges, there are 
challenges for the health system. These include the planning and accessibility of 
resources, such as medication, equipment, and access to appropriately trained health 
care professionals (International Diabetes Federation, 2013; Ministry of Health, 
2014). Additional health costs stem from long-term complications, such as kidney 
failure and nerve damage that are associated with poorly controlled type 1 diabetes 
(Donaghue et al., 2009; International Diabetes Federation, 2013; Wilson & Sharma, 
1995). The burden on the health system is likely to be greater if these long-term 
complications arise at an early age (Ministry of Health, 2014). As a consequence, it 
is important for health care planners to gather data on the demographics, prevalence 
and trends of diabetes in specific populations, and in particular for the youth 
population for whom diabetes management can pose significant challenges (Ministry 
of Health, 2014).
The current study gathered these data for youth (15-24 year olds) with type 1 
diabetes residing within the CDHB catchment area. The results indicate that the 
majority of youth with type 1 diabetes in the CDHB catchment area are European 
New Zealanders, with males slightly out numbering females. These results are 
similar to the previous study by Wu et al., (2005) but in the current study the number 
of adolescents with type 1 diabetes exceeded that of young adults. This is in contrast 
to the findings of Wu et al., (2005) who found the opposite (Table 2.2). 
The difference in findings between the two studies may be because of the 
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difference in the total number of the general youth population in each age band (see 
Table 2.3). An increased number in the general population of adolescents compared 
to that of young adults may suggest the likelihood of more presentations of youth 
with type 1 diabetes. Of note is that the difference in the total population 
compositions constitutes a confounding factor that may affect evaluating change in 
prevalence over time if analyses are only based on crude prevalences. However, the 
age-standardisation used in the current study increases the reliability of results in 
accounting for this factor because the ASPR reliably estimates the change in 
prevalence (Boniol & Heanue, 2007). 
The age-standardised prevalence of youth with type 1 diabetes had increased 
by 46 per 100,000 (12%) from the previous audit (Wu et al., 2005), but, based on the 
ASPR results, this was not statistically significant. This finding is similar to the 
results of an earlier study of 15 to 19 years old with type 1 diabetes in the CDHB 
catchment area which similarly did not find a statistically significant increase over 
time (Willis et al., 2002). In comparison to the Wu et al. (2005) results, the age-
specific prevalence in the current study was greater in each age band (Table 2.3), but
this was not statistically significant. The increase in the prevalence of adolescents 
with type 1 diabetes was greater than that of young adults. Again, as explained 
above, this increase could be expected given the increase in the general adolescent 
population from the 2001 to 2006 in comparison to that in the general young adult 
population (see Table 2.3). 
The results also indicated that a high percentage of youth with type 1 diabetes 
in the CDHB catchment area resided in the least deprived socioeconomic areas 
(53.5% in deprivation quintiles 1 and 2). This result may simply be representative of 
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the wider Canterbury population, that is, youth of European descent in Canterbury 
(which includes most of the cases of youth with type 1 diabetes in this region) may 
be more likely, in general, to reside in least deprived socioeconomic areas (Maré, 
Mawson, & Timmins, 2001). It was not possible to determine if this is a statistically 
significant result.  This would have required: an estimated prevalence of the CDHB 
youth residing in the different deprivation quintiles; and the linking of residential 
mesh blocks to the different socioeconomic deprivation levels in the CDHB area and
to the target youth age ranges. These were not possible in the current study due to 
time constraints.  It is therefore, recommended that future research explores this 
aspect in greater depth. 
It should be noted that the present study may not have identified all youth 
with type 1 diabetes within the CDHB catchment area and there may be missing 
entries. Capture-recapture was applied in the present study, using the previous study 
records (Wu et al., 2005), but potentially missing entries could have been cross-
checked by using an additional capture-recapture method. This could have included 
setting a search date of two to three years back to check hospital records more 
extensively, rather than only checking records one year back. It is expected that 
youth with diabetes have a medical examination at least once a year. Records may be 
missed if they had not attended their annual check-up in 2010, or have not been 
admitted to the hospital during that time. More entries may have been captured, if the 
search period was extended to, for example, two years back from the anchor date. 
Although the aforementioned limitations may have resulted in missing 
entries, this number is believed to have been minimised because multiple sources 
were checked for youth entries, including youth databases, inpatient and outpatient 
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records, and records of patients who had been discharged from hospital. Furthermore, 
the composition of demographic factors for youth with type 1 diabetes in the present 
study (i.e., 91.5% Europeans, and 48.4% female and 51.6% males), was similar to 
the total CDHB youth population (Statistics New Zealand, 2007). For instance, 
according to the 2006 census records, the total population of European youth in the 
CDHB was 83% and the percentage of males was higher than females. This gives
confidence that the results of the current study are an accurate representation of 
youth with type 1 diabetes in the CDHB catchment area. 
Achieving optimal diabetes control is challenging both for individuals with 
type 1 diabetes, and also for health service providers at a population level (Lunt et 
al., 2006). In adolescence and young adulthood, there are additional developmental 
challenges that may have an impact on type 1 diabetes management and control 
(Borus & Laffel, 2010; Hamilton & Daneman, 2002; Pinhas-Hamiel et al., 2014). 
The current research found that the overall mean HbA1c of youth (15-24 year olds) 
with type 1 diabetes in the CDHB catchment area exceeded the recommendation for 
healthy control, falling into the poor to extremely poor diabetes control category 
(NZSSD, 2009b). This is despite the implementation of upgraded service strategies 
(Lunt et al., 2006). This result is similar to the findings from previous audits (Lunt et 
al., 2002; Lunt et al., 2006). This signals a need for conducting more frequent audits 
on diabetes control and evaluating and reviewing current services for youth with type 
1 diabetes, as well as exploration of additional services, particularly for youth with 
poorly controlled diabetes. 
The results of the current study also showed that females had significantly 
poorer diabetes control than males. This is similar to earlier findings by Lunt et al. 
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(2006), and this is also consistent with previous overseas research (e.g., Burke, 2004; 
Lagreca, Swales, Klemp, Madigan, & Skyler, 1995). Differences observed in 
diabetes control, on the basis of gender, may be partly attributed to differential 
psychological, social, and physiological aspects. For young women, these include 
variations in insulin requirements during the menstrual cycle because of hormonal 
changes, and also eating disorders, which are more common in females (Glick, 2009; 
Lagreca et al., 1995). A study by Tosh, Wong, Shen, Zhang, and Orr demonstrated 
gender-specific correlates of glycaemic control and showed females had worse 
outcomes than males. The study found that females with type 1 diabetes (aged 12 to 
21), compared to males, had poorer quality of life, lower level of self-confidence, 
poorer level of diabetes management, and more misuse of insulin (e.g., delaying, 
missing, or altering their insulin doses). These factors may result in there being 
gender differences in diabetes control, and this creates the need to address unique 
requirements of each vulnerable group, such as that for females with poor diabetes 
control. 
Although there was a statistically significant improvement in HbA1c from 
2001 to 2005 (Lunt et al., 2006), the current study found that overall there was no 
change from 2001 to 2010. This suggests that diabetes control may have worsened in 
the period 2005 to 2010. A direct comparison between the results of the current study 
and Lunt et al. (2006) was not feasible, because of the lack of access to detailed 
information with regards to the age categories in Lunt et al. (2006). Without further 
information this result cannot be confirmed. 
To conclude, the absolute figures obtained in the present study suggest an 
increased demand on health care resources in Canterbury associated with youth with 
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type 1 diabetes compared to seven years ago. It is recommended that the results from 
the present study be used to inform planning and decision-making related to diabetes 
health services both in the short term and in the longer term. For example, if youth 
receive effective health services in the short term, this may delay or prevent the onset 
of long-term complications, and therefore reduce future health care costs. 
The overall mean value of HbA1c suggests that on average youth, who reside 
in the CDHB catchment area, have poorly controlled diabetes and, therefore, have an 
increased likelihood of the early onset of diabetes complications. In addition, females 
had statistically significant poorer diabetes control than males. Furthermore, the 
population mean HbA1c has not improved since 2001, suggesting that while there
has been no deterioration in results for youth with type 1 diabetes in the CDHB area, 
neither has there been any overall improvement in outcome. Further action to achieve 
better diabetes control (i.e., lower the mean HbA1c) in youth with type 1 diabetes is 
therefore recommended. 
In addition to medical interventions to improve HbA1c, it is essential to study 
and understand psychosocial characteristics that influence glycaemic control and 
diabetes self-management. Research shows that there are several key psychosocial 
factors that could impact on diabetes control. The next chapter presents a study of 
psychosocial factors (i.e., self-efficacy, illness perceptions, and quality of life) in 




Understanding illness beliefs, self-efficacy, and 
diabetes quality of life in relation to 
glycaemic control in youth with type 1 
diabetes
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CHAPTER 3: PSYCHOSOCIAL EVALUATION
Introduction 
Diabetes is a chronic condition and as such may be considered a burden but 
with an extra load on youth because they are at a demanding stage developmentally 
(Delamater, 2000; Delamater et al., 2014). In addition to the increased physiological 
requirements during this period, there are other factors including psychosocial, 
cognitive, and emotional factors that may create obstacles to adequate diabetes self-
management and influence diabetes outcome (Delamater et al., 2014; Hagger & 
Orbell, 2003; Kovacs, Goldston, Obrosky, & Bonar, 1997; Wysocki et al., 1992). 
During the years of emergence from early adolescence to adulthood, in addition to 
the naturally occurring physical developments, youth acquire and develop their 
identities, beliefs, and perceptions in the context of their surroundings, but also in 
relation to any chronic illness they have (Borus & Laffel, 2010; Delamater et al., 
2014; Herge et al., 2012). These beliefs and perceptions have been found to impact 
on diabetes control and self-management behaviour (Delamater et al., 2014; Mc 
Sharry, Moss-Morris, & Kendrick, 2011; National Collaborating Centre for Women's 
and Children's Health, 2004; Skinner, John, & Hampson, 2000).  
Poorly controlled diabetes has been found to be associated with low self-
efficacy, emotional distress, poor quality of life (QoL), depression, anxiety, poor 
communication in relation to diabetes, and negative coping and adjustment strategies 
(Delamater et al., 2014; Fogel & Weissberg-Benchell, 2010; Scholes et al., 2013). 
Although there has been extensive research that explores a number of influencing 
factors, there are still gaps in knowledge particularly for the youth developmental 
46
stage, including research on the role of particular psychosocial factors (e.g., illness 
perception) in predicting diabetes control (Delamater et al., 2014). Further research 
on psychosocial determinants and barriers, and how they relate to aspects of diabetes 
management may provide further guidance to help youth who are struggling with 
their diabetes management.  
The current study is concerned with three main psychosocial constructs that 
have been found to be associated with diabetes management, particularly in relation 
to glycaemic control (measured by HbA1c) and diabetes self-control (e.g., Hanna et 
al., 2013; Harvey & Lawson, 2009; Kristensen, Birkebaek, Mose, Hohwu, & 
Thastum, 2014; Nansel, Weisberg-Benchell, Wysocki, Laffel, & Anderson, 2008; 
Nardi et al., 2008; Puri, Sapra, & Jain, 2013; van der Ven et al., 2003; Xiong et al., 
2013). The main constructs are illness perception, self-efficacy, and diabetes-related 
QoL. These constructs encompass several dimensions that include cognitive, 
emotional, physical, behavioural, and social well-being. The current study has two 
broad objectives: to describe key psychosocial characteristics of youth (15-24 years 
old) with type 1 diabetes in the CDHB catchment area; and to explore the 
relationship between these psychosocial characteristics and glycaemic control. The 
review that follows outlines the relevant literature related to the above objectives and 
this is followed by the specific aims, hypotheses, and contributions of this thesis. 
This chapter also describes the methodological basis related to the participants, 
measures, and data collection, entry and analysis. This research in this chapter has 
been presented at the Australasian Society for Behavioural Health and Medicine 
(ASBHM) 12th Annual Scientific Conference, and at the NZSSD 37th Annual 
Scientific Meeting (Obaid, Britt, Basu, & Wallace-Bell, 2013, 2014).
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Illness Perceptions
An individual with a health issue develops perceptions that guide and have an 
impact on the management and clinical outcomes of their condition (Fortenberry et 
al., 2014; Hagger & Orbell, 2003; Weinman & Petrie, 1997). Illness perceptions 
emerge through one’s experiences and exposure to different elements associated with 
an illness (or a health threat), including the daily management of the condition, 
communication with health care professionals, and interaction with family members 
and peers (Leventhal et al., 1997; Petrie, Jago, & Devcich, 2007; Weinman & Petrie, 
1997). 
Individuals develop coping strategies to address a health threat, and these can 
include seeking professional advice, using medication as prescribed, expressing 
emotion, and avoidance or denial (Luyckx, Vanhalst, Seiffge-Krenke, & Weets, 
2010). Reactions towards a health condition and strategies to cope with it can be 
drawn from interpretations of the different elements (e.g., physical and psychosocial 
factors) linked to the condition, which lead to the individual creating representations 
of that illness (Diefenbach & Leventhal, 1996; Petrie et al., 2007). Illness 
representations are an individual’s “implicit common sense beliefs about their 
illness” (Harvey & Lawson, 2009, p. 7). 
Illness representations are central to the Self-Regulation Model (SRM), which
follows a dynamic cycle comprising: forming views and beliefs about a health threat, 
developing coping strategies and engaging in corresponding physical or mental 
behaviours, and evaluating the current health state and re-assessing inputs from 
perceptions and coping strategies (Diefenbach & Leventhal, 1996; Leventhal; 
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Leventhal et al., 1997; Leventhal, Diefenbach, & Leventhal, 1992). In the appraisal 
phase the illness perceptions and coping actions may be altered. There are two 
parallel processes in this cycle, which correspond to cognitive and emotional 
representations generated from both internal and external situational stimuli in 
response to a health threat. The processes and parallel paths are depicted in Figure 
3.1 (Leventhal et al., 1997).  
Figure 3.1. Illness representations cycle described in a parallel response model, which has (based on 
the generated response) two interactive paths of cognitive and emotional representations (Leventhal et 
al., 1997). 
Emotional representations reflect emotional reactions that form an adaptation 
towards an illness, which could lead either to constructive or to maladaptive coping 
strategies (Diefenbach & Leventhal, 1996). Emotional representations include 
expressing emotions such as concern, anger, fear, and anxiety, or conversely, seeking 
emotions, such as reassurance (Diefenbach & Leventhal, 1996). Emotionally driven 
coping strategies, such as denial, avoidance, suppression, or venting may also 
contribute to the emotional representations (Diefenbach & Leventhal, 1996; 
Leventhal et al., 1997). 
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Cognitive representations include five core dimensions: identity, which
reflects beliefs about attribution of symptoms to an illness and associating labels with 
those symptoms; consequences, which represent beliefs on the impact of the illness 
and its expected outcomes (e.g., seriousness of a condition and vulnerability to 
develop complications); timeline, which reflects the period for which the illness is 
going to last (e.g., acute, episodic, or chronic); control or cure, which represent 
thoughts associated with how much an individual has control over the illness 
management or recovery from it (i.e., personal control, and treatment control and 
effectiveness) (Lau & Hartman, 1983); and cause, which depicts personal views on 
causes responsible for the illness or condition (e.g., internal causes including 
biological factors or external causes including environmental factors) (Hagger & 
Orbell, 2003; Leventhal et al., 1992). Further research has also identified coherence
as an additional core dimension, which reflects views associated with the overall 
understanding of an illness (Weinman, Petrie, Moss-Morris, & Horne, 1996). 
Cognitive and emotional illness representations can be evaluated using SRM 
based measures. These measures include self-report assessment tools, such as the 
Illness Perceptions Questionnaire (IPQ) and the Brief-IPQ (BIPQ) (Broadbent, 
Petrie, Main, & Weinman, 2006; Moss-Morris et al., 2002); and semi-structured 
interviews, such as the Personal Models of Diabetes Interview (PMDI) (Hampson, 
Glasgow, & Toobert, 1990). All of the SRM based measures were constructed such 
that higher scores indicate stronger beliefs with regards to the corresponding 
dimension (Hagger & Orbell, 2003). Stronger beliefs on identity, consequences, 
timeline, and emotional representations denote negative perceptions. These negative 
perceptions indicate a highly perceived symptomatic condition, more serious 
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consequences and impact on life, greater emotional reactions to an illness, and 
chronic rather than acute views of illnesses. In contrast, higher scores on 
controllability and coherence depict positive perceptions, which reflect stronger 
beliefs about the manageability of the illness and recovery form it, and a greater 
understanding of the illness. 
Studies have explored the association between illness representations, and 
health behaviours and outcomes, but with much of the research focusing on cognitive 
representations (Broadbent, 2010; Kucukarslan, 2012). Significant associations 
across studies of various illnesses outcomes and illness representations have been 
reported (Hagger & Orbell, 2003). A meta-analysis of empirical studies of illness 
presentations by Hagger and Orbell (2003) found the following key findings: 
stronger views on identity, consequences, and timeline were associated with 
increased use of negative coping strategies and emotion expression, and worse 
physical, psychological, and social well-being. In contrast, stronger views on the 
controllability dimension (i.e., high degree of perceived control over an illness) were 
positively associated with constructive coping strategies, and improved 
psychological and social well-being. In Hagger and Orbell’s (2003) meta-analysis,
studies of diabetes and illness perceptions constituted the largest illness group (12 
studies). Findings from this meta-analysis and later research have demonstrated 
associations between illness perceptions and diabetes-related variables, including 
glycaemic control, diabetes self-management behaviours, and physical and 
psychosocial well-being (Hagger & Orbell, 2003; Harvey & Lawson, 2009). The 
associations were found across different age groups and for type 1 and type 2 
diabetes. Stronger beliefs on controllability and treatment effectiveness across studies 
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were consistently associated with improved glycaemic control, better adherence to a 
diabetes regimen, and enhanced QoL (Harvey & Lawson, 2009). In contrast, poorer 
glycaemic outcomes were correlated with greater emotional reactions towards 
diabetes, more concern, higher level of identity perceptions, and cyclical or 
unpredictable timeline. A higher score on consequences was also associated with 
poorer outcomes: strong beliefs about diabetes as a threatening disease (i.e., 
seriousness of diabetes and feelings of vulnerability to the development of 
complications) were associated with poorer self-management, higher distress levels, 
and non-attendance at diabetes clinics (Kibbey, Speight, Wong, Smith, & Teede, 
2013; Lawson, Bundy, Lyne, & Harvey, 2004; Queralt, 2010). It should also be 
noted that significant associations between illness perception and HbA1c and 
diabetes self-management have not always been detected (Klis, Vingerhoets, de Wit, 
Zandbelt, & Snoek, 2008; McGrady, Peugh, & Hood, 2014; Nouwen, Law, Hussain, 
McGovern, & Napier, 2009; Queralt, 2010). 
 The above provides an overview of illness perceptions and in relation to 
diabetes; a more specific and detailed literature review specific to youth with type 1 
diabetes and illness perceptions follows. Studies that used HbA1c as an outcome 
measure, which is the primary outcome measure in the present study, are detailed 
first, then research that investigates illness perceptions using self-report outcome 
measures is presented. 
Youth with type 1 diabetes and illness perceptions 
The role of illness perceptions in glycaemic control and adherence to diabetes 
self-management was investigated among youth (15-25 years) with type 1 diabetes 
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by Griva, Myers and Newman (2000). Their study examined whether illness 
perceptions can explain some of the variation in HbA1c, and whether it can predict 
adherence to diabetes self-management recommendations including SMOBG, insulin 
use, diet, and exercise, and an overall adherence component (Griva et al., 2000). The 
study comprised 64 Caucasian youths from London, United Kingdom (UK) who 
were attending two diabetes clinics. The mean HbA1c in this sample was 8.7% (SD = 
1.4%). Illness perception beliefs were assessed using the IPQ, which is focused on 
cognitive representations (identity, timelines, consequences, and control) and does 
not address the emotional representations of SRM. An initial examination of 
groupings based on gender and age (15-19 years old, and 20-24 years old) revealed 
no significant differences in the variables between females and males, or the age 
bands, and therefore, the combined group was included for further analyses.
Zero-order correlations among domains of illness perception, metabolic 
control and adherence showed several significant associations; additionally 
interrelationships of IPQ components had significant correlations. On the IPQ 
dimensions, perceived seriousness of consequences was positively associated with 
strength of illness identity (r = 0.41, p < 0.001) and negatively associated with 
control beliefs (r = −0.29, p < 0.01). Illness identity perceptions were also negatively 
associated with the latter (r = −0.31, p < 0.01). Lower HbA1c (better glycaemic 
control) was significantly associated with positive perceptions of identity, 
consequences, and controllability (r = 0.31, r = 0.23, r = −0.35, respectively, p <
0.01). Perceived diabetes control was positively associated with all adherence 
components. Participants who had higher perceived control had better adherence to 
SMOBG, insulin, dietary, and exercise recommendations (t(62) = 7.80, p < 0.001; 
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t(62) = 2.79, p = 0.007; t(62) = 3.25, p = 0.002; t(62) = 2.82, p < 0.006; respectively), 
compared to those in the poor adherence group. Participants with negative identity 
perceptions (more attribution of symptoms to diabetes) reported poor adherence to 
SMOBG (t(62) = −2.68, p < 0.009), dietary adherence and poor overall adherence 
(t(62) = −2.74, p < 0.000), compared to those in the good adherence group. The 
consequences and timeline did not have significant associations with any of the 
adherence components.  
Hierarchical multiple regression analysis of the role of illness beliefs in 
predicting HbA1c demonstrated significant contributions from two illness perception 
components: perceived consequences and identity (∆R2 = 5.7% and 6.5% 
respectively), with the total proportion of contribution accounting for a 12.2% of the 
variance in HbAlc levels. On overall adherence, perceived control was the only 
significant predictor accounting for more than third (39%) of the variance of the total 
adherence. In summary, the above study provided empirical evidence of the role of 
illness perceptions in glycaemic control and adherence. The findings suggest the 
potential usefulness of illness perception beliefs as predictors of adherence and 
metabolic control for youth (15-25 years) with type 1 diabetes. An analysis of the 
emotional representation component, however, was not provided because the IPQ 
focuses on cognitive representations.
Pereira, Almeida, Rocha, and Leandro (2011) investigated the relationship 
between several psychological variables, including illness perceptions (measured by 
BIPQ), adherence, QoL, and HbA1c. The study recruited 85 children and adolescents 
(12-19 years old) with type 1 diabetes from two central hospitals in Portugal and 
clinics run by the Diabetic Association of Portugal. The mean HbA1c in the sample 
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was 9.1% (SD = 1.6%). Multiple hierarchical regression analyses revealed that 
participants’ emotional representation predicted metabolic control and QoL (beta = 
0.356, p < 0.001; beta = 0.254, p < 0.05, respectively). Greater perception of diabetes 
as a threatening disease (i.e., emotional representation) predicted higher HbA1c and 
poorer diabetes-related QoL. Adherence to recommendations of self-management 
behaviours was predicted by the personal control illness representation (beta = 
−0.364, p < 0.001), with lower perception of personal control predicting lower 
adherence. Higher perceived consequences was associated with poorer QoL (beta = 
0.284, p < 0.05). 
The Pereira et al. (2011) study provides evidence for the effect of the illness 
representations on metabolic control, adherence, and QoL. This study used 
hierarchical regression analyses, which provided confirmatory analysis of the 
relationships amongst the study variables. However, it did not control for age in the 
regression models; the age range included both children and adolescents. 
Illness representations in youth (15-20 years) with type 1 diabetes were 
examined in relation to predicting glycaemic control, frequency of SMOBG 
(downloaded from meter), and adherence to diabetes self-management 
recommendations (McGrady, 2012; McGrady et al., 2014). The participating youth 
(N = 99) were recruited from a hospital in the mid-western United States of America 
(USA). Data were collected at two time points that were about 18 weeks apart: Time 
1 and Time 2. The data included scores from the Diabetes Illness Representation 
Questionnaire (DIRQ), HbA1c, self-reported diabetes self-management behaviours, 
as well as the self-reported and meter downloaded frequency of SMOBG. The mean 
HbA1c at Time 1 (N = 96) was 8.96% and at Time 2 (N = 88) was 8.69%. The 
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HbA1c and illness perception had mostly no significant correlation at either Time 1 
or Time 2, except at Time 1 on the coherence (r = −0.22, p < 0.05) and treatment 
control (r = −0.31, p < 0.01) scales. There were several significant associations 
between illness perceptions and adherence and frequency of SMOBG at both time 
points; for example, stronger perceived treatment effectiveness was positively 
correlated with more frequent SMOBG (r = 0.25, p < 0.01).
The regression analyses in the hierarchal and structural equation models 
presented a confirmatory evidence for the significant associations; the models 
controlled for age and gender. The Time 1 model revealed that illness representations 
accounted for 23% (p < 0.01) of the variance in self-reported frequency of SMOBG 
and 7% of the variance in adherence to emergency precautions (p < 0.05); the 
remaining variables including HbA1c had non-significant associations. The Time 2 
model presented evidence of the following relationships: illness representations (p <
0.05) accounted for an 8% of the variance in self-reported blood glucose monitoring, 
8% in adherence to recommendations for insulin use and diet and 10% in exercise, 
and 16% in adherence to emergency precautions. McGrady (2012) also examined 
mediational models and found that the frequency of SMOBG and adherence were 
two of the variables that mediated the relationships between perceived timeline, 
understanding, and consequences illness representations and metabolic control. 
In summary, the study by McGrady (2012) presented evidence for the role of 
illness perceptions in diabetes self-management behaviours for youth (15-20 years) 
with type 1 diabetes, but there was no evidence supporting the hypothesis that illness 
perceptions have a direct role in predicting metabolic control. Not detecting an 
association, however, does not imply a correlation was non-existent, further 
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investigations are required to determine that. The study did, however, demonstrate 
the indirect effect of illness perception, through diabetes self-management behaviour 
(including the frequency of SMOBG), on HbA1c. 
A longitudinal study by Fortenberry et al. (2014) examined illness 
perceptions in children and adolescents (10-17 year olds) with type 1 diabetes. The 
study investigated the illness perceptions (measured by IPQ-Revised) over time, and 
in relation to HbA1c, adherence, and QoL. The study participants (N = 213) were 
recruited from a university/private partnership clinic and a community-based private 
practice, California, USA. This study was part of a larger study that followed 
participants with type 1 diabetes aged 10-14 years for 2.5 years, and had 6-month 
follow-up intervals. A series of multilevel models were used to examine longitudinal 
trajectories of illness perception in the participants over time, and also examined the 
relationship between illness perceptions and diabetes outcomes. 
Results indicated that illness perceptions changed over time and showed 
significant (p < 0.01) positive slopes for chronicity, consequences, personal and 
treatment control, as well as for coherence. This suggests that over time adolescents 
perceived their condition with an increased level of chronicity and negative 
consequences (i.e., more threatening views). Furthermore, as they became older, 
adolescents had an increased level of perceived personal and treatment control over 
the illness, and had more understanding of their condition. Results from the 
multilevel prediction models showed that better HbA1c was significantly (p < 0.05) 
associated with perception of less severe consequences, higher level of coherence 
and fewer negative emotions. A higher level of adherence was predicted (p < 0.05) 
by greater level of perceived personal control, treatment control, coherence, and 
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lower negative emotional representations. Finally, better QoL was predicted by lower 
cyclicality, consequences, and negative emotional representations; and higher 
treatment control, and coherence.  
The study by Fortenberry et al. (2014) had the strength of longitudinal 
analysis and it also controlled for factors such as age and gender. The study, 
however, examined the data at only three time points during the study and this 
limited establishing more complex models because of the small number of follow up 
data (Fortenberry et al., 2014). 
A study was conducted in Auckland, New Zealand, to assess the psychosocial 
status of adolescents (11-17 year olds) with type 1 diabetes, and to explore the 
relationship between psychosocial factors and glycaemic control (as part of a larger
study to develop and evaluate a psychological screening tool) (Huggard, 2009). 
Psychosocial measures included an assessment of illness perceptions using the BIPQ. 
The study recruited 112 youth from the Auckland DHB. The mean HbA1c was 8.5% 
(SD = 1.97%). Preliminary analysis of the sample HA1c determined a cut-off HbA1c 
to create two groups: HbA1c 10% and above, and HbA1c below 10%. Descriptive 
correlations and t-test comparisons were used in the Huggard (2009) study. Results 
on the total BIPQ score representing the overall diabetes illness perception were 
reported, the individual dimension results were not reported. The study found a 
statistically significant difference in the overall illness perception between females 
and males, with the males having less troubling illness beliefs. In addition, HbA1c 
was significantly and positively correlated with the total illness perception score (r = 
0.32, p = 0.001). This suggests views on diabetes as a negatively threating condition 
were associated with poorer glycaemic control. The two HbA1c categories (i.e., 
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10+% and <10%) were compared in relation to the total illness perception score 
using an independent-samples t-test. Participants in the HbA1c ≥10% (i.e., poor 
control) group had significantly higher total illness perception scores, indicating they 
had more negative diabetes-related beliefs, in comparison to those in the HbA1c 
<10% group.  
The study by Huggard (2009) provided an explorative analysis of the 
relationship between HbA1c and illness perception within a New Zealand context. 
Nevertheless, this relationship needs further investigation using confirmatory 
analysis. In addition, including HbA1c as a categorical variable (two groups) may 
limit full exploration of HbA1c associations with other variables. 
An Iranian study by Bazzazian and Besharat (2010) produced similar findings 
to the Huggard (2009) study. Bazzazian and Besharat (2010) validated a translated 
version of BIPQ with 300 individuals (aged 18-30 years old) with type 1 diabetes, 
who were members of the Iranian Diabetes Society. They reported significant 
association between HbA1c and the majority of the BIPQ dimensions: consequence 
(r = 0.595, p < 0.01), personal control (r = −0.638, p < 0.01), identity (r = 0.760, p < 
0.01), concern (r = 0.129, p < 0.05), coherence (r = −0.177, p < 0.01), emotional 
response (r = 0.549, p < 0.01). The above two studies provide preliminary evidence 
for the association of HbA1c with illness perceptions, but the findings need be 
investigated further using confirmatory analysis.
Another New Zealand study, which was also based in Auckland, investigated 
associations of illness perceptions with HbA1c and adherence to diabetes self-
management behaviour (medication, diet, and exercise) (Broadbent, Donkin, & 
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Stroh, 2011). The study recruited individuals with type 1 and type 2 diabetes. The 
inclusion age was 16 years and over, and this therefore included not only youth but 
also adults. A total of 157 completed the questionnaires, 49 of whom had type 1 
diabetes (Mage = 43.2, SD = 20.6 years). The study had a combined sample analysis 
(i.e., type 1 and type 2) in the descriptive part of the analysis, but the regression 
analysis was conducted on the diabetes types. The analyses were inclusive of all ages 
and did not differentiate youth from adults. The illness perception measure used in 
this study was the BIPQ. 
The majority (86%) of individuals who were on insulin medication (78 
participants), reported adherence to insulin (adherent all the time group). Individuals 
in the good adherence group, in comparison to the less adherent group, reported 
higher perceived personal control and less threatening views on consequences. In the 
total sample, 22% reported adherence to diet recommendations and 17% to exercise 
recommendations. Dietary adherence had significant associations with scores on the 
BIPQ dimensions. More positive beliefs were associated with: fewer symptoms (r = 
−0.28, p < 0.001), lower perceived consequences (r = −0.22, p < 0.01), higher 
controllability of personal (r = 0.34, p < 0.001) and treatment (r = 0.20, p < 0.05),
lower emotional representations (r = −0.24, p < 0.05), and the belief that diet 
management could help diabetes (r = 0.23, p < 0.01). Exercise adherence was 
significantly associated with perceptions of personal control (r = 0.20, p < 0.05), 
illness coherence (r = 0.18, p < 0.05), and the perception that exercise could help 
diabetes and also prevent heart problems (r = 0.30, 0.21; p < 0.001, p < 0.05, 
respectively). 
The regression analysis conducted on the type 1 diabetes sample revealed that 
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insulin adherence explained 24% of the variance in HbA1c, and personal control and 
identity combined, explained an additional 15%. The model therefore confirmed that 
higher adherence and perceived personal control were related to better metabolic 
control, but the single contribution of the perceived control and identity in explaining 
HbA1c was not presented. 
The above study conducted by Broadbent et al. (2011) provided information 
on the associations of adherence to diabetes management behaviours (medication, 
diet, and exercise) and HbA1c with the illness perception dimensions. The 
descriptive analysis on the combined sample provided initial indications of the 
relationships between variables, while the regression analysis on type 1 diabetes 
confirmed the contribution of certain illness perceptions in predicting glycaemic 
control. The latter analysis, however, did not control for age or gender in the model. 
In addition, although the study included participants from the adolescent, young 
adults and adult age groups, the average age (M = 43.20; SD = 20.57 years) suggests 
that the participants were mostly adults. Further investigations are required to 
examine the association of illness perceptions in relation to HbA1c in the youth with 
type 1 diabetes. 
In a qualitative study, conducted in the USA, 14 young people (11-22 years 
old) were interviewed to identify themes of illness perceptions according to levels of 
metabolic control (Scholes et al., 2013). Participants were classified into two groups 
based on their HbA1c, with a cut off 7.5% to differentiate the groups with low and 
high HbA1c, that is, above or below the recommended HbA1c. The low HbA1c 
group had a mean of 6.9% (SD = 0.59%) and the high HbA1c group had a mean of 
9.8% (SD = 1.12%). A 60-90 minute interview with each young person was 
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conducted by a paediatric nurse; the interview was open-ended, with participants 
freely discussing their experiences living with type 1 diabetes. Interview themes were 
analysed using an inductive analysis method. The identified illness perceptions were:
cure, reactions to the initial diagnosis, and self-care attitudes. Differences in the two 
HbA1c groups with regards to themes of illness perceptions were observed. The high 
HbA1c group had negative responses and experiences when initially diagnosed. They 
viewed their diabetes as traumatic and experienced fear and isolation, whereas the 
low HbA1c group had no negative reactions to the initial diagnosis, and had positive 
experiences. As for the cure beliefs, the high HbA1c group believed there would be a 
cure for type 1 diabetes, but the low HbA1c group did not believe a cure exists. 
Avoidance of self-management of diabetes was a theme in the high HbA1c group; 
this is in contrast to the low HbA1c, which took responsibility for self-managing 
their diabetes. 
A study in Iran developed and tested a model of adjustment to type 1 diabetes 
incorporating illness perception beliefs using a BIPQ translated to Farsi (Bazzazian 
& Besharat, 2010; Bazzazian & Besharat, 2012). A total of 300 youth aged 18-30 
year olds participated in this research, recruited from Iranian Diabetes Society in 
Tehran. The HbA1c average was 7.5%, suggesting that the youth on average had 
good diabetes control. The hypothesised relationship among the study components, 
which included illness perception and adjustment, was tested using structural 
equation modelling. Adjustment to diabetes was represented by a combination of 
three components: psychological well-being, QoL, and HbA1c. 
Bazzazian and Besharat (2012) found that illness perceptions had a positive 
regression effect on adjustment (t-value = 8.25, p < 0.01), suggesting better 
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adjustment to diabetes can be predicted from positive and less threating illness 
perceptions. However, a direct relationship between illness perception and HbA1c 
was not investigated. This limits conclusions which can be drawn regarding the 
relationship between illness perception and HbA1c. 
There have been other studies that investigated illness perception, but they 
did not include HbA1c in their analysis. Some excluded HbA1c in the analysis based 
on the zero-order associations (Nouwen et al., 2009; Queralt, 2010). If HbA1c was 
not significantly associated with illness perception, then it would be discarded from 
further analysis. These studies are presented below. 
A study by Nouwen et al. (2009) investigated the role of self-efficacy and 
illness representations in relation to dietary self-management and diabetes distress.
Their study recruited 151 adolescents (12-18 years old) with type 1 diabetes from six 
regional hospitals in the UK; the mean HbA1c was 9.1% (SD = 1.9%). The Nouwen
et al. (2009) study did not find a significant association between HbA1c and illness 
perception dimensions (perceived consequences and treatment effectiveness), and 
therefore excluded HbA1c from further analysis. Lower level of perceived 
consequences and stronger beliefs of treatment effectiveness, however, were 
significantly associated with better dietary self-management and less diabetes 
distress. 
Similarly, an association between HbA1c and illness perceptions was not 
detected by Queralt (2010). This study had 85 participants aged 12-18 years, 
recruited from two diabetes clinics in the UK, the mean HbA1c was 9.9% (SD = 
1.9%). The purpose of Queralt’s (2010) study was to examine self-efficacy and 
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illness representations in relation to dietary self-management, metabolic control, and 
diabetes related distress in adolescents with type 1 diabetes. Queralt (2010) found 
that consequence beliefs, motivation toward dietary self-management activities, and 
dietary self-efficacy accounted for 36% of the variance in adolescents’ distress 
levels. Lower distress levels were associated with higher levels of self-efficacy, 
motivation, and lower levels of perceived consequences. 
Other studies that did not include a glucose measure reported a mix of 
significant and non-significant relationships of illness perceptions with other 
diabetes-related variables. A study by Law, Kelly, Huey, and Summerbell (2002),
which recruited 30 adolescents (aged 13-19 years old) with type 1 diabetes,
investigated illness perceptions in association with self-management behaviours and 
psychosocial factors. The participants were recruited from northeast England and had 
a mean HbA1c of 9.1% (SD = 1.4%). The authors found that illness beliefs were not 
associated with any of the self-management behaviours, but were associated with 
psychosocial factors, with illness beliefs accounting for 52% and 32% of the variance 
in anxiety and positive well-being, respectively. The two illness beliefs that 
significantly contributed to the prediction of anxiety and positive well-being were 
consequences and personal control. Lower levels of perceived consequences and 
higher levels of perceived personal control were associated with lower levels of 
anxiety and higher levels of positive well-being. 
A further two studies investigated illness perceptions in association with 
engagement with health services. One of the studies, which was conducted by
Lawson et al. (2004), found that individuals with more negative views on 
consequences, control, and timeline did not seek regular-care (non-attenders), 
64
compared with the group who sought regular-care (attenders). The study also showed 
that the individual’s perceived control predicted clinic appointment attendance. The 
second study, which was conducted by Kibbey et al. (2013), used the BIPQ and a 
battery of psychosocial questionnaires to investigate barriers and enablers that 
contribute to engaging youth in diabetes services. The study found that unsatisfactory 
previous experiences with health providers were contributors to client disengagement 
from diabetes health services. In addition, non-attenders had significantly more 
threatening views of diabetes and emotional distress. 
In summary, the above studies suggest that, in young people with type 1 
diabetes, although illness perceptions did not seem to play a consistent direct role in 
regulating diabetes self-management behaviours or HbA1c, they do have an impact 
on the regulation of psychosocial aspects, which in turn may have an impact on 
diabetes management. The differing study designs, analyses, and combination of 
predictor and outcome variables between studies may have contributed to 
discrepancies in outcomes and interpretations. In addition, factors such as small 
sample size and homogeneity of the sample limit the generalisability of results. For 
these reasons, further investigations are still required to clarify the associations 
between diabetes control and illness perceptions. 
Self-efficacy 
Self-efficacy has been defined as "people's judgments of their capabilities to 
organise and execute courses of action required to attain designated types of 
performances" (Bandura, 1986, p. 391). It, therefore, represents an individual’s belief 
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in their ability to achieve tasks and to conquer challenges. Self-efficacy is a core 
construct in Bandura’s social cognitive theory (Bandura, 1986, 1997, 2001), which 
describes four main components to developing self-efficacy: personal experiences of 
success or failure, observed experiences of others (e.g., providing a model in 
succeeding or failing in certain situations or actions), social pressure of 
encouragement or discouragement from another person, and personal perception of 
physiological factors being linked to one’s ability or inability to accomplish tasks 
(e.g., attributing signs of distress in stressful situations to self-efficacy rather than 
normal bodily reactions to that situation).  
Self-efficacy beliefs have an impact on many aspects of human functioning 
and can affect QoL and health outcomes (Kent, 2011). Behavioural choices can be 
affected by how confident a person feels in achieving particular goals and if he or she 
chooses to undertake or avoid particular tasks (Bandura, 2001; Strecher, McEvoy 
DeVellis, Becker, & Rosenstock, 1986). Self-efficacy beliefs can also affect 
motivation to engage in and complete tasks, to persevere when faced with challenges, 
and to maintain long-term stimulus (Bandura, 1997, 2001; Pajares, 1997). 
Self-efficacy is of critical importance to the management of illnesses that 
involve complex routines and require long term maintenance (Bandura, 1997; Frei, 
Svarin, Steurer-Stey, & Puhan, 2009). In relation to the topic of this thesis, the above 
suggests that self-efficacy is a strong candidate for studies on diabetes control and 
self-management. This is because individuals with diabetes are involved in a 
demanding self-management regimen in which stronger self-efficacy is likely to 
facilitate diabetes self-management.  
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A number of studies have investigated self-efficacy in relation to clinical, 
behavioural, and psychosocial diabetes outcomes (Celano, Beale, Moore, Wexler, & 
Huffman, 2013; Krichbaum, Aarestad, & Buethe, 2003; Mohebi, Azadbakht, Feizi, 
Sharifirad, & Kargar, 2013). Generally, research has shown strong and consistent 
evidence of the influence of self-efficacy on diabetes management and outcome 
across different age groups with type 1 and type 2 diabetes (Celano et al., 2013; 
Krichbaum et al., 2003; Mohebi et al., 2013). Studies have explored the direct 
influence of self-efficacy on diabetes-related aspects and in mediational models, 
including glycaemic control and diabetes self-management behaviours. Stronger self-
efficacy in both adult and adolescent samples has been found to predict good 
adherence to diabetes self-management behaviours (Hurley & Shea, 1992; McCaul, 
Glasgow, & Schafer, 1987; Padgett; Senecal, Nouwen, & White, 2000; Temple, 
2003). Self-efficacy has been found to be a significant predictor of HbA1c, with 
greater self-efficacy associated with lower HbA1c (Aalto & Uutela, 1997; Griva et 
al., 2000; Rubin, Peyrot, & Saudek, 1993; Talbot, Nouwen, Gingras, Gosselin, & 
Audet, 1997). Research has also found self-management to mediate the association 
between self-efficacy and HbA1c (Griva et al., 2000; Hackworth et al., 2013; 
Johnston-Brooks, Lewis, & Garg, 2002); self-efficacy was a significant predictor of 
overall and specific self-management components and subsequently HbA1c (Austin, 
Guay, Senécal, Fernet, & Nouwen, 2013). In addition, self-efficacy mediated the 
relationship between self-management and several diabetes-related factors including 
diabetes distress and motivation to engage in dietary self-management (Kneckt; 
Queralt, 2010; Sacco et al., 2007; Syrjala, Kneckt, & Knuuttila, 1999). Stronger self-
efficacy mediated mastery skills and adherence to diabetes self-management 
behaviours in young people with diabetes. Lower self-efficacy, on the other hand, 
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mediated the relationship between non-adherence to SMOBG and non-supportive 
parenting styles (Herge et al., 2012; Law et al., 2002; Ott, Greening, Palardy, 
Holderby, & DeBell, 2000). Finally, self-efficacy was significantly associated with 
diabetes-related QoL and social functioning – stronger self-efficacy was associated 
with better outcomes (Aalto, Uutela, & Aro, 1997). 
Research findings have demonstrated the important role of self-efficacy in 
relation to clinical and behavioural aspects for individuals with type 1 diabetes 
(Hanna et al., 2013; van der Ven et al., 2003). The findings suggest that self-efficacy 
is of particular importance in adolescence and young adulthood, because it is a key 
factor for improved diabetes control and self-management behaviours (Hackworth et 
al., 2013). The next section details studies that recruited individuals with type 1 
diabetes in the adolescent and young adulthood age range. It presents research that 
examined self-efficacy in association with HbA1c and adherence to diabetes self-
management, using either a direct effect model, or mediational models, or both. 
Studies that included HbA1c in both direct and mediational effect relationships are 
discussed first, then research that investigated HbA1c in either direct associations or 
mediational associations. This is followed by studies that only used self-report 
measures and other diabetes control indices. 
Youth with type 1 diabetes and self-efficacy 
Johnston-Brooks et al. (2002) conducted a cross-sectional and longitudinal 
study to explore the role of self-efficacy in predicting self-management and HbA1c, 
and to examine self-management as a mediator in the relationship between self-
efficacy and HbA1c. Young adults (N =110) aged 18-35 years old with type 1 
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diabetes from Colorado, USA, participated in the research. This research used a 
panel study design with baseline measurement, follow-up at 3 and 6 months, and an 
extra follow-up for HbA1c data at 9 months. The baseline HbA1c sample mean was 
8%. Predictor variables included self-efficacy and outcome variables included 
HbA1c and adherence to self-management behaviours (diet, exercise, SMOBG, 
medication use). The study used a self-efficacy measure that had been used in an 
earlier study (Kavanagh, Pierce, Lo, & Shelley, 1993).
Cross-sectional analyses revealed that greater self-efficacy was a significant 
predictor of better self-management (beta = 0.63, p < 0.0005), and it significantly 
predicted lower HbA1c (beta = −0.30, p < 0.05). In a different model, self-
management was found to meditate the association between self-efficacy and 
HbA1c. Overall self-management and SMOBG were found to significantly mediate 
the HbA1c and self-efficacy relationship. In the longitudinal part of the study, 
predictors were regressed on the furthest points of outcome variables from baseline, 
and this provided stronger evidence for the stability and predictability of variables. 
The regression analysis in the longitudinal study of the direct effects demonstrated 
that greater self-efficacy longitudinally predicted better adherence to dietary and 
exercise self-management behaviours (beta = 0.36, p < 0.005; beta = 0.29, p < 0.05, 
respectively) and also predicted lower HbA1c (beta = −0.3, p < 0.005). An 
examination of the mediational effects showed that higher levels of self-efficacy at 
baseline significantly predicted dietary self-management during follow-up. The 
findings also showed that HbA1c was reliably predicted at the 9 months follow-up by 
the mediated relationship of self-efficacy and diet self-management. 
The study by Johnston-Brooks et al. (2002) contributed to gaps in knowledge 
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with regards to empirical evidence of direct and mediational relationships among the 
variables of self-efficacy, HbA1c, and diabetes self-management. Of note is that the 
study population included not only youth but also adults. It is recommended that 
future research either controls for the age factor or the research is conducted with a 
more specific age range (e.g., youth), because this would help to clarify associations 
of factors for this developmental stage. 
In the study by Griva et al. (2000), which has already been discussed in the 
context of illness perception in this chapter, self-efficacy was also investigated in 
association to HbA1c and self-management. Self-efficacy was measured by the 
Generalised Self-efficacy scale and the Self-efficacy for Diabetes Scale (DSES). 
Bivariate correlations showed several significant associations amongst the study 
variables. Stronger diabetes-specific self-efficacy beliefs were associated with fewer 
diabetes-related symptoms (r = 0.29, p < 0.01) and fewer perceived consequences (r
= 0.39, p < 0.001). Better metabolic control (i.e., lower HbA1c levels) was 
significantly correlated with a greater sense of both generalised and diabetes-specific
self-efficacy (r = −0.37 and r = 0.51, respectively, p < 0.01, and p < 0.001). 
Adherence was significantly associated with diabetes self-efficacy (beta = −0.424; p 
< 0.0005) and perceived identity (beta = −0.387; p < 0.001). Furthermore, those 
who had poor adherence to SMOBG had lower generalised and diabetes-specific
self-efficacy expectancies (t(62) = −4.25; t(62) = 5.02, p < 0.001 respectively), 
compared to those who had good adherence to SMOBG. Similarly, those with poor
adherence to exercise had lower generalised self-efficacy and control beliefs than 
those in the good adherence group (t(62) = 2.59, p < 0.01 and t(62) = 2.82, p <
0.006, respectively). 
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A regression model that accounted for the variance in total adherence did not 
find self-efficacy to contribute significantly to a partial explanation of the variance in 
total adherence, and as mentioned previously, perceived control only contributed 
39% of the variance. In a hierarchical multiple regression analysis that accounted for 
variance in HbA1c, diabetes-specific self-efficacy and generalised self-efficacy 
contributed to 29.9% (beta = 0.548; p < 0.00001) and 4.4% (beta = −0.24; p < 0.01) 
of the variance in HbA1c, respectively. The addition of adherence to the model 
accounted for another 15.8% of the variance in HbA1c, and adherence was a 
significant predictor of HbA1c. In addition, diabetes-specific self-efficacy was found 
to mediate the association between adherence and metabolic control. 
Iannotti et al. (2006) investigated self-efficacy in association with glycaemic 
control and adherence. A new instrument, which is related to these factors, was 
constructed and validated as part of the study. This tool incorporated measures of 
self-efficacy for diabetes self-management (SEDM), and negative and positive 
outcome expectations for diabetes self-management (OEDM-N and OEDM-P, 
respectively). A total of 168 young people aged 10-16 years old with type 1 diabetes
with a mean HbA1c of 8.3% (SD = 1.78%) from Maryland, USA, were recruited for 
this study. The adolescents were separated into two age groups: 10-12, and 13-16 
year olds. Zero-order correlations showed that stronger self-efficacy in both age 
groups was significantly associated with better diabetes self-management (r = 0.25, p 
< 0.05; r = 0.37, p < 0.001, in younger and older groups respectively). Furthermore, 
stronger self-efficacy and better adherence to diabetes self-management in the older 
age group were associated with lower HbA1c (r = −0.21, p < 0.05; r = −0.34, p < 
0.001, respectively). Stronger self-efficacy was positively correlated with fewer 
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negative perceived outcomes in both age groups (r = 0.48 and r = 0.4, younger and 
older group respectively, p < 0.0001).
These relationships were further investigated using hierarchical multiple 
regressions. The predictor variables included SEDM, OEDM-P and OEDM-N, and 
the outcome measures included reported adherence and HbA1c for the younger and 
older age groups. The younger age group regression model had a non-significant
result, suggesting that self-efficacy did not predict adherence or HbA1c in that age 
group. The older age group model, however, revealed that self-efficacy was 
significantly associated with adherence and self-management. The contribution of 
self-efficacy in the variance of HbA1c was 5.5% (beta = −0.26, p <0.05) and 12.2% 
(beta = 0.33, p < 0.01) for adherence. The regression analysis confirmed that 
stronger self-efficacy beliefs predicted better adherence to diabetes self-management 
and lower HbA1c levels. The results of this study suggest the important role of self-
efficacy in older adolescents, who are expected to take more responsibility of their 
diabetes, compared to children.
A study by Young (2003) investigated the role of self-efficacy in predicting 
glycaemic control and adherence. The study recruited 50 adolescents (13-17 years 
old) with type 1 diabetes from the Auckland Diabetes Centre, New Zealand. The 
mean HbA1c at the start of the study was 8.6% (SD = 1.9%). Bivariate correlations 
revealed that self-efficacy, measured by the DSES, was associated with adherence (r
= 0.31, p < 0.05). Greater self-efficacy was correlated with better adherence. 
Glycaemic control was associated with adherence (r = −0.38, p < 0.01), but not with 
self-efficacy. A higher level of adherence was correlated with lower HbA1c. 
Hierarchal regression analyses in this study included self-efficacy as a predictor of 
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two outcome measures: adherence and HbA1c. The models controlled for covariates, 
including age and gender. In a model that included the outcome variable HbA1c, age 
was a significant predictor of HbA1c. An increase in age was associated with a 
higher HbA1c (beta = 0.33, p < 0.05). Age in this model explained 10.2% of the 
variance of HbA1c. In this model, contrary to what was hypothesised, a stronger self-
efficacy was associated with poorer HbA1c (beta = 0.37, p < 0.05). Self-efficacy 
contributed 8% of the variation in HbA1c. In a different regression analysis, 
including adherence as an outcome variable, self-efficacy did not significantly 
predict adherence. 
Young (2003) presented evidence for the association between self-efficacy 
and HbA1c, such that greater self-efficacy predicted poorer HbA1c outcomes. The 
direction of this relationship, however, was different from that found in previous 
research where a significant association was reported between HbA1c and self-
efficacy in UK youth (Griva et al., 2000). Given the conflicting results, there is a 
need for a further investigation of self-efficacy as a predictor of HbA1c in youth.   
Another New Zealand study based in Auckland, which recruited adolescents 
(13-19 year olds) with type 1 and type 2 diabetes, examined self-efficacy in relation 
to diabetes self-management and HbA1c as part of a larger study (Singh, 2008). The 
mean HbA1c was 9%. The zero-order correlations presented significant associations 
between self-efficacy, self-management, and HbA1c. In a regression model, self-
efficacy (measured by SEDM) was a significant predictor of self-management (beta 
= 0.71; p < 0.01). In a different model, HbA1c was not predicted by self-efficacy or 
by diabetes self-management. This study provided further evidence of the association 
between self-management and self-efficacy, but not for an association between self-
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efficacy and HbA1c. This study had a mixed sample of both type 1 and type 2 
diabetes, and the analysis represented an effect on the combined sample. Type 1 and 
type 2 diabetes are two distinctively different conditions despite the common factors 
between them (American Diabetes Association, 2014), and because of this separate 
analysis is required. 
A descriptive study examined the correlations amongst HbA1c, self-efficacy,
and emotional distress for a sample of 30 young adults (18-30 year olds) with type 1 
diabetes (Burke, 2004). This was part of a larger study that assessed factors affecting 
diabetes self-management in college students. The participants were recruited from 
the University of Illinois at Urbana-Champaign, USA, and the sample was drawn 
from six separate university campuses. The study by Burke (2004) did not find any 
significant correlations between HbA1c and the self-efficacy scores. The study did, 
however, find that better emotional adjustment to diabetes was associated with 
stronger self-efficacy beliefs. This study only presented descriptive correlations and 
therefore conclusions that can be drawn are limited. 
A study in Taiwan investigated the impact of self-efficacy beliefs on HbA1c 
in 52 Taiwanese adolescents (12-20 years old) with type 1 diabetes (Chih, Jan, Shu, 
& Lue, 2010). The mean HbA1c was 8.6% (SD = 1.6%). Pearson’s correlation 
coefficient showed a significant association between self-efficacy and HbA1c (r = 
−0.3, p < 0.05), suggesting that stronger self-efficacy was associated with better 
HbA1c. Logistic regression analysis, using HbA1 level < 7% as a dependent 
variable, revealed that stronger self-efficacy was a significant predictor of HbA1c 
with an odds ratio of 1.63 (95% CI: 1.03, 2.59). To put this result another way, 
participants with stronger self-efficacy were 1.63 times more likely to achieve the 
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recommended HbA1c target. The study provides further evidence of the importance 
of self-efficacy in diabetes control, but because HbA1c was treated as a categorical 
variable this places a limit on the exploration of the association of HbA1c with other 
variables. 
Hackworth et al. (2013) recruited 123 youth (13-25 years old) from urban and 
rural Victoria, Australia, to investigate the role of self-efficacy (measured by the
DSES) in predicting self-management behaviours and HbA1c. The mean HbA1c was 
8.3% (SD = 1.5%). This study investigated the direct and indirect relationship 
amongst the study variables. Pearson’s correlations between variables included a 
significant relationship between self-efficacy and diabetes self-management (r = 
0.32, p <0.01), but not with HbA1c. Although self-efficacy was not significantly 
correlated with HbA1c, it was hypothesised that self-efficacy had an influence on 
metabolic control through its effect on diabetes self-management, which was 
significantly associated with HbA1c. Structural equation modelling in this study 
showed that higher self-efficacy significantly predicted better diabetes self-
management (beta = 0.65, p < 0.01), and subsequently higher levels of diabetes self-
management predicted improved metabolic control (beta = −0.31, p < 0.01). This 
model found that self-efficacy contributed to metabolic control through its 
relationship path with diabetes self-management: Higher self-efficacy indirectly 
contributed to lower HbA1c.  
In a mediational model, a pathway including self-efficacy linked to 
adherence, diabetes self-management, and HbA1c was examined in 70 young people 
(9-21 year olds) with type 1 diabetes from Hong Kong (Stewart et al., 2000). In the 
exploratory analysis section of this study, the bivariate relationships demonstrated 
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that self-efficacy, measured by the Littlefield (1992) self-efficacy scale, was 
significantly correlated with adherence but not with HbA1c. Stronger self-efficacy 
reflected better adherence to diabetes self-management. Regression analysis showed 
that self-efficacy had an influence on adherence, which in turn had an influence on 
HbA1c. This suggested that, similar to other research findings, stronger self-efficacy 
beliefs were associated with better adherence and subsequently lower HbA1c. 
The stability of this model over time was further explored in an extended 
research of the same study. The later study examined longitudinal analysis of the 
above mentioned pathway by following up 56 participants 12-24 months post the 
initial participation (Stewart et al., 2003). Longitudinally, adherence was a significant 
predictor of diabetes control, but self-efficacy was not found to significantly predict 
adherence over time. The authors reported that this finding may be attributed to the 
weak reliability of the imported self-efficacy measure used (weak test re-test 
reliability). In addition, the broad age range and not controlling for the age factor as a 
moderator in this study may have influenced the longitudinal model outcomes.   
A study conducted in Massachusetts, USA, examined whether self-efficacy in 
youth was related to metabolic control (Grossman, Brink, & Hauser, 1987). In this 
study the self-efficacy for diabetes scale (SED) was developed, validated and used. 
The sample consisted of 68 adolescents (12-16 years old) with type 1 diabetes. 
Metabolic control in this research was defined by four medical indices, which did not 
include HbA1c because it was not available for all participants during the study 
period. The four indices were: average blood glucose levels, urine glucose levels, 
urine acetones, and 24-hour glycosuria. The researchers determined a 3-point rating 
system for each of the four indices to represent level of control; these levels were 
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coded by an experienced paediatric/adolescent diabetologist. The sum of the four 
indices for each subject gave the total medical index. 
A t-test found no difference in diabetes self-efficacy beliefs based on gender; 
consequently a combined sample analysis was used throughout the study. Scores of 
the total SED and the diabetes-specific component of SED were significantly 
associated with the total medical index (r = 0.25, p < 0.05). Greater self-efficacy was 
associated with better metabolic control. The generic SED components were not 
found to be associated with metabolic control. 
Results from this study are limited because of the scope of the analysis which 
only included basic statistical methods to describe associations between metabolic 
control and self-efficacy. Confirmatory statistical methods are required to test these 
associations (e.g., regression analysis). Furthermore, a more reliable outcome 
measure representing metabolic control (i.e., HbA1c) was not available for this 
study. Nonetheless, the results suggest that self-efficacy had an impact on blood 
glucose.
In a longitudinal study, self-efficacy was investigated in youth throughout the 
transitioning period from high school to post-high school and in association with 
diabetes self-management (Hanna et al., 2013). The study recruited 114 adolescents 
(aged 17-19 years old) with type 1 diabetes, with a mean HbA1c of 8.5% (SD = 
1.4%), who were living with their parent or guardian, in Indianapolis, USA. Data 
were collected at two time points, the first time point (T1) was during the last 6 
months of high school, and the second time point (T2) was collected in the year after 
graduation from high school. The study found an increase in diabetes self-
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management progressing from high school to post-high school, and youth with 
higher levels of self-efficacy (measured by DSES) had better diabetes self-
management. These findings were not associated with whether the youth was living 
with parents or not. Thus, this study provided evidence that self-efficacy is important 
for diabetes self-management regardless of the emergence period and the living 
situation. 
The association of self-efficacy and adherence to diabetes self-management 
(diet, SMOBG, insulin injections, and exercise) was examined in youth with type 1 
diabetes (Littlefield et al., 1992). This study recruited 193 youth (13-18 year olds) 
with type 1 diabetes in Canada. Descriptive analysis showed that self-efficacy was 
significantly correlated with adherence (r = 0.57, p < 0.001), with higher self-
efficacy associated with better adherence. In addition, adherence was negatively 
correlated with HbAlc (r = −0.24, p < 0.001). HbA1c was only used to examine the 
validity of the adherence scale, and was not included in subsequent analysis. In the 
regression model the contribution of self-efficacy in predicting the variance in 
adherence was about 20% of the variance (p < 0.0001).  
This study used general self-report measures that were developed as part of 
the study; the reliability and validity of these measures were unknown, and this limits 
conclusions that can be drawn from the results. This study, however, suggested the 
importance of considering self-efficacy in interventions for youth with diabetes 
because it may have implications for diabetes self-management. 
In addition to the above studies, which included multiple generic and specific 
components related to diabetes, there have been other studies which have 
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investigated self-efficacy in association with adherence to dietary self-management 
(Austin et al., 2013; Nouwen et al., 2009; Queralt, 2010). Results from these studies 
followed a similar trend of significant associations in pathways, including self-
efficacy and diabetes-related clinical, behavioural, and psychosocial factors. Findings 
from these studies suggested that self-efficacy has an influence on several diabetes 
domains, such that stronger self-efficacy is directly and indirectly correlated to 
positive diabetes outcomes. 
In summary, self-efficacy has been investigated in diabetes research and has 
been found to be associated with diabetes control and self-management. Stronger 
self-efficacy beliefs have been consistently found to predict better diabetes 
management. Studies that have investigated the role of self-efficacy in predicting 
HbA1c have included children and adolescents, but rarely has this investigation been 
conducted in youth (15-24 year olds) with type 1 diabetes. Moreover, the studies that 
have, reported inconsistent results, and therefore further research is required. 
Quality of Life (QoL) 
The concept of QoL has been extensively addressed in health research (Bakas 
et al., 2012). Quality of life comprises a broad range of aspects associated with daily 
functioning, which include physical, behavioural, and psychosocial well-being (Felce 
& Perry, 1995; Theofilou, 2013). In the context of diabetes research, investigating 
QoL assesses the impact of diabetes on emotional and psychosocial functioning and 
evaluates factors associated with diabetes control and self-management (Hornquist, 
Wikby, Stenstrom, Andersson, & Akerlind, 1995; Nieuwesteeg et al., 2012). Quality 
of life in different age groups with type 1 and type 2 diabetes has been found to be 
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associated with a broad range of diabetes outcomes including clinical, behavioural, 
and psychosocial (Hornquist et al., 1995; Imayama, Plotnikoff, Courneya, & 
Johnson, 2011; Naughton et al., 2014; Nieuwesteeg et al., 2012). 
Studies of the QoL in individuals with diabetes have investigated generic 
health related QoL (HRQoL) and diabetes-specific QoL (de Wit, Delemarre-van de 
Waal, Pouwer, Gemke, & Snoek, 2007; Matza, Swensen, Flood, Secnik, & Leidy, 
2004; Solans et al., 2008), and each have unique contributions towards understanding 
the QoL of individuals with diabetes (El Achhab, Nejjari, Chikri, & Lyoussi, 2007; 
Harding, 2001; Nansel et al., 2008). Generic HRQoL is useful when comparing 
individuals with diabetes with their healthy counterparts or with those who have 
other chronic conditions, and on a population level (Kiadaliri, Najafi, & Mirmalek-
Sani, 2013; Solans et al., 2008). Although generic HRQoL is useful for some 
research objectives, diabetes-specific QoL can be utilised to learn more about 
specific populations, and to evaluate the effectiveness of interventions (Wiebe, 
Guyatt, Weaver, Matijevic, & Sidwell, 2003). Diabetes-specific QoL is a more 
focused multidimensional construct, which was found to be mostly associated with 
adherence and HbA1c, whereas the generic HRQoL is highly associated with 
depression (El Achhab et al., 2007; Nansel et al., 2008; Rubin & Peyrot, 1999). In 
this next section general key findings related to research on youth, and of relevance 
to this thesis, are summarised and the focus turns to studies that investigated QoL in 
youth with type 1 diabetes. This is followed by detailed review of literature 
investigating QoL in relation to diabetes control, as measured by HbA1c. 
Youth with diabetes generally experience lower QoL compared to those 
without diabetes (Graue, Wentzel-Larsen, Hanestad, Båtsvik, & Søvik, 2003; 
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Kalyva, Malakonaki, Eiser, & Mamoulakis, 2011; Trento et al., 2013; Varni, 
Limbers, & Burwinkle, 2007). Nonetheless, findings from a few studies showed that 
youth with diabetes had similar HRQoL compared to those who do not have diabetes 
(Kristensen et al., 2014; Laffel et al., 2003; Lukács, Varga, Barótfi, Kiss-Tóth, & 
Barkai, 2012). Compared to youth with other chronic diseases, youth with diabetes 
had better HRQoL (Kalyva et al., 2011; Varni et al., 2007). Youth with better 
glycaemic control had better generic HRQoL compared to those with poor diabetes 
control (Graue et al., 2003; Kalyva et al., 2011; Wagner, Müller–Godeffroy, 
Sengbusch, Häger, & Thyen, 2005). Younger age was associated with better HRQoL, 
whereas older age was associated poorer QoL (Graue et al., 2003; Wagner et al., 
2005). 
The majority of the studies on diabetes-specific QoL reported that lower 
HbA1c was associated with better QoL (Abdul-Rasoul, Alotaibi, Abdulla, Rahme, & 
Alshawaf, 2013; de Wit et al., 2012; Guttmann-Bauman, Flaherty, Strugger, & 
McEvoy, 1998; Kalyva et al., 2011; Spitz & Kanani, 2006). This association, 
however, was not always detected (Graue et al., 2003; Grey, Boland, Yu, Sullivan-
Bolyai, & Tamborlane, 1998; Ingersoll & Marrero, 1991; Kent, 2011; Vandagriff, 
Marrero, Ingersoll, & Fineberg, 1992), and one study, examining QoL reported that 
better glucose control was associated with higher worry and anxiety scores in 
Jamaican youth (Tulloch-Reid & Walker, 2009). In this study the anxiety and worry 
scale represented level of worries about money matters, concerns about the future 
and life stresses. 
Other factors that have been found to be associated with QoL in youth with 
diabetes included age, gender, diabetes duration, and psychological attributes. Older 
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age was associated with poorer diabetes-related QoL (Abolfotouh, Kamal, El-
Bourgy, & Mohamed, 2011; de Wit et al., 2012; Graue et al., 2003). Males had better 
QoL than females gender (Abolfotouh et al., 2011; Graue et al., 2003; Kent, 2011; 
Lukács et al., 2012; Trento et al., 2013). Poorer QoL was also associated with lower 
self-efficacy and self-esteem, depression, later age of onset, longer diabetes duration, 
fear of hypoglycaemia, and fear of complications (Abolfotouh et al., 2011; Kent, 
2011). 
Youth with type 1 diabetes and quality of life 
Various approaches and analytical methods have been used to explore QoL in 
relation to dimensions of type 1 diabetes, with a relatively large number of studies1
examining this in young people (Abdul-Rasoul et al., 2013; Al-Akour, Khader, & 
Shatnawi, 2010; Al-Hayek et al., 2014; Anderson et al., 2014; Cutler, 2004; de Wit et 
al., 2012; Diem, Frost, Augustiny, & Radanov, 2004; Faro, 1999; Faulkner, 2003; 
Grey, 2012; Grey, Davidson, Boland, & Tamborlane, 2001; Guo et al., 2013; 
Hackworth et al., 2013; Hanna, Weaver, Slaven, Fortenberry, & DiMeglio, 2014; 
Hesketh, Wake, & Cameron, 2004; Hilliard et al., 2013; Hoey et al., 2001; Huang et 
al., 2004; Huggard, 2009; Kalyva et al., 2011; Kent, 2011; Kristensen et al., 2014; 
Laffel et al., 2014; Lawrence et al., 2012; Lukács et al., 2012; Malik & Koot, 2009; 
Nansel et al., 2008; Nardi et al., 2008; Naughton et al., 2014; Pereira et al., 2011; 
Puri et al., 2013; Reid et al., 2013; Skinner, Hoey, McGee, & Skovlund, 2006; Stahl-
Pehe et al., 2014; Tan et al., 2005; Xiong et al., 2013).
Many of these studies presented descriptive analyses (e.g., bivariate 
  
1 Intervention studies were excluded
82
correlations) as part of the preliminary investigations or as the main analysis 
component. The majority of the descriptive studies found significant zero-order 
associations between QoL and HbA1c – lower HA1c was mostly associated with 
better QoL (Abdul-Rasoul et al., 2013; Cutler, 2004; de Wit et al., 2012; Faulkner, 
2003; Guo et al., 2013; Huggard, 2009; Kristensen et al., 2014; Laffel et al., 2014; 
Nansel et al., 2008; Nardi et al., 2008; Puri et al., 2013; Xiong et al., 2013). One 
study, however, found that lower HbA1c was associated with worse QoL (Grey, 
2012), and two other studies did not find any significant associations (Diem et al., 
2004; Faro, 1999). 
Confirmatory analysis methods (e.g., multivariate analysis) were also used, 
which provided stronger evidence for the examined relationships. The larger number 
of studies, which used inferential analysis, examined QoL as an outcome measure 
(Al-Akour et al., 2010; Al-Hayek et al., 2014; Grey et al., 2001; Hackworth et al., 
2013; Hanna et al., 2014; Hilliard et al., 2013; Hoey et al., 2001; Huang et al., 2004; 
Kalyva et al., 2011; Kent, 2011; Lawrence et al., 2012; Lukács et al., 2012; Malik & 
Koot, 2009; Naughton et al., 2014; Stahl-Pehe et al., 2014). A fewer number (n = 6) 
examined QoL as a predictor of diabetes outcome, such as HbA1c (Hesketh et al., 
2004; Laffel et al., 2014; Reid et al., 2013; Skinner et al., 2006; Tan et al., 2005). 
Pereira et al. (2011) examined QoL as both a predictor and an outcome measure in its 
relationship with HbA1c. The two directions in investigating the relationship 
between QoL and HbA1c suggest that one can influence the other (i.e., a 
bidirectional relationship). The set of studies that analysed QoL as an outcome 
measure provided information on the impact of diabetes-related variables, such as 
HbA1c, on QoL. In contrast, the set of studies that had QoL as a predictor explored 
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the effect of QoL on diabetes outcomes, such as investigating the contribution of 
QoL in predicating HbA1c levels. 
Research suggests that an individual’s QoL can be predicted from diabetes 
control such that lower HbA1c partially predicts better QoL (Al-Akour et al., 2010; 
Al-Hayek et al., 2014; Hilliard et al., 2013; Hoey et al., 2001; Huang et al., 2004; 
Kalyva et al., 2011; Lawrence et al., 2012; Lukács et al., 2012; Malik & Koot, 2009; 
Naughton et al., 2014; Stahl-Pehe et al., 2014). This association, nevertheless, was 
not always detected, and specifically not always in the youth age sample (Hanna et 
al., 2014; Kent, 2011). 
Another question remains open, which is whether an individual’s QoL can 
influence and contribute to predicting diabetes control (as measured by HbA1c), and 
what the size of that influence is. This question has been rarely addressed for the 
population of youth (15-24 year olds) with type 1 diabetes. The present study 
examines QoL as one of several key predictors contributing to variations in HbA1c. 
The hypotheses and contributions of the present study are discussed later. The 
following presents a detailed review of research which included QoL as an 
independent factor in the prediction of HbA1c in youth with type 1 diabetes. Studies 
that included a continuous HbA1c variable are reviewed first, followed by studies 
that used a categorical HbA1c to conduct the statistical analysis. 
A large scale study involving 2077 participants examined the relationship 
between QoL and HbA1c as part of a study validating a diabetes-specific QoL scale 
(Skinner et al., 2006). This study recruited adolescents aged 10-18 years with type 1 
diabetes from 22 diabetes centres in 18 countries across Europe, Asia, and North 
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America. In this study, bivariate correlations indicated significant association 
between QoL and HbA1c. Regression analysis was used to explore the contribution 
of the QoL multidimensional construct in variations of HbA1c levels. A hierarchal 
regression model included the five diabetes-specific QoL subscales (four of which 
have multiple items): impact of diabetes, worries about diabetes, satisfaction with 
treatment, and satisfaction with life; and the fifth subscale that deals with a single 
item on health perception. The model also controlled for age and gender and found 
those factors to contribute 1.4% of the variance in HbA1c. The diabetes-specific QoL
dimensions of symptom impact, future worries, and impact on activities contributed 
an additional 5.2% to the variance of HbA1c. Higher HbA1c was associated with 
poorer QoL. 
This study demonstrated the role of QoL in predicting HbA1c, and had a 
strong statistical power because of the large sample size. The percentage of 
contribution of the QoL items in the regression model suggested that there remains a 
large unexplained proportion for the variation in HbA1c, which can be attributed to 
other factors. For this reason it would be useful to investigate other key factors that 
are known to have an effect on HbA1c and to test the strength of their relationship 
with QoL. 
A more recent study conducted in Florida, USA, examined QoL as a predictor 
of HbA1c, and examined the QoL in a mediational relationship between adherence 
and HbA1c (Reid et al., 2013). The study recruited 70 children and adolescents (9-18 
year olds) with type 1 diabetes from an outpatient paediatric endocrinology clinic. 
The mean HbA1c was 9.3% (SD = 2.1%). The Pediatric Quality of Life (PedsQL) 
InventoryTM–Core module and the PedsQL–Diabetes module were used to evaluate a 
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young person’s QoL from the parent and young person perspectives. The parent 
report scores were significantly lower (representing lower QoL) than that of the 
young person report. The young person report scores had a significant correlation 
with adherence but did not have a significant correlation with HbA1c, unlike the 
parent report which had a significant relationship with both. For subsequent 
regression analysis, the authors used the parent report data because these results were 
similar to that found in previous research.
A multiple regression analysis was conducted to examine the relationships 
between QoL, diabetes control, and adherence (Reid et al., 2013). A full hierarchal 
model that controlled for several factors (e.g., demographic race and adherence) 
accounted for an adjusted-R2 41.6% in predicting HbA1c; the QoL contribution was 
14% of the variance in glycaemic control. The model suggested that higher QoL was 
associated with better glycaemic control (beta = −0.425, p < 0.01). 
The second part of the QoL data analysis included inspecting the mediational 
relationship between adherence and glycaemic control. The findings provide 
evidence for the significant mediational role of QoL from the path of adherence to 
the outcome variable of HbA1c. Put differently, the significant relationship between 
adherence to diabetes self-management and better diabetes control can be partially 
explained by improved QoL. The study by Reid et al. (2013) presented further 
evidence that QoL is a significantly (directly and indirectly) associated with 
glycaemic control. This suggests the importance of QoL when addressing 
determinants contributing to poor diabetes control in young people. The study, 
however, included analysis of data of young participants through their parents’ 
reports, rather than the young persons themselves. In addition, the age of the young 
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participants was not controlled for in the regression model and the sample included 
ages that belong to the diabetes groups of children and youth, which are quite distinct 
groups (Alberti & Zimmet, 2011). 
The study by Pereira et al. (2011), which was discussed in the section on 
illness perception, presented evidence of the role of QoL in predicting HbA1c. The 
QoL in this study was assessed using a Portuguese version of the Diabetes Quality of 
Life Questionnaire (DQoL) (Pereira et al., 2011). This study found that poorer QoL 
predicted high values of HbA1c (beta = 0.25, p < 0.05) and less adherence to 
diabetes control (beta = −0.215, p < 0.05). 
The TEENs study, which was a very large international study that included 
20 countries and nearly 6,000 participants, investigated the association of QoL and 
HbA1c in a subsample (n = 1382) that included youth with type 1 diabetes 
(Anderson et al., 2014; Laffel et al., 2014). The participant’s age range in this 
subgroup was 19-25 year olds. The study included participants from 219 diabetes 
centres located in different countries: Europe, the USA, Latin America, the Middle 
East, Africa, and India. The average HbA1c in this sample was 8.4%. The QoL was 
assessed using PedsQL 3.0 Diabetes Module, which has five subdomains: diabetes 
symptoms, treatment barriers, treatment adherence, worries about complications, and 
communication. Logistic regression analysis was used to examine the association of 
each of the subdomains with HbA1c as a categorical variable. The categories are 
HbA1c < 7% and HbA1c ≥ 7%. Participants who reported better QoL on the scales 
of diabetes symptoms, treatment barriers, and treatment adherence were more likely 
to meet the target HbA1c; with odds ratios, respectively: 2.16, 2.22, and 3.16. 
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The results of the above study suggest that QoL can predict the chances of 
meeting target blood glucose levels. Strengths of this study include the statistical 
power and that the age group was well defined to ages from the youth diabetes group. 
However, as stated earlier, including HbA1c as a categorical variable may limit full 
exploration of HbA1c associations with other variables. It is recommended that 
future research analyses HbA1c using a continuous variable to determine the 
contribution of QoL in the prediction of HbA1c.  
The association between QoL and metabolic control was examined in 
Malaysian children and youth with type 1 diabetes (Tan et al., 2005). Quality of Life 
was measured by the DQoL. Participants (N = 52) aged 12-20 years were recruited 
from an outpatient Paediatric Diabetes Clinic. The majority (78.8%) had an HbA1c 
of more than 8%; the mean HbA1c was 10.0% (median = 9.8%). Based on the 
HbA1c descriptive statistics, a cut-off HbA1c level was determined such that HbA1c 
> 10% depicts poor control, and HbA1c ≤ 10% represents good control. By this 
definition for this sample, 22 participants had poor control and 30 had good control. 
Two parallel sets of analysis were conducted; each included a different cut-off point 
of HbA1c (i.e., 10% and 8%). Logistic regression was used to analyse the data with 
HbA1c as the dependent variable (poor control = 0, good control = 1) and QoL as an 
independent variable in the regression models. 
The results showed that children and youth with better QoL were more likely 
to have better HbA1c control, based on the 10% cut-off. No significant associations 
between HbA1c category and QoL were detected in the data at the 8% cut-off point. 
Although this study presented some evidence for an association between HbA1c and 
QoL in analysing the 10% cut-off data, it is limited in statistical power, choice of 
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analysis, and HbA1c cut-off point for good glycaemic control. In normal 
circumstances HbA1c = 10% is classified in the poor glycaemic control group. 
Despite the results being similar to what has been found in previous research, the 
results might be misleading because a different cut-off point that defined the good
glycaemic control group was used.  
Changes in QoL in relation to metabolic control in 83 children and 
adolescents (5-18 year olds) were assessed over a period of two years (Hesketh et al., 
2004). The participants were recruited from an outpatient clinic at the Royal Hospital 
in Melbourne, Australia. The baseline HbA1c mean was 8.1%. Two HbA1c 
categories (grouped participants) were created based on a cut-off point that lies in the 
75th percentile, HbA1c 8.8.% – a statistically useful division. The QoL assessments 
were administered, using the Child Health Questionnaire (CHQ) with a parent proxy 
for 5-11 year olds, and CHQ adolescent self-report (12-18 year olds). This research 
monitored changes in the study variables from baseline to follow-up, and checked for 
the predictability of changes based on the baseline variables (i.e., HbA1c and QoL). 
The baseline data for the parent report scores were stable from baseline to 
follow-up with no significant changes. In contrast to this, the adolescents’ report 
scores had significant changes in many of the CHQ subscales. The mean HbA1c for 
the combined sample had significant changes from baseline to follow-up with a mean 
rise of 0.75% (SD = 1.1%), which suggested a deterioration in diabetes control. The 
study found that lower HbA1c levels at baseline predicted increases in HbA1c at 
follow-up, and this accounted for 25% of the variance in HbA1c change between 
baseline and follow-up. The children and adolescents QoL scores at baseline did not 
predict HbA1c at follow-up nor its change from baseline to follow-up, except for a 
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subscale that is related to physical functioning and well-being. The scores of this 
subscale predicted the follow-up HbA1c, and its change from baseline to follow-up. 
This study provided an insight on the role of QoL in longitudinally predicting 
HbA1c, finding that physical functioning and well-being contributed to the 
predictability of HbA1c. In addition, findings from this study suggested that the 
children’s QoL was more stable compared to that of adolescents. This finding, 
combined with the predictability of HbA1c from QoL, suggests the importance of 
assessing and targeting QoL for better diabetes control in adolescence, and 
potentially youth. 
In summary, although there were numerous studies addressing the QoL 
construct in the context of diabetes research, there was a paucity of studies that 
investigate the role of QoL in predicting metabolic control. The general findings 
overwhelmingly indicated that better QoL is associated with better diabetes outcome. 
Nonetheless, most investigations addressed the effect of HbA1c on QoL, but not the 
opposite. Findings from the few studies of QoL as a predictor of HbA1c suggest that 
QoL plays a role in explaining variance of the HbA1c. The available research is still 
limited in its conclusions because of methodological weaknesses, such as weak 
statistical power, using the parent’s rather than the adolescent’s report, and analysing 
HbA1c as a categorical variable. Further investigations are required to explore and 
address gaps in literature with regards to QoL as a predictor of HbA1c. The 
following section discusses the significance of the present research, its aims, and the 
hypotheses of the present study. 
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Significance, Aims, and Hypotheses
Illness perception, self-efficacy, and QoL are key psychosocial factors that 
have direct and indirect associations with critical behavioural and clinical diabetes 
outcomes, such as adherence and glycaemic control (Delamater et al., 2014). There 
are limited studies that investigate these factors both in the youth population and in 
relation to diabetes control. In New Zealand, the present study is the first to examine 
a combination of these psychosocial factors in relation to diabetes control in youth 
with type 1 diabetes. Between 2003 and 2011 four studies in New Zealand examined 
some of these factors in children and adults, and the samples age ranges included 
individuals from the youth group (Broadbent et al., 2011; Huggard, 2009; Singh, 
2008; Young, 2003); no previous study has investigated any of these psychosocial 
factors with youth in Canterbury. 
The study by Young (2003) presented evidence for a significant association 
between HbA1c and self-efficacy in adolescents aged 13-17 years old, but the 
direction of association contradicted previous research. The study by Huggard 
(2009), discussed earlier, presented only descriptive analysis and compared groups of 
poor and good diabetes control using the variables HbA1c, QoL, and illness 
representations. This study found significant associations between the study variables 
in the participants, whose age ranged from 11 to 17 years. The study by Broadbent et 
al. (2011), to investigate illness perceptions in association with HbA1c, had a wide 
age range that mostly represented an adult sample (Mage = 43.2, SD = 20.57). The 
fourth study, that by Singh (2008), had participants with both type 1 and type 2 
diabetes in the sample and self-efficacy was not found to predict HbA1c. Thus far, 
the analyses have been descriptive, there have been a wide range of participant ages, 
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or samples have included participants with a mix of those with type 1 and type 2 
diabetes, or the findings have been inconsistent with earlier research.  
From the above it can be seen that there are no studies in New Zealand that 
examine a combination of the three psychosocial factors that are of interest for this 
thesis. In addition, of the studies that do examine one or two of the psychosocial 
factors, the age range does not include youth above 17 years of age and is therefore 
not representative of the entire diabetes youth population for whom research shows 
that diabetes self-management and control can be particularly problematic (Borus & 
Laffel, 2010; Hamilton & Daneman, 2002; Pinhas-Hamiel et al., 2014; Tan et al., 
2005).  
The current study also addresses some of the gaps in knowledge, at an 
international level, such as the combined and individual roles of QoL, self-efficacy, 
and illness perceptions in predicting glycaemic control. The examination of their 
contribution can inform diabetes care systems, and in particular interventions that 
target those with poor control.
The role of illness perception in influencing metabolic control is still unclear 
in youth with type 1 diabetes; at present, evidence is scarce and somewhat 
inconsistent. Only two quantitative studies have examined the association between 
illness perceptions and HbA1c in a sample of youth (Griva et al., 2000; McGrady, 
2012). A further two studies investigated illness perceptions and HbA1c but there 
was a mix of children and adolescents, ranging in ages from 10-17 and 12-19 
(Fortenberry et al., 2014; Pereira et al., 2011). Of the two, Pereira et al. (2011) did 
not control for the age factor. The latter two studies found that illness perceptions, in 
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children and adolescents, had direct associations with HbA1c and those relationships 
were in the expected directions (e.g., higher level of negative emotions predicted 
poorer HbA1c). 
There was some degree of inconsistency in the findings of studies that had 
included adolescents and young adults (Griva et al., 2000; McGrady, 2012). The 
study by McGrady (2012) did not find significant associations (cross-sectionally or 
longitudinally) between illness perceptions and HbA1c. The study, however, did find 
significant mediational relationships that included: HbA1c, illness perception, self-
reported adherence, and blood glucose monitoring frequency. These results suggest 
that illness perceptions have an indirect effect on HbA1c through other process 
variables. The study by Griva et al. (2000), in contrast, found illness perceptions had 
a direct relationship with HbA1c and their study showed that perceived consequences 
and identity explained 12.2% of the variance in HbAlc. 
As a consequence, further research is required to explore and understand the 
direct and indirect associations between HbA1c and illness perceptions. It should be 
noted that the study by Griva et al. (2000) only presented evidence for the cognitive 
representations and did not include analysis of an emotional representation 
component. Emotional representations in association with HbA1c are still unexplored 
for the youth age range. The studies by Fortenberry et al. (2014) and Pereira et al. 
(2011) both found that higher negative emotions predicted poorer HbA1c in children 
and adolescents. There is, therefore, insufficient known about the contribution of 
different illness representations to HbA1c specifically for youth with type 1diabetes. 
The self-efficacy construct in young people with type 1 diabetes has been 
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evaluated previously in association with clinical, behavioural, and psychosocial 
diabetes outcomes. There are, however, very few studies that examine the direct 
influence of self-efficacy on HbA1c particularly for youth (see literature review 
section on self-efficacy). Of the studies discussed, only three investigated the role of 
self-efficacy in predicting HbA1c (Griva et al., 2000; Iannotti et al., 2006; Johnston-
Brooks et al., 2002). One of the studies addressed it for the late childhood and early 
adolescence stages: 10-16 years old (Iannotti et al., 2006), and the other study 
included adults aged 25 to 35 years old in the research sample (Johnston-Brooks et 
al., 2002). For the youth diabetes group, Griva et al. (2000) provided evidence for the 
significant association of self-efficacy and HbA1c in a direct effect model. Self-
efficacy alone predicted nearly 30% of the variance in HbA1c, which suggests this 
construct has an essential role in diabetes control. The sample from this study was 
homogenous and therefore further investigations with different samples are needed to 
clarify the direct association of self-efficacy in its relationship with HbA1c. It is also 
particularly important to conduct further research in this area. This is because 
findings from the aforementioned New Zealand study by Young (2003) showed a 
different direction for the relationship between HbA1c and self-efficacy, which 
contradicted that found in the above study by Griva et al. (2000). 
No previous study has been conducted in Canterbury to examine the role of 
self-efficacy in predicting HbA1c specifically in youth with type 1 diabetes, and only 
two studies throughout New Zealand reported examining this construct in samples of 
adolescents that included 13-19 year olds with type 1 or type 2 diabetes (Singh, 
2008), and 13-17 years old with type 1 diabetes (Young, 2003). The former study did 
not find a significant association of self-efficacy as predictor of HbA1c, while the 
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latter study (as mentioned above) found results that contradicted previous research. 
Finally, although there have been many studies on QoL as an outcome 
measure in its relationship with HbA1c, there is little research on the role of QoL in 
predicting glycaemic control. Only two studies investigated this association in a 
sample of children and adolescents with type 1 diabetes (Pereira et al., 2011; Skinner 
et al., 2006). The first study had participants aged 10-18 years old, which found QoL 
(future worries and impact) to contribute 5.2% of the prediction of HbA1c; higher 
HbA1c was associated with poorer QoL (Skinner et al., 2006). The second study by 
Pereira et al. (2011) found that poorer QoL predicted high values of HbA1c (beta = 
0.25, p < 0.05). The remainder of studies had limitations such as assessing QoL from 
the parents’ reports rather than the adolescents’ report; analysing HbA1c as a 
categorical variable; and setting a cut-off of 10% to differentiate good or poor 
diabetes control groups, which is well above recommended guidelines. These limit 
the conclusions that can be drawn from earlier research about the relationship of QoL 
as a predictor of HbA1c in youth aged 15-24 years old with type 1 diabetes.    
The present study aims to contribute to the international and national body of 
knowledge. The specific aims of the present study include: 
a) describe key psychosocial characteristics of youth (15-24 years old) with 
type 1 diabetes in the CDHB catchment area 
b) explore descriptive inter-relationships amongst variables in this study, and 
in relation to HbA1c 
c) use confirmatory analysis in the form of multiple regression models, to 
investigate the relationship between these psychosocial characteristics and 
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glycaemic control
d) determine the combined and individual contribution and effect size of 
illness perception, self-efficacy, and QoL in predicting HbA1c 
In the present study it was hypothesised that youth with type 1 diabetes 
residing in Canterbury would follow a similar trend to youth in other countries in 
terms of their descriptive psychosocial characteristics and HbA1c. It was also 
hypothesised the direction of the relationships of the key psychosocial characteristics 
and HbA1c would follow trends found in similar studies: threatening views of 
diabetes would be associated with higher HbA1c levels, and weaker self-efficacy 
beliefs and poorer QoL would be associated with higher HbA1c. Furthermore it was 
hypothesised that diabetes control would be predicted by the combined psychosocial 
constructs, with a significant contribution from the individual factors. 
Method
Participants 
Letters of invitation to participate in the current study were sent to 248 youth 
(15-24 years old) with type 1 diabetes in the CDHB catchment area. The youth were 
identified from CDHB records as part of the study presented in Chapter 2 (Obaid et 
al., 2012a, 2012c). Descriptive information and demographic characteristics from the 
study in Chapter 2 (gathered before the Canterbury earthquakes) were used in the 
current study. Of the 248 youth contacted regarding participation in the current study, 
56 agreed to participate (females = 33; males = 23), completed the questionnaires, 
and had a record of a recent HbA1c. This gives a response rate of 23%. 
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Measures
Glycated haemoglobin (i.e., HbA1c) was used as the primary outcome 
measure and as an indicator of the level of diabetes control. This biomarker (see 
Chapter 1) is considered the gold-standard to monitor the progress of the diabetes 
condition, and the risk for developing diabetes-related complications (Bruns, 2007; 
Hanas et al., 2014). In the current study the most recent HbA1c records, taken within 
6 months of completion of the questionnaires, were obtained from CDHB clinical 
records. The HbA1c data and demographic variables (e.g., age and gender) were 
collected according to the procedure outlined in Chapter 2. 
The predictor variables in the current study represented three key 
psychosocial factors (i.e., illness representations, self-efficacy, and QoL), which are 
multidimensional constructs. The following measures were administered to the 
participants. The measures were selected based on their reliability, suitability for 
youth, and length of time they took to complete. One consideration was that the 
CDHB Diabetes Centre (associate host institution) wanted to minimise the time 
required to fill out the questionnaires. The questionnaires, Appendix 3.1, were sent 
post the Canterbury earthquakes. The following describes the measures used in the 
current study, including their psychometric properties.
The Brief Illness Perception Questionnaire (BIPQ) 
The original BIPQ, which was developed in New Zealand, was adapted from 
the longer 80-item Illness Perception Questionnaire-Revised (IPQ-R) (Broadbent et 
al., 2006; Moss-Morris et al., 2002). The BIPQ has nine items; each assessing an 
illness perception dimension (Broadbent et al., 2006). The BIPQ is a general measure 
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that can be applied to different illnesses; for example, it is acceptable to change the 
wording slightly to replace illness with diabetes (Broadbent et al., 2006). 
The first eight BIPQ items are quantitative, whereas the ninth item is a 
qualitative open-ended question on the cause of illness. The BIPQ eight quantitative 
items are: consequences, timeline, personal control, treatment control, identity, 
coherence, concern, and emotions. The latter two items reflect emotional 
representations. Each dimension has a 10-point Likert scale; for example, the scores 
range from no effect at all to severely affects my life. The quantitative BIPQ items 
were used in this study, and the ninth item was excluded from the questionnaire2.
Stronger beliefs on identity, consequences, timeline, and emotional 
representations denote negative perceptions (Broadbent et al., 2006; Hagger & 
Orbell, 2003). The negative perceptions indicate a highly perceived symptomatic 
condition, more serious consequences and impact on life, and greater emotional 
reactions to an illness. In contrast, unless reversed, higher scores on the 
controllability and coherence depict positive perceptions, which reflect stronger 
beliefs on the manageability of the illness and recovery from it, and more 
understanding views of the illness (Broadbent et al., 2006; Hagger & Orbell, 2003). 
A total BIPQ score (BIPQ-Total) can be also computed. Personal control, 
treatment control, and coherence scores are reversed and then added to scores of the 
remaining items. The overall score represents the degree to which the illness is 
perceived as threatening or benign. A higher score indicates a more threatening and 
  
2 Permission was sought and granted from the authors to exclude the ninth item. The CDHB Diabetes Centre 
requested only including the quantitative items. In addition, the term illness was replaced with diabetes.
98
negative views about the illness (Broadbent et al., 2006). Research suggests stronger 
beliefs about diabetes as a threatening condition negatively impacts on diabetes 
control (Harvey & Lawson, 2009).  
The BIPQ has the advantage of being a reliable quick measure that is easy to 
understand. This is useful in situations when time is limited; for example, when 
several other questionnaires are administered (Broadbent, 2010). Research on the 
psychometric properties of the BIPQ suggests it has good test-retest reliability, 
concurrent, and discriminant validity (Broadbent et al., 2006; Ng, 2012). 
Furthermore, findings from a translated version (into Farsi) that had a sample of 
young individuals with type 1 diabetes, showed cross-cultural validity, good 
reliability, and concurrent validity (Bazzazian & Besharat, 2010). 
The psychometric properties in the original version were based on data from a 
general sample across multiple illnesses including a sample of 119 adults with type 2 
diabetes (Broadbent et al., 2006). The study found the BIPQ scale had good 
discriminant validity in distinguishing between illnesses, such as diabetes, asthma, 
myocardial infarction and minor illnesses. That is, the scale has the ability to 
uniquely assess an illness identified by the distinct patient beliefs of that illness. 
Broadbent et al. (2006) evaluated the test-retest reliability of the BIPQ using 
a sample of participants who had renal disease, retested three and six weeks from 
baseline. The Pearson’s correlations were significant for all 8 items, with correlations 
of r = 0.42 to r = 0.75 (for the individual subscales) suggesting good reliability of the 
BIPQ, and the study showed good concurrent validity. The authors found that higher 
personal control was associated with lower HbA1c (r = −0.3, p < 0.01); higher 
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identity and treatment control beliefs were associated with poorer HbA1c (r = 0.25 
and r = 0.25, p < 0.05, respectively). 
Bazzazian and Besharat (2010) recruited 300 individuals aged 18-30 years 
old with type 1 diabetes, to evaluate the psychometric properties of a translated Farsi 
BIPQ. The Pearson’s correlations coefficients of the individual items (retested over 
four weeks) ranged from r = 0.5 to r = 0.75, which suggests good reliability. The 
study also provided evidence for the applicability of the scale and its cross-cultural 
validity, with factor analysis showing that the BIPQ in this study was structurally 
equivalent to the original version. Furthermore, there were significant associations 
between HbA1c and majority of the BIPQ dimensions: consequence (r = 0.595, p < 
0.01), personal control (r = −0.638, p < 0.01), identity (r = 0.760, p < 0.01), concern 
(r = 0.129, p < 0.05), coherence (r = −0.177, p < 0.01), emotional response (r = 
0.549, p < 0.01), and this also provides evidence of the concurrent validity of the 
BIPQ.
Self-Confidence in Diabetes Self-care (CIDS) 
The Self-Confidence in Diabetes Self-care (CIDS) assesses diabetes-specific 
self-efficacy in individuals with type 1 diabetes (van der Ven et al., 2005). More 
specifically, the CIDS assesses the perceived ability to perform self-management
tasks specifically constructed for individuals with type 1 diabetes. The CIDS has 21 
items which are rated on a 5-point Likert scale (van der Ven et al., 2003). This scale 
ranges from 1 (No, I am sure I cannot) to 5 (Yes, I am sure I can). Each CIDS item 
begins with, “I believe I can . . . ”. For instance: “I believe I can check my blood 
glucose at least two times a day”. A total score is calculated by the summation of the 
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CIDS items, and then these are transformed to a 0-100 scale with higher scores 
indicating greater self-efficacy (van der Ven et al., 2005). Greater self-confidence in 
carrying out diabetes self-management tasks has been mostly found to positively 
influence diabetes control (Littlefield et al., 1992; Ott et al., 2000; van der Ven et al., 
2005). 
The CIDS has the advantage of being specific to type 1 diabetes and 
evaluates diabetes-specific self-efficacy rather than generic self-efficacy, a factor that 
is consistent with recommendations in the literature review section above. 
Furthermore, CIDS is easy to understand, and takes only a few minutes to fill out 
(van der Ven et al., 2003). The CIDS is a valid and reliable measure based on its 
psychometric properties as reported in the original research by van der Ven et al. 
(2003). The original research involved USA (n = 190) and Dutch (n = 151) 
participants (>18 years old) and the scale was constructed using two languages 
concurrently: English and Dutch. 
The original research presented evidence for the excellent internal 
consistency and test-retest reliability of the CIDS scale in both samples (van der Ven 
et al., 2005). The Cronbach alpha was more than 0.8, and the test-retest Spearman’s 
coefficient was 0.85 (p < 0.0001) (van der Ven et al., 2003). In addition, the CIDS 
had good concurrent validity. Two of the outcome measures used in evaluating the 
scale’s concurrent validity were glycaemic control, as measured by HbA1c, and 
diabetes self-management behaviours scale. The English version CIDS scores were 
significantly associated with HbA1c (r = −0.25, p < 0.005), but the Dutch version 
scores were not. The self-management behaviours were significantly associated with 
CIDS in both samples (USA, r = 0.42; Dutch, r = 0.44; p < 0.0001). These 
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correlations suggest that greater self-efficacy is associated with lower HbA1c levels, 
and with higher level of adherence to self-management behaviours. The high 
psychometric similarities between the two concurrent scales (i.e., English and Dutch 
versions) indicated the cross-cultural validity. 
Pediatric Quality of Life Inventory™ Diabetes Module (PedsQL 3.2)
The Pediatric Quality of Life Inventory™ Diabetes Module (PedsQL 3.2) 
assesses diabetes-specific QoL (Varni et al., 2003; Varni et al., 2012). It has 33 items 
which are categorised in five dimensions. These are: diabetes symptoms (About my 
diabetes), treatment barriers (Treatment I), treatment adherence (Treatment II), 
worries about complications (Worry), and communication related to diabetes 
(Communication). The items are scored on a 5-point Likert scale. The scores are 
reversed and then transformed to a 0-100 scale. Higher scores indicate lower 
problems with that particular aspect (Varni et al., 2003). For example, a higher score 
on the treatment adherence scale indicates not having problems with adhering to the 
diabetes self-management tasks. Better treatment adherence positively affects 
diabetes control (Nansel et al., 2008; Varni et al., 2003). A total score of the PedsQL 
scale (PedsQL-Total) can be computed by summing scores of the 33 items (i.e., 
dimensionless items). A higher score indicates fewer problems associated with 
overall diabetes-specific QoL. 
The PedsQL 3.2 takes about five minutes complete and is suitable to use for 
youth with type 1 diabetes (Varni et al., 2003; Varni et al., 2012). The PedsQL 3.2 
module has two slightly different versions: Teen (13-18 year old) and Adult (>18 
year old) reports. The difference between the two versions is minimal and mainly in 
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the questionnaire wording to make it age appropriate. For example, in the Teen’s 
report: “My parents and I argue about my diabetes care”, in the Adult’s report: “My 
spouse, significant other, and/or other family members and I argue about my diabetes 
care”.  
The PedsQL 3.2 was derived from a previous version, PedsQL 3.0 diabetes 
module. The latter measure was revised so that it is more suitable for all patients with 
type 1 diabetes, including newly diagnosed patients. The creators of the measures 
recommended using the modified version instead of the older version for all 
individuals with type 1 diabetes (Varni et al., 2012). The process of deriving PedsQL 
3.2 involved conducting in-depth interviews with individuals with type 1 diabetes 
and a qualitative analysis of the interviews was carried out to create the modified 
version. There is no published research reporting on the psychometric properties of 
the PedsQL 3.2; rather, there is an assumption that the evidence for the reliability and 
validity of the PedsQL 3.0 also applies to the PedsQL 3.2.  
Research on the psychometric properties of the PedsQL 3.0 suggest it has 
good internal consistency, with a Cronbach alpha of 0.8 for the total score (Nansel et 
al., 2008; Varni et al., 2003). In addition, the reliability coefficients of the five 
dimensions are also at an acceptable level. The treatment barriers, treatment 
adherence, and worry had a Cronbach alpha between 0.6 and 0.7, and the remaining 
two items (i.e., diabetes symptoms and communication) had an alpha of more than 
0.7 (Varni et al., 2003). The PedsQL 3.0 was significantly associated with several 
outcomes measures (e.g., HbA1c and adherence). Findings from analysing data of 
one of the two cohorts in this study showed that HbA1c was significantly associated 
with the total score (r = −0.26, p < 0.01), diabetes symptoms (r = −0.24, p < 0.05), 
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treatment barriers (r = −0.23, p < 0.05), and treatment adherence (r = −0.23, p < 
0.05). These results suggest that lower HbA1c levels were associated with fewer
problems of diabetes-related QoL. 
Statistical Analysis
Descriptive and inferential statistical analyses were carried out to investigate 
the psychosocial characteristics of adolescents and young adults with type 1 diabetes 
in association with glycaemic control. Prior to conducting the analyses, the reliability 
of the questionnaires was checked. The psychosocial data were then investigated for 
patterns and descriptive correlations, before conducting the confirmatory analysis. 
The preliminary analyses guided the investigations of the role of the psychosocial 
factors in predicting glycaemic control (HbA1c).
The psychosocial factors dataset was missing eight data points. Incomplete 
data (n = 8) were imputed by computing a truncated mean of the scores (see William, 
2011). The following is an example of how this was computed: if an answer was 
missing from the CIDS scale (21-items), the truncated mean was based on 20 
observations instead of 21. The method requires at least 50% of the scores to be 
recoded. This was easily achieved because very few observations were missing from 
the dataset. Data from the questionnaires were processed and analysed using 
Statistical Package for the Social Sciences (SPSS 19) and R-Gui (Braun & 
Maindonald, 2010; Kinnear & Gray, 2012; R Core Team, 2014). 
The reliability of the measures used in the current study was assessed through 
evaluating their internal consistency, using the Cronbach alpha (Bland & Altman, 
1997; Cronbach, 1951; Gliem & Gliem, 2003). This reliability index is suitable to 
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use for measures with multiple items administered to participants in a cross-sectional 
design, such as that in the current study (Bland & Altman, 1997; Gliem & Gliem, 
2003). Cronbach alpha above 0.7 indicates acceptable internal consistency and higher 
values reflect more reliable measures with stronger internal consistency (Bland & 
Altman, 1997; Gliem & Gliem, 2003). Conversely, a Cronbach alpha that is below 
0.7 needs to be interpreted with caution, because lower values suggest weaker 
internal consistency (Gliem & Gliem, 2003). 
The descriptive analyses included exploring the bivariate correlations 
between the study variables. The analyses involved the continuous variables: HbA1c, 
age, and questionnaire scores. The bivariate interrelationships in the current study 
were evaluated using the Pearson Product Moment Correlation (PPMC), also referred 
to as Pearson’s correlation (Lomax & Hahs-Vaughn, 2012). The PPMC coefficient 
(r) was used to indicate how linearly dependent the variables are. The r range is 
between -1 and 1. A perfect linear relationship between two variables has an absolute 
r value of 1 (i.e., |r| = 1); whereas zero indicates no linear relationship. The sign of r
determines the direction of the relationship. The strength of the correlation is 
determined by the |r| value which can be classified as: small correlation (0.1 ≤ |r| < 
0.3); medium correlation (0.3 ≤ |r| < 0.5); and large correlation (0.5 ≤ |r| ≤ 1.0) 
(Cohen, 1988; Cohen, 1992). It is should be noted that the relationship between the 
study variables (e.g., HbA1c) and the gender variable was also explored. The 
categorical variable of gender was analysed using independent-samples t-tests to 
compare differences between females and males in relation to the study variables. 
The association between the psychosocial characteristics and HbA1c was 
investigated using regression analysis. Regression analysis was used to investigate 
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the relationship between HbA1c (outcome variable) and the questionnaire scores 
(predictor or explanatory variables). Age and gender were controlled for. Since there 
were more than two predictors involved in the regression analysis, multiple linear 
regression (MLR) was utilised (Chatterjee & Simonoff, 2013; Cohen, Cohen, West, 
& Aiken, 2003; Kahane, 2008; Schuster & Eye, 1998; Su & Yan, 2009). Conditions 
to use MLR analysis were checked and assumptions were validated (Chatterjee & 
Simonoff, 2013). Guidelines of the MLR analysis and validation included inspecting 
the level of measurement, appropriate sample size, scatter plots, bivariate 
relationships of HbA1c and the questionnaire scores, potential outliers, 
multicollinearity, and residuals plots of the fitted models (Cohen et al., 2003; Simon, 
2003). The residuals diagnostic plots included inspecting various scatter plots to 
check linearity of the model, homogeneity of the residuals, and to check leverage and 
Cook’s distance of the residuals (Fox, 1991; Stevens, 2012). The residuals were also 
inspected for normality with the aid of the quantile-to-quantile (QQ) plots (Snijders 
& Bosker, 2011). Reliable and parsimonious models were derived. The MLR 
procedures and guidelines are outlined below.  
The variables level of measurement and sample size in this study were first
checked for adequacy for an MLR model. There need to be at least two predictor 
variables (metric or dichotomous) and one outcome variable (metric) to be able to 
apply an MLR model. The ratio of cases per predictor was calculated to ensure that 
the sample size was suitable to provide reliable correlation estimates. The guidelines 
specify that a ratio of minimum five cases per predictor (5:1) is required to produce a 
reliable model (Green, 1991; Osborne & Costello, 2004). 
The bivariate relationships table was then used to aid in making informative 
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selections of variables to build meaningful regression models. The Pearson’s 
correlation coefficient is a descriptive measure of the bivariate relationships and its 
strength, which can guide variables selection for regression analysis. It should be 
noted, however, in a regression model the relationship of an explanatory variable 
with an outcome variable can be described while taking away the effect of another 
variable or several other variables (Cohen et al., 2003). This means that the 
correlation coefficients and statistical significance of the effect of individual 
variables may change depending on which combination of variables are included in 
or omitted from the model (Cohen et al., 2003).
In the current study, a decision was made to include a comprehensive 
representation of all the variables that have been previously found to have an 
association with HbA1c. This meant that this analysis also included variables that did 
not present a significant association with HbA1c in the current study. The selection 
of certain variables (e.g., total score or separate dimensions) was guided by results 
from the interrelationships and extent of linear dependency among variables (using 
the bivariate correlations table). The selection of variables also complied with the 
acceptable level of cases to variables ratio in a regression model. 
The scatter plots of the variables in association with HbA1c were also 
examined to identify possible influential points. Data points of HbA1c equal to or 
greater than 138 mmol/mol differed from other groups of observations in all plots. 
These were suspected as influential observations. It was statistically determined 
whether these points (or any other observations) were outliers after implementing 
MLR models. 
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There are several methods to statistically identify outliers and influential 
points. These include checking the leverage, Cook’s distance, DFFITS (standardised 
difference in fit statistic), and DFBETAS (scaled difference in Beta). These statistics 
are used to test how influential each point is in a regression procedure – an R-
command (influence.measures) can be used to check these (Boomsma, 2014; 
Chatterjee & Simonoff, 2013; Simon, 2003; Yan, 2009). The leverage statistics 
identify observations that are far away from corresponding average predictor values 
and the potential influence of these observations on a fitted regression model. 
Guidelines of this indicate that a leverage value needs to be less than the value of 
twice the number of predictors divided by the number of cases (i.e., 2p/n)
(Boomsma, 2014; Stevens, 2012). Cook’s distance is a measure of changes in 
regression coefficients when an observation is deleted – it identifies problematic 
points, affecting a regression model, and a value less than 1 is an acceptable Cook’s 
distance (Boomsma, 2014; Stevens, 2012). The DFFITS is a scaled measure of the 
change in the predicted value for the ith observation and is calculated by deleting the 
ith observation. The DFFITS is similar to Cook’s distance, a large value indicates that 
the observation is an outlier in the x domain, DFFITS need to be less than 1 
(Boomsma, 2014; Stevens, 2012). The DFBETA measures the scaled change in each 
estimated beta coefficient when the ith observation is deleted from the regression, a 
value of less than 1 is acceptable (Boomsma, 2014; Stevens, 2012). 
After identifying potential outliers, these were closely examined to check for 
any errors and if they belonged to a particular group of observations. The model was 
then run, with and without the outliers, to investigate the effect of removing these 
points on a regression model. Checking the stability of the model included testing for 
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changes in effect sizes, significance levels (p-value), and coefficients sign. If there 
were considerable changes in any of these, the outliers should be removed from the 
dataset. This is because of their influence on the model and its reliability.  
In addition to identifying outliers, the model fit was examined. To examine 
this, the standardised and studentised residuals of each point were checked for 
goodness of fit of the regression line (Boomsma, 2014; Chatterjee & Simonoff, 
2013). Studentised residuals are the standardised residuals with the ith case removed 
from the equation; where the standardised residuals are the raw residuals (i.e., the 
difference between the data response and the fitted response) divided by the standard 
deviation of the residuals (Boomsma, 2014; Stevens, 2012). Theoretically, points 
having standardised/studentised residuals between −2.5 and 2.5 are with a usual 
response compared with the predicted value from the model (Chatterjee & Simonoff, 
2013). Points outside this range are potentially outliers and could influence the model 
specifications (Chatterjee & Simonoff, 2013). 
The software R-Gui can produce plots which automatically detect and flag 
influential points (Boomsma, 2014; R Core Team, 2014). These plots include a graph 
of standardised residuals versus leverage. This plot identifies outliers with high 
leverage and high residuals. Furthermore, points with unacceptable Cook’s distance 
range are marked on this plot. Points with standardised residuals outside the 
guidelines are also identified on a normality Q-Q plot of residuals. Further to using 
the diagnostic plots to capture potential outliers, the plots can be used to validate 
other MLR assumptions. These include testing for the normality of the residuals (the 
theoretical and the observed quantiles need to coincide), model misspecification (the 
residuals need to be independent of the fitted values), and homogeneity (constant 
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variance of the residuals). Violations to the MLR assumptions may cause biased 
coefficients and invalid t-statistics, and the validity of the p-values of the regression 
coefficients can be affected (Kitagawa, 2010).
Multicollinearity was also examined. Multicollinearity exists when two or 
more model predictors are highly linearly dependent (strongly correlated with each 
other), which could lead to identification problems (Cohen et al., 2003; Hutcheson & 
Sofroniou, 1999). The presence of multicollinearity within a set of predictors can 
cause misinterpretation of the significance of individual independent variables in the 
regression model. Predictors used in building a model should be relatively 
independent of each other. An examination of the bivariate relationships could reveal 
potential collinearity amongst variables, if the absolute value of Pearson’s correlation 
coefficient is greater than 0.8 (Argyrous, 2011; Chen & Popovich, 2002; Hutcheson 
& Sofroniou, 1999). A more formal measure for multicollinearity is the Variance 
Inflation Factor (VIF), which is a measure of the amount of multicollinearity in a set 
of multiple regression variables. The VIF value should be less than 10 in regression 
models (Hutcheson & Sofroniou, 1999; Mason & Perreault, 1991; O’brien, 2007). 
Tolerance is also a measure of collinearity; its guideline is that a tolerance value less 
than 0.1 indicates that a variable is linearly dependent on other variables, and the 
variable under consideration should be investigated further (Hutcheson & Sofroniou, 
1999; O’brien, 2007). 
Assumptions validations and guidelines are important in deriving 
scientifically adequate regression models. A reliable and good explanatory model 
could be selected based on different criteria. Different models can be built given a set 
of predictors. Selecting variables to build a model can be based on including all 
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potential predictors in the model or combinations of variables, assuming that either 
method is possible from a practical perspective. In the current study there were 18 
independent variables (including the questionnaires subscales), with hundreds of 
possibilities of equations to include combinations of variables. Given that this was 
not feasible, the MLR assumptions need to be validated for all models while in the 
process of selecting an optimal model. Alternatively, simultaneous forced entry 
(SPSS: Enter) of a set of selected variables can be used to fit a model; the selection 
can be based on previous research findings and strength of bivariate relationships in 
the current study. In addition, systematic methods could be used to eliminate or add 
variables, to yield a good quality and parsimonious model. Systematic methods 
include Backward selection and Forward selection methods (Stevens, 2012). 
The Backward elimination procedure starts with a maximum model and then 
starts eliminating variables according to the p-value (alternatively the effect size can 
be used), the highest p-value gets removed first, and stops when it reaches a pre-
specified threshold (e.g., p-value < 0.1). In contrast, the Forward selection method 
starts with no variables in the equations (intercept-only model), and then variables 
are introduced one by one. Variables with stronger effect sizes (in either direction) 
are kept in the model, weaker effect sizes are eliminated as they are entered and in 
relation to other variables in the equation. The Backward and Forward selection 
methods could produce several models that are potentially valid, choosing an 
explanatory model could be filtered further by using other criteria.  
The coefficient of multiple determination (R2) can be used to determine the 
quality of a model (Linneman, 2011). This has a range from 0 to 1, where 1 is a 
perfect fit of the model to the sample observations. The R2 is described as the 
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proportion of variance explained by regression, or a summary of the explanatory 
power of the regression (Linneman, 2011). However, adding more variables to a 
model always increases the value of this, which may be misleading when comparing 
models having a different number of explanatory variables. 
To account for the number of predictor variables, the adjusted-R2 was used in 
the current study. This is calculated such that it compensates for the addition of 
variables in the model. The adjusted-R2 value could increase or decrease with the 
addition of a variable depending whether the variable adds or does not add to the 
explanatory power of the model. In this study the adjusted-R2 was used to compare 
different models, but this by itself is not sufficient to indicate the reliability of a 
model, because it only indicates how good the fit is. The overall adequacy of a model 
can be examined by integrating all the tests of validations and methods of selecting 
predictors to derive a reliable model with sound specifications. A final model can be 
compiled following a series of steps and iterating these when necessary. 
Reporting the statistics of a final model can be obtained from output of the R-
Gui or SPSS programmes (the latter was used because of its convenient tables 
display). In SPSS tables can be used to summarise regression results of an overall 
model and the model’s predictor (or explanatory) variables. These tables include: 
model summary, analysis of variance (ANOVA), and coefficients. Assuming that we 
have k predictor variables, N observations, goodness of fit and significance measures 
for the entire model are given by: adjusted-R2, F-ratio(k, N-(k+1)), and p-value of the 
model. The F-ratio (also referred to as overall F) is another indicator of the observed 
variability in the samples responses; the brackets include the degrees of freedom (df) 
of the regression (effect) and residuals (errors), respectively. The significance of the 
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F-ratio indicates if the model is a significant fit to the data and only indicates 
whether at least one variable has a significant effect on the outcome variable, but it 
does not indicate which one is significant (Stevens, 2012).    
The coefficients table provides information about the explanatory variables. 
This table includes unstandardised (B) coefficients, standardised (beta) coefficients, 
and statistical significance (p-value) (Berkman & Reise, 2012; Simon, 2003). The 
unstandardised B coefficient for a variable, x, represents the effect of a one unit 
increase in a predictor, x, on the outcome variable, y, holding all other predictor 
variables constant (Gerstman, 2015). This was used in the current study to present 
practical interpretations for the relationship between HbA1c and each of the 
significant predictors; for example, the number of units that is needed to change on a 
specific scale to predict a change in HbA1c. The standardised beta coefficients are 
the results of a regression where all variables (both predictor and outcome variables) 
have been converted to z-scores; that is, they are measured in the number of standard 
deviations from their respective means (Gerstman, 2015). The beta coefficient for a 
predictor variable, x, therefore represents how many standard deviations we would 
expect y to increase when x increases by one standard deviation. It is useful when the 
predictors are measured in very different units, and it is also useful as a measure of a 
comparable effect size (Gerstman, 2015). The current study used beta to measure the 
magnitude of the effect of the predictor variables (having different units) on the 
outcome variable. 




Reliability of BIPQ, CIDS, and PedsQL 3.2
The Cronbach’s alpha coefficient for the BIPQ was 0.704, suggesting good 
reliability (see Bland & Altman, 1997; Gliem & Gliem, 2003). The Cronbach alpha 
coefficient for the CIDS in the current study was 0.923, which represents excellent 
internal consistency (see Bland & Altman, 1997; Gliem & Gliem, 2003). The total 
PedsQL had a Cronbach alpha coefficient of 0.922, which suggests excellent internal 
consistency (see Bland & Altman, 1997; Gliem & Gliem, 2003). Most of the 
reliability coefficients of the individual scales of PedsQL were also in the acceptable 
to excellent range (Table 3.1), except for the treatment barrier scale which was just 
slightly less than 0.7. Cronbach alpha less than 0.7 can be acceptable but needs to be 
interpreted with caution (Bland & Altman, 1997; Gliem & Gliem, 2003). 
Table 3.1
Reliability (internal consistency) of the PedsQL scales






The above results in this section indicated valid reliability of the BIPQ, CIDS, 
and PedsQL 3.2 measures. The findings allow proceeding confidently to the next part 
of the data analyses and interpretation. 
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Descriptive Statistics
This section describes both the raw data and preliminary interpretations of 
observed mean scores, as well as presenting descriptive and explorative analyses on 
the variables included in the current study. 
The mean age was 19.9 (SD = 3.0) years. The mean HbA1c was 77 
mmol/mol (SD = 26 mmol/mol), which is above the recommended level and is 
classified in the suboptimal diabetes control range. The majority of youth (66.1%) 
had unsatisfactory levels of HbA1c, with more than half of those individuals (35.7%) 
falling in the poor and very poor HbA1c ranges (Table 3.2). Very few individuals 
(5.4%) achieved an optimal diabetes control.
Table 3.2
A description of type 1 diabetes control in the study population (N=56), defined by HbA1c range
HbA1c 
(mmol/mol)
Diabetes control categories+ n % M SD
Excellent Control (< 50 mmol/mol) 3 5.4% 42 4
Very good control (50-54 mmol/mol) 7 12.5% 52 1
Acceptable but higher than ideal (55-64 mmol/mol) 9 16.1% 59 3
Suboptimal glycaemic control (65-79 mmol/mol) 17 30.4% 71 5
Poor glycaemic control (80-99 mmol/mol) 11 19.6% 88 6
Very poor glycaemic control (>100 mmol/mol) 9 16.1% 123 20
Note. +Source of categories is NZSSD (2009b)
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The mean BIPQ total score was in the middle of the scale with a relatively 
small deviation from the mean (Table 3.3). This suggests that on average the youth 
had moderate perceptions of diabetes as a threatening condition. The highest mean 
score was observed in the timeline subscale (Mscore= 94.9), which indicates that the 
youth had a strong perception of the chronicity of the diabetes condition. The lowest 
mean score was observed in the treatment control (reversed) score, which indicates 
that the youth perceived treatment as being helpful in controlling their diabetes. The 
second two lowest means scores, which were well below the total score average,
were coherence and personal control (reversed) scores. These mean scores indicated 
that on average the youth in the current study had a good understanding of their 
illness and a high level of perceived personal control over their diabetes. The mean 
scores on the remaining dimensions (consequences of diabetes, concern and 
emotional representations, and identity) indicated that on average the youth had 
slightly more threating views on these subscales compared to the other subscales.  
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Table 3.3
Mean psychosocial scores of the youth with type 1 diabetes who 
completed the study questionnaires, N = 56
Scale M SD
BIPQ-Total 50.3 12.0
BIPQ 1-Consequences 60.5 21.2
BIPQ 2-Timeline 94.9 12.0
BIPQ 3- Personal control (reversed) 36.8 22.1
BIPQ 4-Treatment control (reversed) 17.5 18.8
BIPQ 5-Identity 55.7 19.6
BIPQ 6-Concern 61.7 24.4
BIPQ 7-Coherence (reversed) 22.1 20.3
BIPQ 8-Emotions 53.8 27.4
PedsQL-Total 61.1 15.5
PedsQL-Diabetes symptoms 56.7 14.8
PedsQL-Worry 48.7 22.2
PedsQL-Treatment Barriers 69.7 19.1
PedsQL-Treatment Adherence 66.0 21.0
PedsQL-Communication 64.3 23.7
CIDS 75.4 15.9
The total score on the PedsQL 3.2 had a mean score of 61.1. This indicated 
that they were closer to the higher end of the scale, which suggests having fewer 
problems associated with diabetes QoL (Table 3.3). All the dimension scores, except 
worry, were above 50, indicating fewer problems related to diabetes QoL. The lowest 
mean score (M = 48.7) was on the worry scale, which indicated that the youth in the 
current study on average had problems associated with worrying about diabetes 
complications. The highest mean score (M = 69.7) was on the treatment barriers 
subscale, which suggested that the youth had the least problems associated with 
barriers to diabetes treatment (e.g., pain from pricking finger and taking insulin 
injections, and embarrassment caused by diabetes treatment). The mean score on the 
CIDS scale was relatively high (M = 75.4) – Table 3.3. This suggests that the youth, 
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on average had strong self-efficacy related to their diabetes self-management.  
Relationships among variables
The full interrelationships table can be found in Appendix 3.2. The following 
descriptions present relationships that met the significance criterion (i.e., p < 0.05) of 
the bivariate relationships. 
Glycaemic control: HbA1c
Glycaemic control was significantly associated with several variables. These 
were: age (r = −0.363, p < 0.01); BIPQ total score (r = 0.295, p < 0.05), personal 
control (r = 0.363, p < 0.01), and coherence (r = 0.282, p < 0.05); and PedsQL total 
score (r = −0.268, p < 0.05), treatment adherence (r = −0.351, p < 0.01), and 
communication (r = −0.315, p < 0.05). These results suggest that lower HbA1c 
levels were associated with older age, and increased perceived personal control and 
understanding of diabetes. In addition, lower HbA1c levels were associated with 
fewer problems related to treatment adherence and communication. Higher levels of 
HbA1c were associated with poorer QoL and more negative views on diabetes as a 
threatening disease. 
Illness perception: BIPQ
The BIPQ total score had several significant interrelationships with other 
variables included in the analysis; this is in addition to its significant association with 
HbA1c. BIPQ was correlated with CIDS (r = −0.428, p < 0.01), PedsQL total score 
(r = −0.751, p < 0.01), and each of the five PedsQL dimensions (see Appendix 3.2). 
These results suggest that more negative views on diabetes as a threatening disease 
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are associated with lower levels of self-efficacy and poorer QoL.  
The inter-correlations amongst the BIPQ individual subscales presented 
several significant associations. The BIPQ consequences score was correlated with 
identity (r = 0.434, p < 0.001), concern (r = 0.302, p < 0.05), and emotions scores (r
= 0.529, p < 0.01). This suggested that more perceived consequences of diabetes 
were associated with a highly perceived symptomatic condition, and higher levels of 
concern and negative emotions.  
Perceived personal control was associated with treatment control (r = 0.409, p 
< 0.01), coherence (r = 0.441, p < 0.01), identity (r = 0.270, p < 0.05). This suggests 
that a higher level of perceived control was correlated with more understanding of 
diabetes and a higher level of perceived treatment control. In contrast, a lower level 
of perceived control was associated with a highly perceived symptomatic condition. 
A higher level of perceived emotions was correlated with higher perceived 
identity (r = 0.377, p < 0.05) and concern (r = 0.475, p < 0.01), and lower level of 
coherence (r = 0.325, p < 0.05). The BIPQ timeline scores were not associated with 
any of the variables. 
Self-efficacy: CIDS 
Self-efficacy was significantly associated with personal control, treatment 
control, and coherence (r = −0.528, p < 0.01; r = −0.268, p < 0.05; r = −0.405, p < 
0.01, respectively). These relationships suggest that greater self-efficacy in diabetes 
self-management was associated with higher perceived personal and treatment 
control, and understanding of illness. Furthermore, self-efficacy in diabetes self-
119
management was significantly associated with the PedsQL total score, treatment 
barriers, treatment adherence, and communication (r = 0.568; r = 0.440; r = 0.634; r
= 0.562; p < 0.01, respectively). These correlations suggest that higher self-efficacy 
in diabetes self-management were associated with better overall QoL, and fewer 
problems with treatment barriers, adherence, and communication.  
Quality of Life: PedsQL 
In addition to the mentioned above associations related to the QoL 
components, the total PedsQL 3.2 score was significantly associated with all of the 
BIPQ dimensions, except for the BIPQ timeline (Appendix 3.2). The associations 
were in a negative direction, ranging from r = −0.374 to r = −0.598 (p < 0.01). These 
correlations suggest that higher perceived personal and treatment control, and 
coherence were associated with better overall QoL. In contrast, higher perceived 
consequences, identity, concern, and emotions related to diabetes were associated 
with poorer QoL. 
The PedsQL diabetes symptoms scores were significantly associated with 
BIPQ consequences (r = −0.451, p < 0.001), personal control (r = −0.330, p < 0.05), 
identity (r = −0.615, p < 0.01), coherence (r = −0.285, p < 0.05), and emotions (r = 
−0.485, p < 0.01). These results suggest that fewer problems related to diabetes 
symptoms were correlated with higher perceived control, more understanding of 
diabetes, a lower perceived somatic identity and fewer negative emotions.  
The PedsQL treatment barriers score was significantly correlated with most 
of the BIPQ scores, except timeline and concern. More barriers to treatment were 
correlated with higher perceived consequence (r = −0.461, p < 0.01), less perceived 
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personal (r = −0.424, p < 0.01) and treatment control (r = −0.461, p < 0.01), more 
somatic diabetes (r = −0.422, p < 0.01), lower level of coherence (r = −0.468, p < 
0.01), and more perceived negative emotions (r = −0.501, p < 0.01). 
PedsQL treatment adherence was significantly associated with the majority of 
BIPQ dimensions except for timeline. Fewer problems associated with treatment 
adherence were correlated to higher perceived personal and treatment control (r = 
−0.413, p < 0.001; r = −0.405, p < 0.01, respectively), and more understanding of 
the illness (r = −0.426, p < 0.01). In contrast, more problems in treatment adherence 
were associated with more perceived consequences (r = −0.294, p < 0.05), diabetes 
as a somatic condition (r = −0.389, p < 0.01), more concern (r = −0.321, p < 0.05), 
and negative emotions (r = −0.468, p < 0.01). 
The PedsQL worry was associated with BIPQ consequences (r = −0.285, p < 
0.05), concern (r = −0.563, p < 0.01), coherence (r = −0.325, p < 0.01), and 
emotions (r = −0.473, p < 0.01). More worries about diabetes complications were 
correlated with higher perceived consequences, lower level of coherence, more 
concern and negative emotions.
PedsQL communication was significantly associated with BIPQ 
consequences, personal control (r = −0.341, p < 0.05), identity (r = −0.289, p < 
0.05), coherence (r = −0.465, p < 0.01), and emotions (r = −0.392, p < 0.01). A 
higher level of communication was associated with fewer problems with negative 
emotions, identity, perceived consequences, and higher levels of perceived personal 
control and coherence.  
The five PedsQL dimensions were all significantly interrelated. The results of 
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the PedsQL interrelationship in general suggest that fewer problems in one of the 
dimensions was associated with a better QoL outcome on the dimension that it was 
significantly associated with. As an example, the PedsQL diabetes symptoms score 
was positively associated with all other PedsQL dimensions: worry (r = 0.400, p < 
0.01), treatment barriers (r = 0.488, p < 0.01), treatment adherence (r = 0.454, p < 
0.01), and diabetes communication (r = 0.400, p < 0.01). These correlations suggest 
that individuals who experience fewer problems associated with diabetes symptoms 
also experienced fewer problems associated with worries, treatment barriers and 
adherence, and diabetes communication. 
Gender differences 
Independent-samples t-tests were conducted on individual variables, 
including HbA1c and the questionnaires scores, to assess if there were any gender 
differences. Comparing females and males revealed that females had poorer QoL 
associated with diabetes symptoms compared to males (t(54) = −2.58, p = 0.013). In 
addition females perceived diabetes as being more symptomatic compared to males 
(t(54) = 2.01, p = 0.049). Gender differences were not detected in any other 
variables, including HbA1c, age, and questionnaires scores. Based on the above 
findings, because there is at least one significant difference according to the gender 
groups, this variable was included as a potential moderator in the regression model. 
Regression analysis predictor variables selection
Selection of the predictor variables of HbA1c for inclusion in the regression 
analysis involved examining the level of correlation amongst variables. In the current 
study, because the BIPQ and PedsQL total scores were strongly correlated (i.e., high 
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linear dependency; r = 0.75) the PedsQL total score was replaced by its five 
dimensions, which represent the aforementioned five QoL constructs: diabetes 
symptoms, treatment barriers, treatment adherence, worry, and communication. 
These dimensions had significant associations with BIPQ, but were all less than 0.7 
which suggests multicollinearity is relatively less likely to be present; this was 
further confirmed in the regression model using specific statistical analysis (e.g., 
VIF). Furthermore, the total BIPQ was included instead of the eight individual items 
to reduce the number of variables in the model; hence, the five PedsQL were selected 
and not the eight BIPQ items. Additional investigations were performed including all 
eight BIPQ items as well as statistically significant terms from the previous analysis.
Regression Analysis 
Multiple linear regression models were used to investigate whether there were 
any relationships between HbA1c and the predictor variables, and to understand 
variations in HbA1c across the study population and in relation to psychosocial 
factors. The MLR assumptions were checked. The ratio of the number of cases to 
predictor variables (56:9 or 6:1) fulfilled the MLR requirements. Scatter plots of the 
bivariate relationships and the Pearson’s correlation coefficients of HbA1c and 
predictor variables (Appendix 3.3) were then inspected. The strength of correlations 
of predictors with HbA1c, using absolute values, ranged from low (r = 0.087) to 
medium correlations (r = 0.363). The scatter plots and strength of relationships 
reflected neither obvious departure from linearity nor clear patterns in the bivariate 
relationships. In addition, there were no indications of potentially strong collinearity 
amongst variables, because all the Pearson’s correlation coefficients values were less 
than 0.7 (Appendix 3.4). Formal tests of multicollinearity were used to confirm this 
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and results are presented in this section. Moreover, on the scatter plots, the HbA1c 
observations at or exceeding 138 mmol/mol were marked as potential outliers (four 
entries). Suspected outliers were removed from the dataset to re-examine the scatter 
plots and the Pearson’s correlation coefficients. After removing the potential outlier, 
the |r| ranged from 0.099 to 0.389 (Appendix 3.5). Further investigations were 
undertaken to determine this statistically as detailed below.
Regression models were fitted, incorporating selected sets of variables, as 
previously outlined in the methods section. First, a MLR model was built using the 
Enter method having all variables of interest (i.e., age, BIPQ total score, and the five 
PedsQL dimensions). Second, models were systematically fitted using the Forward 
and Backward selections methods. The Enter and Forward selection methods results 
are presented shortly. The Backward selection method was implemented as a means 
of cross-checking the results; the results of the Forward and Backward selection 
methods were essentially the same in this study.
The regression model using the Enter method had a statistically significant F-
ratio: F(9,46) = 3.28, p = 0.004, R2= 0.391, adjusted-R2 = 0.271, indicating a 
statistically significant relationship that explains some of the variation in HbA1c. The 
effect sizes and statistical significance of the predictor variables in this model are 
shown in Table 3.4, ranked from strongest to weakest effect sizes. Figure 3.2 shows 
the diagnostic plots of this model. 
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Table 3.4
Summary of the regression model using the Enter method to explain variation in HbA1c, N = 56
Predictor Variable B beta p
PedsQL-Treatment Adherence −0.644 −0.527 0.008*
PedsQL-Worry 0.451 0.391 0.007*
CIDS 0.567 0.351 0.040*
Age −2.497 −0.276 0.030*
PedsQL- Communication −0.266 −0.246 0.148
BIPQ-Total 0.476 0.222 0.231
PedsQL-Treatment Barriers 0.139 0.104 0.580
PedsQL-Diabetes Symptoms 0.080 0.046 0.767
Gender 1.828 0.035 0.795
F(9,46) = 3.28, p = 0.004, R2= 0.391, adjusted-R2 = 0.271 
Note. * Statistically significant predictors
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Figure 3.2. Diagnostic plots for the regression model using the Enter method to explain variation 
in HbA1c, F(9,46) = 3.28, p = 0.004, R2 = 0.391, adjusted-R2 = 0.271. The diagnostic plots check 
for (a) model misspecification: the residuals should be independent of the fitted values, (b) 
normality of the residuals: the theoretical and the observed quantiles should coincide, (c) 
homogeneity (constant variance of the residuals), (d) outliers (points with high leverage and high 
residuals). 
The flagged outliers (4 observations) in Figure 3.2 plots were individually 
examined. It was determined that they belonged to the subgroup HbA1c ≥ 138 
mmol/mol. A model was implemented using the Enter method excluding these 
outliers, to compare it to the previous model of Table 3.4. The new model (without 
the outliers) also had a statistically significant F-ratio: F(9,42) = 3.43, p = 0.003, R2 = 

















































































































0.423 adjusted-R2 = 0.3. The model summary is presented in Table 3.5, and Figure 
3.3 presents the diagnostic plots for this model. After removing the outliers, the 
results changed considerably. This included changes in the statistical significance, 
sign of betas, and effect sizes, which indicated that the outliers had an influence on 
the model and reliability of results. 
Table 3.5
Summary of the regression model using the Enter method and after removing potential outliers to 
explain variation in HbA1c, N = 52
Predictor Variable B beta p
PedsQL-Worry 0.381 0.450 0.003*
BIPQ-Total 0.665 0.447 0.023*
Age −1.977 −0.314 0.015*
PedsQL-Treatment Adherence −0.302 −0.336 0.101
CIDS 0.240 0.217 0.223
PedsQL-Treatment Barriers 0.186 0.199 0.297
PedsQL-Communication −0.121 −0.160 0.351
Gender −2.159 −0.059 0.669
PedsQL- Diabetes Symptoms 0.033 0.028 0.863
F(9,42) = 3.43, p = 0.003, R2 = 0.423, adjusted-R2 = 0.3
 Note. * Statistically significant predictors 
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Figure 3.3. Diagnostic plots for the regression model using the Enter method to explain variation in 
HbA1c, F(9,42) = 3.43, p = 0.003, R2= 0.423, adjusted-R2 = 0.3. The diagnostic plots check for (a) 
model misspecification, (b) normality of the residuals, (c) homogeneity, and (d) influential outliers. 
To further assess the stability of Table 3.5 model, the new set of potential 
outliers in Figure 3.3 were checked and removed; these outliers did not belong to a 
subgroup. The new model had very small changes to the p values and effect sizes, 
and no changes to sign of betas or the overall results; hence, indicating the stability 
of the model in Table 3.5. Multicollinearity was also checked in the Table 3.5 model, 
all VIF values were less than 3. The normality and linearity assumptions were 
checked in Figure 3.3, and these were all found to be acceptable. The 


















































































































influence.measures checks were also acceptable. The current model therefore 
complied with the MLR assumptions and can be used as an explanatory model. 
The model of Table 3.5 was simplified further by using the Forward selection 
method. A model with the highest adjusted-R2 (0.329) was selected: F(3,48) = 9.35, 
p < 0.0001, R2 = 0.369. A summary of this model is presented in Table 3.6, and 
Figure 3.4 presents the diagnostic plots. In Figure 3.4, outliers were flagged. These 
were inspected and were removed to check their impact on the model, the model 
remained stable (overall results are similar). The BIPQ total score, PedsQL-Worry 
score, and age had statistically significant relationship with HbA1c, Table 3.6. The 
combination of these variables explain 36.9% of the variance in HbA1c for values 
less than 138 mmol/mol. Threatening views about diabetes (i.e., high BIPQ total 
score), less worries about diabetes complications, and younger age were associated 
with high HbA1c. 
Table 3.6
Summary of the regression model using the Forward selection method to explain variation 
in HbA1c, N = 52 
Predictor Variable B beta p
BIPQ-Total 0.727 0.489 0.001*
PedsQL-Worry 0.343 0.405 0.003*
Age −2.095 −0.332 0.006*
F(3,48) = 9.35, p < 0.001, R2 = 0.369, adjusted-R2 = 0.329
Note. * Statistically significant predictors 
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Figure 3.4. Diagnostic plots for the regression model using the Forward selection method to explain 
variation in HbA1c, F(3,48) = 9.35, p < 0.001, R2 = 0.369, adjusted-R2 = 0.329. The diagnostic plots 
check for (a) model misspecification, (b) normality of the residuals, (c) homogeneity, and (d) 
influential outliers. 
The BIPQ subscales and HbA1c  
A similar procedure using the above methods was followed to explore the 
relationship between HbA1c and individual BIPQ subscales. The contribution of the 
BIPQ subscale in explaining the variance of HbA1c was examined. A model was 
fitted that comprised the eight BIPQ subscales and the significant terms found in the 












































































































previous analysis (i.e., age and PedsQL-Worry). A set of outliers (HbA1c ≥ 138 
mmol/mol) found in previous analysis were excluded from this model because of its 
influence on the reliability and validity of results. The Forward selection method was 
used to simplify further the model (see Table 3.7 and Figure 3.5). Other potential 
outliers were detected and inspected closely – the model remained stable after 
removing these (and the overall results are similar). Multicollinearity was also 
checked – all VIF values were less than 2. The fitted model (F(4,47) = 6.93, p < 
0.001, R2 = 0.371, adjusted R2 = 0.318) satisfied the four principal assumptions for 
linear regression: linearity, homoscedasticity, independence and normality. Perceived 
personal control, concern, age, and worry were significantly associated with HbA1c 
(Table 3.7). The combination of these variables explained 37.1% of the variation in 
HbA1c. The results suggest that high perceived personal control and low perceived 
concern were associated with low HbA1c levels. Age and worry had similar 
relationships with HbA1c to that presented in the previous section.  
Table 3.7
Summary of the regression model using the Forward selection method  to explain variation in 
HbA1c, N = 52
Predictor Variable B beta p
Age −2.816 −0.447 0.001*
PedsQL-Worry 0.336 0.397 0.006*
BIPQ 6-Concern 0.245 0.313 0.033*
BIPQ 3-Personal control (reversed) 0.260 0.293 0.019*
F(4,47) =6.93, p < 0.001, R2 = 0.371, adjusted-R2 = 0.318
Note. * Statistically significant predictors 
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Figure 3.5. Diagnostic plots for the regression model using the Forward selection method to explain 
variation in HbA1c, F(4,47) = 6.93, p < 0.001, adjusted-R2 = 0.318. The diagnostic plots check for 
(a) model misspecification, (b) normality of the residuals, (c) homogeneity, and (d) influential 
outliers.
Worry scale and HbA1c 
The worry scale comprised of three questions representing worries about the 
complications of diabetes: going low, going high, and long-term complications. A 
total score on the scale contributed significantly to explaining the variation in 
HbA1c. Regression analysis was carried out to explore the contribution of individual 
worry questions in explaining HbA1c. A similar procedure for validating the model, 









































































































as outlined in the above sections, was carried out. The influential set of outliers, 
HbA1c ≥ 138, was removed. Table 3.8 presents results of the worry scale questions 
and HbA1c relationships, F(5,46) = 8.08, p < 0.001, R2 = 0.467, adjusted-R2 = 0.41. 
The model remained stable with the removal of further outliers. The four principal 
assumptions for linear regression were satisfied (Figure 3.6): linearity, 
homoscedasticity, independence and normality. In addition to age and BIPQ total 
score, going low was significantly associated with HbA1c, Table 3.8. The results 
suggest worrying more about going low is associated with lower HbA1c. 
Table 3.8
Summary of the regression model using the Enter method to explain variation in HbA1c, N =52
Predictor Variable B beta p
Worry: going low 0.336 0.396 0.019*
BIPQ-Total 5.272 0.354 0.010*
Age −2.094 −0.332 0.004*
Worry: long-term complications −0.140 −0.215 0.145
Worry: going high −0.140 0.207 0.212
F(5,46) = 8.08, p < 0.001, R2 = 0.467, adjusted-R2 = 0.410
Note. * Statistically significant predictors 
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Figure 3.6. Diagnostic plots for the regression model using the Enter method to explain variation in 
HbA1c, F(5,46) = 8.08, p < 0.001, R2= 0.467, adjusted-R2 = 0.41. The diagnostic plots check for (a) 
model misspecification, (b) normality of the residuals, (c) homogeneity, and (d) influential outliers.







































































































The mean HbA1c (77 mmol/mol) in the current study was above the 
recommended level and in the suboptimal glycaemic control range, but is comparable 
to the mean HbA1c values found in other studies that had a similar age range (e.g., 
Griva et al., 2000; Hackworth et al., 2013; McGrady et al., 2014). A large percentage 
(82.2%) of youth in the current study had HbA1c levels higher than recommended, 
with more than half of the youth (66.1%) having HbA1c > 65 mmol/mol, and only a 
small percentage (5.4%) in the excellent control range. These results showed a 
similar pattern to that found in the audit study in Chapter 2, with the vast majority of 
youth not meeting the minimally acceptable HbA1c targets. 
Poor diabetes control (high HbA1c) is associated with higher risks for 
diabetes-related complications, increased likelihood of hospital admissions, and 
poorer QoL (Angus & Waugh, 2007; Levine et al., 2001; Palta et al., 1997). This 
means that more than 60% of youth with type 1 diabetes in the CDHB catchment 
area, in the present study cohort, were vulnerable to these risks, and that further 
action is required to facilitate improvements in diabetes control. This may be 
achieved through, for example, interventions specifically designed to suit the unique 
needs of youth with type 1 diabetes. To identify the needs of youth that can influence 
diabetes outcomes, an understanding of their diabetes-related attributes is necessary. 
This includes understanding key psychosocial characteristics associated with diabetes 
control.   
The current study explored psychosocial characteristics of youth (15-24 year 
olds) with type 1 diabetes and the relationships between these characteristics and 
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HbA1c. The results show that lower HbA1c was associated with older age. 
Furthermore, perception of diabetes as a threatening condition was related to poorer 
diabetes control. Higher levels of perceived personal control and understanding of 
diabetes were associated with lower HbA1c. In addition, better overall diabetes-
specific QoL and fewer problems associated with diabetes-related communication 
(e.g., with health professionals or other people) and adherence to treatment were 
associated with better glycaemic control. All of these findings were as expected and 
are consistent with previous research (Al-Hayek et al., 2014; Bazzazian & Besharat, 
2010; Fortenberry et al., 2014; Huggard, 2009; Laffel et al., 2014; McGrady et al., 
2014; Pereira et al., 2011; Pinhas-Hamiel et al., 2014). Furthermore, the bivariate 
relationships in the current study had mostly moderate strength associations, with a 
maximum Pearson’s correlation |r| = 0.363, which was also similar to that reported in 
the previous research.
A series of regression analyses in the current study presented consistent and 
supporting evidence of the role of some of the psychosocial factors (worry and 
illness perceptions) in predicting glycaemic control. A new understanding emerged 
from interpreting the relationships of the significant psychosocial factors with 
HbA1c. These relationships are discussed after a summary and interpretation of the 
results is outlined. 
The results of the exploratory regression analysis showed that nine predictors 
together explained 42.3% of the variation in HbA1c. The predictors were: age, 
gender, illness perception, self-confidence in diabetes self-care, diabetes symptoms, 
worry about diabetes, treatment barriers, treatment adherence, and communication. A 
combination of these variables has not been presented in previous research; hence, 
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data on a similar model are not available. Significant predictors of HbA1c in this 
model included: age, illness perception and worry; the remaining variables had non-
significant (p > 0.05) relationships with HbA1c. 
The nine predictors’ model was further simplified using systematic selection 
methods, which resulted in an ‘optimal’ model with the abovementioned three 
significant predictors (age, illness perceptions, and worry). Consistent with the full 
model findings, higher age predicted lower HbA1c, higher scores on the BIPQ 
predicted higher HbA1c, and more frequent worry about diabetes complications 
predicted lower HbA1c. The former two findings were generally consistent with 
previous research (Griva et al., 2000; Pereira et al., 2011; Pinhas-Hamiel et al., 
2014), but the worry finding diverted from what was expected. This is discussed 
shortly. The simplified model in the current study explained 36.9% of variation in 
HbA1c. The BIPQ contributed the most (17.7%) to explaining the HbA1c variation, 
followed by age and worry (12.9% and 6.2%, respectively). 
The current study further explored which particular illness representations 
contributed significantly to the HbA1c variation. In addition to age and PedsQL-
Worry, two of the BIPQ subscales were found to significantly contribute to HbA1c. 
These were concern and personal control, contributing respectively 3.5% and 10.1% 
to the variance of HbA1c. Higher perceived personal control was associated with 
lower HbA1c levels, and more perceived concern was associated with higher HbA1c.
These results were consistent with the general trend found in previous research 
(Harvey & Lawson, 2009). Griva et al. (2000), using the IPQ instrument, showed that 
12.2% of the variance in HbAlc was significantly explained by perceived 
consequences and identity. An analysis of a total score was not available in the study 
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by Griva et al. (2000); nonetheless, the overall findings support the role of illness 
beliefs in predicting HbA1c. 
There have been very few studies investigating the role of QoL as a predictor 
of HbA1c. The study by Skinner et al. (2006) used the diabetes-specific QoL and 
found that symptom impact, future worries, and impact on activities contributed 
5.2% to the variance of HbA1c and that higher HbA1c was associated with poorer 
QoL. Reid et al. (2013) found that the overall QoL contributed 14% of the variance 
in glycaemic control; individual dimensions analysis was not presented in this study. 
The results in the Reid et al. (2013) study suggested that lower QoL was associated 
with higher HbA1c levels (beta = −0.425, p < 0.01). Pereira et al. (2011) also found 
that QoL was significantly correlated with HbA1c (beta = 0.244, p < 0.05); higher 
HbA1c was associated with poorer QoL. 
A significant contribution from a QoL dimension was also found in the 
current study. Worry about diabetes complications explained 6.2% of the variance in 
HbA1c. A further exploration of the worry scale revealed that worrying about going 
low was a significant term contributing 13.7% to explaining HbA1c. That is, contrary 
to previous research findings, the current study found that more worries about 
diabetes complications (specifically worrying about going low) were associated with 
better diabetes control. There is, however, one other study that had a similar finding 
(Tulloch-Reid & Walker, 2009). Tulloch-Reid and Walker (2009) found that their 
good diabetes control group (HbA1c < 7%) had more worry and anxiety levels 
compared to the poor control group in Jamaican youth with type 1 and type 2 
diabetes. However, when controlling for age in regression analysis (the mean age 
was 19 years old), the relationship between HbA1c (outcome measure) and 
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worry/anxiety (predictor variable) became non-significant. Furthermore, the worry 
and anxiety being measured in the study by Tulloch-Reid and Walker (2009)
represented a more general worry construct, measuring concern about future and life 
stresses and money matters. 
Previous research has investigated worry as a dimension within QoL, rather 
than evaluating the influence of worry on its own in explaining HbA1c. This 
relationship has potential clinical implications, and therefore, it is recommended that 
this be researched further. This seems particularly important given that the current 
study also found that perceptions of diabetes as a threatening disease play a role in 
predicting HbA1c; greater perceptions of diabetes as threatening could predict higher 
HbA1c. 
The current study findings provide a new understanding of the importance of 
balancing worries about diabetes complications and perception on diabetes as a 
threatening condition. That is, the more frequently youth worry about diabetes 
complications, the more likely it is that HbA1c will be lower. Conversely, with more 
overall threatening views of diabetes and greater concern about diabetes, HbA1c is 
likely to be higher. This could have clinical implications for assessing and carefully 
handling worries about complications and negative views on diabetes.
Further research is needed to examine these relationships. Such research 
could clarify the association between HbA1c and worry using, for example, a 
longitudinal study design and structural equation modelling could be used to 
investigate the significance of different paths associated to HbA1c and worry by 
direct and mediational effects associations. The paths might include measures related 
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to hypoglycaemia to reflect the going low dimension, such as fear of hypoglycaemia 
and frequency of hypoglycaemic episodes. Hoey et al. (2001) showed that 
adolescents who had at least one severe hypoglycaemic episode in the previous 3 
months were more worried than those than who had not had hypoglycaemic
episodes. The Hoey et al. (2001) results, however, also showed that lower HbA1c 
was associated with fewer worries. The lack of studies in this area and the 
inconsistency in results of the relationship between HbA1c and worry, given the 
importance of the clinical implications of findings, encourages further investigations.
In addition to the above interpretations, relationships found amongst the 
current study variables can be discussed from a different perspective – results from 
the regression output can be interpreted as follows. Referring to the simplified model 
in Table 3.6, one unit change (say an increase) in the BIPQ scale corresponds to an 
increase of 0.7 mmol/mol in HbA1c, which means an increase of 7 mmol/mol for a 
shift of 10 points on the transformed BIPQ scale. This corresponds to a one point 
shift on the original Likert scale. A change of at least 5 mmol/mol in HbA1c is 
considered clinically significant and can be associated with a reduction or increase in
the risk for diabetes complications (Little, Rohlfing, & Sacks, 2011; Urrechaga, 2012). 
For this reason, it could be clinically important to monitor youths’ views about 
diabetes as a threatening (or benign) condition. The personal control and concern
subscales follow a similar pattern, but with a higher level of change required in the 
score to achieve movement on the HbA1c scale. These two factors require at least 20 
points shift on the transformed scale to make a change in HbA1c levels; that is, on 
the Likert scale moving two points up or down the scale is associated with a 
significant HbA1c change.
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One unit change (e.g., increase) on the total score of the worry subscale 
corresponds to a 0.3 change in HbA1c in the same direction (i.e., increase). From a 
clinical perspective this might be considered insignificant. However, if we move, say 
25 units on the 0 to 100 worry scale, the HbA1c is likely to change by about 7.5 
mmol/mol, which then is a clinically significant change. The above units belong to 
the linearly transformed scale (i.e., 0 to 100) and to translate this on the original 
scoring scale (i.e., five scores from 0 to 4) one unit change on the worry subscale 
might have a significant effect on HbA1c levels. The going low scale has a similar 
trend to that of the overall score; a one score shift on the Likert scale is associated 
with a significant change in HbA1c level. The above findings need to be further 
investigated by replicating the current study longitudinally, and possibly by using 
other instruments that include a measure of worries in relation to diabetes 
complications.
Research shows that other predictors such as treatment adherence and self-
confidence in diabetes self-management may explain some of the variation in HbA1c 
(Griva et al., 2000; Iannotti et al., 2006; Johnston-Brooks et al., 2002). In the current 
study, statistically significant results for both treatment adherence and self-
confidence were not detected. The bivariate relationship of treatment adherence and 
HbA1c had a moderate correlation strength but was not significant (r = −0.271); 
whereas the CIDS correlation with HbA1c was weak (r = −0.099) and also 
statistically insignificant. In the regression model, both treatment adherence and 
CIDS remained as non-significant contributors in explaining HbA1c when 
controlling for the effect of the other predictor variables. A study by Griva et al. 
(2000) found that stronger confidence and more adherence to diabetes self-
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management are related to better diabetes control in mediational relationships, hence, 
models exploring mediational relationships may reveal more information on self-
efficacy and diabetes control in youth. 
Limitations of this study include the response rate of the completed 
questionnaires. A larger sample might potentially have led to the detection of other 
significant associations of variables in relation to HbA1c. Given the total population 
of CDHB youth with type 1 diabetes was 248 it was unlikely that a large sample size 
would be obtained. A significant challenge to this research were the effects of the 
2011 Canterbury earthquakes which caused many people to move houses, resulting 
in 26 invalid addresses and return to sender letters; this would have contributed to 
the smaller sample size. In addition to this, the homogeneity of the sample is another 
limitation, in that only CDHB youth were part of the current study. The sample size 
and inclusion of youth from one region within New Zealand limits the 
generalisability of results.  
Another limitation of this study was using strict systematic methods to build 
models. The systematic methods used had their advantages in making it possible to 
select a valid model based on efficient criteria, but with the disadvantage of the 
possibility of missing an optimum model. Nonetheless, it was practically not possible 
to build and validate all combinations of models. The main aim of the study was to 
explain the variation in HbA1c in relation to the psychosocial characteristics of youth 
with type 1 diabetes, whilst meeting requirements for the selected statistical analysis 
tests. 
Finally, the built models also have the limitation of only explaining HbA1c 
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less than 138 mmol/mol. Observations equal to or more than 138 mmol/mol were 
statistically determined as influential outliers and were excluded from the models. 
These might potentially fit a different model and have different outcomes. Future 
directions might include investigating models with a larger population and N sample, 
and with higher numbers in the extremely poor diabetes control subgroup. 
In conclusion, the hypotheses of the present study were supported, with the 
two exceptions for the relationship of worry and self-efficacy with HbA1c. Youth 
with type 1 diabetes residing in Canterbury follow a similar trend to youth in other 
countries in terms of their descriptive psychosocial characteristics and HbA1c. 
Threatening views of diabetes were associated with higher HbA1c levels and poorer 
QoL was associated with higher HbA1c. In addition, diabetes control can be 
significantly explained by a combination of psychosocial constructs including 
cognitive and emotional representations, as well as diabetes-specific QoL. There 
was, however, no significant relationship between diabetes-specific self-efficacy 
beliefs and HbA1c in this study. Furthermore, the worry construct had an interesting 
association with HbA1c (more worry about diabetes complications were correlated 
with lower HbA1c), which was different from the expected general trend. The 
relationships presented in this study added to existing research and bridged some of 
the gaps in knowledge. In addition, more research questions emerged as a result of 
these study findings – particularly pertaining the HbA1c and worry relationship. 
This study constituted a platform for the next study, presented in Chapter 4, 
by providing information specific to CDHB youth. The current study data served as a 
normative sample, which was used to guide the next study analysis, involving the 
psychosocial measures. These were used as a secondary outcome measure to evaluate 
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CHAPTER 4: MOTIVATIONAL INTERVIEWING INTERVENTION 
Introduction 
This chapter presents a study of a Motivational Interviewing (MI) 
intervention trial with youth with type 1 diabetes. The organisation of this chapter is 
as follows. A literature review is presented with an overview and general background 
on diabetes interventions for youth with type 1 diabetes. A description of MI and a 
review of literature on MI in diabetes interventions are then presented, and then a 
literature review on MI interventions with youth with type 1 diabetes. The literature 
review section is followed by a section on the significance, specific aims, and 
hypothesis of the current research. This chapter also describes the methodological 
basis related to the study design, participants, measures, and data collection, entry 
and analysis. Interpretation of the results and discussion concludes the chapter. 
Overview of Diabetes Interventions 
Youth with type 1 diabetes face persisting challenges associated with 
managing diabetes (Borus & Laffel, 2010; Hamilton & Daneman, 2002; Pinhas-
Hamiel et al., 2014). The daily medical and self-management routine is demanding 
and requires consistent self-regulation to achieve the recommended targets (Borus & 
Laffel, 2010). Youth with type 1 diabetes, especially those with poorly controlled 
diabetes, may require interventions (e.g., medical, behavioural, or psychosocial) to 
assist improving diabetes outcome (Hood, Rohan, Peterson, & Drotar, 2010). 
There has been extensive research investigating interventions for youth with 
diabetes (Hampson et al., 2000; Hood et al., 2010; Winkley, Landau, Eisler, & 
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Ismail, 2006). The complexity and combination of factors involved in diabetes 
management, and individuals unique needs, make it challenging to develop effective 
interventions that will work for all youth. Meta-analyses of diabetes interventions 
report a small to medium effect on diabetes outcomes, such as HbA1c, in youth with 
type 1 diabetes (Hampson et al., 2000; Winkley et al., 2006). Although these effects 
are only modest they still suggest that interventions have a role in reducing some of 
the impact of diabetes and the high risk of complications for those with poor diabetes 
control (Hood & Nansel, 2007).  
Different types of interventions have been developed to facilitate effective 
diabetes management, and thereby improve glycaemic control, for youth with type 1 
diabetes. These include family-based, group-based, and individual-based 
interventions; and may incorporate psychosocial, behavioural, motivational, and 
didactic intervention components (Plante & Lobato, 2008). In family-focused 
interventions, parents (in the current thesis this also refers to guardians) are directly 
involved in attending and participating in the intervention sessions and procedures 
(Anderson, Svoren, & Laffel, 2007; Plante & Lobato, 2008). Group-based and 
individual-based interventions can involve parents indirectly or directly in the 
intervention, depending on the study design and procedures (e.g., Anderson et al., 
2007; Plante & Lobato, 2008; Silverman, Haines, Davies, & Parton, 2003). 
Although research emphasises the importance of parental involvement and 
the sharing of responsibility for diabetes management in children and adolescents 
with type 1 diabetes, research also suggests that the degree of this involvement varies 
and that it declines as the young person gets older (Hanna & Guthrie, 2003). It is 
expected that this involvement vanishes in the transitioning to adulthood. Youth 
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increasingly seek autonomy and independence in diabetes-related tasks and decision 
making, as they do in other areas of their lives (Comeaux & Jaser, 2010). Increased 
independent decision-making in relation to diabetes management was found to 
improve metabolic control (Hanna & Guthrie, 2003). Diabetes interventions for 
adolescents can facilitate gaining skills that are necessary for making adequate 
diabetes-related decisions, which can lead to achieving improved glycaemic control 
(Klok, Sulkers, Kaptein, Duiverman, & Brand, 2009; Ott et al., 2000). In addition, 
because their parent(s) may have assumed much of the responsibility for their 
diabetes management, adolescents may lack knowledge and experience at earlier 
stages of their lives about diabetes, and improved diabetes control can be achieved 
through building self-efficacy and competence in diabetes management (Klok et al., 
2009; Ott et al., 2000).
Research shows interventions can have a positive influence on behavioural 
and psychosocial factors that have been found to affect diabetes management and 
QoL in youth (Harvey, 2015; Hood et al., 2010; Murphy, Rayman, & Skinner, 2006; 
Savage, Farrell, McManus, & Grey, 2010; Urban, Berry, & Grey, 2004). Several 
reviews have evaluated the effectiveness of diabetes interventions (educational, 
psychosocial, and behavioural) for youth with type 1 diabetes. A review by Urban et 
al. (2004) reported that improvements in metabolic control, self-efficacy, diabetes 
stress, and QoL were demonstrated as a result of psychosocial interventions. 
However, Urban et al. (2004) also found inconsistent evidence for education 
interventions as a means of improving metabolic control. Savage et al. (2010)
suggested that education interventions are less effective than psychosocial 
interventions. A review by Murphy et al. (2006) suggested that none of the 
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educational interventions on its own has been shown to be effective for youth with 
poorly controlled diabetes. These findings suggest that interventions that target 
factors other than increasing knowledge are necessary, especially for youth with poor 
diabetes control. 
A review by Hood et al. (2010) found that multi-component interventions that 
target psychosocial factors (e.g., emotional and social factors) were effective in 
improving metabolic control. The same study also found interventions that only 
focused on direct behavioural processes (e.g., increase frequency of SMOBG) and 
neglected targeting other factors (e.g., illness perceptions and self-efficacy) were 
unlikely to have an impact on metabolic control (Hood et al., 2010). 
The above findings emphasise the need to develop interventions that target a 
combination of factors (e.g., psychosocial and behavioural). In addition, 
interventions that can foster self-efficacy, autonomy, and active engagement of youth 
in managing their diabetes are likely to promote positive diabetes outcomes (Harvey, 
2015). Motivational Interviewing is an intervention that meets these criteria and has 
attributes which make it a potentially suitable and effective intervention for youth 
(Miller & Rollnick, 2013; Welch, Rose, & Ernst, 2006). 
Motivational Interviewing has been applied to a range of health behaviours 
including dietary behaviours, exercise promotion, oral health, and diabetes (Gayes & 
Steele, 2014; Lundahl, Kunz, Brownell, Tollefson, & Burke, 2010; Martins & 
McNeil, 2009; Morton et al., 2014). Motivational Interviewing can be delivered in 
brief, yet effective, doses particularly in situations where time is limited, such as in 
busy hospital clinics (Martins & McNeil, 2009; Rubak, Sandbæk, Lauritzen, & 
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Christensen, 2005; Vasilaki, Hosier, & Cox, 2006). Motivational Interviewing 
promotes a facilitative counselling environment and the level of MI acceptability 
amongst patients is high (Britt, Hudson, & Blampied, 2004; Martins & McNeil, 
2009). 
The following section provides a description of MI, then a detailed review of 
literature on MI in diabetes interventions.
What is Motivational Interviewing?
Motivational Interviewing is an evidence-based behaviour change approach –
it is defined as:
“a collaborative goal oriented style of communication with particular 
attention to the language of change. It is designed to strengthen the individual’s 
motivation for and movement towards a specific goal by eliciting and exploring the 
person's own reasons for change within an atmosphere of acceptance and 
compassion.” (Miller & Rollnick, 2013, p. 29)
Fundamental concepts of MI include an emphatic guiding communication 
style, working in a collaborative relationship towards achieving a mutually agreed 
change. This way of working is captured by what is termed the Spirit of MI, which 
comprises four elements: partnership, acceptance, compassion and evocation (Miller 
& Rollnick, 2013).
Partnership fosters the active role of the client in moving towards change and 
eliminates the authoritative role of a practitioner. The practitioner and client 
collaboratively work with each other, strengthening the client’s motivation for 
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change using the client’s own resources for change. Acceptance refers to the right of 
a client to make decisions related to change; that is, if they want to change and how 
to make that change. This component honours the person’s autonomy and recognises 
their absolute worthiness in making decisions related to change. Compassion is to 
pursue the welfare and best interests of clients and to seek to understand clients’ 
experiences, values, and motivations. This includes respecting others and their 
experiences and feelings without being judgmental. Evocation involves drawing out 
the client’s own reasons and motivations for wanting to change through the 
practitioner guiding the conversation in order to elicit change talk, without imposing 
any ideas or motives on the client. 
In addition, MI comprises four processes (Figure 4.1): engaging, focusing, 
evoking, and planning. These can be recursive, overlapping, and not necessarily 
applied in order (Miller & Rollnick, 2013).  
Figure 4.1. The four processes in MI: engaging, focusing, evoking, and planning 
(Miller & Rollnick, 2013).
Engaging is the process of establishing a working relationship between both 
the client and practitioner. A working alliance needs to be sustained throughout the 
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consultation to facilitate positive outcomes (Miller & Rollnick, 2013). Focusing 
involves mutually establishing a particular agenda or area of potential change and 
maintaining a focus of conversation in the direction of the desired change. Evoking is 
to facilitate, from within the client’s conversation, the emergence of motivations for 
change or movement in the direction of change. That is, the practitioner skilfully 
guides the conversation to elicit and strengthen the clients talk about change. 
Planning is to develop a specific action plan that would promote positive changes for 
the client using the client’s own resources when the client reaches a stage of being 
ready and committed to change.
Motivational Interviewing also involves using micro-counselling skills of 
reflections, open-ended questions, affirmations, and summaries. These micro-
counselling skills are used throughout the four processes (Miller & Rollnick, 2013). 
Reflective listening is a core skill in MI and good MI practice involves the 
practitioner using more reflections than questions (Miller & Rollnick, 2013). 
Reflections take two main forms: simple or complex. Simple reflections are to repeat 
or rephrase what the client said to clarify or emphasise understanding of the client’s 
part of the conversation. In contrast, complex reflections add new meanings based on 
what the client said, and are more powerful than simple reflections. As an example, 
reframing or paraphrasing specific parts of the conversations can help evoke the 
client’s motivations for change and to make clients recognise the deeper meaning of 
what they spoke out.
Open-ended questions are useful to elicit elaborative answers that may guide 
change, compared to closed questions that have yes-no or factual answers. The latter 
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limits the conversation while the former, especially evocative questions, expands it to 
facilitate the MI processes. Affirmations are reinforcement statements to 
acknowledge the client’s positive actions, efforts or strengths with the view to 
strengthening the client’s self-efficacy and confidence in their ability to change. 
Summaries are useful both to bring together the shared understanding from the 
collaborative conversation between the client and practitioner, and also to highlight 
specific parts of the conversation that may facilitate change. Summaries may also be 
used to maintain focus or to shift focus if necessary. 
Eliciting and strengthening change talk is a key component of MI. Change 
talk is “any self-expressed language that is an argument for change” (Miller & 
Rollnick, 2013, p. 159). Change talk was found to be related to positive client 
outcomes (Apodaca & Longabaugh, 2009; Magill et al., 2014). Examples of change 
talk are: desire to change (e.g., want and wish), ability to change (e.g., can and able), 
reasons to change (e.g., if, then statements), needs to change (e.g., must and have to), 
commitment (e.g., promise), activation (e.g., willing), and taking steps. Opposite to 
change talk is sustain talk which is the client’s speech not in favour of moving 
towards change, or sustaining the current behaviour (e.g., I don’t want to test my 
blood glucose and adjust the insulin dose). 
A skilled MI practitioner will manage sustain talk during the session so that it 
is quietened and avoid the emergence of discord. Discord is when the client becomes 
defensive, arguing, talking over the practitioner, is inattentive, or displays behaviours 
that signal dissonance in the practitioner-client relationship. The practitioner, 
metaphorically speaking, needs to maintain a dancing partnership rather than a 
wrestling encounter with the client. Sustain talk and discord are predictive of non-
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change and their emergence is related to the practitioner’s behaviour (Miller & 
Rollnick, 2002; Moyers & Martin, 2006). 
Motivational Interviewing can be learnt and applied by individuals from a 
wide range of backgrounds and expertise, such as health practitioners, counsellors, 
and researchers (Miller & Rollnick, 2013). It can be learnt through attending 
workshops, role plays, systematic feedback, supervision, and ongoing peer support 
(Miller & Rollnick, 2013). Training, ongoing coaching, and feedback ensure 
effective implementation of MI and optimises outcomes, which would otherwise be 
compromised by poor delivery of MI (Miller & Rollnick, 2013). Research shows that 
a practitioner’s in-session behaviours have an influence on client language and can 
predict clients’ outcomes (Apodaca & Longabaugh, 2009; Magill et al., 2014; 
Moyers & Martin, 2006). Poor delivery may include engaging in MI-inconsistent 
behaviours (confronting, directing, and warning) and there is evidence that high 
levels of MI-inconsistent behaviours are predictive of poor client’s outcomes 
(Apodaca & Longabaugh, 2009). 
Evaluation of MI treatment fidelity is essential to provide feedback for 
training and clinical supervision, and for clinical trials of MI (Jelsma, Mertens, 
Forsberg, & Forsberg, 2015; Miller & Rollnick, 2013). Treatment fidelity can be 
used to evaluate whether a treatment has been implemented effectively (i.e., 
treatment integrity), and to differentiate treatments in clinical trials (i.e., treatment 
differentiations). The use of reliable and empirically validated tools are necessary for 
measuring treatment fidelity and are becoming a pre-condition to interpreting results 
in clinical trials of MI (Christie & Channon, 2014; Jelsma et al., 2015). Formal and 
reliable assessment measures include Motivational Interviewing Treatment Integrity 
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(MITI) Code 3.1.1 (Moyers, Martin, Manuel, Miller, & Ernst, 2010) and its recent 
revision, the MITI 4.0 (Moyers, Manuel, & Ernst, 2014). 
Research is still emerging evaluating the efficacy of MI for health behaviour 
change, such as diabetes self-management. The following provides a review of 
literature evaluating the efficacy of MI in diabetes interventions. 
Motivational Interviewing in Diabetes Interventions 
Motivational interviewing has been investigated in the context of diabetes 
research including type 1 and type 2 diabetes and across different age ranges. The 
interventions have included MI as a standalone intervention, in addition to other 
intervention components, or an adapted form of MI-based interventions – in this 
thesis, these forms will be collectively referred to as MI interventions unless 
otherwise stated. 
Motivational Interviewing has shown promise in improving diabetes 
outcomes, such as those related to diabetes management and psychosocial 
functioning (Christie & Channon, 2014; Hettema, Steele, & Miller, 2005; Martins & 
McNeil, 2009). The evidence, however, is still not conclusive. Uncertainty has arisen 
from weak study designs (with threats to internal and external validity) and lack of 
adequate fidelity measures which leads to a lack of clarity regarding the treatment 
integrity and interventionists competence in delivering MI (Christie & Channon, 
2014; Mulimba & Byron-Daniel, 2014). 
A meta-analysis and systematic review by Jones et al. (2014) examined the 
effect of MI on HbA1c in people with type 1 and type 2 diabetes. The review 
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identified 13 randomised controlled trials (RCTs) that measured changes in HbA1c 
before and after treatment. The majority of these studies included adults with type 2 
diabetes; only three studies recruited children and adolescents with type 1 diabetes. A 
total of six studies found significant reduction in HbA1c in the MI group post 
intervention (Brug et al., 2007; Chen, Creedy, Lin, & Wollin, 2012; Hawkins, 2010; 
Rubak, Sandbaek, Lauritzen, Borch-Johnsen, & Christensen, 2011; Welch, Zagarins, 
Feinberg, & Garb, 2011; West, DiLillo, Bursac, Gore, & Greene, 2007). Two of 
these studies also found significantly lower HbA1c compared to that in the control 
group (Channon et al., 2007; Hawkins, 2010); and one study found that both 
intervention and control groups had lower HbA1c but the controls had the lower 
mean HbA1c (Welch et al., 2011). In contrast, four studies did not find any 
significant changes in HbA1c post intervention (Ismail et al., 2010; Minet, Wagner, 
Lønvig, Hjelmborg, & Henriksen, 2011; Pill, Stott, Rollnick, & Rees, 1998; Robling 
et al., 2012), and eight studies did not find any significant difference in changes in 
HbA1c between the MI and control groups (Brug et al., 2007; Chen et al., 2012; 
Ismail et al., 2010; Minet et al., 2011; Pill et al., 1998; Robling et al., 2012; Rubak et 
al., 2011; West et al., 2007). 
In contrast to the above findings, one study found a significant increase in 
HbA1c in both the MI and control groups; but with a significantly higher increase in 
the control group than in the MI group (Partapsingh, Maharaj, & Rawlins, 2011).
Furthermore, in a study that used MI-based education sessions, HbA1c increased 
significantly post intervention, and was significantly higher compared to the control 
group (Wang et al., 2010). 
The meta-analysis and systematic review by Jones et al. (2014) found that 
156
HbA1c decreased by 0.17% (95% CI: −0.09, 0.43%) post MI interventions, 
compared to control groups. This decrease, however, was not statistically significant. 
Jones et al. (2014) concluded that the impact of MI interventions on metabolic 
control appears to be inconclusive, based on their review of the small number of 
studies available and the limitations in the research, such as those mentioned 
previously. 
A review by Christie and Channon (2014) found that MI was generally 
effective in improving diabetes outcomes in the paediatric and adult populations. 
Findings from the studies on adults provided evidence for improvements in HbA1c, 
self-management, self-efficacy, diabetes knowledge and QoL in individuals who 
received an MI intervention compared to control groups (Christie & Channon, 2014). 
Nonetheless, MI did not have an impact on diabetes management in all of the studies, 
with positive effects not detected in two of the adults studies (Christie & Channon, 
2014). 
In the paediatric and youth population, Christie and Channon (2014) reported 
six studies of children and adolescents with type 1 diabetes. These studies had 
findings that mostly suggest the potential effectiveness of MI for young people with 
diabetes (Christie & Channon, 2014). Christie and Channon (2014), however, also 
reported that the current studies suffer methodological weaknesses, such as lacking 
fidelity checks of the quality of the MI delivered. They state that “it is essential that 
studies carefully address the process and fidelity issues as a precondition for 
seriously evaluating outcomes of Motivational Interviewing interventions in order to 
create a clearer picture of its role in facilitating change in health behaviour” (Christie 
& Channon, 2014, p. 385).
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A recent meta-analysis by Gayes and Steele (2014) concluded that MI is an 
effective and appropriate intervention for targeting health behaviour changes in 
young people, with MI having a positive impact on both physical and psychosocial 
health outcomes where the target was several health conditions. They found that MI 
had the largest effect size (Hedges’s g = 0.914) for type 1 diabetes, of all the other 
health conditions (paediatric obesity, dental health, calcium intake, and asthma) 
examined in the meta-analysis. It should be noted, however, that these conclusions 
were based on only four studies that included MI in an intervention for young people 
with type 1 diabetes (Channon et al., 2007; Channon, Smith, & Gregory, 2003; 
Viner, Christie, Taylor, & Hey, 2003; Wang et al., 2010). Three of these studies 
evaluated the effect of a combined intervention that included an MI component and 
had inconsistent results. In addition, fidelity data were not provided.
The following sections present a detailed review of studies that included MI 
in interventions that target youth with type 1 diabetes. Studies that used MI as a 
standalone intervention are detailed first, followed by research that used MI-based or 
that used MI as an adjunct component in interventions for youth with type 1 diabetes. 
Standalone MI interventions with youth  
In a pilot UK study by Channon et al. (2003) the impact of MI on metabolic 
control, diabetes self-management, and well-being was investigated. The study 
included 22 adolescents (14-18 years old) with poorly controlled type 1 diabetes. The 
mean HbA1c for the MI group was 10.8%, and 10.1% for the control group. The 
control group (n = 25) consisted of those who declined to participate in the 
intervention but had their HbA1c available for the study. The MI intervention period 
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was 6 months, unless a participant selected not to continue. Participants in the MI 
group had the choice of determining the number of sessions within the intervention 
period. The sessions were conducted by the same interventionist each time. The 
mean number of sessions over the intervention period was five sessions (min = 1 
session; max = 9 session, with a mean of 4.7). The intervention was delivered by a 
researcher trained in MI. The training was conducted over 3 months, and consisted of 
a workshop, training videos, role play and supervision. Weekly supervision took 
place during the intervention using recorded sessions. Treatment fidelity was not 
reported and it is not clear whether this was evaluated using formal measures or was
based on observational feedback from the supervisor. 
Outcome measures included HbA1c and psychosocial questionnaires. The 
HbA1c data were measured three times within 6 months (i.e., baseline, during, and 
post the intervention). The psychosocial questionnaires (pre-intervention and post-
intervention,) included: Well-being Questionnaire (WQ), Diabetes Knowledge Scale 
(DKS), Summary of Diabetes Self-care Activities (SDSCA), the Diabetes Readiness 
to Change Questionnaire (RCQ), and Personal Models of Diabetes Questionnaire 
(PMDQ), which measures illness perceptions. Participants also filled out Post-
Intervention Satisfaction Questionnaire (PISQ). 
There was a significant reduction in HbA1c both during and post the 
intervention compared to the mean HbA1c at baseline; the reductions were 1.1% and 
0.8%, respectively. Conversely, there was no significant reduction in HbA1c in the 
control group. The majority of the psychosocial questionnaires did not have 
significant changes. There were, however, significant changes in two dimensions of 
the PMDQ: there was a significant reduction in fear of hypoglycaemia, and also 
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improved perception for coping with diabetes. The PISQ indicted that youth made at 
least one positive diabetes self-management behaviour change. The DRCQ also had 
some changes for 39% of the participants, of which the majority (64%) indicated a 
movement towards action, and a minority (27%) indicated a decrease in readiness to 
change. These results need to be treated with caution because of the small number of 
participants.
This pilot study by Channon et al. (2003) provided evidence for the potential 
efficacy of MI as an intervention for youth with poorly controlled type 1 diabetes. 
The study however had limitations. Channon et al. (2003), on the one hand, found 
that youth reported at least one behavioural change in the PISQ. On the other hand, 
significant changes were not found in the scores of SDSCA. This inconsistency, 
according to the authors, made the results (including significant changes in HbA1c) 
difficult to interpret but the reported inconsistency could well be because of the lack 
of statistical power required to detect significant changes on the SDSCA. The small 
sample size and homogenous sample also limited the generalisability of the results. 
Moreover, during the intervention half of the HbA1c data were missing (n = 11), and 
post-intervention only 17 participants had a record of HbA1. For these reasons, the 
results need to be interpreted cautiously (Channon et al., 2003). It was also unclear if 
the observed changes could be attributed to the MI rather than to other factors (e.g., 
placebo effect of regular contact with the researcher or simply the passage of time). 
Consequently, as a result of the difficulties in interpreting the study data, Channon et
al. (2003) suggested that future research includes more intensive assessment of 
change and behavioural markers of diabetes self-management behaviours.
Huws-Thomas (2007) recruited 66 teenagers with type 1 diabetes from five 
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diabetes clinics in South Wales, UK. The inclusion criteria were adolescents aged 14-
17 years old who attended participating diabetes centres. A cut-off HbA1c value was 
not determined; hence the study was open to adolescents with both good and poor 
diabetes control. Teenagers were excluded from participation if they were newly 
diagnosed with type 1 diabetes, had learning disabilities and disorders of 
communication, or had other conditions that could interfere with an investigation of 
intervention effects (e.g., thyroid dysfunction). 
The study participants were randomly assigned to an MI intervention group, 
or to a control group, who received support visits. Participants in each group received 
individual sessions within a period of 12 months. The frequency and location of 
appointments in the MI group was less structured than that in the control group. The 
latter involved arranging appointments every 6-8 weeks (mean of 6 visits), whereas 
the former was determined by the participants (mean number of visits was 4). 
The same practitioners implemented the intervention each time. The control 
group received support visits from two diabetes nurses. The MI intervention was 
delivered by the study principal investigator, who was in training as a health 
psychologist. She received MI training by two professional MI trainers. The training 
took place prior to the intervention, with supervision and feedback during the 
intervention. The training and feedback were mostly based on observations from 
simulated and actual in-session behaviours. A formal method of evaluation was not 
used, and Huws-Thomas (2007) stated: 
“Due to time constraints it was decided not to use formal MI 
assessment tools such as Motivational Interviewing Skill Code [(MISC) 
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Miller, 2000]. The most preferred method of learning was based on the role 
of SC as an ‘expert coach’ with specific structured feedback based on positive 
reinforcement and collaborative problem solving. This structured feedback 
took the form of a) written observations and suggestions for improvement and 
b) face to face feedback during supervision.” (p. 140)
The primary outcome measure was HbA1c, and a battery of psychosocial 
questionnaires constituted the secondary outcome measures. The psychosocial 
assessments included using: PMDQ, Self-Efficacy for Diabetes Scale (SED), DQoL 
Measure for Youths, and WQ. All of the questionnaires were completed at baseline 
and 12 months; DQoL and WQ were also completed at a 24-month follow-up. The 
HbA1c was assessed at baseline, 6-month, 12-month, and 24-month post 
intervention. The baseline HbA1c mean of the MI and control groups were, 
respectively, 9.3% (SD = 2.1%) and 9% (SD = 1.56%).
There were significant differences in results for the primary and secondary 
outcome measures between the study groups, after adjusting for baseline values. The 
difference in mean HbA1c between the study groups was statistically significant at 
the 12-month follow-up (difference = 0.5%, p = 0.04), and a similar result was 
maintained at the 24-month follow-up (difference = 0.4%, p = 0.003). The MI 
intervention group had significantly lower HbA1c than the control group, suggesting 
improved metabolic control in the MI group at both follow-up. The analysis was 
based on the complete dataset from 47 participants (MI group n = 27, and control 
group n = 20).
At the 12-month follow-up, DQoL, well-being, and illness perceptions were 
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also significantly different between the study groups (p < 0.005). The MI group, 
compared to the control group, had greater life satisfaction, lower level of worry, 
experienced less anxiety, had more positive well-being, and perceived diabetes to 
have a lesser impact on their lives. The MI group also had higher scores on the total 
PMDQ, compared to that in the control group, suggesting the MI group had less 
threatening views on diabetes. Scores on the self-efficacy questionnaire, although 
indicated a higher level of confidence in the MI group compared to that in the control 
group, were not statistically significantly different.   
Statistical differences in scores of some of the scales between the study 
groups were maintained at the 24-month follow-up, but with a smaller difference 
from that found at the 12-month follow-up. The MI group, compared to the control 
group, had greater satisfaction, lower level of worry and anxiety, and diabetes had a 
smaller impact on their lives at 24-month follow-up. 
This study provides evidence for the efficacy of a standalone MI intervention 
with adolescents who have type 1 diabetes, with improvement in both HbA1c and 
psychosocial outcomes. The multi-centre study design increases the generalisability 
of the results; however, there were limitations to the study. More than half of the 
study participants (i.e., 52% of total participants, n = 34; and 58% of the MI 
participants, n = 22) had good metabolic control (HbA1c < 8%, M[n=34] = 7.2%), and 
therefore do not represent those youth with type 1 diabetes with poor diabetes control 
who are most in need of intervention. In addition, Huws-Thomas (2007) did not 
include measures to assess different self-management behaviours, such as SMOBG. 
Assessing adherence to diabetes self-management behaviours is a standard clinical 
practice/check for type 1 diabetes and there has been a strong recommendation to 
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include such data in clinical trials (Hampson et al., 2001; Jones et al., 2014). 
Finally, formal evaluation methods to assess the MI fidelity were not used in 
the Huws-Thomas (2007) study. Huws-Thomas (2007) stated that internal validity 
and skill efficacy in MI were sufficiently observed by an on-going process of 
supervision and feedback. In addition, discriminant validity could not be determined 
because there were technical difficulties with the number and quality of the recorded 
audios and  therefore, it was not formally assessed whether the treatment in the MI 
intervention group compared to the supportive counselling group were distinctive 
from each other. Furthermore, Huws-Thomas (2007) stated that the simultaneous 
occurrence of the interventionist training, intervention development, and supervision 
in a short time span was one of the key weaknesses in the study. This also suggests 
that the MI would have been applied more skilfully towards the end of the 
intervention and may have created a bias in results. 
Multicomponent interventions which include MI      
A qualitative preliminary study evaluated the impact of an intervention that 
comprised of MI and externalising conversations (EC) in adolescents with type 1 
diabetes (Knight et al., 2003). Twenty adolescents with type 1 diabetes were 
recruited from child and adolescent diabetes services in the UK. The participants 
were adolescents (aged 13-16 years) with type 1 diabetes who had difficulties 
adjusting to or coping with diabetes. Eligible adolescents, who were willing to 
engage in the intervention procedure, constituted the intervention group (n = 6) and 
the remaining eligible participants preferred to be part of the control group (n = 14), 
standard care.
164
The intervention comprised of six 1-hour weekly group sessions, which were 
based on MI and EC. The intervention was delivered by a senior registrar in child 
psychiatry and also by a community psychiatric nurse. The study did not report on 
the interventionists’ training in MI, and there was also no data on treatment fidelity.
The study groups completed questionnaires that included components on 
illness perceptions, emotional reactions, and coping mechanisms towards diabetes. 
The questionnaires were completed pre-intervention and post-intervention, and at the 
6-month follow-up. The results suggest that the MI-EC intervention was successful 
in improving diabetes illness perceptions in adolescents. The intervention group, 
compared to the control group, demonstrated less threatening views on diabetes, had 
more sense of perceived control, more acceptance of their condition, and had lower 
perceived impact of diabetes on their lives. 
Viner et al. (2003) evaluated a motivational and solution-focused therapy 
group intervention to improve glycaemic control in young people, aged 11-17 years. 
The study recruited 41 adolescents with poorly controlled type 1 diabetes (HbA1c > 
8.5%) from four urban UK hospital diabetes clinics. Six weekly group sessions were 
offered in the intervention, in groups of four to five young people per session. The 
control group consisted of adolescents who were invited to participate but who opted 
not to participate and they received standard care. 
The intervention was based on several approaches and had a combination of 
techniques adopted from the following four approaches: MI, solution-focused 
therapy, cognitive behaviour therapy (CBT), and systemic and narrative therapy. The 
motivational enhancement component in the study was based on using MI and 
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included: addressing ambivalence (e.g., discussing the advantages and disadvantages
of change), enhancing motivation to change (e.g., reflection of motivational 
statements), and preparation to change (e.g., psycho-education). Training of the 
interventionists (and their expertise, educational, or clinical background) was not 
described, and there was also no data on treatment fidelity. 
The outcome measures included an assessment of glycaemic control (HbA1c) 
and psychosocial questionnaires: the Strengths and Difficulties Questionnaire (SDQ); 
and the SED scale. The psychological assessments were collected at baseline and 
repeated 6 months post intervention. Glycaemic control was assessed at baseline and 
then three time points grouped as 1-3 months, 4-6 months and 7-12 months. A 
combined intervention effect was assessed without individually assessing which 
intervention component was the most or least effective. The mean HbA1c in the 
intervention and control groups were 10.2% and 10%, respectively, at baseline. At 
the 4-6 month follow-up, HbA1c dropped to 8.7% and 9.8%, respectively. There was 
a significant improvement in HbA1c at 4-6 months post-intervention (i.e., 1.5% 
reduction in HbA1c) compared to no significant change in the control group. This 
improvement was partly maintained at 7-12 months post-intervention from baseline 
(i.e., 1.3% reduction in HbA1c), but there was no significant difference between the 
intervention and control groups. There was also a significant improvement in self-
efficacy in the intervention group at the 6-month follow-up (mean SED Pre, 145,
SED Post = 158; F = 6.7, p = 0.014)), but not in the control group.
Nansel et al. (2007) evaluated the effect of a diabetes self-management 
intervention, or what they referred to as a diabetes personal trainer intervention, for 
youth with type 1 diabetes. The study recruited 81 adolescents (aged 11-16 years old) 
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with type 1 diabetes from two paediatric endocrinology clinics in Baltimore, 
Maryland, USA. Participants were eligible to take part in the study if they had 
diabetes for at least one year; there was no inclusion criteria based on HbA1c of a 
specific level (i.e., participants with good or poor diabetes control were eligible to 
participate). 
The intervention was guided by principles of MI, applied behaviour analysis, 
and problem-solving. The use of MI in the intervention was mainly to engage 
participants in the intervention and to facilitate the use of applied behaviour analysis. 
MI was also used to facilitate collaboration between the trainer and adolescents, and 
to avoid the participants perceiving the trainer as another authority figure that 
dictates orders with regard to diabetes management.  
The intervention consisted of six sessions and supplementary telephone calls 
conducted over a period of 2 months. The initial intervention session was conducted 
with both the adolescent and a parent and subsequent sessions involved the 
adolescent only. The non-professional interventionists (i.e., personal trainers) 
received 80 hours training in several areas related to the intervention, including 
diabetes management, MI, applied behaviour analysis, and parent-child issues in 
diabetes management. The training procedures included educational sessions, role 
plays, group activities, and individual practice with feedback. There were also 
weekly group supervisory sessions for the personal trainers. The authors report that 
the fidelity of MI was monitored to ensure adequate competency in delivering MI – a 
sample of recorded intervention sessions were evaluated for all trainers and were 
found adequate – but the authors did not provide data to support this.   
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The outcome measures comprised: metabolic control (measured by HbA1c), 
adherence (measured by a Diabetes Self-Management Profile), and psychosocial 
factors (measured by DQoL, SEDM, OEDM-N, and OEDM-P). Data were collected 
at baseline and at 12-month follow-up (Nansel et al., 2007). Additional follow-up 
data included self-report data (adherence, self-efficacy, and outcome expectations) 
collected at 6-month, and HbA1c data assessed at 9 months. The latter was also 
obtained from medical records 24-month post intervention (Nansel et al., 2009). 
At the 9-month and 12-month follow-up the results suggested that there was a 
trend for an overall intervention effect on HbA1c (F = 3.71, p = 0.06; F = 3.79, p = 
0.06, respectively), with a significant intervention-by-age interaction (F = 4.78, p = 
0.03). The significant interaction term suggested that the intervention had a greater 
effect on HbA1c in older adolescents than in younger ones. A further stratified 
analysis of the intervention effect on two age groups, 11-13 years (n = 42) and 14-16 
years (n = 36), revealed that the intervention significantly reduced HbA1c (p = 0.02) 
only in the older age group. Similar results were obtained at the 24-month follow up, 
with slight improvements. There was a reduction in the HbA1c, from baseline, in the 
intervention group (0.39%), whereas there was an increase in the control group 
(0.3%). There was a significant overall effect of the interaction on HbA1c (F = 6.92, 
p = 0.01) and a significant intervention-by-age interaction (F = 7.71, p = 0.01) 
(Nansel et al., 2009). Analysis of the psychosocial measures showed no intervention 
effect, with the exception of 12-month follow-up when the intervention group had 
lower positive outcome expectations and reported higher disease impact, compared 
to the control group.   
Wang et al. (2010) compared MI-based education and structured diabetes 
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education (SDE) for improving metabolic control and psychosocial outcomes in 
adolescents with type 1 diabetes. The study recruited children and adolescents aged 
12-18 years, with poorly controlled diabetes (HbA1c ≥ 9%), from the Children’s 
Medical Centre in Dallas, USA. The participants were randomised to either MI-based 
education (n = 21) or SDE (n = 23).
Two MI-based education sessions were provided: one immediately after 
baseline and the other 3-4 months later. In addition, participants received two 
telephone follow-ups scheduled one and two months after baseline. A third education 
session was also provided for participants who continued to have poor diabetes 
control (HbA1c ≥ 9%). The MI-based education used MI at the beginning of the 
intervention, followed by one or more educational sessions. There was no 
information on the frequency of sessions in the SDE group. 
Three diabetes educators delivered the MI-based intervention, and six 
educators were assigned to the SDE group. The latter group did not receive 
additional training. The MI interventionists received training from an MI trainer and 
psychologist in the form of a 2-day workshop, but the trainer’s level of skill in MI 
was not noted. The authors stated that “skill refreshers were done with an MI 
psychologist” (Wang et al., 2010, p. 1741), but there was no information on feedback 
or on-going supervision. All of the MI and SDE visits were recorded and coded by a 
blinded coder, who also received a 2-day workshop training in MITI 3.0. 
The HbA1c and psychosocial data were collected at baseline, 3-month, 6-
month, and 9-month follow-up points (T0, T1, T2, and T3, respectively). The 
psychosocial questionnaires included: Centre for Epidemiologic Studies Depression 
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Scale (CES-D), the Epidemiology of Diabetes Interventions and Complications 
Quality of Life Questionnaire (EDIC-QOL), and the SDSCA. 
The SDE group had significantly lower HbA1c than the MI group over the 6-
month follow-up and after adjusting for T0 (F = 4.84, p = 0.03). There were no 
significant differences in the psychosocial scores between the two groups at any of 
the follow-up points and after controlling for baseline measurements. The MITI 
coding results showed that the spirit was 4 on average (at the competent level). The 
percent of MI-adherent, however, was 70% which is below beginning proficiency 
(i.e., <90%). In addition, other MITI summary scores (e.g., %reflection-to-question 
ratio) were not reported. This suggests that although those who provided the MI-
based education may have generally been consistent with the spirit of MI, they did 
engage in behaviours inconsistent with MI, and their skill level was unclear for other 
key MI practitioner behaviours.   
Robling et al. (2012) evaluated Talking Diabetes, a consulting skills 
intervention aimed to train health practitioners to guide sessions constructively with a 
focus on agenda settings and support of patient led behaviour change. The study by 
Robling et al. (2012) is referred to as the DEPICTED study: the Development and 
Evaluation of a Psychosocial Intervention in Children and Teenagers Experiencing 
Diabetes. The study design was a pragmatic cluster RCT, which involved 26 
participating UK diabetes services. Seventy-nine healthcare practitioners (13 teams) 
received training in the intervention, and 359 children with type 1 diabetes aged 4-15 
years and their main carers were in the intervention group; the control group had 13 
teams, and 334 children with type 1 diabetes and their main carers. 
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Talking Diabetes used an approach that aimed to equip practitioners with 
skills for constructive sessions that facilitate and enhance adolescents’ engagement in 
their own health care and diabetes management. The intervention used a guiding 
communication style, shared agenda setting, person-centred approach, and had 
discrete strategies and skills drawn from MI. Information on the discrete strategies 
and skills drawn from MI were not clearly described. 
The training of practitioners included using web-based modules (e.g., formal 
didactic content) and two training workshops two weeks apart were delivered by two 
trainers. The workshops provided review, practice, and feedback on strategies and 
skills of the intervention. Training specific to MI skills was not clearly described in 
the paper. The authors used a supplemented version of an earlier version of a MITI 
measure by Moyers, Martin, Manuel, Hendrickson, & Miller (2005) to suit the 
combined intervention. For elements that were relevant to MI the study reported on 
treatment fidelity data on scales of guiding style and spirit (evocation, collaboration, 
and autonomy-support). The scores on the spirit ratings were below the standard MI 
beginning proficiency (i.e., < 3.5) before and after training. The study did not report 
on other practitioner behaviours such as the percentage of complex reflections or 
open questions. 
The primary outcome measure was HbA1c, which was collected at baseline 
and at 12-month follow-up. The mean HbA1c at baseline for the control group was 
9.2% (SD = 1.8%) and for the intervention group was 9.4% (SD = 1.8%). Secondary 
outcome measures included: clinical measures (hypoglycaemic episodes, body mass 
index, and insulin regimen); and psychosocial questionnaires, including general and 
diabetes-specific QoL, emotional adjustment to diabetes, self-reported and carer-
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reported importance of, and confidence in, undertaking diabetes self-management. 
The level of HbA1c slightly increased in both groups from baseline to follow-up 
(intervention group = 9.7%; and control groups = 9.5%), but there was no significant 
difference between the intervention and control groups. The intervention had no 
effect on the secondary measures except for a few changes. An increase in the short-
term ability to cope with diabetes in the intervention group was observed and carers 
in the intervention group reported greater excitement about clinic visits and improved 
continuity of care. In contrast, some aspects of diabetes-specific QoL improved in in 
the control group, compared to the intervention group, manifested by reduced
problems with treatment barriers and with treatment adherence. The overall results of 
this study suggested that there was no improvement in diabetes outcome as a result of 
the intervention. The intervention, however, was not entirely MI and the level of 
skills of the practitioners was below beginning proficiency on the fidelity measure. 
A pilot study by Stanger et al. (2013) adapted a multicomponent motivational 
intervention, which included MI/CBT and family-based contingency management 
(CM) for adolescents with poorly controlled type 1 diabetes. The study recruited 17 
adolescents (ages 12-17 years) with poorly controlled type diabetes, and their 
parents, from the Arkansas Children’s Hospital Endocrinology Clinic, USA. The 
mean pre-treatment HbA1c was 11.6% (SD = 2.5%), and the mean SMOBG 
frequency per day was 4.1 (SD = 1.9). 
Adolescents and their parents received 1-hour-per-week sessions over 14 
weeks of MI/CBT, clinic-based CM, and parent-directed CM. The intervention 
sessions were delivered by Masters’ level clinicians, who had weekly supervision 
sessions with the study principal investigator (supervisor). The interventionists had to 
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complete structured adherence checklists after each session, which were reviewed by 
the supervisor to ensure completion of treatment components. The MI section of the 
intervention included a menu, which was adopted from a study by Channon, Huws-
Thomas, Gregory, and Rollnick (2005). Training and treatment fidelity specific to MI 
were not reported. The outcome measures were HbA1c, SMOBG frequency (was 
downloaded weekly during the 14 weeks of treatment), and an assessment of 
adherence measured by the Self-Care Inventory (SCI). 
All outcome measures had significant improvement from pre-intervention to 
post-intervention. The HbA1c improved by 2.5% (p < 0.0001), the SMOBG 
frequency increased by 2.2 tests per day (p < 0.001), and there was an increase in the 
SCI score indicating improved level of adherence. These results, therefore, support 
the potential efficacy of a multicomponent motivational intervention for youth with 
poorly controlled type 1 diabetes.
A multicentre RCT was conducted to investigate the effect of MI and CBT on 
metabolic control in adolescents with type 1 diabetes (Berger et al., 2013; Rami-
Merhar et al., 2014). The study applied MET, which is MI including giving feedback 
to participants, such as HbA1c information. Participants in the study (n = 75) were 
Austrian children and youth (aged 13-20 years) with poorly controlled diabetes. The 
participants were randomised to an intervention group receiving individual MI and 
CBT sessions and control group receiving standard treatment, over a period of 6 
months. The intervention group had four sessions of MI, eight sessions of CBT, and 
10 supportive e-mail correspondences conducted by trained clinical psychologists.  
Information on the interventionists training and data on treatment fidelity were not 
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available in the abstract and a publication of a full manuscript was not available at 
the time of writing this thesis. Glycaemic control was assessed at baseline and then at 
the 6-month, 12-month, and 24-month follow-up. The baseline HbA1c for the 
intervention and control groups was: 9.95% (SD = 0.26%) and 9.24% (SD = 0.28%), 
respectively. 
There was a slight improvement in HbA1c in the intervention group (9.74%; 
SD = 1.75%), but this was not statistically significant at the 6-month, 12-month, and 
24-month follow-up. Analysis of stratified age groups revealed that older youth (aged 
16-20 years old) in the intervention group had significantly improved HbA1c 
compared to the younger group, (p = 0.032). This suggests that youth, compared to 
children, may have benefited more from the combined MI and CBT intervention. 
Gender differences were apparent at the 6-month follow-up, with males in the 
intervention group having improved HbA1c compared to females (who had a slight 
increase in HbA1c). The control group, in contrast, did not have significant 
differences based on gender. Thus, although the overall results did not indicate the 
effectiveness of the intervention, it appears that this intervention may be more 
effective for older youth. The above study showed the potential benefit of a 
combined MI and CBT intervention. 
Christie et al. (2014) examined the efficacy of the Child and Adolescent 
Structured Competencies Approach to Diabetes Education (CASCADE), which 
provided an intensive psycho-educational structured programme that incorporates 
motivational, patient-centred, and psychological approaches to improve metabolic 
control and psychosocial functioning in young people with type 1 diabetes. The study 
involved multiple UK centres and many healthcare practitioners; 28 paediatric 
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diabetes services across London, south-east England and the Midlands, and 43 health 
professionals, grouped in 14 teams, were trained in the intervention. The study 
recruited 362 children and adolescents (aged 8-16 years) with poorly controlled type 
1 diabetes (i.e., HbA1c ≥ 8.5%). The mean HbA1c of the intervention and control 
groups were 9.9 mmol/L (SD = 1.5 mmol/L) and 10 mmol/L (SD = 1.5 mmol/L), 
respectively. 
The intervention comprised four group education sessions delivered by a 
paediatric diabetes specialist nurse and another team member (healthcare 
practitioner). The interventionists received structured training workshops that were 
conducted over two days, followed by a one-day refresher training, and ongoing 
support during the intervention (e.g., queries-related or supportive telephone calls). 
Information specific to the trainers’ skills in MI was not reported. The workshops 
included training in multiple components that were related to the intervention 
content, the underpinning philosophy and delivery skills. The intervention was 
described as being based on MI and solution-focused therapy. Components drawn 
from MI were integrated in the intervention and included: open-ended questions, 
affirmations, reflective listening, simple summaries, considering the pros and cons of 
behaviour change, and establishing the importance and confidence of change. In 
addition, an active rather than passive approach in the role of patients in their 
diabetes management was integrated in the intervention. The fidelity of the overall 
delivery of the intervention was measured in this study, but treatment fidelity 
measures specific to MI were not available. 
The primary outcome was glycaemic control, measured by HbA1c at baseline 
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and follow-up (i.e., 12 months and 24 months post intervention). The secondary 
outcomes measures included psychosocial questionnaires and surveys that were 
related to diabetes self-management. These measures included: general and diabetes-
specific QoL (PedsQL modules); emotional and behavioural adjustment (SDQ);
diabetes self-efficacy scale (DSES); decision-making, skills and responsibility for 
diabetes management (The Diabetes Family Responsibility Questionnaire, DFRQ); 
diabetes regimen, including insulin dose and number of injections;, frequency and 
severity of hypoglycaemic episodes; and frequency of hospital admissions and the 
reason for admission. The questionnaire data were collected at baseline and at 
follow-ups (12-month and 24-month). 
There were no significant changes in the primary and the secondary outcome 
measures at the 12-month or 24-month follow-up, which suggests that the 
intervention had no impact on metabolic control or secondary outcomes. Further 
analysis revealed that higher level of HbA1c predicted an increase in HbA1c at 12 
months, which suggested a poor response to the CASCADE intervention. 
Summary
There are currently ten studies in total that have included MI in interventions 
to improve diabetes outcomes for youth with type 1 diabetes. Only two of these 
studies investigated the effect of a standalone MI intervention (Channon et al., 2003; 
Huws-Thomas, 2007); the remaining eight studies incorporated MI as an adjunct 
intervention component or adapted some of the MI strategies and skills in the 
interventions (Christie et al., 2014; Knight et al., 2003; Nansel et al., 2007; Rami-
Merhar et al., 2014; Robling et al., 2012; Stanger et al., 2013; Viner et al., 2003; 
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Wang et al., 2010).  
The majority of studies had results that suggested positive intervention effects 
on diabetes outcomes, as evidenced by reductions in HbA1c, increased SMOBG, 
better QoL, and improved psychosocial functioning (Knight et al., 2003; Nansel et 
al., 2007; Rami-Merhar et al., 2014; Stanger et al., 2013; Viner et al., 2003). The 
study samples comprised mostly children and adolescents younger than 18, except 
for the study by and Rami-Merhar et al. (2014), which included individuals aged up 
to 20 years old. Rami-Merhar et al. (2014) found that older youth (aged 16-20 years 
old) in the intervention group had significantly improved HbA1c compared to the 
younger group (13-15 years old).  
Two of the studies that implemented multicomponent interventions, reported 
no intervention effects (Christie et al., 2014; Robling et al., 2012). These two studies, 
as well as other studies that incorporated strategies and skills from MI in their 
multifaceted interventions, evaluated the effect of the interventions as a whole rather 
than the effect of MI on its own (Christie et al., 2014; Robling et al., 2012). 
Finally, the one study that used an MI-based education intervention found 
that the control group (receiving SDE) had better outcomes compared to the MI-
based education intervention group (Wang et al., 2010). Again, in this study, the 
effect of the combined intervention (MI + education) was analysed and the effect of 
MI on its own is unclear. Moreover, the level of MI skill was questionable in that 
study given that the interventionists engaged more MI non-adherent behaviour than 
recommended. 
Although there appears to be emerging evidence of the potential of MI for 
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youth with type 1 diabetes, there are critical limitations in the above studies. These 
limitations make it difficult to draw conclusions specific to the efficacy of MI in 
diabetes interventions for youth. The weakness and limitations in the above reviewed 
research are presented in the following section. 
Limitations of the research into MI and diabetes interventions for youth 
The findings of the current evidence for the efficacy of MI for youth are not 
based on specific evaluations of MI, with most interventions incorporating some 
form of MI, or elements of MI, and report analysis of the effect of combined 
approaches. For this reason the results are not explicit to MI, whether it is supporting 
evidence (positive intervention effects) or non-supporting evidence (having no or 
negative intervention effects). One conclusion to draw from the literature reviewed 
above is that determining the efficacy of MI in interventions for youth with diabetes 
is still in its infancy: there are only two MI-specific studies and the results of these 
are only tentatively promising.
Evidence from the two studies that evaluated MI in a standalone intervention 
also had limitations. Channon, Smith, and Gregory (2003) had difficulties 
interpreting their results, because of inconsistencies in their result data, and they also 
noted that the findings need to be considered with caution. They were unable 
conclude if the observed changes were attributable to MI, or as the result of other 
factors, such as increased contact with youth. In addition, the small number of 
participants and missing data weakened statistical power. 
A key weakness in Huws-Thomas (2007) was the study sample, which 
included 52% adolescents with good diabetes control (mean HbA1c = 7.2%), and 
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who, therefore probably had been doing relatively well in engaging in diabetes 
management behaviours. This study, therefore, did not address the common clinical 
challenge of engaging adolescents with poor diabetes control and to examine the 
efficacy of MI in influencing that. In addition, this study although it used the 
measures of HbA1c and a range of psychosocial questionnaires, it did not assess 
diabetes self-management behaviours, such as frequency of SMOBG. In examining 
the efficacy of MI, it is important to evaluate process variables related to behaviour 
change, this is in addition to primary variables such as blood glucose measures 
(Hunt, 2011; Jones et al., 2014). Changes in HbA1c come as a result of a 
complicated management process that involves lifestyle changes and adhering to, for 
example, SMOBG and adjusting insulin dose.  
Neither Channon et al. (2003) nor Huws-Thomas (2007) formally evaluated 
the fidelity of the MI using reliable and validated coding systems. Evaluation of 
treatment fidelity is vital to ensure that what is perceived as MI in the intervention is 
actually MI and to assure the quality of the delivered MI (Jelsma et al., 2015). Miller 
and Rollnick (2013) state that “it is insufficient simply to claim that MI was provided 
in a clinical study. Outcomes are difficult to interpret apart from information about 
MI fidelity, for which a range of measures have already been developed and 
evaluated” (p. 380). 
Evaluations of MI treatment fidelity, using validated MI fidelity measures 
(e.g., MITI), were also absent from the vast majority of studies, and incomplete in 
Wang et al. (2010). Wang et al. (2010) did report outcomes from a formally validated 
evaluation measure, MITI 3.0, yet they did not include data on essential evaluation 
components (e.g., % reflection-to-question ratio). The available data on the integrity 
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evaluation in Wang et al. (2010) suggested a low level of MI competency of the 
interventionists in delivering MI, specifically in being on average below beginning 
proficiency in adhering to MI. This is an example of why it is important to use 
quality assurance measures, so that results can be interpreted on the basis of a 
complete picture, rather than jumping into qualifying or disqualifying MI from being 
an efficacious intervention when important data is missing. 
Research shows that interventionists’ skills on MI fidelity measures is 
directly associated with client outcomes (Miller & Rollnick, 2013). This suggests 
that potential confounders relating to the proficiency skills in MI can be ruled out if 
adequate delivery of MI is ensured. In other words, if the fidelity measures reflect 
poor MI practice, then outcomes cannot be fully attributable to MI. Assessments of 
fidelity should be a precondition to clinical trials that evaluate the efficacy of MI 
(Christie & Channon, 2014). Interventionists need to demonstrate a good quality MI 
to be able to interpret to the outcomes with confidence, since practitioner proficiency 
was found to be associated with MI efficacy and client outcomes (Miller & Rollnick, 
2013). The above applies to interventions that can distinguish the MI component in 
an intervention, but it becomes very challenging to evaluate fidelity to a specific 
intervention component when a hybrid of components exits (Miller & Rollnick, 
2013).
Embedding discrete MI strategies (e.g., importance and confidence ratings) 
and using some of the skills (but out of an MI context) in practices or interventions 
(e.g., educational session) is not MI (Miller & Rollnick, 2009). MI is more complex 
than simply applying a set of disconnected techniques (Miller & Rollnick, 2009). 
Studies that included or were informed by MI and used discrete strategies and 
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techniques simply cannot be used to evaluate the efficacy of MI (e.g., CASCADE 
and DEPICTED). 
Thus, there are limitations and contamination of results in studies constituting 
current evidence on the efficacy of MI for youth with diabetes. Meta-analyses and 
reviews of MI in the context of diabetes (and in health behaviour change in general) 
have urged addressing critical limitations to be able to scientifically evaluate the 
effect of MI in diabetes interventions (e.g., Christie & Channon, 2014; Gayes & 
Steele, 2014; Hampson et al., 2001; Martins & McNeil, 2009; Suarez & Mullins, 
2008). The limitations that need to be addressed include: using validated and reliable 
measures to evaluate the fidelity of the delivered MI and to report data on the formal 
measures; outcome measures should include behavioural markers to assess changes 
in direct behaviours (e.g., SMOBG), as well as the psychosocial assessments and 
HbA1c; and the targeted population should comprise of youth with poorly controlled 
diabetes. 
Significance, Aims, and Hypotheses of the Current Research  
Motivational Interviewing is a promising approach that has the potential to 
have a positive impact on diabetes outcomes. The currently tentative findings from 
previous research indicate its potential, but there is a lack in empirical-based 
evidence that examines MI as a standalone intervention for youth with poor diabetes 
control. Furthermore, none of these previous studies have evaluated the efficacy of 
MI with young adults (20-24 years old). This age group is important to study as it 
forms part of the emerging adult group of 18-25 year olds (Arnett, 2000, 2007). 
Diabetes management for emerging adults is at high risk of deterioration in the 
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transition to adulthood, and responsibility for diabetes self-management rests 
increasingly with the individual, and also in the transfer to adult diabetes care 
systems (Garvey, Markowitz, & Laffel, 2012; Lotstein et al., 2013; Peters, Laffel, & 
the American Diabetes Association Transitions Working Group, 2011). Emerging 
adults are therefore vulnerable for poor diabetes control, leading to adverse health 
outcomes, acute diabetes complications, and premature mortality (Garvey et al., 
2012; Peters et al., 2011). Hence, the importance of research targeting this age group. 
The primary objective of the current study was to evaluate the efficacy of MI 
as an intervention for youth (16-24 years old) with type 1 diabetes, who have poor 
glycaemic control (HbA1c > 64 mmol/mol). This level of glycaemic control suggests 
the need for more intensive intervention. This includes evaluating whether MI 
contributes to improved diabetes self-management, such as increased self-monitoring 
of blood glucose and insulin adjustment, as well as clinical improvement in the 
glycaemic control. Clinical, behavioural, and psychosocial measures were used to 
assess the intervention’s efficacy. These include HbA1c, level of glycaemic 
variability, frequency of SMOBG, engagement in other diabetes self-management 
behaviours (e.g., insulin medication, timing and adjustment), and psychosocial 
questionnaires. A detailed section on the outcome measures is presented shortly. In 
addition, a formal treatment fidelity evaluation was conducted using the MITI 3.1 
coding system.  
This study aims to contribute to current knowledge and bridge some of the 
gaps in examining the efficacy of MI in interventions for youth with diabetes. This 
research aims to address some of the limitations in previous research to more clearly 
evaluate the efficacy of MI with youth with type 1 diabetes. This research is also the 
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first trial of MI with youth with type 1 diabetes in New Zealand.  
Should the MI intervention be effective in improving diabetes self-
management, this will have important positive health implications. As well as having 
the capacity to benefit the individual patients and their families, the study has the 
potential to be of benefit more broadly because many of the healthcare costs 
associated with diabetes stem from the complications arising from poorly controlled 
diabetes. 
In the current study it was hypothesised that an MI intervention for youth 
with type 1 diabetes would have a positive impact on clinical, behavioural, and 
psychosocial measures. It was hypothesised that these improvements would be 
observed post-intervention, and then maintained at follow-up. The hypothesised 
improvements would be manifested by reduction in HbA1c post-intervention, 
reduction in the level of GV, increase in frequency of SMOBG, increased level of 
engagement in diabetes self-management behaviours, and improvement in 
psychosocial factors (i.e., illness perceptions, self-efficacy, and QoL).  
Method
Participants 
166 youth (16-24 years old) with type 1 diabetes in the CDHB catchment area 
were sent letters inviting their participation in the current study. The youth were 
identified from CDHB records as part of a larger study that was presented in 
Chapters 2 and 3 (Obaid et al., 2012a), which involved collating information about 
the youth from CDHB records from multiple electronic and physical sources, 
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including the most recent HbA1c. Potential participants were eligible to receive an 
invitation to take part in the current study if their most recent HbA1c was more than 
64 mmol/mol. This level of metabolic control is considered unsatisfactory and may 
require additional intensive intervention. The selection of this cut off point was based 
on classification of diabetes control categories and previous research linking 
increased HbA1c to higher risks for diabetes complications (DCCT Research Group, 
2002; Donaghue et al., 2009; NZSSD, 2009b). Individuals with type 1 diabetes who 
have high HbA1c are at an increased risk of having diabetes complications and this 
risk elevates with higher levels of HbA1c (DCCT Research Group, 1993; Fullerton et 
al., 2014; Nathan & Group, 2014; Nordwall et al., 2015). This group, compared to 
youth who have good metabolic control, are also more likely to need a multifaceted 
intervention (e.g., psychosocial and behavioural) to assist improving their diabetes 
control. 
Research Design
The current research used single-case experimental design, with a non-
concurrent multiple-baseline design across participants. This design required at least 
three randomly selected participants identified as having poor diabetes control, in 
which each of the participants was randomly assigned to pre-determined baseline 
lengths of 3-5 weeks. The number of participants who agreed to take part in this 
study was N = 9 (participants are described in the results section of this chapter). 
Each baseline period was assigned three participants. The distribution of participants 
to the pre-determined baseline and the designated intervention weeks are depicted in 
Table 4.1. Recruiting three participants in each baseline allowed for between person 
replication and in case participants drop out of the study. 
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Table 4.1
Distribution of participants to the baseline and intervention weeks. The intervention weeks are 1, 
2, 4, 8 weeks apart for each participant
 Intervention week
Baseline 1 2 3 4 5 6 7 8 9 10
3 weeks 3(S1) 3(S2) 3(S3) 3(S4)
4 weeks 3(S1) 3(S2) 3(S3) 3(S4)
5 weeks 3(S1) 3(S2) 3(S3) 3(S4)
Total+ 3 6 6 6 3 3 3 3 3
 Note. Si = Session number
 +Total number of participants in the respective weeks
Single-case multiple-baseline experimental design has the advantage of 
enabling a new intervention to be trialled on a small number of participants, whilst 
still maintaining confidence that any observable changes can be attributed to the 
intervention by controlling for potential confounds (Horner et al., 2005; Watson & 
Workman, 1981). Put another way, this design enhances internal validity, which is 
the ability of the research design to rule out alternative explanations of the results 
(Horner et al., 2005). This design also minimises threats to internal validity by 
comparing results within- and between-participants, both during and after 
intervention, with each participant serving as his or her own control (Horner et al., 
2005). Replication of the effects (i.e., intervention) across participants and using a 
range of different and intensive assessments of dependent variables (i.e., behavioural, 
psychosocial, and clinical outcomes) enhances the external validity of the results 
(Horner et al., 2005). Furthermore, the non-concurrent multiple-baseline design is 
experimental rather than correlational or descriptive, and it allows for the exploration 
of relationships between the independent variable and the dependent variables
(Byiers, Reichle, & Symons, 2012; Horner et al., 2005).  
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Intervention 
The MI intervention comprised four individual sessions conducted over 8 
weeks initiated at the end of each of the respective baseline periods. The average 
session duration was 41 minutes (range 25 to 60 minutes). After the intervention, 
follow up data were collected at 2 weeks, 3 months, 6 months, 9 months, and 12 
months post-intervention. A booster MI session was provided after 6 months from 
the end of the MI intervention (mean length of booster sessions was 35 minutes, with 
a range 20 to 51 minutes). 
The MI intervention and booster session were delivered by two experienced 
MI practitioners. One is a Registered Clinical Psychologist and the other is a 
Registered Nurse, both of whom hold a PhD and who are members of The 
Motivational Interviewing Network of Trainers (MINT), which is an international 
organisation of trainers in MI. Participants were randomly and evenly assigned to the 
interventionists for individual MI sessions. The sessions’ dates were arranged with 
participants to suit their schedules; the sessions were spaced 1, 2, 4, and 8 weeks 
apart for each participant (Table 4.1 above). The location of the intervention sessions 
was at the Clinic of the School of Health Sciences Centre, University of Canterbury. 
All intervention sessions were audio-recorded. 
Treatment fidelity
Treatment fidelity was evaluated using the MITI 3.1.1 (Moyers, Martin, 
Manuel, Miller, & Ernst, 2010). A retrospective random sample of 30% of the 
recoded intervention sessions were sent to an MITI coding expert (a member of the 
MINT) based in the USA for independent evaluation (coding). The MITI is a reliable 
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and empirically validated tool designed to measure treatment integrity for clinical 
trials of MI and to provide feedback for training and clinical supervision (Jelsma et 
al., 2015). The MITI has a standard coding system and evaluation protocol for 
assessing relational and technical aspects of MI. The relational evaluation gives an 
overall impression of the interventionist’s performance in terms of their 
communication style within a session, and is represented by 5-point global ratings. 
The global ratings encompass the MI-spirit, which includes autonomy, collaboration, 
and evocation as well as direction and empathy. A Global Clinician Rating score is 
calculated from the average of the autonomy, collaboration and evocation scale 
scores. An average of 4 or more on the MI-spirit indicates a competency level in 
delivering MI.  
The technical aspects of MI are measured by behaviour counts. The 
behaviour counts represent a record of particular clinician behaviour instances during 
a session. The behaviours are classified into eights components: MI adherent (e.g., 
emphasise control and support), MI non-adherent (e.g., confronting and giving 
orders), giving information, questions (open or closed), and reflections (complex or 
simple). These behaviour counts are used to calculate summary scores, which are as 
follows. The percent of complex reflections (%CR), which is the number of complex 
reflections divided by of the total of all reflections; competency in MI requires 
complex reflections to be at least 50% of the total reflections. The percent of open 
questions (%OQ), which is the number of open questions divided by of the total of 
all questions; a percent of at least 70% indicates competency in MI. The reflection to 
question ratio (R:Q), which is the ratio of the total reflections to the total number of 
questions; a ratio of 2:1 is the minimum for achieving a competent level in MI. The 
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percent of adhering to MI (%MI-adherent), that is, the MI adherent counts divided by 
the total of MI adherent and non-adherent counts; a competency level in MI requires 
100% adherence. 
Measures
Outcome measures in the current study are summarised as follows (see 
schematic representation and Table 4.2) and a description of each of these measures 
is presented in the following sections. 
Primary outcome measures: 
1. HbA1c at
a. pre-determined baseline period (baseline)
b. each of the follow-up points
2. Glycaemic variability was evaluated using blood glucose readings 
obtained from the participants SMOBG data at 
a. baseline
b. intervention weeks  
Secondary outcome measures (process variables):
1. Frequency of SMOBG provided by participants on weekly basis obtained 
from their blood glucose meters at 
a. baseline
b. intervention weeks  
c. each of the follow-up times
2. 24-hour (24hr) recall interview to measure adherence behaviours; 
Appendix 4.1 (Budde, 2009; Johnson, Silverstein, Rosenbloom, Carter, & 
Cunningham, 1986) was conducted at 
a. baseline
b. intervention weeks  
c. each of the follow-up times
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and included: 
i. Insulin compliance, 
a. insulin medication adherence, the total number of usage 
b. insulin adjustment, total number of times insulin correctly 
adjusted  
c. insulin timing, average time between meals and insulin 
usage  
ii. Diet adherence, total number of meals and a bedtime snack (the 
number of carbohydrate servings eaten)
iii. Physical activity adherence, the frequency and type of exercise. 
iv. SMOBG testing frequency 




c. at each of the follow-up times
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Table 4.2
Outcome measures that were used to evaluate the efficacy of the MI intervention
Follow-up




HbA1c ü ü ü ü ü ü
Glycaemic 
variability




SMOBG ü ü ü ü ü ü ü
Adherence+
assessment 
ü ü ü ü ü ü ü
Psychosocial 
measures
ü ü ü ü ü ü
Note. Wk = week; M=months; +24hr recall interview
Primary outcome measure: Blood glucose 
Glycated haemoglobin (HbA1c)
HbA1c was used as a primary outcome measure and as an indicator of the 
level of diabetes control. This biomarker, as described in Chapter 1, is considered the 
gold-standard to monitor the progress of the diabetes condition, and the risk for 
developing diabetes-related complications (Bruns, 2007; Hanas et al., 2014). 
Baseline HbA1c was collected during the participants’ assigned baseline (i.e., before 
the start of the intervention), and then post-intervention at each of the follow-up (i.e., 
2-week, 3-month, 6-month, 9-month, and 12-month). 
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The HbA1c results were examined using statistical and clinical analyses. The 
clinical analysis was performed to examine the significance of changes in HbA1c in 
individual participants, from the latest baseline point to intervention and then at post-
intervention points. A 0.5% (i.e., in IFCC units corresponds to at least 5 mmol/mol) 
change in HbA1c is considered clinically significant (Little et al., 2011). This level of 
change represents a meaningful change in HbA1c and it eliminates trivial changes 
due to biological or analytical variations (Little et al., 2011; Urrechaga, 2012). It also
provides a reliable clinical significance threshold for determining whether diabetes 
control is stable, improving, or deteriorating (Little et al., 2011). 
The HbA1c results were also examined using inferential statistics to evaluate 
statistical difference and equivalence in the study group data over time (i.e., from 
baseline to each follow-up). Inferential confidence intervals (ICI) were used to 
establish a modified 95% CI about each of two means (Tryon, 2001; Tryon & Lewis, 
2008, 2009). The modified CIs are algebraically equivalent to a null hypothesis 
statistical test between two means, and provide context for expanding on the 
alternative hypothesis (Tryon, 2001; Tryon & Lewis, 2008). The ICI can be used to 
examine whether two means are equivalent, that is, ICIs provide means for inferring 
on equivalence in two means rather than only accepting or rejecting the null 
hypothesis if the means are not different at an alpha level of .05 (e.g., such as in 
ANOVA comparisons). 
The ICI results can be interpreted based on three main cases. The first case is 
when the ICIs do not overlap; the results are then statistically significant and the 
means are different from each other. The second case, which is statistical 
equivalence, is when the maximum probable difference estimate (i.e., the upper CI 
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limit of the greater mean minus the lower CI limit of the lesser mean) fits within an 
inconsequential difference between the two CIs. The inconsequential difference can 
be based on a delta (∆) bound of the maximum difference that can be dismissed on 
substantive ground. The coefficient of variation (CV) for HbA1c was used to 
calculate delta, thereby accounting for biological variation amongst participants 
(Fraser, 2001). The HbA1c CV is 5.6% (Gomes et al., 2001; Westgard, 2014), and 
the delta corresponds to the maximum change in baseline mean that is considered 
insignificant (i.e., CV*baseline HbA1c). Appendix 4.2 illustrates how ICIs were 
calculated to evaluate statistical difference and equivalence, the significance level 
was 0.05 (which corresponds to 95% CI). The third case, which is statistical 
indeterminacy, is when the means are neither statistically different nor equivalent. 
Evidence for or against cannot be drawn in the case of the statistical indeterminacy, 
and therefore conclusions about results must be suspended until further investigations 
(Tryon, 2001). 
The effect sizes for the statistically significant results were calculated using 
Cohen’s d (Cohen, 1992), which is the difference between mean baseline and follow-
up results divided by the standard deviation of the mean score at baseline. The 
magnitude of the effect was interpreted using Cohen’s (1997) guidelines, with d = 
0.2 representing a small effect, d = 0.5 a moderate effect, and d = 0.8 a large effect.
Glycaemic variability
Glycaemic variability (GV) was assessed to evaluate whether there were any 
changes in blood glucose oscillation profiles and their level of stability over time 
during baseline and intervention. Instability of blood glucose and long-term episodes 
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of hypoglycaemia and hyperglycaemia are associated with an increased risk for 
developing diabetes-related complications (Kilpatrick, 2009; Krishna et al., 2013; 
Robeva et al., 2007). The evaluation of GV provides information on the quality of 
blood glucose profiles and may account for the frequency and severity level of 
hypoglycaemia and hyperglycaemia excursions (i.e., mild, moderate, or severe 
excursions) (Dailey, 2007; Kovatchev et al., 2000; Kovatchev et al., 2006).  
There are several methods to measure GV from SMOBG data. These include 
basic mathematical calculations (e.g., mean and standard deviation, and coefficient of 
variation), and advanced mathematical methods such as: mean amplitude of 
glycaemic excursions (MAGE), mean daily difference (MDD), glycaemic risk 
assessment diabetes equation (GRADE), and liability index (LI) (Tylee & Trence, 
2012). In the context of GV, there has been criticism in the literature of the basic 
averaging of data and standard deviation and its derivatives (DeVries, 2013; Satya 
Krishna, Kota, & Modi, 2013). The validity of results from these simple methods 
may have an impact from the violations in the underlying assumptions that relate to 
the normal distribution, whereby the blood glucose data distribution is naturally 
asymmetric and breaches the Gaussian shape attributes (Kovatchev, Cox, Gonder-
Frederick, & Clarke, 1997). In contrast, the advanced GV assessment methods, 
although complicated in their mathematical representations and outcomes in 
quantifying GV, have several drawbacks. They have an inherited bias towards 
hyperglycaemia readings, are insensitive to hypoglycaemia readings, and their results 
may also be affected by the asymmetry of the blood glucose data distribution 
(Kovatchev et al., 2006; Ruiz de Adana, Domínguez-López, Tapia, González, & 
Soriguer, 2008). Alternative new measures have emerged to overcome some of these 
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limitations: measures such as low blood glucose index (LBGI), high blood glucose 
index (HBGI), and average daily risk range (ADRR) (Kovatchev et al., 1998; 
Kovatchev et al., 2000; Kovatchev et al., 2006). Studies validating and using these 
measures have found them reliable and more accurate than the previously introduced 
variability measures (Kovatchev et al., 1998; Kovatchev et al., 2006; Patton & 
Clements, 2013). They also have an advantage of being independent of the diabetes 
type and the number of blood glucose readings per day (Kovatchev et al., 2006; 
Robeva et al., 2007). 
The ADRR, LBGI, and HBGI measures use normalisation and mathematical 
procedures to derive a symmetrical scale that has transformed blood glucose values 
(Kovatchev et al., 1997; Kovatchev et al., 1998; Kovatchev et al., 2000; Kovatchev 
et al., 2006). The procedures are outlined shortly and the formal equations are 
presented in Appendix 4.3. The underlying concept of these measures is to convert 
the blood glucose readings into risk values, in which each blood glucose reading is 
transformed and then given a risk weight, depending on where the raw value lies on 
the actual blood glucose scale. The symmetrisation of the actual blood glucose scale 
involves using mathematical transformation such that the target range is transformed 
to have zero at its centre, which is mapped to 6.25 mmol/L on the actual blood 
glucose scale. Transformed values on either side of this centre are given a sign and a 
numerical weight. The left side values are given a negative sign and the right side 
values are given a positive sign. The transformed blood glucose values f(BG) are then 
converted into risk values using the risk function r(BG), which represent the risk 
associated with different blood glucose levels and have a value from 0 to 100. The 
LBGI is computed from the left branch of the processed values, whereas the HBGI is 
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computed from the right branch values. The computed indices in the separate 
branches are summed and then divided by the total number of blood glucose readings 
(i.e., averaged), yielding an aggregated risk value for each of LBGI and HBGI. 
The LBGI is a measure of the risk of hypoglycaemia accounting for the 
frequency and severity of hypoglycaemia, and it is independent of the 
hyperglycaemic episodes (Kovatchev et al., 1998; Kovatchev et al., 2000; Kovatchev 
et al., 2003). In contrast, HBGI is independent of the hypoglycaemic episodes and it 
provides a measure of the risk of hyperglycaemia accounting for the frequency and 
severity of hyperglycaemia (Kovatchev, Cox, Gonder-Frederick, & Clarke, 2002; 
Kovatchev et al., 2000; Kovatchev et al., 2006). Empirical research has led to the 
derivation of stratified levels of blood glucose risks values and these categories 
represent the degree of risks for future hypoglycaemia and hyperglycaemia episodes 
(Kovatchev et al., 2000; Kovatchev et al., 2003). The LBGI has the following risk 
categories: minimal (LBGI ≤ 1.1), low (1.1 < LBGI ≤ 2.5), moderate (2.5 < LBGI ≤ 
5), and high (LBGI > 5) (Kovatchev et al., 2003); and HBGI has the following risk 
categories: low (HBGI ≤ 4.5), moderate (4.5 < HGBI ≤ 9), and high (HBGI > 9) 
(Kovatchev et al., 2000). The accuracy of outcomes from LBGI and HBGI can be 
optimised by using a recommended minimum number of blood glucose readings; 
approximately 130 blood glucose readings collected over 4 to 5 weeks is 
recommended (Kovatchev et al., 1998; Kovatchev et al., 2000; Kovatchev et al., 
2003). The original research, which used 50 blood glucose readings collected over 2 
to 3 weeks, however, suggests that valid outcomes can be achieved with fewer 
readings and over a shorter time frame (Cox et al., 1994; Kovatchev et al., 1998). In 
current study, the LBGI and HBGI were calculated using these guidelines and 
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previously outlined mathematical procedure (Appendix 4.3). Four out of the seven 
participants (Participants B, C, D, and F), in this study, had more than 130 readings 
in each of the baseline and intervention periods. The remaining two participants 
(Participants A and E) had more than 50, but less than 130, readings in each of the 
baseline and intervention periods.  
The LBGI and HBGI, as mentioned previously, were designed to be 
specifically sensitive to hypoglycaemia and hyperglycaemia, respectively. They 
measure the level of risk associated with deviations from the clinical target range, 
with progressive weight accounting for the extent of the excursions. Each of the 
LBGI and HBGI is a unique measure that is specific to evaluating (respectively) the 
low and high glycaemic levels, and cannot be simply combined to provide an 
assessment of a complete profile (i.e., having both the low and high blood glucose 
fluctuations). A single measure that could analyse the overall quality of the 
fluctuations in a blood glucose profile and capture long-term trends for predicting 
dangerously significant blood glucose oscillations would be useful (Kovatchev et al., 
2006). Studies suggest that highly variable and unstable blood glucose may be 
associated with the risk of acute diabetes complications, including physiological 
complications (Krishna et al., 2013; Trence & Hirsch, 2012; Tylee & Trence, 2012). 
The quantified overall GV, using a single measure, could be used to indicate risks for 
future significant glycaemic episodes. A combined measure, equally sensitive to both 
hypoglycaemia and hyperglycaemia, was derived to evaluate GV and to quantify the 
degree of risk for significant excursions. A mathematically combined left and right 
side branches of the risk functions r(BG), Appendix 4.3, were used in the new 
assessment measure calculations: ADRR (Kovatchev et al., 2006). 
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The ADRR is a measure of the average daily risk range which assesses GV 
and the degree of risk for future extreme excursions. The measure takes into account 
the frequency and extent of the glycaemic excursions and assigns risk values 
accordingly. The values of ADRR were classified into four categories: low risk 
(ADRR < 20), low-moderate risk (20 ≤ ADRR < 30), moderate-high risk (30 ≤ 
ADRR ≤ 40), and high risk (ADRR > 40) (Kovatchev, 2012; Kovatchev et al., 2006). 
The ADRR can be calculated from consecutive or non-consecutive days, where there 
are at least three readings per day within a period of 30 days. The authors indicated 
that the minimum required number of days to obtain reliable results is 14 (Kovatchev 
et al., 2006). In the current study, the days rule (14 < days < 30, and 3 readings per 
day) was applied, and in case of more than 30 days in each of the periods, only the 
last 30 days were used. The majority of participants had at least three readings per 
day in at least 14 days within a month in each of the baseline and intervention 
periods3. In addition to being consistent across participants, in line with the ADRR 
underlying mechanism, the outlined method is also considered sufficient to reflect 
reliably the current diabetes management status in each of the baseline and 
intervention periods in terms of glycaemic excursions and to quantify the degree of 
risk for future glycaemia (Kovatchev et al., 2006). 
The ADRR score in conjunction with specific LBGI and HBGI scores 
provided the means to analyse blood glucose profiles obtained from SMOBG. The 
former provided information on the GV as a whole, in terms of assessing the quality 
  
3 The Participant E had 11 days within five weeks that included readings which are at least 
three per day. 
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of the blood fluctuations, the extent of the different excursions, and the degree of risk 
for having future instability in the blood glucose profile. The latter two provided 
specific information on directions and degree of that causing the instability of blood 
glucose profile, that is, hypoglycaemia, or hyperglycaemia, or both. Outcomes from 
these measures were compared from baseline to intervention, and checked for any 
patterns across participants. The participants’ follow-up blood glucose profiles 
lacked a sufficient number of data points to reliably carry out the analysis; this is 
because the GV section of this thesis was added after data collection had finished. 
Future studies could consider adding an adequate protocol so that sufficient data are
collected for GV analysis during follow-up. 
Secondary outcome measures: Psychosocial questionnaires
The secondary outcome measures comprised a set of psychosocial 
questionnaires to measure changes in illness perceptions, self-efficacy and QoL. The 
questionnaires were BIPQ, CIDS, and PedsQL 3.2, and were the same set of 
questionnaires that were used in the cross-sectional study of this thesis (Chapter 3). 
The measures were described previously in Chapter 3, and have shown adequate 
reliability and suitability to use in this thesis. The measures were administrated to 
participants at baseline and then post-intervention at each of the follow-ups (i.e., 2-
week, 3-month, 6-month, 9-month, and 12-month).  
The questionnaire data were analysed by clinical and statistical analytical 
procedures to examine changes in the individual and the group data over time. These 
procedures required identifying a minimal clinically important difference (MCID) 
(Cook, 2008; Hilliard et al., 2013). The MCID is identified based on calculating a 
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value beyond which (increase or decrease) is considered meaningful and that is not 
due to a measurement error (Cook, 2008; Harvill, 1991; McManus, 2012). The 
standard error of measurement (SEM) was used to determine MCID; meaningful 
variations in scores need to be equal to, or greater than, SEM (Harvill, 1991; Hilliard 
et al., 2013; Wyrwich, Tierney, & Wolinsky, 1999). The SEM was estimated using a
questionnaire’s reliability coefficient (e.g., Cronbach alpha) and a questionnaire’s SD 
of a normative sample (i.e., SEM = SD*Sqrt[1-α]) (Harvill, 1991; Hilliard et al., 
2013; Wyrwich et al., 1999). Data from the cross-sectional study of this thesis 
(Chapter 3) provided a normative platform to estimate the MCID for the current 
study analyses, as an MCID for each of the questionnaires (i.e., BIPQ, CIDS, and 
PedsQL 3.2) was not available in the literature. The only existing MCID relevant to 
the current study, was presented in research by Hilliard et al. (2013), was for the 
PedsQL 3.0 but not for PedsQL 3.2, and the latter is the version used in the current 
study. 
The group data analysis involved using ICIs to evaluate statistical difference 
and equivalence. The ICI procedures were described earlier in the Measures section
in this chapter. The delta was set to SEM to account for inconsequential difference 
resulting from measurement errors. Additionally, the effect size was calculated for 
any statistically significant result (Cohen, 1992).
Changes in an individual participant’s questionnaire data were examined 
using reliable change index (RCI) (Jacobson & Truax, 1991). The RCI procedure 
determined whether the changes were clinically significant, that is, the RCI 
determined if a change in score were due to a real change or a chance variation 
(Jacobson & Truax, 1991; Zahra & Hedge, 2010). The RCI was estimated by 
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calculating the difference of two data points (e.g., XBL= score at baseline and XFollow-
up= score at follow-up) and then dividing the result by the standard error of difference 
(Sdiff) between the scores. The Sdiff is estimated using SEM, such that Sdiff = 
Sqrt(2)*SEM (Jacobson & Truax, 1991). The Sdiff describes the spread of the 
distribution of the difference scores. An RCI greater than 1.96 in absolute value 
would be unlikely to occur (p < 0.05) without actual change, which suggests a 
clinically significant change in score. 
Secondary outcome measures: Adherence recall interview 
Adherence has proven difficult for researchers to measure due to the 
complexity of the different aspects of the diabetes medical regimen, its individuality 
amongst patients, and reliance on self-report (Budde, 2009; McNabb, 1997; Rudell, 
Thrift-Perry, Savre, Perret, & Caron, 2012). Researchers have previously assessed 
adherence using self-report questionnaires (e.g., SDSCA), SMOBG, and the 24hr 
recall interview (Budde, 2009). The current study used the latter two to assess 
adherence. Increased frequency of SMOGB was found to be associated with 
reduction in HbA1c, and is considered a core adherence component (Schutt et al., 
2006). The 24hr recall interview provided a measure for other essential adherence 
components. 
The 24hr recall interview assesses adherence related to the diabetes medical 
regime and lifestyle adjustments (Johnson et al. 1986). A modified version of the 
24hr recall interview (also referred to as recall interview), which was adapted by 
Budde (2009), was used in the current study. The modified recall interview
incorporated two additional components: insulin adjustment and weekly SMOBG 
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frequency. The recall interview assessed adherence to the following essential 
adherence behaviours: diet frequency, SMOBG frequency, insulin frequency, insulin 
timing, insulin adjustment, and exercise frequency. 
Recall interview data (i.e., diet frequency, SMOBG frequency, insulin 
frequency, insulin timing, and insulin adjustment) were collected once a week on a 
random day. The participants were randomly called on a weekly basis throughout the 
baseline and intervention periods, and then once at each follow-up. The 24hr recall 
items were recorded from the previous day from the time when a participant got up 
until the time he or she went to bed.
The score on each adherence component is the total number of Yes boxes 
checked (See Appendix 4.1: 24hr recall interview). A specific number of yes checks 
is needed to meet an acceptable level of adherence. The adherence assessment and 
the acceptable levels in the current study were guided by adherence 
recommendations in New Zealand on diabetes management (CDHB, 2015; Diabetes 
New Zealand, 2014; Reed, 2014), which were equivalent to those found in Budde 
(2009). The acceptable levels provide a general guide of what might be ideal for 
individuals with type 1 diabetes, especially those struggling with diabetes control. 
Hence, in the context of the current study any consistent improvement in adherence 
was positively perceived even if the acceptable levels were not met. Changes in 
adherence behaviours over time were evaluated graphically. Data analysis involved 
visual inspections of graphs to identify patterns across participants and to check 
changes in adherence behaviours in individual participants. 
The adherence components are defined as follows (Budde, 2009). Diet 
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frequency was defined as the total number of meals (i.e., breakfast, lunch and dinner) 
plus a bedtime snack. The SMOBG frequency was defined as the total number of 
blood glucose tests at the three meals and before bedtime. Insulin frequency was 
defined as the total number of insulin doses at the three meals and before bedtime. A 
score of four was considered the acceptable level for each of diet, SMOBG, and 
insulin frequency. Insulin timing was estimated using the time elapsed between the 
insulin dose and meal time, which needed to be at most 15 minutes apart. Hence, 15 
minutes was subtracted from the reported insulin timing and an average time was 
calculated, whereby zero minutes is considered to be the acceptable timing average. 
The insulin adjustment frequency referred to the number of times the correct amount 
of insulin was taken at the three meals. The acceptable level for insulin adjustment 
was three, indicating that at each meal time the participant took the correct amount of 
insulin, according to her or his blood glucose level and number of carbohydrate units 
consumed.
Weekly data (i.e., physical activity and objective SMOBG) were also 
collected throughout baseline and intervention, and during a week close to each 
follow-up. The physical activity was recalled using a 7-day chart that was filled out 
by participants on a weekly basis. Twenty minutes of physical activity three times a 
week was considered the minimum acceptable level. The weekly SMOBG data 
(tabulated) were provided by participants from their blood glucose meters. A 
frequency of 28 was considered the minimum acceptable level of SMOBG per week, 
equating to four daily tests per week. The weekly SMOBG actual blood glucose 
readings were used to analyse GV, as outlined previously.  
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Results
Results are presented as follows: 
• Participants’ characteristics
• Treatment fidelity 
• Primary outcome measure: 
o HbA1c* 
o GV 
• Secondary outcome measures:
o Psychosocial questionnaires* 
o Adherence assessment: 24hr recall interview 
* The results of the group data (i.e., statistical tests) will be presented first, followed 
by the individual data (including evaluation of clinically significant change). 
Participants’ Characteristics
Of the 166 youth contacted regarding participation in the current study, nine 
agreed to participate and had a record of a recent HbA1c. Table 4.3 outlines the 
descriptive characteristics of those who completed the study, those who withdrew at 
baseline, or at a later stage during the intervention. 
Table 4.3






Gender Male 3 1 0 2
Female 6 1 2 3
Ethnicity European 9 2 2 5
Age (years)
M 19.8 20 20.5 19.4
Range (18-23) (18; 22) (18; 23) (18-22)
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All of the participants who agreed to take part in the study were European, 
with an average age of 19.8 years, and with more females (n = 6) than males (n = 3). 
Two participants withdrew at baseline: one participant aged 22 did not engage in the 
baseline data collection, and the other participant aged 18 chose not continue because 
of being very busy during the time of the study. Two further participants withdrew 
after the start of the intervention and during follow-up. One of these participants 
(aged 23 years) moved to Auckland and withdrew just after the 2-weeks follow-up. 
The other participant (aged 18 years) was planning to travel overseas and withdrew 
just after her third MI session because of time pressures. The two participants who 
withdrew from the study after the commencement of the intervention agreed that the 
researcher could obtain HbA1c data through their GP for the remainder of the study. 
Five participants (females = 3, males = 2) with an age range of 18 to 22 (average 
19.4 years) completed the intervention. 
Treatment Fidelity 
All of the audio recordings reviewed by the independent MITI coder met the 
threshold for competency, which provided evidence to suggest that  that it was MI 




Fidelity – average summary scores on the MITI 3.1.1 from a sample of 
30% of sessions
Measure Rating/percentage
Global clinician rating 5
Reflection to Question Ratio (R:Q) 2
Percent Open Questions (%OC) 72%
Percent Complex Reflections (%CR) 56%
Percent MI-Adherent (% MIA) 100%
Primary Outcome Measure: Blood Glucose  
Glycated haemoglobin (HbA1c)
Statistical tests of group data 
The HbA1c results were not statistically equivalent at baseline and during 
follow-up (Table 4.5). The results tended to be the same or slightly higher than at 
baseline and all of the follow-up assessments. The difference, however, was not 
statistically significant. Hence, because the results were neither equivalent nor 
different this resulted in statistical indeterminacy and suspension of conclusion about 
the findings (Tryon, 2001).
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Table 4.5
HbA1c means, inferential confidence intervals and results of statistical tests
Time M r 95% CI Different Equivalent
∆ ≈ 4 mmol/mol
Baseline 70.50 67.77 - 73.23
2-week follow-up 70.83 0.310 66.24 - 75.42 ns ns
Baseline 71.00 67.36 - 74.64
3-month follow-up 74.40 0.191 68.93 - 79.87 ns ns
Baseline 71.00 68.94 - 73.06
6-month follow-up 74.80 0.798 71.71 - 77.89 ns ns
Baseline 70.50 67.59 - 73.41
9-month follow-up 74.50 0.271 68.55 - 80.45 ns ns
Baseline 71.75 69.05 - 74.45
12-month follow-up 71.75 0.999 66.08 - 77.42 ns ns
Note.
r = Pearson’s correlation
∆= 1 CV of baseline mean 
* = statistically significant at .05 level 
ns = not statistically significant at .05 level
Clinically significant change in individual data
Results from the HbA1c individual data, investigating clinically significant 
changes from baseline to each follow-up, are presented in Table 4.6 and Figure 4.2. It 
should be noted that pre- and post-intervention data were non-concurrently collected 
for participants. Data collection occurred during their assigned baseline and at 
subsequent follow-up. The graphs show relative time points from start of intervention 
and at each follow-up. The observed results for Participant A showed he had a 
clinically significant increase from baseline to the 2-week follow-up, which was 
maintained during the 6-month and 9-month follow-up. Participant B had a clinically 
significant increase at the 6-month follow-up, his HbA1c, however, did not show any 
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clinically significant change during the other follow-up (2-week, 3-month, 9-month, 
and 12-month) assessments. Participant C had no clinically significant change in 
HbA1c from baseline to the follow-up assessments (2-week, 3-month, and 6-month). 
Participant D had a clinically significant decrease in HbA1c at the 2-week follow-up, 
then a clinically significant increase at the 6-month follow-up. This participant also 
had a clinically significant decrease at the 9-month and 12-month follow-up, which 
suggests improvements in HbA1c during the latter part of follow-up, after the 
significant increase at 6 months (Table 4.6). Participant E had a stable HbA1c during 
the 2-week and 3-month follow-up, then a significant increase at the 6-month follow-
up followed by a non-significant decrease in HbA1c at the 9-month, then a clinically 
significant decrease at the 12-month follow-up. Participant F had a clinically 
significant drop at the 2-week follow-up, then a trend of increasing HbA1c that had 
two clinically significant increases at the 9-month and 12-month follow-up. 
Participant G had no changes at the 2-week follow-up, followed by a significant 
decrease at the 3-month follow-up.  
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Table 4.6
Clinically significant change in HbA1c individual data
Follow-up
Participant 2-week 3-month 6-month 9-month 12-month
A +13 +16 m +18 m
B +7
C^ m m
D −5 +7 −6 −7
E +5 −5
F −6 +9 +14
G^^ −6 m m m
Note. 
− = clinically significant decrease from baseline (i.e., |reading2 –reading1| ≥ 5mmol/mol) 
+ = clinically significant increase from baseline (i.e., |reading2 –reading1| ≥ 5mmol/mol) 
^ Participant C withdrew from the study upon the 2-week follow-up. After seeking permission from the 
participant, HbA1c blood test results were accessed through her GPs.  
^^ Participant G withdrew from the study just after the third MI session. After seeking the participant’s 
permission, HbA1c readings were sought through her GP. The 3-month HbA1c reading was the only 
available reading for that patient post the intervention  
m = missing HbA1c; empty cell means there was no clinically significant change from baseline. 
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Figure 4.2. Results from HbA1c. * = Clinically significant change 
(i.e., |reading2 –reading1| ≥ 5 mmol/mol). Wk = week and M = 
month. The HbA1c targets for acceptable and optimal diabetes 
control are, respectively, 55-64 mmol and < 55 mmol/mol.
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In summary, Participant D was the only participant who had a clinically 
significant decrease post intervention that was maintained during the 9-month and 
12-month follow-up, despite a clinically significant increase at the 6-month follow-
up. It can be noted that three of four participants (Participants B, D, and E) who had 
data at the 6-month follow-up had a trend of an increasing HbA1c at the 6-month 
follow-up, and then a drop in HbA1c in the subsequent follow-ups (9-month and 12-
month). The decrease in HbA1c resulted in either a close value to that at baseline 
(Participant B) or a clinically significant decrease (Participants D and E). It should be 
noted here the participants had their booster session at the 6-month follow-up, 
changes in HbA1c results are expected to show months post the booster session (i.e., 
at or after 9 months), because HbA1c measures the average blood glucose of the past 
2-3 months. 
Finally, although there was a clinically significant decrease in HbA1c for 
some of the cases throughout the follow-up, none of the participants post intervention 
achieved targets for optimal glycaemic control (< 55 mmol/mol). Nonetheless, the 
three participants who had a downtrend post the booster session achieved a lower 
HbA1c (from baseline) that was approaching or at the upper limit of acceptable range 
(i.e., 64mmol/mol). 
Glycaemic Variability 
Results from ADRR, LBGI, and HBGI are presented in Table 4.7 and 
Appendix 4.4 presents the SMOBG charts. The categories and corresponding scores 
across participates in Table 4.7, from baseline to intervention, generally indicated an 
improvement in terms of the ADRR and HBGI risk outcomes. Furthermore, the 
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LBGI categories were maintained in the low risk range but with varying scores, 
except for one participant who had a category change from low to moderate risk. 
Table 4.7
Results from SMOBG analysis of LBGI (indicates risk for hypoglycaemic excursions), HBGI 
(indicates risk for hyperglycaemic excursions), and the ADRR (reflects the risk for glucose 
variability).  
Participant Measure Baseline (score) Intervention (score)
A
ADRR Moderate-high risk (38) Low-moderate risk (21.1)
LBGI Moderate risk (3) Low risk (1.4)
HBGI High risk (11.6) Moderate risk (7.6)
B
ADRR High risk (47.1) Moderate-high risk (38.8)
LBGI Low risk (1.4) Low risk (0.9)
HBGI High risk (19.7) High risk (19.6)
C
ADRR High risk (45.2) High risk (42.4)
LBGI Low risk (0.6) Low risk (0.6)
HBGI High risk (21.2) High risk (19.6)
D
ADRR Moderate-high risk (35.7) Moderate-high risk (37.1)
LBGI Low risk (2.1) Moderate risk (3.3)
HBGI High risk (11) High risk (10.6)
E
ADRR High risk (59.7) High risk (53.1)
LBGI Low risk (1.6) Low risk (2)
HBGI High risk (28.5) High risk (22.9)
F
ADRR Low-moderate risk (25.8) Low-moderate risk (20.3)
LBGI Low risk (0.6) Low risk (2.1)
HBGI High risk (12.6) Moderate risk (5.1)
Two participants (Participants A and B) had a considerable drop in scores, 
from baseline to intervention, which downgraded the ADRR category to a lower risk 
grade. This downgrade indicates a lower risk for having extreme glycaemic 
excursions and suggests a comparatively more stable GV than that in the higher 
category. The severity of the GV manifested by the ADRR scores was also reduced 
for the majority of the remainder participants, but a risk category change was not 
observed. Score reductions suggest an improved GV profile and less frequent 
extreme excursions, whereas a score increase indicates a less stable blood glucose 
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profile and more extreme glycaemic excursions.  
The LBGI results varied amongst participants. Participant A had a reduction 
in the score and LBGI risk category, which indicated he had a lower risk for 
hypoglycaemia from baseline to intervention. Participant B also had a reduction in 
the LBGI score and remained in the same category of a low level risk. Participant C’s 
score was maintained in the very low risk range (approaching zero) from baseline to 
intervention. Two of the remaining participants (Participants E and F) had an 
increase in the LBGI scores, which indicates a greater risk for hypoglycaemia, yet 
they were still categorised in the low risk range. Participant D, however, had an 
increase in the LBGI score indicating an increase in the risk for hypoglycaemia. 
The HBGI category was changed for two of the participants, and the reminder 
of participants had some degree of reduction in the score but not in the grade. 
Participant A and Participant F had a large decrease that downgraded the risk level 
from high to moderate risk, indicating a substantial decrease in the frequency of 
hyperglycaemia episodes during the study. The HBGI score for the remainder of 
participants also decreased from baseline to intervention, indicating a reduced risk 
for hyperglycaemia, but the decrease was not sufficient for a category change. The 
decrease in score suggested less extreme elevated blood glucose and fewer 
hyperglycaemic episodes. 
Secondary Outcome Measures: Psychosocial Measures
Statistical comparisons for each psychosocial measure are made within 
groups across time from baseline to each follow-up (i.e., 2-week, 3-month, 6-month, 
9-month and 12-month). Questionnaire data were missing the two participants who 
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withdrew from the study (Participants C and G), but Participant C provided the 2-
week follow-up data and this was included in the analysis. Additionally, some 
participants did not complete the questionnaires at various times during follow-up: 
Participant F at the 9-month and 12-month follow-up, and Participant A at the 12-
month follow-up.  
Statistical tests of group data
Quality of life: PedsQL 
The PedsQL total score results are presented first, and then the five PedsQL 
dimensions results are presented separately (i.e., About my diabetes, Treatment I, 
Treatment II, Worry, and Communication). There was a statistically significant 
increase in the total score of the PedsQL scale during follow-up, with the exception 
of the 9-month follow-up (Table 4.8). The largest increase in the PedsQL total score 
was observed from baseline to the 3-month follow-up, with a moderate-to-high effect 
size (d = 0.72). The remaining effect sizes corresponding to the statistically 
significant increases in the PedsQL total score were also moderate: d = 0.52, 0.51, 
0.49, in order, at the 2-week, 6-month and 12-month follow-up from baseline. The 
increase in the scores suggested an improved diabetes-specific QoL indicating that 
diabetes became less problematic over time, from baseline up to the 12-month 
follow-up point. The results of the 9-month follow-up were neither statistically 
equivalent nor different than baseline, resulting in statistical indeterminacy. 
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Table 4.8
PedsQL total score means, inferential confidence intervals and results of statistical tests
Time M r 95% CI Different Equivalent
∆ = 3.98
Baseline 55.74 52.76 - 58.73
2-week follow-up 64.65 0.952 62.00 - 67.30 * ns
Baseline 57.05 50.11 - 63.98
3-month follow-up 70.76 0.895 66.06 - 75.46 * ns
Baseline 57.05 52.74 - 61.35
6-month follow-up 66.67 0.95 61.46 - 71.88 * ns
Baseline 58.62 52.46 - 64.77
9-month follow-up 68.56 0.935 62.55 - 74.57 ns ns
Baseline 53.16 48.61 - 57.71
12-month follow-up 64.14 0.987 59.68 - 68.60 * ns
Note.
r = Pearson’s correlation
∆ = MCID
* = statistically significant at .05 level
ns = not statistically significant at .05 level
The PedsQL About my diabetes (diabetes symptoms) results (Table 4.9) 
during follow-up, with the exception of 2-week follow-up, were statistically 
significantly higher than baseline, with a moderate effect size (d = 0.42, 0.48, 0.5, 
and 0.41, respectively). Higher scores indicate lower problems associated with 
diabetes symptoms and QoL. This suggests the participants were experiencing fewer 
problems with diabetes symptoms. The 2-week follow-up results were statistically 
indeterminate in relation to baseline.
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Table 4.9
PedsQL About my diabetes score means, inferential confidence intervals and results of statistical 
tests
Time M r 95% CI Different Equivalent
∆ = 4.94
Baseline 53.89 49.68 - 58.09
2 weeks post-intervention 61.11 0.904 57.92 - 64.30 ns ns
Baseline 54.33 51.86 - 56.80
3-month follow-up 61.67 0.977 59.38 - 63.96 * ns
Baseline 54.33 50.98 - 57.68
6-month follow-up 62.67 0.957 59.63 - 65.70 * ns
Baseline 54.17 49.39 - 58.94
9-month follow-up 64.17 0.965 60.02 - 68.32 * ns
Baseline 47.78 45.27 - 50.29
12-month follow-up 55.56 0.999 53.29 - 57.82 * ns
Note. 
r = Pearson’s correlation
∆ = MCID
* = statistically significant at .05 level
ns = not statistically significant at .05 level
The PedsQL Treatment I (treatment barriers) results during follow-up were not 
statistically equivalent to baseline, but also were not statistically different, resulting in 
statistical indeterminacy (Table 4.10). The scores, however, tended to be higher than 
that at baseline, suggesting a trend to fewer personal and social problems related to 
treatment (e.g., pain from finger pricks and insulin shots, arguments with parents or 
partners about diabetes care, and feeling embarrassed by their diabetes treatment). 
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Table 4.10
PedsQL Treatment I means, inferential confidence intervals and results of statistical tests
Time M r 95% CI Different Equivalent
∆ = 7.98
Baseline 61.25 54.41 - 68.09
2 weeks post-intervention 71.67 0.776 64.19 - 79.14 ns ns
Baseline 64.50 55.97 - 73.03
3-month follow-up 80.00 0.758 71.76 - 88.24 ns ns
Baseline 64.50 58.43 - 70.57
6-month follow-up 77.00 0.889 69.90 - 84.10 ns ns
Baseline 63.13 50.26 - 75.99
9-month follow-up 78.75 0.747 67.22 - 90.28 ns ns
Baseline 54.17 37.81 - 70.52
12-month follow-up 75.00 0.710 62.00 – 88.00 ns ns
Note.
r = Pearson’s correlation
∆ = MCID
* = statistically significant at .05 level
ns = not statistically significant at .05 level
The PedsQL Treatment II (treatment adherence) results during follow-up were 
not statistically equivalent to baseline, but also were not statistically different, 
resulting in statistical indeterminacy (Table 4.11). The scores, however, were all 
higher than those at baseline, suggesting a trend to fewer problems related to 
treatment adherence (e.g., taking blood glucose tests and insulin medication, keeping 
track of carbohydrates, and doing physical activity). 
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Table 4.11
PedsQL Treatment II means, inferential confidence intervals and results of statistical tests
Time M r 95% CI Different Equivalent
∆ = 9.44
Baseline 61.11 53.73 - 68.49
2-week follow-up 65.28 0.895 59.69 - 70.87 ns ns
Baseline 60.00 40.55 - 79.44
3-month follow-up 67.50 0.433 47.31 - 87.69 ns ns
Baseline 60.00 53.18 - 66.82
6-month follow-up 61.67 0.954 53.15 - 70.19 ns ns
Baseline 65.62 57.85 - 73.39
9-month follow-up 64.58 0.957 55.78 - 73.39 ns ns
Baseline 59.72 54.03 - 65.41
12-month follow-up 66.67 0.996 60.41 - 72.93 ns ns
Note.
r = Pearson’s correlation
∆ = MCID
* = statistically significant at .05 level
ns = not statistically significant at .05 level
The PedsQL Worry (worries about diabetes complications) results during 
follow-up, with the exception of 3-month follow-up, were statistically significantly 
higher than baseline (Table 4.12). The effect size was large at each of the follow-ups
that had a statistically significant result (2-week, 6-month, 9-month, and 12-month): 
d = 0.79, 1.2, 0.86, and 0.88, respectively. These results suggest that through most of 
the follow-up period (except at the 3-month follow-up) participants had fewer 
problems associated with worries about diabetes complications. At the 3-month 
follow-up, however, the results were statistically indeterminate in relation to baseline 
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despite the increase in the score from baseline. 
Table 4.12
PedsQL Worry means, inferential confidence intervals and results of statistical tests
Time M r 95% CI Different Equivalent
∆ = 13.08
Baseline 33.33 27.11 - 39.55
2-week follow-up 51.39  0.925 42.55 - 60.23 * ns
Baseline 35.00 10.69 - 59.31
3-month follow-up 75.00 −0.194 54.56 - 95.44 ns ns
Baseline 35.00 28.13 - 41.87
6-month follow-up 65.00  0.934 56.17 - 73.83 * ns
Baseline 39.58 24.89 - 54.28
9-month follow-up 62.50  0.932 54.55 - 70.45 * ns
Baseline 36.11 29.65 - 42.57
12-month follow-up 63.89  0.999 58.4 - 69.37 * ns
Note.
r = Pearson’s correlation
∆ = MCID
* = statistically significant at .05 level 
ns = not statistically significant at .05 level
The PedsQL Communication results (at each of the five follow-ups) were not 
statistically equivalent to baseline, but also were not statistically different, resulting 
in statistical indeterminacy (Table 4.13). The scores, however, tended to be higher 
than those at baseline, suggesting a trend to fewer problems with regards to diabetes-
related communication, such as asking questions and conveying feelings about 
diabetes to nurses and doctors, and explaining their diabetes to other people. 
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Table 4.13
PedsQL Communication means, inferential confidence intervals and results of statistical tests
Time M r 95% CI Different Equivalent
∆ = 10.73
Baseline 64.58 58.58 - 77.25
2-week follow-up 78.13  0.863 72.1 - 84.15 * ns
Baseline 70.0 50.53 - 89.47
3-month follow-up 95.0 −0.088 88.15 - 101.85 ns ns
Baseline 70.0 61.02 - 78.98
6-month follow-up 77.5  0.808 63.58 - 91.42 ns ns
Baseline 73.44 60.79 - 86.09
9-month follow-up 82.81  0.728 66.76 - 98.86 ns ns
Baseline 75.0 55.59 - 94.41
12-month follow-up 79.17  0.866 51.15 - 107.19 ns ns
Note. 
r = Pearson’s correlation
∆ = MCID
* = statistically significant at .05 level
ns = not statistically significant at .05 level
Illness perceptions: BIPQ
The BIPQ results during follow-up, with the exception of the 9-month and 12-
month follow-up, were statistically significantly lower than baseline, with a moderate 
effect size: d = 0.43, 0.51, and 0.64, respectively (Table 4.14). These suggest diabetes 
became viewed as being a less threatening condition. At the 9-month and 12-month 
follow-up, however, the results were statistically indeterminate in relation to baseline. 
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Table 4.14
BIPQ means, inferential confidence intervals and results of statistical tests
Time M r 95% CI Different Equivalent
∆ = 2.78
Baseline 56.46 54.98 - 57.94
2-week follow-up 51.56 0.972 49.98 - 53.15 * ns
Baseline 55.00 53.69 - 56.31
3-month follow-up 48.75 0.995 47.61- 49.89 * ns
Baseline 55.00 52.42 - 57.58
6-month follow-up 47.13 0.986 43.65 - 50.60 * ns
Baseline 53.75 48.00 - 59.50
9-month follow-up 47.19 0.866 40.85 - 53.53 ns ns
Baseline 56.25 52.60 - 59.9
12-month follow-up 53.33 0.991 49.17 - 57.50 ns ns
 Note.
 r = Pearson’s correlation
 ∆ = MCID
 * = statistically significant at .05 level
 ns = not statistically significant at .05 level
Self-efficacy: CIDS
The CIDS results during follow-up, with the exception of the 2-week follow-
up (Table 4.15), were statistically significantly higher than baseline, with effect sizes 
that were moderate-to-large: d = 0.74, 0.92, 1.03, and 0.78, respectively. These results 
suggest that the participants during most of the follow-up experienced increased 
confidence in their ability to carry out diabetes self-care tasks. At the 2-week follow-
up, however, the results were statistically indeterminate in relation to baseline.
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Table 4.15
CIDS means, inferential confidence intervals and results of statistical
Time M r 95% CI Different Equivalent
∆ = 4.410
Baseline 68.75 60.26 - 77.25
2-week follow-up 74.63 0.308 64.32 - 84.94 ns ns
Baseline 66.07 61.4 - 70.75
3-month follow-up 75.95 0.847 71.76 - 80.15 * ns
Baseline 66.07 61.07 - 71.07
6-month follow-up 78.33 0.848 71.89 - 84.78 * ns
Baseline 63.69 62.45 - 64.93
9-month follow-up 78.27 0.998 77.14 - 79.4 * ns
Baseline 61.91 56.25 - 67.57
12-month follow-up 75.00 0.993 67.77 - 82.23 * ns
 Note.
 r=Pearson’s correlation
 ∆ = MCID
 * = statistically significant at .05 level
 ns = not statistically significant at .05 level
Clinically significant change 
The clinically significant changes (|RC| > 1.96) in the questionnaires scores 
from baseline are presented in Tables 4.16-4.18 and Figures 4.3-4.7. An empty cell in 
the tables indicates that there was no clinically significant change in the score from 
baseline. The direction of change is identified by the digit sign and is interpreted 
according to the corresponding questionnaire’s guideline. The positive sign indicates 
an increase that is clinically significant from baseline, whereas the negative sign 
indicates a decrease that is clinically significant from baseline. The missing data 
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include the 9-month and 12-month questionnaires data for Participant F, and the 12-
month data for Participant A. Participant C had data up to the 2-week follow-up, 
which is just before she withdrew from the study, and Participant G did not have any 
follow-up data available as she withdrew from the study just after the third MI 
session. It should also be noted that pre- and post-intervention data were non-
concurrently collected for participants. This occurred during their assigned baseline 
and at subsequent follow-up. The graphs show relative time points from start of 
intervention and at each follow-up.
Illness perception: BIPQ 
The BIPQ score, for all of the participants, did not have clinically significant 
changes from baseline, and therefore a table or a figure was not depicted.
Self-efficacy: CIDS
There were clinically significant changes in the CIDS scores from baseline to
follow-up (Table 4.16 and Figure 4.3). An increase in the CIDS score suggests an 
improvement in the confidence (belief) in the ability to carry out diabetes self-care 
tasks, whereas a decrease in the score suggests the opposite. At the 2-week follow-up, 
three participants (Participants A, B, and E) had a clinically significant increase in 
their confidence in the ability to carry out diabetes self-care tasks.  Yet one participant 
(Participant F) experienced a decrease in this, which suggests that she was less 
confident than she had been at baseline. Participant A and Participant B maintained 
their improved confidence level throughout the follow-up. At the 6-month follow-up, 
Participant D also had an increased CIDS score which was maintained at the 9-month
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and 12-month follow-up, suggesting that the improvement in confidence to carry out 
diabetes self-care tasks was maintained.
Table 4.16
Clinically significant change on the CIDS scale
Participant Follow-up
2Wk 3M 6M 9M 12M
A +3.05 +3.05 +2.86 +2.10 m
B +2.77 +2.10 +3.43 +2.29 +2.67
C m m m m
D +2.67 +2.29 +2.48
E +2.67 +2.67
F −4.49 m m
Note. 
+ = clinically significant increase in score (i.e., |RC| >1.96) from baseline 
− = clinically significant decrease in score (i.e., |RC| >1.96) from baseline 
m = missing; empty cell means there was no clinically significant change in the 
score from baseline
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Figure 4.3. The CIDS mean scores at baseline and follow-up. * = 
Clinically significant change (i.e., |reading2 –reading1| ≥ 4.41), M = 
month, and Wk = week. 
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Quality of life: PedsQL
The majority of participants had an improved PedsQL total score during 
follow-up (Table 4.17 and Figure 4.4), which suggests fewer problems related to 
diabetes-specific QoL. Participant D had a clinically significant increase in the 
PedsQL total score from baseline throughout follow-up. This participant also had a 
further clinically significant improvement at the 6-month follow-up, compared to that 
at earlier follow-up (i.e., 2-week and 3-month) from baseline, which was maintained 
at the 9-month follow-up point. Participant B had an improved PedsQL total score 
that was maintained throughout follow-up. Participant E had an improvement in the 
PedsQL total score from baseline to the 2-week follow-up, a further improvement at 
the 3-month follow-up, and maintained improved scores from baseline to the 9-month
and 12-month follow-up. Participant F’s score was improved at the 3-month follow-
up, and maintained an improvement at the 6-month follow-up from baseline. 
Table 4.17
Clinically significant change on the PedsQL total score
Participant Follow-up
2Wk 3M 6M 9M 12M
A +2.69 m
B +2.82 +2.28 +2.82 +2.55
C +2.15 m m m m
D +5.10 +2.42 +7.25 +7.25 +5.10
E +5.91 +7.79 +3.76 +4.03
F +9.13 +4.83 m m
Note. 
+ = clinically significant increase in score (i.e., |RC| >1.96) from baseline 
−= clinically significant decrease in score (i.e., |RC| >1.96) from baseline 
m = missing; empty cell means there was no clinically significant change in the 
score from baseline
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Figure 4.4. The PedsQL total mean scores at baseline and follow-
up. * = Clinically significant change (i.e., |reading2 –reading1| ≥ 







Clinically significant changes in the PedsQL five dimensions (i.e., About my 
diabetes, Treatment I, Treatment II, Worry, and Communication) are presented in 
Table 4.18 and Figures 4.5-4.7. Two participants had clinically significant 
improvements in the PedsQL About my diabetes score. The score increased for 
Participant E at the 2-week follow-up and for Participant D it increased at the 9-month 
follow-up. The results suggest that diabetes symptoms (e.g., feeling dizzy, shaky, and 
sweaty) became less problematic for these two participants. Three participants 
(Participants D, E, and F) had a clinically significant increase in the PedsQL
Treatment I score at follow-up, which suggests they experienced fewer problems 
associated with diabetes treatment barriers (e.g., pain from insulin shot or figure prick, 
and arguing with partner/parents about diabetes care). Participant D had an increased 
PedsQL Treatment I score from baseline which was maintained throughout the 
follow-up (i.e., 2-week, 3-month, 6-month, 9-month, and 12-month). Participant E 
had an increased score at the 12-month follow-up, and Participant F had an increased 
score at the 3-month follow-up. The PedsQL Treatment II score had not improved for 
most of the study participants, except for Participant F at the 3-month follow-up. This 
result suggests that Participant F had fewer problems with her treatment adherence 
(e.g., taking blood glucose tests, keeping track of carbohydrates, and exercising) at the 
3-month follow-up. The PedsQL Worry score clinically significantly increased for 
three cases (Participants A, D, and E) during follow-up, indicating fewer problems 
associated with worries about diabetes complications. Participant A had an improved 
Worry score at the 3-month follow-up. Participant D experienced fewer worries 
during the 2-week post-intervention and 6-month follow-up. Participant E 
experienced fewer worries related to diabetes complications during the 3-month and 
9-month follow-up. The PedsQL Communication score clinically significantly 
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increased for two participants (Participants F and E), a 3-month follow-up, suggesting 
better communication related to their diabetes (e.g., telling the doctor or nurses how 
they feel and asking questions, explaining their illness to other people). Participant E, 
however, had a clinically significantly decrease in this score at the 6-month follow-up, 
from baseline, indicating more problems related to communication.
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Table 4.18
Clinically significant change on the five dimensions of the PedsQL scale
Follow-up









Treatment I A m
B
C m m m m
D +2.66 +2.21 +2.66 +3.1 +2.21
E +2.66
F +2.66 m m
Treatment II A m
B
C m m m m
D
E
F +4.68 m m
Worry A +2.25 m
B






C m m m m
D
E +3.29 −2.06
F +2.88 m m
Note. 
+ = clinically significant increase in score (i.e., |RC| >1.96) from baseline 
− = clinically significant decrease in score (i.e., |RC| >1.96) from baseline 
m = missing; empty cell means there was no clinically significant change in the score 
from baseline
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Figure 4.5. The PedsQL Diabetes Symptoms mean scores at 
baseline and follow-up. * = Clinically significant change (i.e., 
|reading2 –reading1| ≥ 4.94), M = month, and Wk = week. 
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(a) (b)
Figure 4.6. The PedsQL (a) Treatment Barriers and (b) Treatment Adherence mean scores at baseline 
and follow-up. * = Clinically significant change (i.e., |reading2 –reading1| ≥ (a) 7.98, (b) 9.44), M = 
month, and Wk = week. 
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(a) (b)
Figure 4.7. The PedsQL (a) Worry and (b) Communications mean scores at baseline and follow-up. * 
= Clinically significant change (i.e., |reading2 –reading1| ≥ (a) 13.08, (b) 10.73), M = month, and Wk = 
week. 
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Secondary Outcome Measures: Adherence Recall Interview 
Diet frequency 
Results from the 24hr recall of diet frequency are depicted in Figure 4.8. The 
diet frequency was defined as the total number of meals (breakfast, lunch and dinner) 
plus a bedtime snack, with four counts viewed as an acceptable level.
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Figure 4.8. The 24hr recall: Diet frequency.  
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Participant A had a stable baseline for the diet frequency counts, with all 
observations below the recommended level of four, and a downward trend towards 
the end of baseline. During the intervention diet frequency was similar to baseline, 
although there were two days where this reached the recommended level. At follow-
up there was a similar pattern, with one day at the recommended level. The results 
suggest a small improvement during intervention, which was maintained at follow-
up. 
Participant B’s baseline diet frequency was stable with one day at the 
recommended level. During intervention there were three days out of seven that 
reached the recommended level. During follow-up Participant B had a different 
pattern from that in baseline and intervention, with his diet frequency dropping to 
include two days in which the frequency was only two, although there was still one 
day at the recommended level. The results suggest an improvement during 
intervention but this was not maintained at follow-up.  
Participant C mostly had a stable baseline, with an upward trend and two days 
out of five at the recommended level. During intervention this participant continued a 
similar pattern, but had lower counts during early intervention and then later in the 
intervention had two days at the recommended level. The follow-up data is only 
available at the 2-week mark and had a count of two, which is below the recommend 
level. The results suggest an improvement in the later part of the intervention which 
was not maintained during follow-up.
Participant D had a near stable baseline and counts mostly were closer to or at 
the recommended level. A similar pattern continued during the intervention but 
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during follow-up there appeared to be deterioration with no counts at the 
recommended level. The results suggest no improvement during intervention and 
follow-up.   
Participant E’s baseline diet frequency was mostly below the recommended 
level; however, during intervention they became more stable and closer to the 
recommended level. During follow-up there appears to have been further 
improvement, with over half of the diet frequency at the recommended level. The 
results suggest an improvement during intervention with further improvement during 
follow-up. 
Participant F had a near stable baseline diet frequency mostly closer to or at 
the recommended level, with an upward trend towards the end of baseline. A similar 
pattern continued during the intervention period. During follow-up, however, all but 
one of the observations were at or close to the recommended level, which suggest an 
improvement in the diet frequency during follow-up. 
In summary, four participants showed an improvement in diet frequency 
during the study. Participant E had a stable improvement in diet frequency during 
intervention, with further improvement at follow-up with more counts at the 
recommended level. Participant A had a slight improvement during intervention, 
which was maintained at follow-up. Participant F had an improvement during follow-
up. Participant B had a slight improvement during intervention which was not 
maintained at follow-up. The other two participants (Participants C and D) had no 
improvement during intervention, and Participant C had a slight decline at the 2-
week follow-up (the remaining follow-up data are missing).
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Frequency of SMOBG 
Results from the 24hr recall of frequency of SMOBG are depicted in Figure 
4.9. The SMOBG frequency was defined as the total number of blood glucose tests at 
the three meals and before bedtime, where an acceptable level is a total of four 
counts.
Figure 4.9. The 24hr recall: Frequency of SMOBG.
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Participant A had a stable baseline for the frequency of SMOBG, with all 
observations below the recommended level of four. During the intervention the 
frequency of SMOBG increased with two counts at the recommended level and no 
counts below two. At follow-up the counts were mostly three with one count at the 
recommend level, which suggests a further improvement from baseline and 
intervention of not having counts less than three. The results suggest an improvement 
during intervention which was maintained at follow-up.
Participant B’s baseline frequency of SMOBG was stable with all counts less 
than the recommended level. During intervention, however, two counts reached the 
recommended level and only one out of seven counts was less than three, which 
suggests an improvement from baseline. An increase in the frequency of SMOBG 
was maintained during follow-up with a slight improvement of not having any counts 
less than three. 
Participant C had a stable baseline with four out of five counts at the 
recommended level. During intervention the frequency of SMOBG decreased, with 
only two points out of the ten at the recommended level. This suggests a slight 
deterioration during intervention. Follow-up data are only available at the 2-week 
follow-up point and was below the recommend level.  
Participant D had a stable baseline with an equal number of counts at three 
and four. During the intervention there was a similar trend to the baseline scores, 
with five counts out of nine at the recommended level. At follow-up a similar pattern 
of being mostly close to the recommended level continued. The results suggest no 
improvement during intervention and follow-up.   
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Participant E’s baseline had a downward trend, with one count at the 
recommended level and another at the end of baseline at zero. During intervention 
there were no counts at zero and two counts at the recommended level, which 
suggests a slight improvement from baseline. During follow-up the pattern suggests a 
further improvement, with three out of four observations at the recommended level. 
Participant F’s baseline was variable, with mostly a frequency of SMOBG 
below the recommended level. During the intervention, however, the frequency of 
testing became more stable, with three tests per day for seven days. This pattern 
suggests a slight improvement, although during intervention the frequency of 
SMOBG was still not at the recommended level. During follow-up, the frequency of 
testing was variable again, although there were two counts at the recommended level. 
The results suggest a slight improvement in the frequency of SMOBG during 
intervention but the follow-up scores regressed to a similar pattern in baseline.  
In summary, four participants had improvements in the frequency of SMOBG 
during the study. Participants A, B, and E had improvements during intervention that 
were maintained at follow-up. Participant F had a small improvement during 
intervention, this, however, was not maintained during follow-up. Participant C 
appeared to have a slight deterioration during intervention, but maintained values that 
were mostly close to the recommended level. Participant D had no improvement 
during intervention or follow-up.
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 Insulin frequency 
Results from the 24hr recall of insulin frequency are depicted in Figure 4.10.
Insulin frequency was defined as the total number of insulin doses at the three meals 
and before bedtime, where an acceptable level is a total of four counts.  
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Figure 4.10. The 24hr recall: Insulin frequency.
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Participant A’s insulin frequency during baseline was stable and mostly 
below the recommended level. During the intervention two out of ten counts were at 
the recommended level and six out of the ten were close to that, suggesting an 
improvement from baseline, which appears to have been maintained during follow-
up. 
Participant B’s baseline was variable and mostly below the recommended 
level, with only one out of four points at the acceptable level. A similar, but more 
stable pattern was observed during intervention, with all points at three, except one 
point at the recommended level, which suggests a small improvement from baseline. 
Follow-up showed a similar variable pattern. The results suggest a slight 
improvement during intervention, which was not maintained at follow-up. 
Participant C during baseline had a variable pattern, with two of the five 
points at the recommended level. A similar pattern continued during intervention, 
with two counts out of 11 at the recommended level. During follow-up she only had 
one point at count two. The results suggest no improvement during intervention or at 
follow-up. 
Participant D had a variable baseline with counts mostly below the 
recommended level. Although the data were still variable during intervention, there 
appears to have been an improvement, with four out of nine counts at the 
recommended level and only one observation less than three. During follow-up the 
observations were more stable, with no points less than three, and one observation at 
the recommended level. The results suggest an improvement during intervention that 
was maintained during follow-up.  
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Participant E’s frequency of insulin use during baseline appeared to show a 
downward trend, with two observations out of five at two and only one at the 
recommended level. There appeared to be an improvement during intervention with 
no counts less than three, and three of the seven counts at the recommended level. A 
similar pattern was observed during follow-up suggesting that the improvement was 
maintained.
Participant F’s baseline was variable, with two points out of seven at the 
recommended level and three points at level two. An improved, more stable, pattern 
was observed during the intervention with four out of seven observations at the 
recommended level and only one observation with a count of two. There appears to 
have been further improvement at follow-up, with most of the observations at the 
recommended level and no counts below three.   
In summary, four of the participants (Participants A, D, E, and F) had 
improvements in the insulin frequency during intervention, which was maintained 
during follow-up. The remaining two participants (Participants B and C) had no 
improvement during intervention or follow-up. 
Insulin timing 
Results from the 24hr recall of insulin timing, measured in minutes, are 
depicted in Figure 4.11. Insulin timing was estimated by deducting the time between 
the insulin dose and meal time, which needed to be at most 15 minutes apart, and 
therefore 15 minutes was subtracted from the reported insulin timing. An average 
time was then calculated; zero minutes is considered to be the acceptable timing 
average.
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Figure 4.11. The 24hr recall: Insulin timing (minutes).  
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Participant A had a pattern of alternating insulin timing points at baseline, 
with two out of four timings at the recommended level and another two exceeding 
that. He then had very stable insulin timing during intervention at zero level, with the 
exception of the beginning of the intervention. During follow-up he mostly 
maintained timings at level zero (three out of four). This suggests an improvement in 
insulin timing during intervention, which was maintained during follow-up.  
Participant B’s baseline was near stable, with three out four timings at the 
recommended level, and only the last baseline point sitting above that. A similar 
stable pattern was maintained during intervention, with six out of seven timings at 
the recommended level. An even more stable pattern was observed at follow-up, with 
all the timings at zero. The results suggest good adherence in baseline and 
intervention and an improvement during follow-up.  
Participant C’s baseline was near stable, with four out five timings at the 
recommended level, and with the last baseline point sitting above that. A similar 
stable pattern was maintained during intervention with nine timings out of ten at the 
recommended level. During follow-up a pattern could not be established because of 
missing follow-up points, but the observed follow-up point was at the recommended 
level. The results suggest good adherence in baseline and intervention, which was 
maintained at the follow-up. 
Participant D during baseline had timings that were variable and considerably
exceeded the recommended level, with only one timing out of six at the 
recommended level. A similar but less variable pattern was observed at intervention, 
which had lower levels of timings compared to the extreme timings at baseline. The 
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pattern improved and was more stable during follow-up, with most timings at or very 
close to the recommended level. The results suggest a slight improvement during 
intervention, with further improvement during follow-up. 
Participant E had a stable baseline with all timings at or very close to the 
recommended level. A similar pattern was observed during intervention, with six out 
seven timings at the recommended level. During follow-up this pattern was 
maintained, apart from the 9-month and 12-month follow-up when the timings 
exceeded the recommended level. The results suggest no improvement during 
intervention and a slight deterioration during follow-up. 
Participant F had a variable baseline, with most of values exceeding the 
acceptable level and had extreme values. During intervention, however, a drop in 
insulin timing was observed with five out of seven timings reaching the 
recommended level and no reported extreme values. During follow-up a similar, 
more stable pattern was observed, with two out five timings at the recommended 
level. The results suggest an improvement during intervention which was maintained 
at follow-up but with a slight regression to baseline. 
In summary, four participants showed an improvement in insulin timing 
during the study. Participant A had an improvement in insulin timing during 
intervention, which was maintained at follow-up. Participant B appeared to have had 
good adherence in insulin timing during baseline and intervention, which was further 
improved at follow-up. Participant D had a slight improvement during intervention, 
which was maintained with further improvement at follow-up. Participant F had an 
improvement during intervention which was maintained at follow-up but with a 
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slight regression to baseline. One of the remaining two participants, Participant C, 
had good adherence in baseline and intervention, which was maintained at the 
follow-up. Participants E had no improvement during intervention and a slight 
deterioration during follow-up.
Insulin Adjustment
Results from the 24hr recall of insulin adjustment are presented in Figure 
4.12. The insulin adjustment frequency referred to the number of times the correct 
amount of insulin was taken at three meals; the acceptable level was three, which 
indicated that at each meal time the participant took the correct amount of insulin, 
based on her or his blood glucose level and the number of carbohydrate units 
consumed.
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Figure 4.12. The 24hr recall: Insulin adjustment.  
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Participant A had an insulin adjustment baseline which was trending down 
with most counts below the recommended level of three. During intervention, 
however, he had seven out of ten counts at the recommended level and no counts 
below three. A similar pattern was maintained at follow-up. The results suggest 
improvement during intervention that was maintained during follow-up. 
Participant B during baseline had two out of four counts at the recommended 
level, and then during intervention had all counts at the recommended level, which 
suggests an improvement. During follow-up, however, the counts regressed to a 
similar pattern to baseline, with a count at level one. The results suggest although 
there was an improvement during intervention, it was not maintained during follow-
up.
Participant C’s insulin adjustment was variable and below the recommended 
level during baseline. A similar pattern continued during intervention, which 
suggests no improvement. At the follow-up there were not enough points to establish 
a pattern. The only point for which there was a reading was below the recommended 
level. 
Participant D had variable baseline, with two counts out of six at the 
recommended level. A similar pattern continued during intervention, with an 
improvement from mid-intervention with no counts less two. The follow-up pattern 
was even more stable and with no counts below two. The results suggest a slight 
improvement during intervention and a further improvement during follow-up. 
Participant E baseline counts were variable with all below the recommended 
level and none above two. During the intervention there appeared to be a slight 
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improvement, with two out of the seven counts at the recommended level and none 
of counts at level zero. There was further improvement at follow-up with a more 
stable pattern and no counts less than two. 
Participant F baseline was fairly stable with mostly counts of one. An 
improved, fairly stable pattern was observed during intervention with six out of 
seven values just below the recommended level. During follow-up the pattern was 
more variable but, unlike baseline or intervention, there was one count at the 
recommended level. The results suggest an improvement during intervention and a 
possible further improvement during follow-up.   
In summary, five out six participants had an improvement in their insulin 
adjustment frequency during the study. Participants D, E, and F had an improvement 
during intervention, and with a possible further improvement observed during 
follow-up. Participant A had an improvement during intervention that was 
maintained at follow-up. Participant B although had an improvement during 
intervention, but it was not maintained during follow-up. Participant C did not have 
an improvement during intervention or follow-up. 
Frequency of SMOBG per week 
Results from the frequency of SMOBG per week are presented in Figure 
4.13. The weekly SMOBG data (tabulated) were provided by participants from their 
blood glucose meters. A frequency of 28 was the minimum acceptable level of 
SMOBG per week.
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Figure 4.13. Frequency of SMOBG per week.  
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Participant A’s weekly frequency of SMOBG during baseline was variable 
and below the recommended level of 28, with three out of six weeks in the 20s range. 
A similar pattern was observed during intervention and follow-up, although data 
were missing for the later intervention and follow-up. The available data suggest no 
improvements to the frequency of SMOBG during intervention and follow-up. 
Participant B’s frequency of SMOBG at baseline was fairly stable but mostly 
below the recommended level. Whilst during early to mid-intervention there were 
three weeks in which the frequency was close to the recommended level, this 
however was not maintained during the latter part of the intervention. A similar 
pattern to the latter intervention period continued during follow-up, which suggests a 
slight decline from baseline in the frequency of SMOBG. 
Participant C had similar patterns during baseline and intervention, with the 
2-week data consistent with these patterns. The frequency of SMOBG always 
exceeded the recommended level, indicating a high frequency of SMOBG on a daily 
basis during baseline and intervention.  
Participant D’s frequency of SMOBG during baseline was close to the 
recommended level, with the exception of one week at the end of baseline which was 
above the recommended level. A similar pattern continued during intervention with a 
frequency of SMOBG that was close to or at the recommended level most weeks, 
and two weeks where this was exceeded. Again, a similar pattern appeared during 
follow-up, with the frequency of SMOBG exceeding the recommended level at the 9-
month and 12-month follow-up, which suggests an improvement towards the end of 
the follow-up period. 
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Participant E had a variable baseline, with no frequency of SMOBG at the 
recommended level, which was similar during intervention and follow-up. This 
suggests no change during intervention or follow-up, although here was one week 
during follow-up which the frequency of SMOBG reached the recommended level. 
Participant F during baseline had a frequency of SMOBG that was all at or 
above the recommended level. During intervention there was an improvement, with 
the frequency of SMOBG exceeding the recommended level in all weeks, which was 
maintained during follow-up 
In summary, two of the participants appeared to have had some improvement 
in the frequency of SMOBG. Participant F had a small improvement during 
intervention which was maintained during follow-up. Participants D and E had small 
improvements during follow-up. Participant C satisfied the minimum frequency of 
SMOBG recommendations during baseline, intervention, and the 2-week follow-up 
without any further changes. The remaining two participants had no improvements. 
Participant A had no change in the frequency of SMOBG during intervention and
follow-up, whereas Participant B had a slight deterioration in the frequency of 
SMOBG during the latter part of the intervention and follow-up.  
Physical Activity 
Results from the total physical activity per week are depicted in Figure 4.14; 
three participants (Participants A, B, and E) did not provide data on physical activity 
throughout baseline, intervention, or the follow-up period. A minimum of 20 minutes 
three times a week of physical activity was considered the minimum acceptable 
level.
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 Figure 4.14. The total physical activity per week: Exercise frequency.  
Participant C’s physical activity levels during baseline were variable, and 
mostly below the recommended number of three. During the intervention the pattern 
changed, with all but one week meeting or exceeding the recommended level, which 
suggests an improvement in the physical activity frequency during intervention. It 
was not possible to discern a pattern during follow-up because the only data available 
was for the 2-week follow-up point, and the earlier improvement was not maintained 
at that 2-week follow-up mark.   
Participant D maintained similar patterns of activity during baseline, 
intervention, and follow-up. All of the readings exceeded the recommended level, 
with the participant exercising at least four times per week. The results suggest the 
participant satisfied the minimum physical activity recommendations throughout 
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baseline, intervention, and follow-up.  
Participant F’s physical activity during baseline was variable, ranging from 
two to five times per week, but mostly exceeded the recommended level. During 
intervention also the two available data points exceeded the recommended level but 
because further data during intervention is not available it is not possible to comment 
on any trends during intervention. Similarly, during follow-up all weeks at least met 
the recommended level, but missing data again limit the conclusions that can be 
drawn. 
In summary, two of the participants had already met the minimum physical 
activity frequency recommendation. Participant C had an improvement in the 
physical activity frequency during intervention. Because of missing data it is unclear 
if this improvement were maintained during follow-up, although the improvement 
was not maintained at the 2-week follow-up.   
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Summary 
The main findings of the analysis are as follows. The HbA1c results were 
neither statistically equivalent nor different at baseline and during follow-up and 
hence resulted in statistical indeterminacy. Individual data indicated that only one 
participant (Participant D) had a clinically significant decrease in HbA1c post 
intervention that was maintained at the 9-month and 12-month follow-up, despite a 
clinically significant increase at the 6-month follow-up. Three participants 
(Participants B, D, and E) who had data at the 6-month follow-up had a trend of an 
increasing HbA1c, and then a drop in HbA1c in the subsequent follow-ups (9-month 
and 12-month).  
Glycaemic Variability outcomes, from baseline to intervention, generally 
showed improvements in the ADRR and HBGI risk outcomes, suggesting an 
improved stability in blood glucose fluctuations and therefore a lower risk for 
extreme blood glucose levels. The LBGI categories were maintained in the low risk 
range but with varying scores, except for one participant (Participant D) who had a 
category change from low to moderate risk. 
The majority of the psychosocial results showed significant improvements 
from baseline to follow-up in the group data. Improvements were observed in the 
following measures: PedsQL total score, diabetes symptoms, and worry, as well as 
BIPQ, and CIDS. These results suggest improved overall diabetes QoL, fewer 
problems associated with diabetes symptoms, fewer worries about diabetes 
complications, less perceived threatening views about the diabetes condition, and a 
higher level of self-efficacy. Clinically significant changes in individual data were 
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also observed for most of the study participants during the study (Tables 4.16-4.18). 
Improvements in diabetes self-management behaviours (as measured by the 
recall interview) were observed for all participants during the study. Of the six 
participants, four participants showed an improvement in diet frequency, four 
participants had improvements in the frequency of SMOBG, four participants had 
improvements in the insulin frequency during intervention, four participants showed 
an improvement in insulin timing during the study, five participants had an 
improvement in the insulin adjustment frequency during the intervention or follow-
up or both, two of the participants had some improvement in the (weekly) SMOBG 
frequency, and two out three participants had already met the minimum physical 
activity frequency recommendation. In addition, although all participants improved 
at least one adherence behaviour during intervention, which was then maintained at 
follow-up, all except one participant (Participant C who withdrew) made 




The data analyses suggest that the MI intervention contributed to positive 
changes in the primary and secondary outcomes measures. Group data suggest that 
the MI intervention contributed to clinically significant improvements in 
psychosocial functioning, but the intervention’s contribution to changes in HbA1c 
was indeterminant. Individual data also suggest the intervention contributed to 
improvements in GV, adherence behaviours, and psychosocial functioning for the 
majority of the participants. There was also a pattern in the individual data, 
suggesting improved HbA1c after the booster session. 
The above major findings are discussed as follows: primary outcome 
measures, secondary outcome measures, summary of findings, limitations, and 
recommendations for future research. 
Primary Measure: Blood Glucose 
Glycated haemoglobin (HbA1c) 
The results of the statistical tests of the group data for HbA1c, from baseline 
to follow-up, were statistically indeterminate; that is, both the statistical equivalence 
and the statistical difference tests failed resulting in the statistical indeterminacy. 
This means that no conclusion can be withdrawn about the impact of the MI 
intervention on HbA1c for the group data. This result may be due to a lack of 
statistical power because of the small number of participants and the missing data, in 
that three out of seven participants having data missing. 
The results of the clinically significant change using single-case experimental 
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design showed that only one participant had a clinically significant improvement. 
This improvement was observed from baseline to the 2-week follow-up and was 
maintained during the 9-month and 12-month follow-up, despite a clinically 
significant increase at the 6-month follow-up. Nevertheless, a conclusion about the 
efficacy of MI cannot be drawn from the one participant’s improved HbA1c profile, 
a consistent pattern need to be observed across the other participants.
For participants with a complete data set there was a notable pattern of an 
increase at the 6-month follow-up in three of four participants. This increase was 
followed by a clinically significant decrease at the 9-month or 12-month follow-up, 
or at both, with the 12-month follow-up reading always lower than that at 9-month 
follow-up. The common peak at the 6-month follow-up could be attributed to a 
seasonal effect phenomenon of increased HbA1c during autumn and winter (Hill, 
Peters, Thompson, Matthews, & Hindmarsh, 2013; Mianowska et al., 2011; 
Nordfeldt & Ludvigsson, 2000). 
The 9-month HbA1c reflected a period after the booster session. A reduction 
in HbA1c occurred despite a potentially expected increase due to the seasonal effect 
during winter. The observed changes in HbA1c may be attributed to the MI 
intervention and the booster session in particular. A meta-analysis by Hettema et al. 
(2005) stated that “if MI is offered as a stand-alone intervention, long-term effects 
may be enhanced by booster sessions” (p. 104). Future research could investigate the 
role of booster sessions in MI interventions for diabetes, which was also 
recommended in previous diabetes research (Britt, 2008).
There is evidence for the usefulness of booster sessions in other MI research. 
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For example, Chapman and Armitage (2009) found that adding a booster session 
improved the long-term impact of MI to increase fruit and vegetable intake beyond 6
months. Similarly, Longabaugh et al. (2001) found that the MI plus a booster at 12-
month follow-up reduced alcohol related injuries by 30% in participants who 
presented at an emergency department with an injury and screened positive for heavy 
or harmful drinking, compared to those who received standard care. 
An alternative explanation to the observed pattern of a decreased HbA1c after 
6 months from the MI intervention is a sleeper effect (Miller & Rollnick, 2013). 
Intervention effects on outcome variables vary depending on what they measure and 
whether they are slower-moving outcome measures (Miller & Rollnick, 2013). An 
HbA1c reading represents the average blood glucose level over the previous 2 to 3 
months, that is, there will be a delay until an effect on HbA1c can be observed. 
Furthermore, for an observed change in HbA1c there need to behavioural changes 
(e.g., medication compliance, exercise, and dietary compliance), and the effect of 
these behaviours on HbA1c may not be immediate. 
At the 12-month follow-up, the level of reduction in HbA1c (from the 6-
month follow-up), was not only a clinically significant decrease, but also suggests 
that the decrease may also contribute to a reduction in the risk for microvascular and 
macrovascular diabetes complications. For example, a large scale study showed that 
a reduction of 1% (11 mmol/mol) for people with type 1 diabetes significantly 
reduced the risk for diabetes complications of retinopathy, nephropathy, neuropathy, 
and cardiovascular conditions (DCCT Research Group, 1993, 1996). Thus, the 
HbA1c reductions observed in the current research were sufficient to potentially 
translate to reductions in diabetes complications.
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To summarise, the above suggests that the MI intervention contributed to 
changes in HbA1c, which was observed mostly post the booster session. A stronger 
conclusion about this effect, however, requires further investigation. 
Previous research has found, after an MI intervention, statistically significant 
reductions in HbA1c based on group data analysis (Channon et al., 2003; Huws-
Thomas, 2007), but the current study did not find statistically significant changes. 
The small number of participants may have contributed to not detecting any 
statistically significant changes in the group data. The detection of statistically 
significant changes on an averaged effect, however, does not necessarily equate to 
being clinically significant or meaningful (Jacobson & Truax, 1991; Sedgwick, 
2014). 
Clinically meaningful results were observed in the context of the single-case 
experimental design. Individual data analysis had the advantage of focusing on 
changes at an individual level and observing emergence of patterns across 
participants. The analysis in the current study involved clinical and statistical 
significance tests and accounted for biological variation in HbA1c; that is, accounted 
for inconsequential differences and detected meaningful changes. Individual data 
analysis and clinical significance have not previously been presented in research 
investigating the efficacy of MI for youth with poorly controlled diabetes. 
Glycaemic variability 
The GV profiles showed improvements from baseline to the end of 
intervention for the majority of participants. The changes were observed in ADRR, 
LBGI, and HBGI. There was a reduction in ADRR scores for five of six participants, 
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with two changing risk categories from a higher to a lower risk level. This means that 
glycaemic excursions, compared to baseline, were relatively less severe towards the 
end of the intervention. It also suggests that participants who had a decrease in 
ADRR scores and risk category were at a substantially reduced risk for having 
extreme glycaemic excursions, and therefore potentially reduced their risk for short-
term and long-term diabetes complications (Bode, 2008; Kovatchev et al., 2006). 
Similarly, the HBGI score for the majority of participants decreased from 
baseline to end of intervention, indicating less frequent hyperglycaemia episodes. 
Furthermore, the HBGI risk category was downgraded for two of six participants, 
which means they became at a substantially lower risk of having extremely elevated 
blood glucose levels and therefore had lowered risks for severe complications. 
Persistent and untreated hyperglycaemia causes serious and life-threatening 
complications, such as diabetic ketoacidosis, nerve damage, kidney damage and heart 
disease (Donaghue et al., 2009).
All, but one, of the participants had a score in the low risk category for 
hypoglycaemia at baseline, which means that they were at a low risk of having low 
blood glucose levels. This is consistent with previous research, which suggests that 
individuals who are compliant to tight glycaemic control and those with lower 
average glucose levels are at greater risk for hypoglycaemia (DCCT Research Group, 
1997; Fowler, 2008; Havlin & Cryer, 1988). This was unlikely for the participants in 
the current study because they all had poorly controlled diabetes. The LBGI score for 
two Participants (D and F) increased towards the end of the MI intervention; but only 
Participant D had an upgraded risk category from low to moderate. It was also noted 
that Participants D and F had a clinically significant drop in HbA1c measured at the 
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2-week follow-up, which appears to be consistent with this increased risk of 
hypoglycaemia, and highlights the difficulties in diabetes control whereby attempts 
to lower blood glucose and avoid the consequences of hyperglycaemia can increase 
the individual’s risk of hypoglycaemia (DCCT Research Group, 1997; Fowler, 2008; 
Havlin & Cryer, 1988).
In summary, the results of the current research suggest that the MI 
intervention contributed to improvements in GV risk factors and improved blood 
glucose stability. There was some reduction in the severity of glycaemic excursions 
and risk for hyperglycaemia for the majority of participants towards the end of the 
intervention, with a minority achieving a change of risk category. The reduction of 
scores, even without a category change, is an indication for improved blood glucose 
stability and less frequent extreme glycaemic episodes. 
Glycaemic Variability has been found to be associated with changes in 
Hb1Ac and the level of risk of complications (Krishna et al., 2013; Rohlfing, Hsiao-
Mei, Little, England, & et al., 2002). It is, therefore, recommended that future studies 
on diabetes interventions include GV evaluations across the study period. For the 
current study there were insufficient SMOBG data to carry out GV evaluations 
during follow-up. 
Secondary Outcome Measure: Psychosocial Functioning
The group data suggest that the intervention contributed to significant 
improvements in psychosocial functioning in the youth, and positive changes were 
mostly maintained or improved further at follow-up. Improvements were observed in 
five out of eight psychosocial measures from baseline to follow-up. These were: 
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PedsQL total score, diabetes symptoms, worry, BIPQ, and CIDS. This means that 
youth at follow-up compared to baseline had improved overall diabetes QoL, with 
fewer problems associated with diabetes symptoms, fewer worries about diabetes 
complications, less threatening views about diabetes, and a higher level of self-
efficacy in relation to diabetes management. The results are consistent with previous 
findings which have found positive effects of standalone MI interventions on 
psychosocial functioning (Channon et al., 2003; Huws-Thomas, 2007).  
The individual data were consistent with the group data, generally showing 
improvements in scores over time. Reliable changes in scores, a measure of clinical 
significance, however, were mostly observed on the CIDS and PedsQL total scores. 
There were some reliable changes observed in the remaining measures, but none in 
BIPQ. This also suggests that although the group data showed statistically significant 
changes at follow-up, and the descriptive individual data displayed that, clinically 
reliable changes were not always observed, and any changes may have been due to 
chance variation. 
A possible explanation for not observing clinically reliable changes in some 
questionnaires, including none in BIPQ, may be because of the estimated SEM and 
Cronbach alpha of these scales (i.e., questionnaire’s reliability). The BIPQ Cronbach 
alpha was found to be 0.704 (see Chapter 3). This reliability affects the SEM value, 
and thus the spread of Sdiff. A relatively low reliability means a high SEM and 
therefore a wide Sdiff, which means the spread of distribution of score changes due to 
chance variation is wider than that when the reliability is high. In contrast, the CIDS 
and PedsQL-Total Cronbach alpha coefficients were both about 0.92, which 
represents excellent internal consistency and therefore Sdiff was narrower and reliable 
264
changes had a greater chance of being detected compared to that of BIPQ. 
The above also suggest that the MI intervention contributed positively to 
clinically meaningful improvements in self-efficacy and the overall diabetes QoL.  
However, the MI effect on illness perceptions remains unclear, given that clinically 
reliable changes were not confirmed at an individual level, despite the detection of 
statistically significant improvement at a group level. Hence, future research is 
recommended to investigate this. 
The degree of the potential impact of MI on the psychosocial measures in the 
group data from the current study ranged from medium to large. Data on the degree 
of impact of a standalone MI intervention for youth with type 1 diabetes have not 
been previously reported; however, meta-analyses of diabetes interventions have 
reported small to medium effect on diabetes outcomes, such as HbA1c and 
psychosocial outcomes (Hampson et al., 2000; Winkley et al., 2006). This suggests 
that MI may be effective, and potentially more beneficial, than other interventions for 
youth, given the moderate to large effects obtained in the current study. Future 
research is recommended to further investigate the effect of MI on psychosocial 
functioning.
Secondary Outcome Measure: Adherence to Diabetes Self-management
The MI intervention contributed to improvements in diabetes adherence 
behaviours, with all participants showing an improvement in at least one adherence 
behaviour during intervention, which was maintained at follow-up. These results are 
consistent with a finding by Channon et al. (2003) that youth reported at least one 
change on adherence behaviours after their MI intervention.
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In addition, five of the six participants (Participants A, B, D, F, and E) made 
improvements in multiple behaviours (at least three behaviours). Furthermore, the 
three participants (Participants A, B and F) who improved adherence to most of the 
24hr adherence behaviours, including blood glucose and insulin components (i.e., 
SMOBG frequency, insulin frequency, insulin timing, and adjustment), also had a 
risk factor downgrade in the GV risk categories between baseline to intervention. 
Thus, improvement in adherence behaviours that relate to blood glucose monitoring 
and insulin may have had an impact on blood glucose fluctuations and lowered the 
risk for extreme values. 
This finding is consistent with evidence that blood glucose monitoring and 
insulin are essential components in diabetes management and also in improving GV 
(Bode, 2008; LeRoith & Smith, 2005). Research recommends the use of SMOBG to 
evaluate GV and therefore make necessary adjustments to address extreme blood 
values and blood glucose instability (Bode, 2008). Research shows that lowering 
HbA1c combined with improving GV by means of SMOBG also reduces the risk for 
complications (Hinzmann, Schlaeger, & Tran, 2012). 
Participants B and F also had changes in HbA1c from baseline to the 2-week 
follow-up, consistent with improvements in adherence behaviours and reduced risk 
for extreme blood glucose values from baseline to intervention. Participant A, on the 
other hand, had an increase in HbA1c, which was in an opposite direction to that 
expected. This is despite of improved adherence behaviours and GV. This result is 
considered an inconsistent finding. 
The interpretations of these results however need to be cautiously approached 
266
because of the limitations of the study (see following sections). This includes 
collecting adherence data only once a week, which may not have reflected the reality 
of adherence during other days of the week; more frequent adherence data would 
have potentially addressed this but it may have led to other problems in terms of 
participant compliance with the study procedure (e.g., being available for daily 
adherence recall interviews). In addition, the GV data for participant A was analysed 
based on a fewer number than that known to produce optimal results (see Method 
section), which may have influenced the results, but even so the analysis was still 
considered reliable. The above result also implies that there may have been other 
factors that had an impact on HbA1c. Research shows factors such as iron 
deficiency, B12 deficiency, excessive alcohol, excessive drugs (e.g., aspirin), 
depressive mood, viruses, and hormones contribute to an elevation in HbA1c 
(Aronoff, Berkowitz, Shreiner, & Want, 2004; Hanas, 2007; Hinzmann et al., 2012; 
NGSP, 2015; Nitin, 2010; Polgreen, Putz, & Stapleton, 2003; Van Tilburg et al., 
2001). This suggests that HbA1c is influenced by a multitude of factors including 
physiological, psychological, and behavioural factors, and not merely one or the 
other. This also means that although individuals with diabetes could be completely 
adhering to medication and self-management recommendations, yet, physiological 
and other factors may interfere and have an impact on the HbA1c results.  
In summary, the MI intervention appeared to have contributed to increased 
adherence to diabetes self-management behaviours, with most participants improving 
multiple adherence behaviours. However, these findings need to be treated with 
caution. Although the current adherence measure had the advantage that it evaluated 
changes in adherence behaviours based on a 24hr recall memory and blood glucose 
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meter weekly data (collected during non-concurrent baselines), it also had 
limitations. The measured 24hr frequencies provided a snapshot of the week, and a 
time point in each follow-up. Because these are only snapshots the results may not 
represent accurately the entire period. In addition, the 24hr recall is a self-report, 
which is less reliable than, for example, the blood glucose meter data or clinical 
measures (e.g., HbA1c). These limitations may have created some inconsistencies in 
findings. For example, two of the four participants who had improvements on the 
24hr recall SMOBG frequency, did not show an improvement on the weekly 
SMOBG. This suggests that evaluating only one instance in a week may not always 
estimate the actual level of adherence or changes in that. 
There is a general recognition of the difficulty of assessing self-management 
behaviours for clinical trials and finding a reliable and accurate representation of this 
(Budde, 2009; McNabb, 1997). There are many factors that contribute to this, which 
are mostly attributable to the complexity of the diabetes regime. Diabetes 
management may differ considerably amongst individuals with diabetes, with 
differing treatment plans, lifestyle adjustments, and co-existing conditions and 
morbidities. Hence, the generic guidelines may not be always applicable and a one-
size-fits-all diabetes management may not simply exist. Therefore a standard 
adherence measure may not accurately represent adherence amongst all research 
participants. It could also fail to capture their true level of adherence when compared 
to others using the same measure. 
Although a standardised measure, such as the 24hr adherence recall 
interview, may not match the diabetes self-management regime of all participants in 
a research study, it is still possible to observe patterns of change over time for each 
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participant, who serves as their own control as is the situation in single-case 
experimental design. In other words, a general adherence measure may be useful for 
monitoring changes in diabetes self-management behaviours within individuals. 
It is recommended that future research collects adherence data from 24hr 
recalls more than once a week to increase confidence of patterns and changes. It is 
also recommended that future studies, with a large number of participants, also 
evaluate changes in adherence measures using statistical and clinical procedures 
rather than only by visual analysis. This, however, may require controlling for 
potential confounding factors from the differing individual adherence amongst 
participants.  
Summary and Conclusion 
The MI intervention in the current study had a positive effect on primary and 
secondary outcome measures. Changes were observed in multiple variables across 
many participants. The overall findings were consistent with previous research on MI 
and diabetes and health behaviour change more generally (Channon et al., 2003; 
Christie & Channon, 2014; Gayes & Steele, 2014; Huws-Thomas, 2007). 
The current study had the strength of using single-case experimental design 
with non-concurrent multiple baseline and person replication, which enhanced 
internal and external validity. The current study allowed comparisons both within-
participants and between-participants, during and after intervention, and with each 
participant serving as their own control, which enhanced internal validity. In 
addition, replication of the effects of the MI intervention across participants and the 
use of a range of different and intensive assessments of dependent variables (i.e., 
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behavioural, psychosocial, and clinical outcomes) enhanced the external validity of 
the results. Moreover, MI was delivered as a standalone alone intervention. The 
treatment fidelity was independently reviewed and confirmed that the MI was 
provided with a high level of skill. The study used both statistical and clinical 
significance analyses and accounted for potentially inconsequential differences (e.g., 
by using MCID, and CV). That is, the differences were clinically and statistically 
significant and reliable, and not because of chance variation, biological variation, or 
analytical biases. The present study, therefore, presented evidence for clinically 
meaningful results.  
The study did, however, have weaknesses and limitations, and therefore, the 
results should be treated with caution. The limitations include a lack of statistical 
power, which may have led to not detecting statistically significant difference or 
equivalence, and therefore giving a result of indeterminacy for some measures. The 
study had a relatively small sample size and some data were missing. Furthermore, 
participants were all recruited from the same service, hence limiting the 
generalisability of results. Another weakness is related to self-report measures (e.g., 
24hr recall data), which are relatively less reliable than objective measures (e.g., 
SMOBG meter readings and HbA1c). Nonetheless, the incorporation of a broad 
range of measures in the current study and observing changes across several 
measures provides more confidence in the treatment effect on the dependent 
variables. Finally, the adherence measure was solely visually analysed, which 
constituted a limitation in interpreting data and therefore findings are to be treated 
with caution. 
To conclude, the current study provided evidence for the efficacy of MI for 
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youth with poorly controlled type 1 diabetes. Although the findings from this study 
are promising, further investigations are required to confirm and generalise results. 
At present, there are only three studies (including the current research) that have
investigated the efficacy of MI as a standalone intervention for youth with type 1 
diabetes. This shows that the MI research in the context of diabetes interventions for 
youth is still developing.
It is recommended that future research addresses the limitations in the current
study to examine the MI efficacy for youth with diabetes in greater depth and to 
confirm the current study findings. This could include recruiting participants from 
multiple centers, and possibly extend it to a national or international level to boost 
recruitment and enhance internal and external validities. In addition, the clinical 
utility of MI could be investigated. Health professionals trained in MI could be 
involved in future trials of an MI intervention for youth with type 1 diabetes. This 
would clarify the practicality of delivering MI in the context a real world setting and 
achieving positive changes. 
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Chapter 5
Conclusions and recommendations 
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CHAPTER 5: CONCLUSIONS AND RECOMMENDATIONS 
Overview of the Thesis and Key Findings 
The management of type 1 diabetes is challenging and is influenced by 
developmental factors including physiological and psychological changes. This is 
particularly the case during adolescence when diabetes control often deteriorates 
(Borus & Laffel, 2010; Hamilton & Daneman, 2002; Pinhas-Hamiel et al., 2014). 
Additional health costs stem from long-term complications associated with poorly 
controlled type 1 diabetes, such as kidney failure and nerve damage (International 
Diabetes Federation, 2013). The burden on the health system may become greater if 
these long-term complications arise at an early age (Zhuo et al., 2014). It is therefore 
important for healthcare planning to study trends in diabetes in specific populations, 
and in particular for the youth population for whom diabetes management can pose 
significant challenges. Poorly controlled diabetes is common among the majority of 
youth with type 1 diabetes, and there is an urgent need to change this to minimise the 
risk of negative long-term consequences (Laffel et al., 2014). 
This thesis has presented three studies, with the first two describing and 
studying specific characteristics of the target population. The third study evaluated an 
intervention for youth with type 1 diabetes. The intervention is one that has shown 
some promise in previous research, although results have been mixed and there were 
also methodological problems that limited the conclusions which could be drawn. 
The first study in this thesis was an audit that provided up-to-date information 
on epidemiological characteristics and clinical outcomes (i.e., diabetes control) for 
the youth population with type 1 diabetes residing in the Canterbury region in New 
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Zealand. Data were collected from CDHB records of youth (15-24 year olds) with 
type 1 diabetes, with an anchor date that is seven years from a previous audit that 
was conducted in the region in 2003 (Wu et al., 2005). The prevalence of youth with 
type 1 diabetes was estimated in 2003 and 2010. The change in prevalence was then 
evaluated over time by using the ASPR (2010 being a reference year). This 
procedure accounted for any differences in the makeup of the population in the 
different years, and therefore gave a reliable estimate for the change in prevalence 
from 2003 to 2010. Changes in diabetes control at a population level in a subgroup of 
CDHB youth with type 1 diabetes (aged 15-20 years old) were also assessed over 
time from 2001 to 2010. 
Key findings from the 2010 audit for the 248 youth with type 1 diabetes, who 
were identified in the CDHB catchment area in 2010, follow. The majority (91.5%; n
= 227) were European New Zealanders. The age-standardised prevalence of youth 
with type 1 diabetes (European New Zealanders) increased from 2003 to 2010 by 45 
per 100,000. The ASPR was 1.19 (95% CI: 0.910 to 1.429). The majority (93.2%; n
= 229) of youth with type 1 diabetes had HbA1c levels that exceeded the 
recommended range for healthy diabetes control (i.e., less than 55 mmol/mol). The 
average HbA1c was 82 mmol/mol, which is classified as poor diabetes control.
Diabetes control had not improved at a population level, when comparing data from 
2010 with that in 2001. 
The second study was a cross-sectional study that investigated the 
relationship between glycaemic control and key psychosocial characteristics: illness 
beliefs, self-efficacy, and QoL in youth with type 1 diabetes within the CDHB 
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catchment area. Youth identified in the audit study, who had a recent HbA1c reading, 
and whose type 1 diabetes was established, were recruited to take part in the 
psychosocial evaluation study. Psychosocial factors play an important role in 
influencing diabetes self-management and diabetes control (Delamater et al., 2014; 
Hagger & Orbell, 2003; Kovacs et al., 1997; Wysocki et al., 1992). Although there 
has been extensive research to explore a number of influencing factors, there are still 
gaps in knowledge particularly for the youth developmental stage, such as the role of 
certain psychosocial factors in predicting HbA1c levels. The current study addressed 
some of the gaps in knowledge in areas, such as investigating the individual and 
combined roles of illness perceptions, self-efficacy, and QoL in predicting glycaemic 
control. The examination of the combined and individual contributions can inform 
diabetes care systems, in particular interventions that target those with poor diabetes 
control. In New Zealand, the present study was the first to examine a combination of 
these key psychosocial factors in relation to diabetes control in youth (15-24 year 
olds) with type 1 diabetes. Nor has any previous study investigated any of these 
psychosocial factors with youth in Canterbury.
Key findings from the psychosocial evaluation of the 56 youth with type 1 
diabetes (response rate was 23%), who agreed to participate in the cross-sectional
study of this thesis follow. The mean HbA1c in this study was 77 mmol/mol (SD = 
26.0 mmol/mol), which is above the recommended level and in the suboptimal 
diabetes control range. The majority of youth (66.1%) had unsatisfactory levels of 
HbA1c, with more than half of those individuals (35.7%) falling in the poor and very 
poor HbA1c range. Only 5.8% were in the excellent diabetes control range. The 
regression analyses showed that: first, significant predictors of HbA1c were age, 
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illness perception and worry, which explained 36.9% of variation in HbA1c. Higher 
age predicted lower HbA1c, higher scores on the BIPQ predicted higher HbA1c, and 
more frequent worry about diabetes complications predicted lower HbA1c. Second, 
two of the BIPQ subscales were found to significantly contribute to HbA1c: concern
and personal control, contributing respectively 3.5% and 10.1% to the variance of 
HbA1c. Higher perceived personal control was associated with lower HbA1c levels, 
and more perceived concern was associated with poorer HbA1c outcome. And third, 
a further exploration of the worry scale revealed that worrying about going low was a 
significant term that contributed 13.7% to explaining HbA1c. This result suggested 
that more worries about diabetes complications (specifically worrying about going 
low) were associated with better diabetes control.  
The third study in this thesis investigated the efficacy of MI as an 
intervention for youth (16-24 years old) with poorly controlled type 1 diabetes 
(HbA1c > 64 mmol/mol). The study evaluated whether MI contributed to improved 
diabetes self-management, such as increased SMOBG and insulin adjustment, as well 
as clinical improvement in the glycaemic control, by using clinical, behavioural, and 
psychosocial measures. These measures comprised HbA1c, GV, frequency of 
SMOBG, adherence to diabetes self-management behaviours (e.g., insulin 
medication, timing and adjustment), and psychosocial questionnaires (BIPQ, CIDS, 
and PedsQL3.2). In addition, the fidelity of the MI intervention was evaluated using 
the MITI 3.1.1 coding system.  
This study contributes to current knowledge and bridges some of the gaps in 
examining the efficacy of MI for youth with diabetes. It also addresses some of the 
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limitations in previous research so that the efficacy of MI for youth with poorly 
controlled type 1 diabetes can be more clearly evaluated. The research included 
evaluating the effect of a standalone MI intervention and provided evidence that the 
MI was delivered with high fidelity using the MITI 3.1.1. The study presents 
clinically meaningful results in the context of the single-case experimental design, 
which has not been presented previously in research that investigates the efficacy of 
MI for youth with poorly controlled diabetes. The current study is the first to explore 
and to quantify the degree of the impact (measured by effect size) of a standalone MI 
intervention on the psychosocial measures in youth with poorly controlled type 1 
diabetes. The current study is also the first to include youth from the emerging adults 
developmental stage (i.e., 18-24 years), which is a vulnerable phase and this age 
group has not been the target for an MI intervention in previous diabetes studies. 
The results of this thesis suggest that the standalone MI intervention had a 
positive impact on multiple diabetes outcomes across several participants; these are 
summarised below. 
Individual data indicated a pattern across three of the six participants that 
suggest an improvement in HbA1c following the booster session at the 6-month 
follow-up, with improvements in HbA1c observed at 9-month and 12-month follow-
up. Although the HbA1c group results were neither statistically equivalent nor 
different at baseline and during follow-up, with a consequential result of statistical 
indeterminacy, the result may be attributed to lack of statistical power.
Glycaemic Variability outcomes, from baseline to intervention, showed 
improvements in the ADRR and HBGI risk outcomes, which suggests improved 
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stability in blood glucose fluctuations as well as a lower risk for extreme blood 
glucose levels. Furthermore, the LBGI categories were maintained in the low risk 
range for all participants except for one (Participant D), whose LBGI moved from 
low to moderate risk. This participant also had reductions in HbA1c, and therefore 
may have achieved tighter control and consequently was at an increased risk of 
hypoglycaemia as has been suggested in previous research (DCCT Research Group, 
1997; Fowler, 2008; Havlin & Cryer, 1988). 
The majority of the psychosocial results showed significant improvements, 
with a medium to large effect from baseline to follow-up in the group data. 
Improvements were observed in the following measures: PedsQL total score, 
diabetes symptoms, worry, BIPQ, and CIDS. The results suggest that the participants 
had improved overall diabetes QoL, fewer problems associated with diabetes 
symptoms, fewer worries about diabetes complications, fewer perceived threatening 
views about the diabetes condition, and a higher level of self-efficacy. Clinically 
significant changes in individual data were also observed for most of the study 
participants during the study, primarily in the PedsQL total score and CIDS, and 
these results were maintained or further improved at follow-up. 
Finally, improvements in diabetes self-management behaviours, as measured 
by the 24hr recall interview, were observed across multiple behaviours for several 
participants during the study. Five of the six participants made improvements on 
multiple behaviours (at least three) during the study. This suggests that participants 
performed adherence behaviours more frequently, with some reaching or exceeding 
the minimum acceptable level. 
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Weaknesses and Strengths of the Current Research
The following presents a summary of the key weaknesses and strengths in 
this thesis, which have already been discussed in each of the respective chapters: 
audit, psychosocial evaluation, and MI intervention.  
Audit
In the audit study, discussed in Chapter 2, a complete number of cases of 
youth (15-24 year old) with type 1 diabetes within the CDHB catchment area may 
not have been identified. That is, there may be entries missing, which may have 
contributed to underestimating the prevalence. Capture-recapture was applied in the 
present study using the previous study records (Wu et al., 2005), but potentially 
missing entries could have been cross-checked using an additional capture-recapture 
method. This, for example, might have included setting a search date of two to three
years back for checking hospital records instead of only one year back from the 
anchor date of November 2010. It is expected that youth with diabetes are examined 
medically at least once a year. It is possible that records may be have been missed if 
they did not attend their annual check-up in 2010, or had not been admitted to the 
hospital during that period. More entries may have been captured, if the search 
period was extended to, for example, two years back from the anchor date. 
Although the limitation discussed above may have resulted in missing entries 
and therefore the prevalence in 2010 may have been underestimated, the number of 
missing entries is believed to have been minimised. This is because multiple sources 
were thoroughly checked for youth entries, including the inpatient and outpatient 
hospital discharges and youth databases. The study had the strength of performing a 
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rigorous and systematic search by means of using medical codes, date of births, cross 
checking different sources in the CDHB hospital and diabetes centre databases, and 
accessing physical records and NHIs. In addition, cross checking records against Wu 
et al.’s data (2005) increased confidence of minimising missing entries. Furthermore, 
the study had the strength of retrieving missing data-point entries by searching the 
physical files held at the CDHB Diabetes Centre based on the NHI, and contacting 
the individual youth’s GP. 
The study had the strength of using a set of reliable procedures for evaluating 
changes in prevalence over time from 2003 to 2010. The study ensured compatible 
datasets (e.g., total and age strata population) for comparing 2003 and 2010. The 
study used the same data source and accounted for the difference in the classification 
of ethnicity in different census years. The study also had the strength that it 
controlled for a potential confounder from the different makeup of subgroups when 
comparing prevalences from two populations. This was ensured by calculating an 
age-standardised prevalence and ASPR rather than just using crude prevalences for 
evaluating change in prevalence over time.  
Psychosocial Evaluation
In the psychosocial evaluation study, discussed in Chapter 3, limitations 
included the response rate (and sample size) of the completed questionnaires, as well 
as the homogeneity of the sample (i.e., youth from one region who attended the same 
health institute). The total population of CDHB youth with type 1 diabetes was 248 
and it was unlikely that a large sample size would be obtained. The research faced 
the challenges posed by the effects of the 2010-2011 Canterbury earthquakes. One 
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consequence of the earthquakes is that many people were forced to move, and as a 
result 26 letters were returned as invalid addresses or return to sender and this would
have contributed to the relatively small sample size. The sample size also seemed to 
play a role in limiting ability of the statistical models to explain extremely elevated 
HbA1c levels that are above 138 mmol/mol. Four HbA1c values (≥138 mmol/mol) 
were considered influential outliers and were therefore excluded from the analysis. A 
larger sample size (with extreme HbA1c values) might overcome this limitation. The 
above suggests that the relatively small sample size and only involving youth from 
one city limits the generalisability of the results.  
Despite the above limitations, the study had the strength of performing 
reliable analyses and detecting significant associations at an inferential level, rather 
than simply a descriptive level. The study involved pre-analysis evaluations, a cycle 
of validations, and controlled for confounding factors in the confirmatory analysis, 
namely: the questionnaires demonstrated valid reliability and therefore analysis was 
carried out with confidence, multicollinearity was minimised, and influential outliers 
were examined and then removed. The confirmatory analysis was then carried out 
using systematic procedures with further evaluation cycles (e.g. residual plots and 
regression diagnostics). The study also had the strength of explaining the variation in 
HbA1c in relation to the psychosocial characteristics of youth with type 1 diabetes, 
whilst meeting requirements for the selected statistical analysis tests. For these 
reasons it can be said that this study presented reliable evidence for the predictability 




In the MI intervention study, discussed in Chapter 4, limitations included lack 
of statistical power to detect statistically significant difference or equivalence, which 
therefore results in indeterminacy. The study had a relatively small sample size and 
some data were missing. Another weakness is related to self-report measures that 
were used (e.g., 24hr recall data), which are relatively less reliable than objective 
measures (e.g., SMOBG meter readings and HbA1c). Nonetheless, the incorporation 
of a broad range of measures in the study and observing changes across several of the 
measures gives greater confidence of the treatment effect on the dependent variables. 
The adherence measure was solely visually analysed, which constituted a limitation 
for the interpretation of data and therefore findings are to be treated with caution. 
Despite the limiting factors outlined the study had a number of strengths. It 
used a single-case experimental design with non-concurrent multiple baseline and 
person replication, which enhanced internal and external validity. The current study 
compared within- and between-participants, both during and after intervention, with 
each participant serving as their own control, which enhanced internal validity. In 
addition, replication of the effects (i.e., the MI intervention) across participants and 
using different and intensive assessments of dependent variables (i.e., behavioural, 
psychosocial, and clinical outcomes) enhanced the external validity of the results. 
Moreover, MI was delivered as a standalone intervention and the analyses were 
specific to the MI effect. Treatment fidelity was independently reviewed, and 
verified, and the measures met or exceeded MI proficiency thresholds. Finally, the 
study used both statistical and clinical significance analyses and accounted for 
potentially inconsequential differences (e.g., by using MCID, and CV). That is, the 
282
differences were clinically and statistically significant and reliable and not due to 
chance variation, biological variation, or analytical biases. The present study, 
therefore, presented evidence for clinically meaningful results.  
Conclusions
Diabetes is a global epidemic with a trend of increasing prevalence as shown 
in international and national research (International Diabetes Federation, 2013; Wild 
et al., 2004). The Canterbury region, in New Zealand, is not an exception and has had 
an increase from 2003 to 2010 in the prevalence of adolescents and young adults 
with type 1 diabetes as the results in the current thesis demonstrate. This suggests an 
increased demand on health resources, and for the healthcare system to consider how 
best to meet the needs of this increased demand. This thesis found that the level of 
diabetes control, at a population level in 2010, was in the poor glycaemic control 
range and that this has remained unchanged since 2001. This implies that poorly 
controlled diabetes has been the norm in this age group and indicates that there is an 
urgent need for more effective interventions that target this particular population. 
It is recommended that health services review the current approach to youth 
with type 1 diabetes with the view to establishing more effective interventions, and 
specifically interventions focussed at youth with the poorest diabetes control. 
Furthermore, it is recommended that the key psychosocial factors that have been 
found to influence diabetes control in this age group be considered in the planning 
for future services to enhance their effectiveness. Key psychosocial factors that 
should be considered include self-efficacy, illness perceptions, perceived personal 
control over diabetes, coping and emotional adjustment, and QoL related factors such 
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as worry. Ongoing audits are also recommended to provide further up-to-date 
information about prevalence and diabetes control in Canterbury over time.
The current thesis found that diabetes control in youth with type 1 diabetes 
was influenced by factors, including diabetes illness perception, perceived personal 
control, diabetes-related concern, and worry about complications. The results were 
generally consistent with previous research in finding that these factors contribute to 
predicting HbA1c, and confirmed the expected direction of prediction (e.g., Griva et 
al., 2000; Pereira et al., 2011). Nonetheless, the worry finding deviated from what 
seems expected and there has been a lack of research investigating this in relation to 
predicting HbA1c. The overall results suggested youth who were worried about 
complications also had better diabetes control. However, this has to be managed 
carefully because having stronger beliefs about diabetes as a threatening condition 
may negatively influence diabetes control. Hence, the current thesis findings present 
a new understanding of the importance of balancing worries about diabetes 
complications and perceptions on diabetes as a threatening condition. This 
relationship has potential clinical implications, and therefore, it is recommended that 
this be researched further.
Further research is recommended to test and confirm if these findings can be 
generalised. It is also recommended that future research address the limitations 
identified in the current research, such as statistical power. This could be achieved by 
extending the research to other catchment areas in the South Inland, or New Zealand 
as a whole. A multi-centre study conducted on a national level is suggested as 
preferable to facilitate a higher response rate. In addition, future research could 
investigate influential factors (e.g., HbA1c and worry), using mediational and direct 
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relationship models in a longitudinal study. This could facilitate establishing the 
causal relationships and to clarify the extent of effect amongst the process variables, 
including direct and mediational relationships (e.g., frequency of extreme glycaemic
episodes as a lateral variable). 
The MI intervention was successful in improving some diabetes outcomes –
clinical, psychosocial, and behavioural changes were observed. Statistically and 
clinically significant positive changes were found across multiple variables. 
Improvements in GV, adherence, and psychosocial factors were observed during the 
study, with improvements in the latter two (which had follow-up data), being 
maintained or further improved during the follow-up period. Improvements in 
HbA1c were observed but with a delayed effect – there was a pattern of reduction 
post the 6-month follow-up. This may be explained by a potential role of a booster 
session or a sleeper effect. It is recommended that the role of booster session(s) be 
investigated in future research. Furthermore, it is recommended to evaluate the effect 
of MI beyond 12 months, for example, at 18-month and 24-month follow-up points. 
Research shows that long-term effects of psychosocial and behavioural interventions 
may not be sustained beyond 12 months (Harvey, 2015). This also suggests the 
potential need for adding a booster session during that period. 
Furthermore, the extent of the potential impact of MI on the psychosocial 
measures in the group data from the current study ranged from medium to large (i.e., 
effect sizes were mostly in the range of 0.5 and 0.8). Data on the degree of impact of 
a standalone MI intervention for youth with type 1 diabetes have not been previously 
reported; however, meta-analyses of diabetes interventions have reported small to 
medium effect on diabetes outcomes, such as HbA1c and psychosocial outcomes 
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(Hampson et al., 2000; Winkley et al., 2006). This suggests that MI may be effective 
and potentially more beneficial than other interventions for youth, given the 
moderate to large effects obtained in the current study. Future research is 
recommended to further investigate the effect of MI on psychosocial functioning.  
The overall findings of this MI study are consistent with previous research 
(Channon et al., 2003; Huws-Thomas, 2007), and the current thesis contributes to 
knowledge in this area by addressing gaps in previous research, such as the lack of 
fidelity measures, clinical significance analysis, and evaluation of MI as a stand-
alone intervention. Further research, however, is required to generalise the findings 
for the youth population. At present, there are only three studies (including the 
current research) that have investigated the efficacy of MI for youth with type 1 
diabetes. Thus, MI research in the context of diabetes interventions for youth is still 
at infancy. The current evidence, nonetheless, shows that MI maybe a promising 
intervention for youth with type 1 diabetes. As well as benefiting individual youth 
and their families, MI has the potential to be of benefit more broadly because many 
of the healthcare costs associated with diabetes stem from the complications arising 
from poorly controlled diabetes. 
“Type 1 diabetes (T1D) in children and young people is increasing worldwide 
… Effective glycaemic control requires a careful balancing act between 
insulin, food and physical activity. Intensive regimens offer the best possible 
control; however, they are oppressive for children, young people and families. 
Fewer than one in six children and young people achieve glycosylated fraction 
of haemoglobin (HbA1c) values in the range identified as providing best 
future outcomes. One-third have a HbA1c value that puts them at significant 
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risk for development of long-term complications. Moderate evidence supports 
the effectiveness of psychological interventions...There is an urgent need for 
clinic-based pragmatic, feasible and effective interventions that improve both 
glycaemic control and quality of life (QoL).” (Christie et al., 2014, p. xxvii)
287
REFERENCES 
Aalto, A. M., & Uutela, A. (1997). Glycemic control, self-care behaviors, and 
psychosocial factors among insulin treated diabetics: A test of an extended 
health belief model. International Journal of Behavioral Medicine, 4(3), 191-
214. doi: 10.1207/s15327558ijbm0403_1
Aalto, A. M., Uutela, A., & Aro, A. R. (1997). Health related quality of life among 
insulin-dependent diabetics: Disease-related and psychosocial correlates. 
Patient Education and Counseling, 30(3), 215-225. 
Abdul-Rasoul, M., Alotaibi, F., Abdulla, A., Rahme, Z., & Alshawaf, F. (2013). 
Quality of life of children and adolescents with type 1 diabetes in Kuwait. 
Medical Principles and Practice, 22(4), 379-384. doi: 10.1186/1753-6561-6-
S4-P7
Abolfotouh, M. A., Kamal, M. M., El-Bourgy, M. D., & Mohamed, S. G. (2011). 
Quality of life and glycemic control in adolescents with type 1 diabetes and 
the impact of an education intervention. International Journal of General 
Medicine, 4, 141-152. doi: 10.2147/ijgm.s16951
Al-Akour, N., Khader, Y. S., & Shatnawi, N. J. (2010). Quality of life and associated 
factors among Jordanian adolescents with type 1 diabetes mellitus. Journal of 
Diabetes and Its Complications, 24(1), 43-47. doi: 
10.1016/j.jdiacomp.2008.12.011
Al-Hayek, A. A., Robert, A. A., Abbas, H. M., Itani, M. B., Al-Saeed, A. H., Juhani, 
A. E., . . . Al-Sabaan, F. S. (2014). Assessment of health-related quality of life 
among adolescents with type 1 diabetes mellitus in Saudi Arabia. Saudi 
Medical Journal, 35(7), 712-717. 
Alberti, K. G., & Zimmet, P. (2011). Classification and diagnosis of diabetes mellitus. 
In J. A. H. Wass & P. M. Stewart (Eds.), Oxford textbook of endocrinology 
and diabetes (2nd ed., pp. 1704-1711). Oxford, England: Oxford University 
Press.
American Diabetes Association. (2008). Diagnosis and classification of diabetes 
mellitus. Diabetes Care, 31(Suppl 1), S55-S60. 
288
American Diabetes Association. (2014). Standards of medical care in diabetes: 2014. 
Diabetes Care, 37 (Suppl 1), S14-80. doi: 10.2337/dc14-S014
Amiel, A. S. (2011). Clinical features of type 1 diabetes mellitus. In J. A. H. Wass & 
P. M. Stewart (Eds.), Oxford textbook of endocrinology and diabetes (2nd ed., 
pp. 1712-1718). Oxford, England: Oxford University Press.
Anderson, B., Laffel, L., Domenger, C., Dain, M., Pilorget, V., Candelas, C., . . . 
Mathieu, C. (2014). Opportunities to enhance diabetes-specific quality of life 
(QoL) in youth with type 1 diabetes (T1D): The global TEENs study. Abstract 
259-OR. Paper presented at the American Diabetic Association 74th Scientific 
Sessions, San Francisco, CA. 
Anderson, B., Svoren, B., & Laffel, L. (2007). Initiatives to promote effective self-
care skills in children and adolescents with diabetes mellitus. Disease 
Management & Health Outcomes, 15(2), 101-108. 
Angus, V., & Waugh, N. (2007). Hospital admission patterns subsequent to diagnosis 
of type 1 diabetes in children: A systematic review. BMC Health Services 
Research, 7(1), 199. 
Apodaca, T. R., & Longabaugh, R. (2009). Mechanisms of change in motivational 
interviewing: A review and preliminary evaluation of the evidence. Addiction 
(Abingdon, England), 104(5), 705-715. doi: 10.1111/j.1360-
0443.2009.02527.x
Argyrous, G. (2011). Statistics for research: With a guide to SPSS (3rd ed.). London, 
England: SAGE.
Arnett, J. J. (2000). Emerging adulthood: A theory of development from the late teens 
through the twenties. American Psychologist, 55(5), 469. 
Arnett, J. J. (2007). Emerging adulthood: What is it, and what is it good for? Child 
Development Perspectives, 1(2), 68-73. doi: 10.1111/j.1750-
8606.2007.00016.x
Aronoff, S. L., Berkowitz, K., Shreiner, B., & Want, L. (2004). Glucose metabolism 
and regulation: Beyond insulin and glucagon. Diabetes Spectrum, 17(3), 183-
190. doi: 10.2337/diaspect.17.3.183
289
Asche, C., LaFleur, J., & Conner, C. (2011). A review of diabetes treatment 
adherence and the association with clinical and economic outcomes. Clinical 
Therapeutics, 33(1), 74-109. doi: 10.1016/j.clinthera.2011.01.019
Atkinson, M. A., & Eisenbarth, G. S. (2001). Type 1 diabetes: New perspectives on 
disease pathogenesis and treatment. The Lancet, 358(9277), 221-229. 
Austin, S., Guay, F., Senécal, C., Fernet, C., & Nouwen, A. (2013). Longitudinal 
testing of a dietary self-care motivational model in adolescents with diabetes. 
Journal of Psychosomatic Research, 75(2), 153-159. doi: 
10.1016/j.jpsychores.2013.04.013
Bakas, T., McLennon, S., Carpenter, J., Buelow, J., Otte, J., Hanna, K., . . . Welch, J. 
(2012). Systematic review of health-related quality of life models. Health and 
Quality of Life Outcomes, 10(1), 134. 
Bandura, A. (1986). Social foundations of thought and action: A social cognitive 
theory. Englewood Cliffs, NJ: Prentice Hall.
Bandura, A. (1997). Self-efficacy: The exercise of control. New York, NY: Worth 
Publishers.
Bandura, A. (2001). Social cognitive theory: An agentic perspective. Annual Review 
of Psychology, 52, 1 - 26. 
Bazzazian, S., & Besharat, M. A. (2010). Reliability and validity of a Farsi version of 
the brief illness perception questionnaire. Procedia - Social and Behavioral 
Sciences, 5(0), 962-965. doi: http://dx.doi.org/10.1016/j.sbspro.2010.07.217
Bazzazian, S., & Besharat, M. A. (2012). An explanatory model of adjustment to type 
I diabetes based on attachment, coping, and self-regulation theories. 
Psychology, Health & Medicine, 17(1), 47-58. doi: 
10.1080/13548506.2011.575168
Berger, G., Brunmayr, F., Muehlehner M., Waldhoer T., Wondratsch C., Koenig M., . 
. . Schober, E. (2013). Gender differences in the effect of motivational 
interviewing and cognitive behavioural therapy in Austrian adolescents with 
type 1 diabetes [Abstract].  Retrieved from 
http://www.easdvirtualmeeting.org/resources/3752
290
Berkman, E. T., & Reise, S. P. (2012). A conceptual guide to statistics using SPSS. 
Thousand Oaks, CA: Sage Publications.
Bland, J. M., & Altman, D. G. (1997). Statistics notes: Cronbach's alpha. British 
Medical Journal, 314(7080), 572. doi: 10.1136/bmj.314.7080.572
Bode, B. W. (2008). Glycemic variability and the role it should play in diabetes 
management and blood glucose monitoring. US Endocrinology, 4(2), 67-70. 
Boniol, M., & Heanue, M. (2007). Age-standardisation and denominators. In M. P. 
Curado, B. Edwards, H. R. Shin, H. Storm, J. Ferlay, M. Heanue & P. Boyle 
(Eds.), Cancer incidence in five continents (Vol. 9, pp. 99-101). Retrieved 
from http://www.iarc.fr/en/publications/pdfs-online/epi/sp160/CI5vol9-7.pdf. 
Boomsma, A. (2014). Regression diagnostics with R. Department of Statistics & 
Measurement Theory, University of Groningen.  Retrieved from 
www.ppsw.rug.nl/~boomsma/apstatdata/Regrdiag_R.pdf
Borch-Johnsen, K. (1989). The prognosis of insulin-dependent diabetes mellitus. An 
epidemiological approach. Danish Medical Bulletin, 36(4), 336-348. 
Borus, J. S., & Laffel, L. (2010). Adherence challenges in the management of type 1 
diabetes in adolescents: Prevention and intervention. Current Opinion in 
Pediatrics, 22(4), 405-411. 
Boyle, P., & Parkin, D. M. (1991). Statistical methods for registries. In O. M. Jensen, 
D. M. Parkin, R. MacLennan, C. S. Muir & R. G. Skeet (Eds.), Cancer 
registration: Principles and methods (pp. 126-158). Lyon, France: 
International Agency for Research on Cancer.
Braun, W. J., & Maindonald, J. (2010). Data analysis and graphics using R: An 
example-based approach. Cambridge, England: Cambridge University Press. 
Retrieved from http://www.eblib.com. 
Britt, E., Hudson, S. M., & Blampied, N. M. (2004). Motivational interviewing in 
health settings: A review. Patient Education and Counseling, 53(2), 147-155. 
Broadbent, E. (2010). Illness perceptions and health: Innovations and clinical 
applications. Social and Personality Psychology Compass, 4(4), 256-266. doi: 
10.1111/j.1751-9004.2010.00260.x
291
Broadbent, E., Donkin, L., & Stroh, J. C. (2011). Illness and treatment perceptions are 
associated with adherence to medications, diet, and exercise in diabetic 
patients. Diabetes Care, 34(2), 338-340. doi: 10.2337/dc10-1779
Broadbent, E., Petrie, K. J., Main, J., & Weinman, J. (2006). The brief illness 
perception questionnaire. Journal of Psychosomatic Research, 60(6), 631-637. 
Brown, L. J., & Scott, R. S. (1988). A population-based diabetes register: 
Development & applications. Community Health Studies, 12(4), 437-443. doi: 
10.1111/j.1753-6405.1988.tb00610.x
Brug, J., Spikmans, F., Aartsen, C., Breedveld, B., Bes, R., & Fereira, I. (2007). 
Training dietitians in basic motivational interviewing skills results in changes 
in their counseling style and in lower saturated fat intakes in their patients. 
Journal of Nutrition Education and Behavior, 39(1), 8-12. doi: 
http://dx.doi.org/10.1016/j.jneb.2006.08.010
Bruns, D. E. (2007). The clinical chemist. Clinical Chemistry, 53(8), 1562-1564. doi: 
10.1373/clinchem.2007.094078
Budde, T. R. (2009). Increasing regimen adherence in young adults with type 1 
diabetes (Doctoral dissertation). University of Wisconsin, Milwaukee, WI.   
Burke, S. D. (2004). Diabetes in transition: Factors affecting diabetes self-
management in college students (Doctoral dissertation). Health Sciences 
Center, University of Illinois at Chicago, Chicago, IL.   
Byiers, B. J., Reichle, J., & Symons, F. J. (2012). Single-subject experimental design 
for evidence-based practice. American Journal of Speech-Language Pathology 
/ American Speech-Language-Hearing Association, 21(4), 397-414. doi: 
10.1044/1058-0360(2012/11-0036)
CDHB. (2015). Canterbury health pathways: Diabetes.  Retrieved from 
http://healthpathways.org.nz/
Celano, C. M., Beale, E. E., Moore, S. V., Wexler, D. J., & Huffman, J. C. (2013). 
Positive psychological characteristics in diabetes: A review. Current Diabetes 
Reports, 13(6), 917-929. doi: 10.1007/s11892-013-0430-8
292
Channon, S., Huws-Thomas, M. V., Gregory, J. W., & Rollnick, S. (2005). 
Motivational Interviewing with teenagers with diabetes. Clinical Child 
Psychology and Psychiatry(10), 43-51. 
Channon, S., Huws-Thomas, M. V., Rollnick, S., Hood, K., Cannings-John, R. L., 
Rogers, C., & Gregory, J. W. (2007). A multicenter randomized controlled 
trial of motivational interviewing in teenagers with diabetes. Diabetes Care, 
30(6), 1390-1395. 
Channon, S., Smith, V. J., & Gregory, J. W. (2003). A pilot study of motivational 
interviewing in adolescents with diabetes. Archives of Disease in Childhood, 
88(8), 680-683. 
Chatterjee, S., & Simonoff, J. S. (2013). Handbook of regression analysis. Hoboken, 
NJ: Wiley.
Chen, P., & Popovich, P. (2002). Correlation: Parametric and nonparametric 
measures. Thousand Oaks, CA: SAGE.
Chen, S. M., Creedy, D., Lin, H.-S., & Wollin, J. (2012). Effects of motivational 
interviewing intervention on self-management, psychological and glycemic 
outcomes in type 2 diabetes: A randomized controlled trial. International 
Journal of Nursing Studies, 49(6), 637-644. doi: 
http://dx.doi.org/10.1016/j.ijnurstu.2011.11.011
Chih, A. H., Jan, C. F., Shu, S. G., & Lue, B. H. (2010). Self-efficacy affects blood 
sugar control among adolescents with type I diabetes mellitus. Journal of the 
Formosan Medical Association, 109(7), 503-510. doi: 10.1016/s0929-
6646(10)60084-8
Choudhary, P., & Amiel, A. S. (2011). Hypoglycaemia in the treatment of diabetes 
mellitus. In J. A. H. Wass & P. M. Stewart (Eds.), Oxford textbook of 
endocrinology and diabetes (2nd ed., pp. 1849-1861). Oxford, England: 
Oxford University Press.
Chowdhury, S. (2015). Puberty and type 1 diabetes. Indian Journal of Endocrinology 
and Metabolism, 19(Suppl 1), S51. 
293
Christie, D., & Channon, S. (2014). The potential for motivational interviewing to 
improve outcomes in the management of diabetes and obesity in paediatric 
and adult populations: A clinical review. Diabetes, Obesity and Metabolism, 
16(5), 381-387. doi: 10.1111/dom.12195
Christie, D., Thompson, R., Sawtell, M., Allen, E., Cairns, J., Smith, F., . . . Viner, R. 
(2014). Structured, intensive education maximising engagement, motivation 
and long-term change for children and young people with diabetes: A cluster 
randomised controlled trial with integral process and economic evaluation -
the CASCADE study. Health Technology Assessment, 18(20), 1-202. doi: 
10.3310/hta18200
Clarke, W., Jones, T., Rewers, A., Dunger, D., & Klingensmith, G. J. (2009). 
Assessment and management of hypoglycemia in children and adolescents 
with diabetes. Pediatric Diabetes, 10 Suppl 12, 134-145. doi: 10.1111/j.1399-
5448.2009.00583.x
Cobelli, C., Dalla Man, C., Sparacino, G., Magni, L., De Nicolao, G., & Kovatchev, 
B. P. (2009). Diabetes: Models, signals, and control. IEEE Reviews in 
Biomedical Engineering, 2, 54-96. doi: 10.1109/RBME.2009.2036073
Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). 
Hillsdale, NJ: L. Erlbaum Associates.
Cohen, J. (1992). A Power Primer. Psychological Bulletin, 112(1), 155-159. doi: 
10.1037/0033-2909.112.1.155
Cohen, J., Cohen, P., West, S. G., & Aiken, L. S. (2003). Applied multiple 
regression/correlation analysis for the behavioral sciences (3rd ed.). Mahwah, 
NJ: Lawrence Erlbaum Associates.
Comeaux, S. J., & Jaser, S. S. (2010). Autonomy and insulin in adolescents with type 
1 diabetes. Pediatric Diabetes, 11(7), 498-504. doi: 10.1111/j.1399-
5448.2009.00625.x
Cook, C. E. (2008). Clinimetrics corner: The minimal clinically important change 
score (MCID): A necessary pretense. The Journal of Manual & Manipulative 
Therapy, 16(4), E82-E83. 
294
Cox, D. J., Kovatchev, B. P., Julian, D. M., Gonder-Frederick, L. A., Polonsky, W. 
H., Schlundt, D. G., & Clarke, W. L. (1994). Frequency of severe 
hypoglycemia in insulin-dependent diabetes mellitus can be predicted from 
self-monitoring blood glucose data. Journal of Clinical Endocrinology and 
Metabolism, 79(6), 1659-1662. doi: 10.1210/jcem.79.6.7989471
Cronbach, L. J. (1951). Coefficient alpha and the internal structure of tests. 
Psychometrika, 16(3), 297-334. 
Cutler, L. R. (2004). Quality of life and hope for the future in young adults with type 1 
diabetes [Abstract] (Doctoral thesis). University of Sydney, Sydney, 
Australia.   
Dailey, G. (2007). Assessing glycemic control with self-monitoring of blood glucose 
and hemoglobin A1c measurements. Mayo Clinic Proceedings, 82(2), 229-
236. doi: 10.4065/82.2.229
Daneman, D., & Hamilton, J. (2001). Is poor metabolic control inevitable in 
adolescents with type 1 diabetes? Anales Españoles de Pediatría, 54(Suppl 1), 
41. 
DCCT Research Group. (1993). The effect of intensive treatment of diabetes on the 
development and progression of long-term complications in insulin-dependent 
diabetes mellitus. The Diabetes Control and Complications Trial Research 
Group. New England Journal of Medicine, 329(14), 977-986. 
DCCT Research Group. (1996). The absence of a glycemic threshold for the 
development of long-term complications: The perspective of the Diabetes 
Control and Complications Trial. Diabetes, 45(10), 1289-1298. 
DCCT Research Group. (1997). Hypoglycemia in the Diabetes Control and 
Complications Trial. The Diabetes Control and Complications Trial Research 
Group. Diabetes, 46(2), 271-286. 
DCCT Research Group. (2002). Effect of intensive therapy on the microvascular 
complications of type 1 diabetes mellitus. The Journal of the American 
Medical Association, 287(19), 2563 - 2569. 
295
de Wit, M., Delemarre-van de Waal, H. A., Pouwer, F., Gemke, R. J., & Snoek, F. J. 
(2007). Monitoring health related quality of life in adolescents with diabetes: 
A review of measures. Archives of Disease in Childhood, 92(5), 434-439. 
de Wit, M., Winterdijk, P., Aanstoot, H. J., Anderson, B., Danne, T., Deeb, L., . . . 
Snoek, F. (2012). Assessing diabetes-related quality of life of youth with type 
1 diabetes in routine clinical care: The MIND Youth Questionnaire (MY-Q). 
Pediatric Diabetes, 13(8), 638-646. doi: 10.1111/j.1399-5448.2012.00872.x
Delamater, A. M. (2000). Quality of life in youths with diabetes. Diabetes Spectrum, 
13(1), 42. 
Delamater, A. M. (2006). Improving patient adherence. Clinical Diabetes, 24(2), 71-
77. doi: 10.2337/diaclin.24.2.71
Delamater, A. M., de Wit, M., McDarby, V., Malik, J., & Acerini, C. L. (2014). 
Psychological care of children and adolescents with type 1 diabetes. Pediatric 
Diabetes, 15(S20), 232-244. doi: 10.1111/pedi.12191
DeVries, J. H. (2013). Glucose variability: Where it is important and how to measure 
it. Diabetes, 62(5), 1405-1408. doi: 10.2337/db12-1610
Diabetes New Zealand. (2014). Living with type 1 diabetes.  Retrieved from 
https://www.diabetes.org.nz/living_well_with_diabetes/living_with_type_1_di
abetes
Diabetes Research Institute. (n.d.). The Diabetes Research Institute: What we do.  
Retrieved from www.diabetesresearchinstitutetrust.co.nz/
Diefenbach, M., & Leventhal, H. (1996). The common-sense model of illness 
representation: Theoretical and practical considerations. Journal of Social 
Distress and the Homeless, 5(1), 11-38. doi: 10.1007/BF02090456
Diem, P., Frost, S. A., Augustiny, K. F., & Radanov, B. P. (2004). Quality of life and 
coping behaviour in type 1 diabetes mellitus: Relationship with metabolic 
control. Diabetes, Nutrition & Metabolism, 17(3), 151-155. 
Donaghue, K. C., Chiarelli, F., Trotta, D., Allgrove, J., & Dahl-Jorgensen, K. (2009). 
Microvascular and macrovascular complications associated with diabetes in 
296
children and adolescents. Pediatric Diabetes, 10(Suppl 12), 195-203. doi: 
10.1111/j.1399-5448.2009.00576.x
El Achhab, Y., Nejjari, C., Chikri, M., & Lyoussi, B. (2007). Disease-specific health-
related quality of life instruments among adults diabetic: A systematic review. 
Diabetes Research and Clinical Practice, 80(2), 171-184. doi: 
10.1016/j.diabres.2007.12.020
Faro, B. (1999). The effect of diabetes on adolescents' quality of life. Pediatric 
Nursing, 25(3), 247-253, 286. 
Faulkner, M. S. (2003). Quality of life for adolescents with type 1 diabetes: Parental 
and youth perspectives. Pediatric Nursing, 29(5), 362. 
Florkowski, C., & Crooke, M. (2010). Standardisation of reporting haemoglobin A1c: 
Adoption of the New Zealand Society for the Study of Diabetes (NZSSD) 
position statement. New Zealand Medical Journal, 123(1310), 43-49. 
Florkowski, C., Crooke, M., & Reed, M. (2014). Implementation of the HbA1c IFCC 
unit—from the laboratory to the consumer: The New Zealand experience. 
Clinica Chimica Acta, 432, 157-161. 
Fogel, N. R., & Weissberg-Benchell, J. (2010). Preventing poor psychological and 
health outcomes in pediatric type 1 diabetes. Current Diabetes Reports, 10(6), 
436-443. doi: 10.1007/s11892-010-0145-z
Fonseca, V. A., Kirkman, M. S., Darsow, T., & Ratner, R. E. (2012). The American 
Diabetes Association diabetes research rerspective. Diabetes Care, 35(6), 
1380-1387. doi: 10.2337/dc12-9001
Fortenberry, K. T., Berg, C. A., King, P. S., Stump, T., Butler, J. M., Pham, P. K., & 
Wiebe, D. J. (2014). Longitudinal trajectories of illness perceptions among 
adolescents with type 1 diabetes. Journal of Pediatric Psychology. doi: 
10.1093/jpepsy/jsu043
Fowler, M. J. (2008). Hypoglycemia. Clinical Diabetes, 26(4), 170-173. doi: 
10.2337/diaclin.26.4.170
Fox, J. (1991). Regression diagnostics: An introduction. Newbury Park, CA: SAGE.
297
Frei, A., Svarin, A., Steurer-Stey, C., & Puhan, M. A. (2009). Self-efficacy 
instruments for patients with chronic diseases suffer from methodological 
limitations: A systematic review. Health Qual Life Outcomes, 7, 86. doi: 
10.1186/1477-7525-7-86
Fullerton, B., Jeitler, K., Seitz, M., Horvath, K., Berghold, A., & Siebenhofer, A. 
(2014). Intensive glucose control versus conventional glucose control for type 
1 diabetes mellitus. Cochrane Database of Systematic Reviews, 2, Cd009122. 
doi: 10.1002/14651858.CD009122.pub2
Garvey, K. C., Markowitz, J. T., & Laffel, L. M. B. (2012). Transition to adult care 
for youth with type 1 diabetes. Current Diabetes Reports, 12(5), 533-541. doi: 
10.1007/s11892-012-0311-6
Gayes, L. A., & Steele, R. G. (2014). A meta-analysis of motivational interviewing 
interventions for pediatric health behavior change. Journal of Consulting and 
Clinical Psychology, 82(3), 521-535. doi: 10.1037/a0035917
Gerstman, B. B. (2015). Basic biostatistics: Statistics for public health practice. 
Burlington, MA: Jones & Bartlett Learning.
Glick, D. (2009). Women's monthly cycle affects blood glucose control, but not 
consistently. Retrieved from 
http://www.diabeteshealth.com/read/2009/08/15/6312/womens-monthly-
cycle-affects-blood-glucose-control-but-not-consistently
Gliem, J. A., & Gliem, R. R. (2003). Calculating, interpreting, and reporting 
Cronbach’s alpha reliability coefficient for Likert-type scales. Paper presented 
at the the Midwest Research-to-Practice Conference in Adult, Continuing, and 
Community Education, The Ohio State University, Columbus, OH. Retrieved 
from https://scholarworks.iupui.edu/handle/1805/344
Gomes, M. B., Castro, S. H., Garfinkel, T., Fernandes, L. M., Cunha, E. F., & Lobao, 
V. I. (2001). Glicemic control in prepubertal and pubertal patients with 
diabetes type 1 - a one year ambulatory follow-up. Jornal de Pediatría, 77(1), 
41-44. 
Graue, M., Wentzel-Larsen, T., Hanestad, B. R., Båtsvik, B., & Søvik, O. (2003). 
Measuring self-reported, health-related, quality of life in adolescents with type 
298
1 diabetes using both generic and disease-specific instruments. Acta 
Pædiatrica, 92(10), 1190-1196. doi: 10.1111/j.1651-2227.2003.tb02483.x
Green, S. B. (1991). How many subjects does it take to do a regression analysis. 
Multivariate Behavioral Research, 26(3), 499-510. doi: 
10.1207/s15327906mbr2603_7
Grey, M. (2012). Quality of life in youth with type 1 diabetes. The Journal of 
pediatrics, 161(2), 180-181. doi: 10.1016/j.jpeds.2012.02.050
Grey, M., Boland, E. A., Yu, C., Sullivan-Bolyai, S., & Tamborlane, W. V. (1998). 
Personal and family factors associated with quality of life in adolescents with 
diabetes. Diabetes Care, 21(6), 909-914. doi: 10.2337/diacare.21.6.909
Grey, M., Davidson, M., Boland, E. A., & Tamborlane, W. V. (2001). Clinical and 
psychosocial factors associated with achievement of treatment goals in 
adolescents with diabetes mellitus. Journal of Adolescent Health, 28(5), 377-
385. doi: 10.1016/S1054-139X(00)00211-1
Griva, K., Myers, L., & Newman, S. (2000). Illness perceptions and self efficacy 
beliefs in adolescents and young adults with insulin dependent diabetes 
mellitus. Psychology & Health, 15(6), 733 - 750. 
Grossman, H. Y., Brink, S., & Hauser, S. T. (1987). Self-efficacy in adolescent girls 
and boys with insulin-dependent diabetes mellitus. Diabetes Care, 10(3), 324-
329. doi: 10.2337/diacare.10.3.324
Guo, J., Whittemore, R., Grey, M., Wang, J., Zhou, Z. G., & He, G. P. (2013). 
Diabetes self-management, depressive symptoms, quality of life and metabolic 
control in youth with type 1 diabetes in China. Journal of Clinical Nursing, 
22(1-2), 69-79. doi: 10.1111/j.1365-2702.2012.04299.x
Guttmann-Bauman, I., Flaherty, B. P., Strugger, M., & McEvoy, R. C. (1998). 
Metabolic control and quality-of-life self-assessment in adolescents with 
IDDM. Diabetes Care, 21(6), 915-918. doi: 10.2337/diacare.21.6.915
Hackworth, N. J., Hamilton, V. E., Moore, S. M., Northam, E. A., Bucalo, Z., & 
Cameron, F. J. (2013). Predictors of diabetes self-care, metabolic control, and 
299
mental health in youth with type 1 diabetes. Australian Psychologist, 48(5), 
n/a-n/a. doi: 10.1111/ap.12007
Hagger, M., & Orbell, S. (2003). A meta-analytic review of the Common-Sense 
Model of illness representations. Psychology & Health, 18(2), 141-184. doi: 
10.1080/088704403100081321
Hägglöf, B., Blom, L., Dahlquist, G., Lönnberg, G., & Sahlin, B. (1991). The 
Swedish childhood diabetes study: Indications of severe psychological stress 
as a risk factor for type 1 (insulin-dependent) diabetes mellitus in childhood. 
Diabetologia, 34(8), 579-583. 
Hamilton, J., & Daneman, D. (2002). Deteriorating diabetes control during 
adolescence: Physiological or psychosocial? Journal of Pediatric 
Endocrinology and Metabolism, 15(2), 115-126. 
Hampson, S. E., Glasgow, R. E., & Toobert, D. J. (1990). Personal models of diabetes 
and their relations to self-care activities. Health Psychology, 9(5), 632-646. 
doi: 10.1037/0278-6133.9.5.632
Hampson, S. E., Skinner, T. C., Hart, J., Storey, L., Gage, H., Foxcroft, D., . . . 
McEvilly, E. A. (2000). Behavioral interventions for adolescents with type 1 
diabetes: How effective are they? Diabetes Care, 23(9), 1416-1422. doi: 
10.2337/diacare.23.9.1416
Hampson, S. E., Skinner, T. C., Hart, J., Storey, L., Gage, H., Foxcroft, D., . . . 
Walker, J. (2001). Effects of educational and psychosocial interventions for 
adolescents with diabetes mellitus: A systematic review. Health Technology 
Assessment, 5(10), 1 - 79. 
Hanas, R. (2007). Type 1 diabetes in children, adolescents, and young adults: How to 
become an expert on your own diabetes. London, England: Class Publishing.
Hanas, R. (2010). Type 1 diabetes in children, adolescents and young adults: How to 
become an expert on your own diabetes. London, England: Class Publishing.
Hanas, R., John, W. G., & International HbA1c Consensus Committee. (2014). 2013 
Update on the worldwide standardization of the hemoglobin A1c 
measurement. Pediatric Diabetes, 15(3), e1-e2. doi: 10.1111/pedi.12047
300
Hanna, K. M., & Guthrie, D. W. (2003). Parental involvement in adolescents' diabetes 
management. Diabetes Spectrum, 16(3), 184-187. 
Hanna, K. M., Weaver, M. T., Slaven, J. E., Fortenberry, J. D., & DiMeglio, L. A. 
(2014). Diabetes-related quality of life and the demands and burdens of 
diabetes care among emerging adults with type 1 diabetes in the year after 
high school graduation. Research in Nursing and Health, 37(5), 399-408. doi: 
10.1002/nur.21620
Hanna, K. M., Weaver, M. T., Stump, T. E., Slaven, J. E., Fortenberry, J. D., & 
DiMeglio, L. A. (2013). Readiness for living independently among emerging 
adults with type 1 diabetes. Diabetes Educator, 39(1), 92-99. doi: 
10.1177/0145721712465341
Harding, L. (2001). Children's quality of life assessments: A review of generic and 
health related quality of life measures completed by children and adolescents. 
Clinical Psychology & Psychotherapy, 8(2), 79-96. doi: 10.1002/cpp.275
Harvey, J. N. (2015). Psychosocial interventions for the diabetic patient. Diabetes, 
metabolic syndrome and obesity: Targets and therapy, 8, 29. doi: 
10.2147/dmso.s44352
Harvey, J. N., & Allagoa, B. (2004). The long-term renal and retinal outcome of 
childhood-onset type 1 diabetes. Diabetic Medicine, 21(1), 26-31. doi: 
10.1046/j.1464-5491.2003.01062.x
Harvey, J. N., & Lawson, V. L. (2009). The importance of health belief models in 
determining self-care behaviour in diabetes. Diabetic Medicine, 26(1), 5-13. 
doi: 10.1111/j.1464-5491.2008.02628.x
Harvill, L. M. (1991). An NCME instructional module on standard error of 
measurement. Instructional Topics in Educational Measurement  Retrieved 
from coeweb.gsu.edu/coshima/EPRS9360/SEM%20Module.pdf
Havlin, C. E., & Cryer, P. E. (1988). Hypoglycemia: The limiting factor in the 
management of insulin-dependent diabetes mellitus. The Diabetes Educator, 
14(5), 407-411. doi: 10.1177/014572178801400508
301
Hawkins, S. Y. (2010). Improving glycemic control in older adults using a 
videophone motivational diabetes self-management intervention. Research 
and Theory for Nursing Practice, 24(4), 217-232. 
Helgeson, V. S., Escobar, O., Siminerio, L., & Becker, D. (2010). Relation of stressful 
life events to metabolic control among adolescents with diabetes: 5-year 
longitudinal study. Health Psychology, 29(2), 153-159. 
Heller, S. R. (2011). Management of type 1 diabetes mellitus In J. A. H. Wass & P. 
M. Stewart (Eds.), Oxford textbook of endocrinology and diabetes (2nd ed.,
pp. 1825-1838). Oxford, England: Oxford University Press.
Herge, W. M., Streisand, R., Chen, R., Holmes, C., Kumar, A., & MacKey, E. R. 
(2012). Family and youth factors associated with health beliefs and health 
outcomes in youth with type 1 diabetes. Journal of Pediatric Psychology, 
37(9), 980-989. doi: 10.1093/jpepsy/jss067
Hesketh, K. D., Wake, M. A., & Cameron, F. J. (2004). Health-related quality of life 
and metabolic control in children with type 1 diabetes: A prospective cohort 
study. Diabetes Care, 27(2), 415-420. doi: 10.2337/diacare.27.2.415
Hettema, J., Steele, J., & Miller, W. (2005). A meta-analysis of research on 
motivational interviewing treatment effectiveness (MARMITE). Annual 
Review of Clinical Psychology, 1, 91-111. 
Hill, N. R., Peters, C. J., Thompson, R. J., Matthews, D. R., & Hindmarsh, P. C. 
(2013). Cyclical variation in HbA(1c) values during the year: Clinical and 
research implications. Diabetes Care, 36(10), e175-e176. doi: 10.2337/dc13-
1247
Hilliard, M. E., Lawrence, J. M., Modi, A. C., Anderson, A., Crume, T., Dolan, L. M., 
. . . Hood, K. K. (2013). Identification of minimal clinically important 
difference scores of the PedsQL in children, adolescents, and young adults 
with type 1 and type 2 diabetes. Diabetes Care, 36(7), 1891-1897. 
Hinzmann, R., Schlaeger, C., & Tran, C. T. (2012). What do we need beyond 
hemoglobin A1c to get the complete picture of glycemia in people with 
diabetes? International Journal of Medical Sciences, 9(8), 665-681. doi: 
10.7150/ijms.4520
302
Hoey, H., Aanstoot, H. J., Chiarelli, F., Daneman, D., Danne, T., Dorchy, H., . . . 
Aman, J. (2001). Good metabolic control is associated with better quality of 
life in 2,101 adolescents with type 1 diabetes. Diabetes Care, 24(11), 1923-
1928. 
Holl, R. W., Swift, P. G., Mortensen, H. B., Lynggaard, H., Hougaard, P., Aanstoot, 
H. J., . . . Aman, J. (2003). Insulin injection regimens and metabolic control in 
an international survey of adolescents with type 1 diabetes over 3 years: 
Results from the Hvidore Study Group. European Journal of Pediatrics, 
162(1), 22-29. doi: 10.1007/s00431-002-1037-2
Hood, K. K., & Nansel, T. R. (2007). Commonalities in effective behavioral 
interventions for children and adolescents with type 1 diabetes: A review of 
reviews. Diabetes Spectrum, 20(4), 251-254. doi: 10.2337/diaspect.20.4.251
Hood, K. K., Peterson, C. M., Rohan, J. M., & Drotar, D. (2009). Association 
between adherence and glycemic control in pediatric type 1 diabetes: A meta-
analysis. Pediatrics, 124(6), e1171-e1179. doi: 10.1542/peds.2009-0207
Hood, K. K., Rohan, J. M., Peterson, C. M., & Drotar, D. (2010). Interventions with 
adherence-promoting components in pediatric type 1 diabetes: Meta-analysis 
of their impact on glycemic control. Diabetes Care, 33(7), 1658-1664. doi: 
10.2337/dc09-2268
Horner, R. H., Carr, E. G., Halle, J., McGee, G., Odom, S., & Wolery, M. (2005). The 
use of single-subject research to identify evidence-based practice in special 
education. Exceptional Children, 71(2), 165-179. 
Hornquist, J. O., Wikby, A., Stenstrom, U., Andersson, P. O., & Akerlind, I. (1995). 
Type II diabetes and quality of life: A review of the literature. 
Pharmacoeconomics, 8 (Suppl 1), 12-16. 
Huang, G.-H., Palta, M., Allen, C., LeCaire, T., D'Alessio, D., & Wisconsin Diabetes. 
(2004). Self-rated health among young people with type 1 diabetes in relation 
to risk factors in a longitudinal study. American Journal of Epidemiology, 
159(4), 364-372. doi: 10.1093/aje/kwh055
Huggard, K. (2009). Psychological screening in adolescents with type 1 diabetes
(Doctoral thesis). University of Auckland, Auckland, New Zealand.   
303
Hunt, J. (2011). Motivational interviewing and people with diabetes. European 
Diabetes Nursing, 8(2), 68-73. 
Hurley, A. C., & Shea, C. A. (1992). Self-efficacy: Strategy for enhancing diabetes 
self-care. Diabetes Educator, 18(2), 146-150. 
Hutcheson, G., & Sofroniou, N. (1999). The multivariate social scientist: Introductory 
statistics using generalized linear models. Thousand Oaks, CA: Sage 
Publications.
Huws-Thomas, M. (2007). A study of motivational interviewing in adolescents with 
type 1 diabetes (Doctoral thesis). University of Wales, Cardiff, Wales. 
Retrieved from orca.cf.ac.uk/54601/1/U584990.pdf  
Iannotti, R. J., Schneider, S., Nansel, T. R., Haynie, D. L., Plotnick, L. P., Clark, L. 
M., . . . Simons-Morton, B. (2006). Self-efficacy, outcome expectations, and 
diabetes self-management in adolescents with type 1 diabetes. Journal of 
Developmental and Behavioral Pediatrics, 27(2), 98-105. 
Imayama, I., Plotnikoff, R. C., Courneya, K. S., & Johnson, J. A. (2011). 
Determinants of quality of life in adults with type 1 and type 2 diabetes. 
Health and quality of life outcomes, 9(1), 115-115. doi: 10.1186/1477-7525-9-
115
Ingersoll, G. M., & Marrero, D. G. (1991). A modified quality-of-life measure for 
youths: Psychometric properties. Diabetes Educator, 17(2), 114-118. 
International Diabetes Federation. (2013). IDF Diabetes Atlas (6th ed.). Brussels, 
Belgium: International Diabetes Federation.
International Diabetes Federation. (2014). IDF Diabetes Atlas update poster (6th ed.). 
Brussels, Belgium: International Diabetes Federation.
Ismail, K., Maissi, E., Thomas, S., Chalder, T., Schmidt, U., Bartlett, J., . . . Treasure, 
J. (2010). A randomised controlled trial of cognitive behaviour therapy and 
motivational interviewing for people with type 1 diabetes mellitus with 
persistent sub-optimal glycaemic control: A Diabetes and Psychological 
Therapies (ADaPT) study. Health Technology Assessment, 14(22), 1-101, iii-
iv. 
304
ISPAD, & International Diabetes Federation. (2011). IDF/ISPAD 2011 Global 
Guideline for Diabetes in Childhood and Adolescence Retrieved from 
http://ispad.site-ym.com/?page=idfispad2011globalG
Jacobson, N. S., & Truax, P. (1991). Clinical significance: A statistical approach to 
defining meaningful change in psychotherapy research. Journal of Consulting 
and Clinical Psychology, 59(1), 12. 
Jelsma, J. G. M., Mertens, V.-C., Forsberg, L., & Forsberg, L. (2015). How to 
measure motivational interviewing fidelity in randomized controlled trials: 
Practical recommendations. Contemporary Clinical Trials. doi: 
10.1016/j.cct.2015.05.001
Jo, E. C., & Drury, P. L. (2015). Development of a virtual diabetes register using 
information technology in New Zealand. Healthcare Informatics Research, 
21(1), 49-55. doi: 10.4258/hir.2015.21.1.49
Johnson, S. B., Silverstein, J., Rosenbloom, A., Carter, R., & Cunningham, W. 
(1986). Assessing daily management in childhood diabetes. Health 
Psychology, 5(6), 545-564. 
Johnston-Brooks, C. H., Lewis, M. A., & Garg, S. (2002). Self-efficacy impacts self-
care and HbA1c in young adults with type I diabetes. Psychosomatic 
Medicine, 64(1), 43-51. 
Jones, A., Gladstone, B. P., Lübeck, M., Lindekilde, N., Upton, D., & Vach, W. 
(2014). Motivational interventions in the management of HbA1c levels: A 
systematic review and meta-analysis. Primary Care Diabetes, 8(2), 91-100. 
doi: http://dx.doi.org/10.1016/j.pcd.2014.01.009
Kahane, L. H. (2008). Regression basics. Los Angeles, CA: SAGE.
Kalyva, E., Malakonaki, E., Eiser, C., & Mamoulakis, D. (2011). Health-related 
quality of life (HRQoL) of children with type 1 diabetes mellitus (T1DM): 
Self and parental perceptions. Pediatric Diabetes, 12(1), 34-40. doi: 
10.1111/j.1399-5448.2010.00653.x
305
Kavanagh, D. J., Pierce, J., Lo, S. K., & Shelley, J. (1993). Self-efficacy and social 
support as predictors of smoking after a quit attempt. Psychology & Health, 
8(4), 231-242. doi: 10.1080/08870449308401918
Kent, D. A. (2011). Factors that impact quality of life in young adults with type I 
diabetes (Doctoral dissertation). Health Sciences Center, University Of 
Illinois, Champaign, IL. Retrieved from 
http://gradworks.umi.com/34/84/3484984.html  
Kiadaliri, A. A., Najafi, B., & Mirmalek-Sani, M. (2013). Quality of life in people 
with diabetes: A systematic review of studies in Iran. Journal of Diabetes and 
Metabolic Disorders, 12(1), 54. doi: 10.1186/2251-6581-12-54
Kibbey, K. J., Speight, J., Wong, J. L. A., Smith, L. A., & Teede, H. J. (2013). 
Diabetes care provision: Barriers, enablers and service needs of young adults 
with type 1 diabetes from a region of social disadvantage. Diabetic Medicine, 
30(7), 878-884. doi: 10.1111/dme.12227
Kilpatrick, E. S. (2009). Arguments for and against the role of glucose variability in 
the development of diabetes complications. Journal of Diabetes Science and 
Technology, 3(4), 649-655. 
Kinnear, P. R., & Gray, C. D. (2012). IBM SPSS statistics 19 made simple. Hove, 
England: Psychology Press.
Kitagawa, G. (2010). Introduction to time series modeling (Vol. 114). Boca Raton, 
FL: CRC Press.
Klis, S., Vingerhoets, A. J. J. M., de Wit, M., Zandbelt, N., & Snoek, F. J. (2008). 
Pictorial Representation of Illness and Self Measure Revised II (PRISM-RII): 
A novel method to assess perceived burden of illness in diabetes patients. 
Health and Quality of Life Outcomes, 6(1), 104-104. doi: 10.1186/1477-7525-
6-104
Klok, T., Sulkers, E. J., Kaptein, A. A., Duiverman, E. J., & Brand, P. L. (2009). 
Adherence in the case of chronic diseases: Patient-centred approach is needed. 
Nederlands Tijdschrift voor Geneeskunde, 153, A420. 
306
Kneckt, M. C. (1999). Self-efficacy as a common variable in oral health behavior and 
diabetes adherence. European Journal of Oral Sciences, 107(2), 89-96. doi: 
10.1046/j.0909-8836.1999.eos107203.x
Knight, K. M., Bundy, C., Morris, R., Higgs, J. F., Jameson, R. A., Unsworth, P., & 
Jayson, D. (2003). The effects of group motivational interviewing and 
externalizing conversations for adolescents with type-1 diabetes. Psychology, 
Health & Medicine, 8(2), 149-158. 
Knip, M., Veijola, R., Virtanen, S. M., Hyöty, H., Vaarala, O., & Åkerblom, H. K. 
(2005). Environmental triggers and determinants of type 1 diabetes. Diabetes, 
54(Suppl 2), S125-S136. 
Kodl, C. T., & Seaquist, E. R. (2008). Cognitive dysfunction and diabetes mellitus. 
Endocrine Reviews, 29(4), 494-511. doi: 10.1210/er.2007-0034
Kovacs, M., Goldston, D., Obrosky, D. S., & Bonar, L. K. (1997). Psychiatric 
disorders in youths with IDDM: Rates and risk factors. Diabetes Care, 20(1), 
36-44. doi: 10.2337/diacare.20.1.36
Kovatchev, B. P. (2012). Diabetes technology: Markers, monitoring, assessment, and 
control of blood glucose fluctuations in diabetes. Scientifica, 2012, 283821. 
doi: 10.6064/2012/283821
Kovatchev, B. P., Cox, D. J., Gonder-Frederick, L., & Clarke, W. L. (2002). Methods 
for quantifying self-monitoring blood glucose profiles exemplified by an 
examination of blood glucose patterns in patients with type 1 and type 2 
diabetes. Diabetes Technology & Therapeutics, 4(3), 295-303. doi: 
10.1089/152091502760098438
Kovatchev, B. P., Cox, D. J., Gonder-Frederick, L. A., & Clarke, W. (1997). 
Symmetrization of the blood glucose measurement scale and its applications. 
Diabetes Care, 20(11), 1655-1658. doi: 10.2337/diacare.20.11.1655
Kovatchev, B. P., Cox, D. J., Gonder-Frederick, L. A., Young-Hyman, D., Schlundt, 
D., & Clarke, W. (1998). Assessment of risk for severe hypoglycemia among 
adults with IDDM: Validation of the low blood glucose index. Diabetes Care, 
21(11), 1870-1875. 
307
Kovatchev, B. P., Cox, D. J., Kumar, A., Gonder-Frederick, L., & Clarke, W. L. 
(2003). Algorithmic evaluation of metabolic control and risk of severe 
hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood 
glucose data. Diabetes Technology & Therapeutics, 5(5), 817-828. doi: 
10.1089/152091503322527021
Kovatchev, B. P., Otto, E., Cox, D., Gonder-Frederick, L., & Clarke, W. (2006). 
Evaluation of a new measure of blood glucose variability in diabetes. Diabetes 
Care, 29(11), 2433-2438. doi: 10.2337/dc06-1085
Kovatchev, B. P., Straume, M., Cox, D. J., & Farhy, L. S. (2000). Risk analysis of 
blood glucose data: A quantitative approach to optimizing the control of 
insulin dependent diabetes. Journal of Theoretical Medicine, 3(1), 1-10. 
Krichbaum, K., Aarestad, V., & Buethe, M. (2003). Exploring the connection between 
self-efficacy and effective diabetes self-f management. The Diabetes 
Educator, 29(4), 653-662. doi: 10.1177/014572170302900411
Krishna, S. V. S., Kota, S. K., & Modi, K. D. (2013). Glycemic variability: Clinical 
implications. Indian Journal of Endocrinology and Metabolism, 17(4), 611-
619. doi: 10.4103/2230-8210.113751
Kristensen, L. J., Birkebaek, N. H., Mose, A. H., Hohwu, L., & Thastum, M. (2014). 
Symptoms of emotional, behavioral, and social difficulties in the danish 
population of children and adolescents with type 1 diabetes: Results of a 
national survey. PloS One, 9(5), e97543. doi: 10.1371/journal.pone.0097543
Kucukarslan, S. N. (2012). A review of published studies of patients' illness 
perceptions and medication adherence: Lessons learned and future directions. 
Research in Social & Administrative Pharmacy, 8(5), 371-382. doi: 
10.1016/j.sapharm.2011.09.002
Laffel, L., Connell, A., Vangsness, L., Goebel-Fabbri, A., Mansfield, A., & Anderson, 
B. J. (2003). General quality of life in youth with type 1 diabetes: Relationship 
to patient management and diabetes-specific family conflict. Diabetes Care, 
26(11), 3067-3073. doi: 10.2337/diacare.26.11.3067
Laffel, L., Domenger, C., Dain, M., Pilorget, V., Candelas, C., Danne, T., . . . 
Mathieu, C. (2014). Global assessment of factors associated with target 
308
glycemic control in youth with type 1 diabetes (T1D): The TEENs Study. 
Abstract 32-OR. Paper presented at the American Diabetic Association 74th 
Scientific Sessions, San Francisco, CA. 
Lagreca, A. M., Swales, T., Klemp, S., Madigan, S., & Skyler, J. (1995). Adolescents 
with diabetes - gender differences in psychosocial functioning and glycemic 
control. Childrens Health Care, 24(1), 61-78. doi: 
10.1207/s15326888chc2401_6
Laing, S. P., Patterson, C. C., Qiao, Z., Keen, H., Swerdlow, A. J., Slater, S. D., . . . 
Bingley, P. J. (1999a). The British Diabetic Association Cohort Study, I: All-
cause mortality in patients with insulin-treated diabetes mellitus. Diabetic 
Medicine, 16(6), 459-465. doi: 10.1046/j.1464-5491.1999.00075.x
Laing, S. P., Patterson, C. C., Qiao, Z., Keen, H., Swerdlow, A. J., Slater, S. D., . . . 
Bingley, P. J. (1999b). The British Diabetic Association Cohort Study, II: 
Cause-specific mortality in patients with insulin-treated diabetes mellitus. 
Diabetic Medicine, 16(6), 466-471. doi: 10.1046/j.1464-5491.1999.00076.x
Lau, R. R., & Hartman, K. A. (1983). Common sense representations of common 
illnesses. Health Psychology, 2(2), 167-185. doi: 10.1037/0278-6133.2.2.167
Law, G. U., Kelly, T. P., Huey, D., & Summerbell, C. (2002). Self-management and 
well-being in adolescents with diabetes mellitus: Do illness representations 
play a regulatory role? The Journal of adolescent health, 31(4), 381-385. doi: 
10.1016/s1054-139x(02)00397-x
Lawrence, J. M., Yi-Frazier, J. P., Black, M. H., Anderson, A., Hood, K., Imperatore, 
G., . . . Seid, M. (2012). Demographic and clinical correlates of diabetes-
related quality of life among youth with type 1 diabetes. The Journal of 
Pediatrics, 161(2), 201-207. doi: 10.1016/j.jpeds.2012.01.016
Lawson, V. L., Bundy, C., Lyne, P. A., & Harvey, J. N. (2004). Using the IPQ and 
PMDI to predict regular diabetes care-seeking among patients with type 1 
diabetes. British Journal of Health Psychology, 9(Pt 2), 241-252. 
Lerman-Garber, I., Barron-Uribe, C., Calzada-Leon, R., Mercado-Atri, M., Vidal-
Tamayo, R., Quintana, S., . . . Villa, A. R. (2003). Emotional dysfunction 
309
associated with diabetes in Mexican adolescents and young adults with type-1 
diabetes. Salud Publica de México, 45(1), 13-18. 
LeRoith, D., & Smith, D. O. (2005). Monitoring glycemic control: The cornerstone of 
diabetes care. Clinical Therapeutics, 27(10), 1489-1499. doi: 
10.1016/j.clinthera.2005.10.010
Leventhal, H. (1998). Self-regulation, health, and behavior: A perceptual-cognitive 
approach. Psychology & Health, 13(4), 717-733. doi: 
10.1080/08870449808407425
Leventhal, H., Benjamin, Y., Brownlee, S., Diefenbach, M., Leventhal, E. A., Patrick-
Miller, L., & Robitaille, C. (1997). Illness representations: Theoretical 
foundations. In K. J. Petrie & J. Weinman (Eds.), Perceptions of health and 
illness (pp. 19–45). London, England: Harwood Academic Publishers.
Leventhal, H., Diefenbach, M., & Leventhal, E. (1992). Illness cognition: Using 
common sense to understand treatment adherence and affect cognition 
interactions. Cognitive Therapy and Research, 16(2), 143 - 163. 
Levine, B.-S., Anderson, B. J., Butler, D. A., Antisdel, J. E., Brackett, J., & Laffel, L. 
M. B. (2001). Predictors of glycemic control and short-term adverse outcomes 
in youth with type 1 diabetes. The Journal of Pediatrics, 139(2), 197-203. doi: 
http://dx.doi.org/10.1067/mpd.2001.116283
Linneman, T. J. (2011). Social statistics: The basics and beyond. New York, NY: 
Routledge.
Little, R. R., Rohlfing, C. L., & Sacks, D. B. (2011). Status of hemoglobin A1c 
measurement and goals for improvement: From chaos to order for improving 
diabetes care. Clinical Chemistry, 57(2), 205-214. doi: 
10.1373/clinchem.2010.148841
Little, R. R., Rohlfing, C. L., Wiedmeyer, H.-M., Myers, G. L., Sacks, D. B., & 
Goldstein, D. E. (2001). The national glycohemoglobin standardization 
program: A five-year progress report. Clinical Chemistry, 47(11), 1985-1992. 
310
Littlefield, C. H., Craven, J. L., Rodin, G. M., Daneman, D., Murray, M. A., & 
Rydall, A. C. (1992). Relationship of self-efficacy and binging to adherence to 
diabetes regimen among adolescents. Diabetes Care, 15(1), 90-94. 
Lomax, R. G., & Hahs-Vaughn, D. L. (2012). An introduction to statistical concepts. 
Hoboken, NJ: Taylor & Francis.
Longabaugh, R., Woolard, R. F., Nirenberg, T. D., Minugh, A. P., Becker, B.,
Clifford, P. R., . . . Gogineni, A. (2001). Evaluating the effects of a brief 
motivational intervention for injured drinkers in the emergency department. 
Journal of Studies on Alcohol, 62(6), 806-816. 
Lotstein, D. S., Seid, M., Klingensmith, G., Case, D., Lawrence, J. M., Pihoker, C., . . 
. Waitzfelder, B. (2013). Transition from pediatric to adult care for youth 
diagnosed with type 1 diabetes in adolescence. Pediatrics, 131(4), e1062-
1070. doi: 10.1542/peds.2012-1450
Lukács, A., Varga, B., Barótfi, S., Kiss-Tóth, E., & Barkai, L. (2012). Health-related 
quality of life of youths with type 1 diabetes: Reliability and validity of the 
Hungarian version of the PedsQL 3.0 diabetes module. Journal of Diabetes 
and Metabolism, 3, 191. doi: 3:191. doi:10.4172/2155-6156.1000191
Lundahl, B. W., Kunz, C., Brownell, C., Tollefson, D., & Burke, B. L. (2010). A 
meta-analysis of motivational interviewing: Twenty-five years of empirical 
studies. Research on Social Work Practice, 20(2), 137-160. doi: 
10.1177/1049731509347850
Lunt, H., Kendall, D., Moore, M. P., Owens, N., Cole, D. R., Willis, J. A., . . . 
Darlow, B. A. (2002). Type 1 diabetes: Glycaemic control during adolescence. 
The New Zealand Medical Journal, 115(1167), U282. 
Lunt, H., Kendall, D., Moore, M. P., Soule, S., & Cole, D. R. (2006). Can HbA1c be 
improved at the population level in adolescents with type 1 diabetes? 
Christchurch, New Zealand: Diabetes Centre and Department of Medicine.
Luyckx, K., Vanhalst, J., Seiffge-Krenke, I., & Weets, I. (2010). A typology of coping 
with Type 1 diabetes in emerging adulthood: Associations with demographic, 
psychological, and clinical parameters. Journal of Behavioral Medicine, 33(3), 
228-238. doi: 10.1007/s10865-010-9249-9
311
Madsen, S. D., Roisman, G. I., & Collins, W. A. (2002). The intersection of 
adolescent development and intensive intervention: Age-related psychosocial 
correlates of treatment regimens in the diabetes control and complication trial. 
Journal of Pediatric Psychology, 27(5), 451-459. doi: 
10.1093/jpepsy/27.5.451
Magill, M., Gaume, J., Apodaca, T. R., Walthers, J., Mastroleo, N. R., Borsari, B., & 
Longabaugh, R. (2014). The technical hypothesis of motivational 
interviewing: A meta-analysis of MI's key causal model. Journal of 
Consulting and Clinical Psychology, 82(6), 973-983. doi: 10.1037/a0036833
Malik, J. A., & Koot, H. M. (2009). Explaining the adjustment of adolescents with 
type 1 diabetes. Diabetes Care, 32(5), 774-779. doi: 10.2337/dc08-1306
Maré, D. C., Mawson, P., & Timmins, J. (2001). Deprivation in New Zealand: 
Regional patterns and changes (Treasury Working Paper 01/09).  Retrieved 
from http://www.treasury.govt.nz/publications/research-policy/wp/2001/01-
09/twp01-09.pdf
Martins, R. K., & McNeil, D. W. (2009). Review of motivational interviewing in 
promoting health behaviors. Clinical Psychology Review, 29(4), 283-293. 
Mason, C. H., & Perreault, W. D., Jr. (1991). Collinearity, power, and interpretation 
of multiple regression analysis. Journal of Marketing Research, 28(3), 268-
280. doi: 10.2307/3172863
Matza, L. S., Swensen, A. R., Flood, E. M., Secnik, K., & Leidy, N. K. (2004). 
Assessment of health-related quality of life in children: A review of 
conceptual, methodological, and regulatory issues. Value in Health, 7(1), 79-
92. doi: 10.1111/j.1524-4733.2004.71273.x
Mc Sharry, J., Moss-Morris, R., & Kendrick, T. (2011). Illness perceptions and 
glycaemic control in diabetes: A systematic review with meta-analysis. 
Diabetic Medicine, 28(11), 1300-1310. doi: 10.1111/j.1464-
5491.2011.03298.x
McCallister, H. A. H. (2006). Demonstrating competence: A qualitative study of 
diabetes management during adolescence (Doctoral dissertation). University 
312
of Texas, Austin, US. Retrieved from 
http://repositories.lib.utexas.edu/handle/2152/2755  
McCaul, K. D., Glasgow, R. E., & Schafer, L. C. (1987). Diabetes regimen behaviors. 
Predicting adherence. Medical Care, 25(9), 868-881. 
McGrady, M. E. (2012). Illness representations and glycemic control in adolescents 
with type 1 diabetes (Doctoral dissertation). University of Cincinnati, Arts and 
Sciences: Psychology, Cincinnati, OH. Retrieved from 
https://etd.ohiolink.edu/ 
McGrady, M. E., Peugh, J. L., & Hood, K. K. (2014). Illness representations predict 
adherence in adolescents and young adults with type 1 diabetes. Psychology &
Health, 29(9), 985-998. doi: 10.1080/08870446.2014.899361
McManus, I. C. (2012). The misinterpretation of the standard error of measurement in 
medical education: a primer on the problems, pitfalls and peculiarities of the 
three different standard errors of measurement. Medical Teacher, 34(7), 569-
576. doi: 10.3109/0142159x.2012.670318
McNabb, W. L. (1997). Adherence in diabetes: Can we define it and can we measure 
it? Diabetes Care, 20(2), 215-218. 
Mianowska, B., Fendler, W., Szadkowska, A., Baranowska, A., Grzelak-Agaciak, E., 
Sadon, J., . . . Mlynarski, W. (2011). HbA(1c) levels in schoolchildren with 
type 1 diabetes are seasonally variable and dependent on weather conditions. 
Diabetologia, 54(4), 749-756. doi: 10.1007/s00125-010-2013-4
Miller, W. R., & Rollnick, S. (2002). Motivational interviewing: Preparing people for 
change (2nd ed.). New York, NY: Guilford Press.
Miller, W. R., & Rollnick, S. (2009). Ten things that motivational interviewing is not. 
Behavioural and Cognitive Psychotherapy, 37(2), 129-140. doi: 
10.1017/S1352465809005128
Miller, W. R., & Rollnick, S. (2013). Motivational interviewing: Helping people 
change. New York, NY: Guilford Press.
Minet, L. K., Wagner, L., Lønvig, E. M., Hjelmborg, J., & Henriksen, J. E. (2011). 
The effect of motivational interviewing on glycaemic control and perceived 
313
competence of diabetes self-management in patients with type 1 and type 2 
diabetes mellitus after attending a group education programme: A randomised 
controlled trial. Diabetologia, 54(7), 1620-1629. doi: 10.1007/s00125-011-
2120-x
Ministry of Health. (2014). Quality standards for diabetes care toolkit. Wellington, 
New Zealand: Ministry of Health.
Ministry of Health. (2015). Virtual Diabetes Register.  Retrieved from 
http://www.health.govt.nz/our-work/diseases-and-conditions/diabetes/about-
diabetes/virtual-diabetes-register-vdr
Mohebi, S., Azadbakht, L., Feizi, A., Sharifirad, G., & Kargar, M. (2013). Review the 
key role of self-efficacy in diabetes care. Journal of Education and Health 
Promotion, 2, 36. doi: 10.4103/2277-9531.115827
Moran, A., Jacobs, D. R., Jr., Steinberger, J., Cohen, P., Hong, C. P., Prineas, R., & 
Sinaiko, A. R. (2002). Association between the insulin resistance of puberty 
and the insulin-like growth factor-I/growth hormone axis. Journal of Clinical 
Endocrinology and Metabolism, 87(10), 4817-4820. doi: 10.1210/jc.2002-
020517
Mortensen, H. B., & Hougaard, P. (1997). Comparison of metabolic control in a 
cross-sectional study of 2,873 children and adolescents with IDDM from 18 
countries. The Hvidore Study Group on Childhood Diabetes. Diabetes Care, 
20(5), 714-720. 
Morton, K., Beauchamp, M., Prothero, A., Joyce, L., Saunders, L., Spencer-Bowdage, 
S., . . . Pedlar, C. (2014). The effectiveness of motivational interviewing for 
health behaviour change in primary care settings: A systematic review. Health 
Psychology Review, 1-19. doi: 10.1080/17437199.2014.882006
Mosca, A., Goodall, I., Hoshino, T., Jeppsson, J. O., John, W. G., Little, R. R., . . . 
Weykamp, C. W. (2007). Global standardization of glycated hemoglobin 
measurement: The position of the IFCC Working Group. Clinical Chemistry 
and Laboratory Medicine, 45(8), 1077-1080. doi: 10.1515/CCLM.2007.246
314
Moss-Morris, R., Weinman, J., Petrie, K., Horne, R., Cameron, L., & Buick, D. 
(2002). The Revised Illness Perception Questionnaire (IPQ-R). Psychology & 
Health, 17(1), 1-16. doi: 10.1080/08870440290001494
Moyers, T., Manuel, J. K., & Ernst, D. (2014). Motivational interviewing treatment 
integrity coding manual 4.1 [unpublished manual]. University of New 
Mexico. Retrieved from casaa.unm.edu/download/MITI4_1.pdf
Moyers, T., & Martin, T. (2006). Therapist influence on client language during 
motivational interviewing sessions. Journal of Substance Abuse Treatment, 
30(3), 245-251. doi: 10.1016/j.jsat.2005.12.003
Moyers, T., Martin, T., Manuel, J. K., Hendrickson, S. M., & Miller, W. R. (2005). 
Assessing competence in the use of motivational interviewing. Journal of 
Substance Abuse Treatment, 28(1), 19-26. doi: 10.1016/j.jsat.2004.11.001
Moyers, T., Martin, T., Manuel, J. K., Miller, W. R., & Ernst, D. (2010). Revised 
Global Scales: Motivational interviewing treatment integrity 3.1.1 (MITI 
3.1.1).  Retrieved from casaa.unm.edu/download/MITI3_1.pdf
Mulimba, A. A. C., & Byron-Daniel, J. (2014). Motivational interviewing-based 
interventions and diabetes mellitus. British Journal of Nursing, 23(1), 8-14. 
Murphy, H. R., Rayman, G., & Skinner, T. C. (2006). Psycho-educational 
interventions for children and young people with type 1 diabetes. Diabetic 
Medicine, 23(9), 935-943. doi: 10.1111/j.1464-5491.2005.01816.x
Naing, N. N. (2000). Easy way to learn standardization: Direct and indirect methods. 
The Malaysian Journal of Medical Sciences, 7(1), 10-15. 
Nam, S., Chesla, C., Stotts, N. A., Kroon, L., & Janson, S. L. (2011). Barriers to 
diabetes management: Patient and provider factors. Diabetes Research and 
Clinical Practice, 93(1), 1-9. doi: 10.1016/j.diabres.2011.02.002
Nansel, T. R., Iannotti, R. J., Simons-Morton, B. G., Cox, C., Plotnick, L. P., Clark, 
L. M., & Zeitzoff, L. (2007). Diabetes personal trainer outcomes: Short-term 
and 1-year outcomes of a diabetes personal trainer intervention among youth 
with type 1 diabetes. Diabetes Care, 30(10), 2471-2477. 
315
Nansel, T. R., Iannotti, R. J., Simons-Morton, B. G., Plotnick, L. P., Clark, L. M., & 
Zeitzoff, L. (2009). Long-term maintenance of treatment outcomes: Diabetes 
personal trainer intervention for youth with type 1 diabetes. Diabetes Care, 
32(5), 807-809. 
Nansel, T. R., Weisberg-Benchell, J., Wysocki, T., Laffel, L., & Anderson, B. (2008). 
Quality of life in children with Type 1 diabetes: A comparison of general and 
diabetes-specific measures and support for a unitary diabetes quality-of-life 
construct. Diabetic Medicine, 25(11), 1316-1323. doi: 10.1111/j.1464-
5491.2008.02574.x
Nardi, L., Zucchini, S., D'Alberton, F., Salardi, S., Maltoni, G., Bisacchi, N., . . . 
Cicognani, A. (2008). Quality of life, psychological adjustment and metabolic 
control in youths with type 1 diabetes: A study with self- and parent-report 
questionnaires. Pediatric Diabetes, 9(5), 496-503. doi: 10.1111/j.1399-
5448.2008.00414.x
Nathan, D. M. (1993). Long-term complications of diabetes mellitus. The New 
England Journal of Medicine, 328(23), 1676-1685. 
Nathan, D. M., & Group, f. t. D. E. R. (2014). The Diabetes Control and 
Complications Trial/Epidemiology of Diabetes Interventions and 
Complications Study at 30 Years: Overview. Diabetes Care, 37(1), 9-16. doi: 
10.2337/dc13-2112
Nathan, D. M., Zinman, B., Cleary, P. A., Backlund, J.-Y. C., Genuth, S., Miller, R., . 
. . Grp, D. E. R. (2009). Modern-day clinical course of type 1 diabetes mellitus 
after 30 years' duration: The diabetes control and complications 
trial/epidemiology of diabetes interventions and complications and Pittsburgh 
epidemiology of diabetes complications experience (1983-2005). Archives of 
Internal Medicine, 169(14), 1307-1316. doi: 10.1001/archinternmed.2009.193
National Collaborating Centre for Women's and Children's Health. (2004). Type 1 
diabetes: Diagnosis and management of type 1 diabetes in children and young 
people.  Retrieved from 
http://www.ncbi.nlm.nih.gov/books/n/nicecg15child/pdf/
Naughton, M. J., Yi-Frazier, J. P., Morgan, T. M., Seid, M., Lawrence, J. M., 
Klingensmith, G. J., . . . Grp, S. D. Y. S. (2014). Longitudinal associations 
316
between sex, diabetes self-care, and health-related quality of life among youth 
with type 1 or type 2 diabetes mellitus. The Journal of Pediatrics, 164(6), 
1376-1376. doi: 10.1016/j.jpeds.2014.01.027
Ng, T. S. (2012). Brief Illness Perception Questionnaire (Brief IPQ). Journal of 
Physiotherapy, 58(3), 202. doi: http://dx.doi.org/10.1016/S1836-
9553(12)70116-9
NGSP. (2015). Factors that interfere with HbA1c test results.  Retrieved from 
http://www.ngsp.org/factors.asp
Nieuwesteeg, A., Pouwer, F., van der Kamp, R., van Bakel, H., Aanstoot, H. J., & 
Hartman, E. (2012). Quality of life of children with type 1 diabetes: A 
systematic review. Current Diabetes Review, 8(6), 434-443. 
Nitin, S. (2010). HbA1c and factors other than diabetes mellitus affecting it. 
Singapore Medical Journal, 51(8), 616-622. 
Nordfeldt, S., & Ludvigsson, J. (2000). Seasonal variation of HbA1c in intensive 
treatment of children with type 1 diabetes. Journal of Pediatric Endocrinology 
and Metabolism, 13(5), 529-535. 
Nordwall, M., Abrahamsson, M., Dhir, M., Fredrikson, M., Ludvigsson, J., & 
Arnqvist, H. J. (2015). Impact of HbA1c, followed from onset of type 1 
diabetes, on the development of severe retinopathy and nephropathy: The 
VISS Study (Vascular Diabetic Complications in Southeast Sweden). Diabetes 
Care, 38(2), 308-315. doi: 10.2337/dc14-1203
Nouwen, A., Law, G. U., Hussain, S., McGovern, S., & Napier, H. (2009). 
Comparison of the role of self-efficacy and illness representations in relation 
to dietary self-care and diabetes distress in adolescents with type 1 diabetes. 
Psychology & Health, 24(9), 1071-1084. doi: 10.1080/08870440802254597
NZSSD. (2009a). NZSSD Position Statement on standardisation of reporting units for 
HbA1c and application of estimated average glucose (eAG) Retrieved from 
http://www.nzssd.org.nz/statements.html
NZSSD. (2009b). NZSSD: Reporting and interpreting glycated haemoglobin (HbA1c) 
results/values.  Retrieved from http://www.nzssd.org.nz/hba1c.html
317
NZSSD. (2011). NZSSD: HbA1c full conversion tables Retrieved from 
http://www.nzssd.org.nz/hba1c.html
O’brien, R. M. (2007). A caution regarding rules of thumb for variance inflation 
factors. Quality & Quantity, 41(5), 673-690. doi: 10.1007/s11135-006-9018-6
Obaid, B., Britt, E., Basu, A., & Wallace-Bell, M. (2013). Youth with type 1 diabetes: 
Understanding their psychosocial characteristics and glycaemic control.
Paper presented at the New Zealand Society for the Study of Diabetes 
(NZSSD) 37th Annual Scientific Meeting, 7-10 May 2013, Napier, New 
Zealand. 
Obaid, B., Britt, E., Basu, A., & Wallace-Bell, M. (2014). Understanding illness 
beliefs, self-efficacy, and diabetes quality of life in relation to glycaemic 
control in youth with type 1 diabetes. Paper presented at the Australasian 
Society for Behavioural Health and Medicine (ASBHM) 12th Annual 
Scientific Conference, February 12-14, Auckland, New Zealand, . 
Obaid, B., Britt, E., Wallace-Bell, M., & Johnson-Elsmore, S. (2012a). The 
demographics and prevalence of youth (15-24 year olds) with type 1 diabetes 
in the Canterbury District Health Board catchment area in 2010: Has the 
prevalence changed since 2003? The New Zealand Medical Journal, 
125(1363), 22-28. 
Obaid, B., Britt, E., Wallace-Bell, M., & Johnson-Elsmore, S. (2012b). Has diabetes 
control for youth with Type 1 diabetes within the Canterbury District Health 
Board area changed from 2002 to 2010? Paper presented at the New Zealand 
Society for the Study of Diabetes (NZSSD) 36th Annual Scientific Meeting, 2-
4 May 2012, Auckland, New Zealand. 
Obaid, B., Britt, E., Wallace-Bell, M., & Johnson-Elsmore, S. (2012c). The 
prevalence and demographic characteristics of youth with Type 1 Diabetes in 
the Canterbury District Health Board catchment area in 2010: Has the 
prevalence changed since 2003? Paper presented at the New Zealand Society 
for the Study of Diabetes (NZSSD) 36th Annual Scientific Meeting, 2-4 May 
2012, Auckland, New Zealand. 
318
Onkamo, P., Vaananen, S., Karvonen, M., & Tuomilehto, J. (1999). Worldwide 
increase in incidence of Type I diabetes: The analysis of the data on published 
incidence trends. Diabetologia, 42(12), 1395-1403. 
Osborne, J. W., & Costello, A. B. (2004). Sample size and subject to item ratio in 
principal components analysis. Practical Assessment, Research & Evaluation, 
9(11). 
Ott, J., Greening, L., Palardy, N., Holderby, A., & DeBell, W. K. (2000). Self-
efficacy as a mediator variable for adolescents' adherence to treatment for 
insulin-dependent diabetes mellitus. Children's Health Care, 29(1), 47-63. 
Padgett, D. K. Correlates of self-efficacy beliefs among patients with non-insulin 
dependent diabetes mellitus in Zagreb, Yugoslavia. Patient Education and 
Counseling, 18(2), 139-147. doi: 10.1016/0738-3991(91)90006-Q
Pajares, F. (1997). Current directions in self-efficacy research. In M. Maehr & P. R. 
Pintrich (Eds.), Advances in motivation and achievement (Vol. 10). 
Greenwich, CT: JAI Press.
Palta, M., Lecaire, T., Daniels, K., Shen, G., Allen, C., & D'Alessio, D. (1997). Risk 
factors for hospitalization in a cohort with type 1 diabetes. Wisconsin Diabetes 
Registry. American Journal of Epidemiology, 146(8), 627 - 636. 
Partapsingh, V. A., Maharaj, R. G., & Rawlins, J. M. (2011). Applying the Stages of 
Change model to type 2 diabetes care in Trinidad: A randomised trial. Journal 
of Negative Results in BioMedicine, 10(1), 13-13. doi: 10.1186/1477-5751-10-
13
Patton, S. R., & Clements, M. A. (2013). Average daily risk range as a measure for 
clinical research and routine care. Journal of Diabetes Science and 
Technology, 7(5), 1370-1375. doi: 10.1177/193229681300700529
Pereira, M. G., Almeida, A. C., Rocha, L., & Leandro, E. (2011). Predictors of 
adherence, metabolic control and quality of life in adolescents with type 1 
diabetes. In C.-P. Liu (Ed.), Type 1 Diabetes - Complications, Pathogenesis, 
and Alternative Treatments.
319
Peters, A., Laffel, L., & the American Diabetes Association Transitions Working 
Group. (2011). Diabetes Care for Emerging Adults: Recommendations for 
Transition From Pediatric to Adult Diabetes Care Systems: A position 
statement of the American Diabetes Association, with representation by the 
American College of Osteopathic Family Physicians, the American Academy 
of Pediatrics, the American Association of Clinical Endocrinologists, the 
American Osteopathic Association, the Centers for Disease Control and 
Prevention, Children with Diabetes, The Endocrine Society, the International 
Society for Pediatric and Adolescent Diabetes, Juvenile Diabetes Research 
Foundation International, the National Diabetes Education Program, and the 
Pediatric Endocrine Society (formerly Lawson Wilkins Pediatric Endocrine 
Society). Diabetes Care, 34(11), 2477-2485. doi: 10.2337/dc11-1723
Petrie, K. J., Jago, L. A., & Devcich, D. A. (2007). The role of illness perceptions in 
patients with medical conditions. Current Opinion in Psychiatry, 20(2), 163-
167. doi: 10.1097/YCO.0b013e328014a871
Pill, R., Stott, N. C. H., Rollnick, S. R., & Rees, M. (1998). A randomized controlled 
trial of an intervention designed to improve the care given in general practice 
to type II diabetic patients: Patient outcomes and professional ability to change 
behaviour. Family Practice, 15(3), 229-235. doi: 10.1093/fampra/15.3.229
Pinhas-Hamiel, O., Hamiel, U., Boyko, V., Graph-Barel, C., Reichman, B., & Lerner-
Geva, L. (2014). Trajectories of HbA1c levels in children and youth with type 
1 diabetes. PloS One, 9(10), e109109. doi: 10.1371/journal.pone.0109109
Plante, W. A., & Lobato, D. J. (2008). Psychosocial group interventions for children 
and adolescents with type 1 diabetes: The state of the literature. Children's 
Health Care, 37(2), 93-111. 
Polgreen, P. M., Putz, D., & Stapleton, J. T. (2003). Inaccurate glycosylated 
hemoglobin A1C measurements in human immunodeficiency virus: Positive 
patients with diabetes mellitus. Clinical Infectious Diseases, 37(4), e53-e56. 
doi: 10.1086/376633
Puri, K., Sapra, S., & Jain, V. (2013). Emotional, behavioral and cognitive profile, 
and quality of life of Indian children and adolescents with type 1 diabetes. 
Indian Journal of Endocrinology and Metabolism, 17(6), 1078. 
320
Queralt, V. C. (2010). The role of motivation, self-efficacy, illness representations and 
family responsibility in relation to diabetes outcomes: Perceptions of 
adolescents with type 1 Diabetes and their parents (Doctoral dissertation). 
University of Birmingham, Birmingham, England. Retrieved from 
http://etheses.bham.ac.uk/907/  
R Core Team. (2014). R: A language and environment for statistical computing. 
Vienna, Austria. Retrieved from http://www.R-project.org/
Rami-Merhar, B., Wagner, G., Brunmayr, F., Muehlehner, M., Karwautz, A., & 
Berger, G. (2014). Intervention with motivational interviewing and cognitive 
behavioral elements in DMT1-adolescents with suboptimal metabolic control 
[Abstract]. Paper presented at the Diabetologie und Stoffwechsel 2014; 9 -
P258. 
Reed, K. (2014). Diabetes Info NZ: Managing type 1 diabetes.  Retrieved from 
http://www.diabetesinfo.org.nz/managing_T1DM.html
Reid, A. M., Balkhi, A. M., St Amant, J., McNamara, J. P. H., Silverstein, J. H., 
Navia, L., & Geffken, G. (2013). Relations between quality of life, family 
factors, adherence, and glycemic control in pediatric patients with type 1 
diabetes mellitus. Children's Health Care, 42(4), 295-310. doi: 
10.1080/02739615.2013.842455
Rewers, M. J., Pillay, K., de Beaufort, C., Craig, M. E., Hanas, R., Acerini, C. L., & 
Maahs, D. M. (2014). Assessment and monitoring of glycemic control in 
children and adolescents with diabetes. Pediatric Diabetes, 15(S20), 102-114. 
doi: 10.1111/pedi.12190
Robeva, R., Kirkwood, J. R., Davies, R. L., Farhy, L., Kovatchev, B. P., Straume, M., 
& Johnson, M. L. (2007). An invitation to biomathematics. Philadelphia, PA: 
Elsevier Science.
Robling, M., McNamara, R., Bennert, K., Butler, C. C., Channon, S., Cohen, D., . . . 
Gregory, J. W. (2012). The effect of the Talking Diabetes consulting skills 
intervention on glycaemic control and quality of life in children with type 1 
diabetes: Cluster randomised controlled trial (DEPICTED study). British 
Medical Journal, 344. doi: 10.1136/bmj.e2359
321
Rohlfing, C. L., Hsiao-Mei, W., Little, R. R., England, J. D., & et al. (2002). Defining 
the relationship between plasma glucose and HbA(1c): Analysis of glucose 
profiles and HbA(1c) in the Diabetes Control and Complications Trial. 
Diabetes Care, 25(2), 275-278. 
Rubak, S., Sandbaek, A., Lauritzen, T., Borch-Johnsen, K., & Christensen, B. (2011). 
Effect of "motivational interviewing" on quality of care measures in screen 
detected type 2 diabetes patients: A one-year follow-up of an RCT, 
ADDITION Denmark. Scandinavian Journal of Primary Health Care, 29(2), 
92-98. 
Rubak, S., Sandbæk, A., Lauritzen, T., & Christensen, B. (2005). Motivational 
interviewing: A systematic review and meta-analysis. The British Journal of 
General Practice, 55(513), 305-312. 
Rubin, R. R., & Peyrot, M. (1999). Quality of life and diabetes. Diabetes/Metabolism 
Research and Reviews, 15(3), 205-218. 
Rubin, R. R., Peyrot, M., & Saudek, C. D. (1993). The effect of a diabetes education 
program incorporating coping skills training on emotional well-being and 
diabetes self-efficacy. The Diabetes educator, 19(3), 210-214. doi: 
10.1177/014572179301900308
Rudell, K., Thrift-Perry, M., Savre, I., Perret, C., & Caron, M. (2012). Instruments 
measuring treatment adherence and compliance in diabetes mellitus: A 
literature review [Abstract]. Value in Health, 15(4), A182-A182. 
Ruiz de Adana, M. S., Domínguez-López, M., Tapia, M. d. l. H., M. J. , González, S., 
& Soriguer, F. (2008). How to evaluate glycemic variability? Therapeutic 
Education in Diabetes, 24(1), 77-81. 
Sacco, W. P., Wells, K. J., Friedman, A., Matthew, R., Perez, S., & Vaughan, C. A. 
(2007). Adherence, body mass index, and depression in adults with type 2 
diabetes: The mediational role of diabetes symptoms and self-efficacy. Health 
Psychology, 26(6), 693-700. doi: 10.1037/0278-6133.26.6.693
Satya Krishna, S. V., Kota, S. K., & Modi, K. D. (2013). Glycemic variability: 
Clinical implications. Indian Journal of Endocrinology and Metabolism, 
17(4), 611-619. doi: 10.4103/2230-8210.113751
322
Savage, D. A., & Bain, S. C. (2011). Genetics of type 1 diabetes mellitus. In J. A. H. 
Wass & P. M. Stewart (Eds.), Oxford textbook of endocrinology and diabetes
(2nd ed., pp. 1719-1722). Oxford, England: Oxford University Press.
Savage, E., Farrell, D., McManus, V., & Grey, M. (2010). The science of intervention 
development for type 1 diabetes in childhood: Systematic review. Journal of 
Advanced Nursing, 66(12), 2604-2619. doi: 10.1111/j.1365-
2648.2010.05423.x
Scholes, C., Mandleco, B., Roper, S., Dearing, K., Dyches, T., & Freeborn, D. (2013). 
A qualitative study of young people's perspectives of living with type 1 
diabetes: Do perceptions vary by levels of metabolic control? Journal of 
Advanced Nursing, 69(6), 1235-1247. doi: 10.1111/j.1365-2648.2012.06111.x
Schuster, C., & Eye, A. v. (1998). Regression analysis for social sciences. San Diego, 
CA: Academic Press.
Schutt, M., Kern, W., Krause, U., Busch, P., Dapp, A., Grziwotz, R., . . . Holl, R. W. 
(2006). Is the frequency of self-monitoring of blood glucose related to long-
term metabolic control? Multicenter analysis including 24,500 patients from 
191 centers in Germany and Austria. Experimental and Clinical 
Endocrinology and Diabetes, 114(7), 384-388. doi: 10.1055/s-2006-924152
Scott, A., Toomath, R., Bouchier, D., Bruce, R., Crook, N., Carroll, D., . . . Wu, D. 
(2006). First national audit of the outcomes of care in young people with 
diabetes in New Zealand: High prevalence of nephropathy in Maori and 
Pacific Islanders. The New Zealand Medical Journal, 119(1235), U2015. 
Sedgwick, P. (2014). Clinical significance versus statistical significance. British 
Medical Journal, 348. doi: 10.1136/bmj.g2130
Senecal, C., Nouwen, A., & White, D. (2000). Motivation and dietary self-care in 
adults with diabetes: Are self-efficacy and autonomous self-regulation 
complementary or competing constructs? Health Psychology, 19(5), 452-457. 
Shaw, K. M., & Cummings, M. H. (2012). Diabetes chronic complications (3rd ed.). 
Hoboken, NJ: Wiley-Blackwell.
323
Sicree, R., Shaw, J., & Zimmet, P. (2009). The global burden: Diabetes and impaired 
glucose tolerance. In International Diabetes Federation (Ed.), IDF Diabetes 
Atlas (4th ed.). Brussels, Belgium: International Diabetes Federation.
Silverman, A. H., Haines, A. A., Davies, W. H., & Parton, E. (2003). A cognitive 
behavioral adherence intervention for adolescents with type 1 diabetes. 
Journal of Clinical Psychology in Medical Settings, 10(2), 119-127. 
Simon, G. (2003). Multiple linear regression basics.  Retrieved from 
http://people.stern.nyu.edu/wgreene/Statistics/MultipleRegressionBasicsColle
ction.pdf
Singh, M. (2008). Adolescent diabetes mellitus: Individual and psychosocial factors 
that best predict adolescent diabetes self-management (Master's thesis MA). 
University of Auckland, Auckland, New Zealand.   
Skinner, T. C., Hoey, H., McGee, H. M., & Skovlund, S. E. (2006). A short form of 
the diabetes quality of life for youth questionnaire: Exploratory and 
confirmatory analysis in a sample of 2,077 young people with type 1 diabetes 
mellitus. Diabetologia, 49(4), 621-628. doi: 10.1007/s00125-005-0124-0
Skinner, T. C., John, M., & Hampson, S. E. (2000). Social support and personal 
models of diabetes as predictors of self-care and well-being: A longitudinal 
study of adolescents with diabetes. Journal of Pediatric Psychology, 25(4), 
257-267. 
Snijders, T. A. B., & Bosker, R. J. (2011). Multilevel analysis: An introduction to 
basic and advanced multilevel modeling (2nd ed.). Los Angeles, CA: SAGE.
Solans, M., Pane, S., Estrada, M.-D., Serra-Sutton, V., Berra, S., Herdman, M., . . . 
Rajmil, L. (2008). Health-related quality of life measurement in children and 
adolescents: A systematic review of generic and disease-specific instruments. 
Value in Health, 11(4), 742-764. doi: http://dx.doi.org/10.1111/j.1524-
4733.2007.00293.x
Spitz, A. F., & Kanani, H. (2006). Change in HbA1c as a measure of quality of 
diabetes care. Diabetes Care, 29(5), 1183-1184. doi: 10.2337/dc05-2032
324
Stahl-Pehe, A., Strassburger, K., Castillo, K., Bachle, C., Holl, R. W., Lange, K., & 
Rosenbauer, J. (2014). Quality of life in intensively treated youths with early-
onset type 1 diabetes: A population-based survey. Pediatric Diabetes, 15(6), 
436-443. 
Stanger, C., Ryan, S. R., Delhey, L. M., Thrailkill, K., Li, Z., Li, Z., & Budney, A. J. 
(2013). A multicomponent Motivational Intervention to improve adherence 
among adolescents with poorly controlled type 1 diabetes: A pilot study. 
Journal of Pediatric Psychology, 38(6), 629-637. doi: 10.1093/jpepsy/jst032
Statistics New Zealand. (2002). 2001 Population census: District Health Board Area 
summary tables.  Retrieved from 
http://www.stats.govt.nz/tools_and_services/tools/TableBuilder/2001-
population-census/top-40-tables.aspx
Statistics New Zealand. (2007). 2006 Population census: District Health Board Area 
summary tables.  Retrieved from http://www.stats.govt.nz/Census/about-2006-
census/district-health-board-area-summary-tables.aspx
Statistics New Zealand. (2011). Street Links.  Retrieved from 
http://www.stats.govt.nz/browse_for_stats/people_and_communities/geograph
ic-areas/streetlink.aspx
Statistics New Zealand. (n.d.). Information by Variable.  Retrieved from 
http://www.stats.govt.nz/Census/about-2006-census/information-by-
variable/ethnicity.aspx#1
Stevens, J. P. (2012). Applied multivariate statistics for the social sciences (5th ed.). 
Hoboken, NJ: Taylor and Francis.
Stewart, S. M., Lee, P. W., Low, L. C., Cheng, A., Yeung, W., Huen, K. F., & 
O'Donnell, D. (2000). Pathways from emotional adjustment to glycemic 
control in youths with diabetes in Hong Kong. Journal of Pediatric 
Psychology, 25(6), 393-402. doi: 10.1093/jpepsy/25.6.393
Stewart, S. M., Lee, P. W. H., Waller, D., Hughes, C. W., Low, L. C. K., Kennard, B. 
D., . . . Huen, K. (2003). A follow-up study of adherence and glycemic control 
among Hong Kong youths with diabetes. Journal of Pediatric Psychology, 
28(1), 67-79. doi: 10.1093/jpepsy/28.1.67
325
Strecher, V. J., McEvoy DeVellis, B., Becker, M. H., & Rosenstock, I. M. (1986). 
The role of self-efficacy in achieving health behavior change. Health 
Education & Behavior, 13(1), 73-92. doi: 10.1177/109019818601300108
Su, X., & Yan, X. (2009). Linear regression analysis: Theory and computing. 
Hackensack, NJ: World Scientific.
Suarez, M., & Mullins, S. (2008). Motivational interviewing and pediatric Health 
behavior interventions. Journal of Developmental and Behavioral Pediatrics, 
29(5), 417-428. 
Svoren, B. M., Butler, D., Levine, B. S., Anderson, B. J., & Laffel, L. M. (2003). 
Reducing acute adverse outcomes in youths with type 1 diabetes: A 
randomized, controlled trial. Pediatrics, 112(4), 914-922. 
Syrjala, A. M. H., Kneckt, M. C., & Knuuttila, M. L. E. (1999). Dental self-efficacy 
as a determinant to oral health behaviour, oral hygiene and HbA1(c) level 
among diabetic patients. Journal of Clinical Periodontology, 26(9), 616-621. 
Talbot, F., Nouwen, A., Gingras, J., Gosselin, M., & Audet, J. (1997). The assessment 
of diabetes-related cognitive and social factors: The multidimensional diabetes 
questionnaire. Journal of Behavioral Medicine, 20(3), 291-312. doi: 
10.1023/A:1025508928696
Tan, S. M. K., Shafiee, Z., Wu, L. L., Rizal, A. M., & Rey, J. M. (2005). Factors 
associated with control of type I diabetes in Malaysian adolescents and young 
adults. International Journal of Psychiatry in Medicine, 35(2), 123-136. 
Temple, A. J. S. (2003). The effects of diabetes self-management education on 
diabetes self-care, diabetes self-efficacy, and psychological adjustment to 
diabetes (Doctoral dissertation). Health Sciences Center School of Nursing, 
Louisiana State University, Baton Rouge, LA Retrieved from 
http://search.proquest.com.ezproxy.canterbury.ac.nz/docview/305243721?pq-
origsite=summon  
Tosh, A. K., Wong, H. D., Shen, C., Zhang, W., & Orr, D. P. (2007). Gender-specific 
factors affecting glycemic control among adolescents with type 1 diabetes 
mellitus. Journal of Adolescent Health, 40(2), S33-S34. doi: 
10.1016/j.jadohealth.2006.11.088
326
Trence, D. L., & Hirsch, I. B. (2012). Motherhood, apple pie, hemoglobin A(1C), and 
the DCCT. Endocrine Practice, 18(1), 78-84. 
Trento, M., Panero, F., Porta, M., Gruden, G., Barutta, F., Cerutti, F., . . . Bruno, G. 
(2013). Diabetes-specific variables associated with quality of life changes in 
young diabetic people: The type 1 diabetes Registry of Turin (Italy). Nutrition, 
Metabolism, and Cardiovascular Diseases. doi: 
10.1016/j.numecd.2013.01.004
Tryon, W. W. (2001). Evaluating statistical difference, equivalence, and 
indeterminacy using inferential confidence intervals: An integrated alternative 
method of conducting null hypothesis statistical tests. Psychological Methods, 
6(4), 371-386. doi: 10.1037/1082-989X.6.4.371
Tryon, W. W., & Lewis, C. (2008). An inferential confidence interval method of 
establishing statistical equivalence that corrects Tryon's (2001) reduction 
factor. Psychological Methods, 13(3), 272-277. doi: 10.1037/a0013158
Tryon, W. W., & Lewis, C. (2009). Evaluating independent proportions for statistical 
difference, equivalence, indeterminacy, and trivial difference using inferential 
confidence intervals. Journal of Educational and Behavioral Statistics, 34(2), 
171-189. doi: Doi 10.3102/1076998609332753
Tulloch-Reid, M. K., & Walker, S. P. (2009). Quality of life in Caribbean youth with 
diabetes. West Indian Medical Journal, 58(3), 250-256. 
Tylee, T. S., & Trence, D. L. (2012). Glycemic variability: Looking beyond the A1C. 
Diabetes Spectrum, 25(3), 149-153. doi: 10.2337/diaspect.25.3.149
UNESCO. (2014). What do we mean by “youth”?  Retrieved from 
http://www.unesco.org/new/en/social-and-human-
sciences/themes/youth/youth-definition/




Unwin, N. (2011). The world pandemic of diabetes. In J. A. H. Wass & P. M. Stewart 
(Eds.), Oxford textbook of endocrinology and diabetes (2 ed., pp. 1795-1799). 
Oxford, England: Oxford University Press.
Urban, A. D., Berry, D., & Grey, M. (2004). Optimizing outcomes in adolescents with 
type 1 diabetes and their families. Journal of Clinical Outcomes Management, 
11(5), 299-306. 
Urrechaga, E. (2012). High-resolution HbA1c separation and hemoglobinopathy 
detection with capillary electrophoresis. American Journal of Clinical 
Pathology, 138(3), 448-456. 
van der Ven, N. C., Hogenelst, M. H., Tromp-Wever, A. M., Twisk, J. W., van der 
Ploeg, H. M., Heine, R. J., & Snoek, F. J. (2005). Short-term effects of 
cognitive behavioural group training (CBGT) in adult type 1 diabetes patients 
in prolonged poor glycaemic control. A randomized controlled trial. Diabetic 
Medicine, 22(11), 1619-1623. 
van der Ven, N. C., Weinger, K., Yi, J., Pouwer, F., Ad'er, H., Van der Ploeg, H. M., 
& Snoek, F. J. (2003). The Confidence in Diabetes Self-Care Scale 
psychometric properties of a new measure of diabetes-specific self-efficacy in 
Dutch and U.S. patients with type 1 diabetes. Diabetes Care, 26(3), 713–718. 
Van Tilburg, M. A., McCaskill, C. C., Lane, J. D., Edwards, C. L., Bethel, A., 
Feinglos, M. N., & Surwit, R. S. (2001). Depressed mood is a factor in 
glycemic control in type 1 diabetes. Psychosomatic Medicine, 63(4), 551-555. 
Vandagriff, J. L., Marrero, D. G., Ingersoll, G. M., & Fineberg, N. S. (1992). Parents 
of children with diabetes: What are they worried about? The Diabetes 
Educator, 18(4), 299-302. doi: 10.1177/014572179201800407
Varni, J. W., Burwinkle, T. M., Jacobs, J. R., Gottschalk, M., Kaufman, F., & Jones, 
K. L. (2003). The PedsQL in type 1 and type 2 diabetes: Reliability and 
validity of the Pediatric Quality of Life Inventory Generic Core Scales and 
Type 1 Diabetes Module. Diabetes Care, 26(3), 631-637. 
Varni, J. W., Curtis, B. H., Abetz, L. N., Lasch, K. E., Piault, E. C., & Zeytoonjian, A. 
A. (2012). Content validity of the PedsQL 3.2 Diabetes Module in newly 
328
diagnosed patients with type 1 diabetes mellitus ages 8-45. Quality of Life 
Research. doi: 10.1007/s11136-012-0339-8 [doi]
Varni, J. W., Limbers, C. A., & Burwinkle, T. M. (2007). Impaired health-related 
quality of life in children and adolescents with chronic conditions: A 
comparative analysis of 10 disease clusters and 33 disease 
categories/severities utilizing the PedsQL 4.0 Generic Core Scales. Health and 
Quality of Life Outcomes, 5, 43. doi: 10.1186/1477-7525-5-43
Vasilaki, E. I., Hosier, S. G., & Cox, W. M. (2006). The efficacy of motivational 
interviewing as a brief intervention for excessive drinking: A meta-analytic 
review. Alcohol and Alcoholism, 41(3), 328-335. doi: 10.1093/alcalc/agl016
Viner, R. M., Christie, D., Taylor, V., & Hey, S. (2003). Motivational/solution-
focused intervention improves HbA1c in adolescents with Type 1 diabetes: A 
pilot study. Diabetic Medicine, 20(9), 739-742. 
Wagner, V., Müller–Godeffroy, E., Sengbusch, S., Häger, S., & Thyen, U. (2005). 
Age, metabolic control and type of insulin regime influences health-related 
quality of life in children and adolescents with type 1 diabetes mellitus. 
European Journal of Pediatrics, 164(8), 491-496. doi: 10.1007/s00431-005-
1681-4
Wang, Y. C., Stewart, S. M., Mackenzie, M., Nakonezny, P. A., Edwards, D., & 
White, P. C. (2010). A randomized controlled trial comparing motivational 
interviewing in education to structured diabetes education in teens with type 1 
diabetes. Diabetes Care, 33(8). doi: 10.2337/dc10-0019
Wass, J., & Owen, K. (2014). Oxford handbook of endocrinology and diabetes. 
Oxford, England: Oxford University Press.
Watson, P. J., & Workman, E. A. (1981). The non-concurrent multiple baseline 
across-individuals design: an extension of the traditional multiple baseline 
design. Journal of Behavior Therapy and Experimental Psychiatry, 12(3), 
257-259. 
Weinman, J., & Petrie, K. J. (1997). Illness perceptions: A new paradigm for 
psychosomatics? Journal of Psychosomatic Research, 42(2), 113-116. doi: 
10.1016/S0022-3999(96)00294-2
329
Weinman, J., Petrie, K. J., Moss-Morris, R., & Horne, R. (1996). The illness 
perception questionnaire: A new method for assessing the cognitive 
representation of illness. Psychology and Health, 11(3), 431-445. doi: 
10.1080/08870449608400270
Welch, G., Rose, G., & Ernst, D. (2006). Motivational interviewing and diabetes: 
What is it, how is it used, and does it work? Diabetes Spectrum, 19(1), 5-11. 
Welch, G., Zagarins, S. E., Feinberg, R. G., & Garb, J. L. (2011). Motivational 
interviewing delivered by diabetes educators: Does it improve blood glucose 
control among poorly controlled type 2 diabetes patients? Diabetes Research 
and Clinical Practice, 91(1), 54-60. 
West, D. S., DiLillo, V., Bursac, Z., Gore, S. A., & Greene, P. G. (2007). 
Motivational interviewing improves weight loss in women with type 2 
diabetes. Diabetes Care, 30(5), 1081-1087. doi: 10.2337/dc06-1966
Westgard, J. (2014). Desirable biological variation database specifications 
https://www.westgard.com/biodatabase1.htm
Weykamp, C., John, W. G., Mosca, A., Hoshino, T., Little, R., Jeppsson, J.-O., . . . 
Reinauer, H. (2008). The IFCC reference measurement system for HbA1c: A 
6-year progress report. Clinical Chemistry, 54(2), 240-248. 
Whiting, D. R., Guariguata, L., Weil, C., & Shaw, J. (2011). IDF diabetes atlas: 
Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes 
Research and Clinical Practice, 94(3), 311-321. doi: 
10.1016/j.diabres.2011.10.029
Wiebe, S., Guyatt, G., Weaver, B., Matijevic, S., & Sidwell, C. (2003). Comparative 
responsiveness of generic and specific quality-of-life instruments. Journal of 
Clinical Epidemiology, 56(1), 52-60. doi: 10.1016/S0895-4356(02)00537-1
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. Y. M. (2004). Global
Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030. 
Diabetes Care, 27(5), 1047. 
William, R. (2011). Missing pata part 1: Overview, traditional methods.  Retrieved 
from http://www3.nd.edu/~rwilliam/stats2/l12.pdf
330
Willis, J. A., Scott, R. S., Darlow, B. A., Nesbit, J. W., Anderson, P., Moore, M. P., . . 
. Cole, D. R. (2002). Incidence of type 1 diabetes mellitus diagnosed before 
age 20 years in Canterbury, New Zealand over the last 30 years. Journal of 
Pediatric Endocrinology and Metabolism, 15(5), 637-643. 
Wilson, B. E., & Sharma, A. (1995). Public cost and access to primary care for 
hyperglycemic emergencies, Clark County, Nevada. Journal of Community 
Health, 20(3), 249-256. 
Winkley, K., Landau, S., Eisler, I., & Ismail, K. (2006). Psychological interventions 
to improve glycaemic control in patients with type 1 diabetes: Systematic 
review and meta-analysis of randomised controlled trials. BMJ: British 
Medical Journal, 333(7558), 65-68. doi: 10.1136/bmj.38874.652569.55
World Health Organization. (2011). Use of glycated haemoglobin (HbA1c) in 
diagnosis of diabetes mellitus: Abbreviated report of a WHO consultation. 
Wu, D., Kendall, D., Lunt, H., Willis, J., Darlow, B., & Frampton, C. (2005). 
Prevalence of Type 1 diabetes in New Zealanders aged 0-24 years. New 
Zealand Medical Journal, 118(1218), U1557. 
Wyrwich, K. W., Tierney, W. M., & Wolinsky, F. D. (1999). Further evidence 
supporting an SEM-based criterion for identifying meaningful intra-individual 
changes in health-related quality of life. Journal of Clinical Epidemiology, 
52(9), 861-873. doi: http://dx.doi.org/10.1016/S0895-4356(99)00071-2
Wysocki, T., Hough, B. S., Ward, K. M., & Green, L. B. (1992). Diabetes mellitus in 
the transition to adulthood: Adjustment, self-care, and health status. Journal of 
Developmental and Behavioral Pediatrics, 13(3), 194-201. doi: 
10.1097/00004703-199206000-00007
Xie, Z., Chang, C., & Zhou, Z. (2014). Molecular mechanisms in autoimmune type 1 
diabetes: A critical review. Clinical Reviews in Allergy and Immunology, 
47(2), 174-192. doi: 10.1007/s12016-014-8422-2
Xiong, F., Li, R., Luo, S. Q., Hou, L., Chen, R. X., & Zhu, M. (2013). Investigation 
and analysis of the quality of life in children and youth with type 1 diabetes in 
China. Paper presented at the Hormone Research in Paediatrics: European 
Society for Paediatric Endocrinology (ESPE) / 9th Joint Meeting, Milan Italy. 
331
Yan, X. (2009). Linear regression analysis: Theory and computing. Hackensack, NJ: 
World Scientific.
Young, M. J. (2003). The role of self-concept, self-efficacy and parental involvement 
in treatment adherence for adolescents with insulin-dependent diabetes 
mellitus (Master's thesis). University of Auckland, Auckland, New Zealand.   
Zahra, D., & Hedge, C. (2010). The reliable change index: Why isn't it more popular 
in academic psychology. The British Psychological Society: PsyPAG(76), 14–
19. 
Zhuo, X., Zhang, P., Barker, L., Albright, A., Thompson, T. J., & Gregg, E. (2014). 
The Lifetime Cost of Diabetes and Its Implications for Diabetes Prevention. 
Diabetes Care, 37(9), 2557-2564. doi: 10.2337/dc13-2484
Ziegler, R., Heidtmann, B., Hilgard, D., Hofer, S., Rosenbauer, J., & Holl, R. (2011). 
Frequency of SMBG correlates with HbA1c and acute complications in 


















Appendix 2.1: Prevalence (Crude, Age-Specific, and Age-Standardised) and Age-
Standardised Prevalence Ratio (Boniol & Heanue, 2007; Boyle & Parkin, 1991)
Crude prevalence = d / y  
Where 
d = number of cases observed in a certain year
y = total population in the same year 
Age-specific prevalence = di / yi
Where 
di = number of cases observed in a certain year for the ith specific age range
yi = total population in the same year for the ith specific age range







di = number of cases observed in a certain year for the ith specific age range
yi = total population in the same year for the ith specific age range
wi = the weight applied to the ith age group and is the size of the reference 
population in the ith age group. It is the total reference population in the ith age 
range
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The age-standardised prevalence ratio (ASPR) is a ratio of two age-
standardised prevalences (ASP1 and ASP2) estimated at, for example, two time points 
(e.g., 2003 and 2010). A confidence interval (CI) is established for the ASPR (for 











= 1.96 (at the 95% level)
VAR(ASPi) = variance which is the standard error squared and is given by 
If the 95% CI includes one, then the ASP1 and ASP2 are not significantly 












Appendix 3.2: Bivariate Correlations Among HbA1c, Age, CIDS, BIPQ, and PedsQL
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Appendix 3.3: Scatter Plots and Bivariate Relationships Between HbA1c and 





Appendix 3.4: Pearson’s Correlations Among HbA1c, Age, Gender, BIPQ, 
CIDS, and PedsQL (N = 56; k = 9)
 
Appendix 3.5: Pearson’s Correlations Among HbA1c, Age, Gender, BIPQ, 
CIDS, and PedsQL (N = 52; k = 9); Potential Outliers Removed: HbA1c ≥ 138 
mmol/mol
Correlations
Pearson Correlation  
HbA1c 
mmol/mol












HbA1c mmol/mol 1 -.389
** -.107 .362** -.099 -.222 .154 -.194 -.271 -.243
Age -.389
** 1 .217 -.181 .094 .250 .078 .191 .153 .193
Gender -.107 .217 1 -.138 -.216 .342
* .203 .161 .036 -.046
BIPQ-Total .362
** -.181 -.138 1 -.424** -.597** -.460** -.697** -.642** -.559**
CIDS -.099 .094 -.216 -.424
** 1 .229 .247 .438** .664** .571**
PedsQL - Symptoms -.222 .250 .342
* -.597** .229 1 .419** .487** .465** .397**
PedsQL - Worry .154 .078 .203 -.460
** .247 .419** 1 .438** .452** .339*
PedsQL - Treatment Barriers -.194 .191 .161 -.697
** .438** .487** .438** 1 .653** .614**
PedsQL - Treatment Adherence -.271 .153 .036 -.642
** .664** .465** .452** .653** 1 .552**
PedsQL - Communication -.243 .193 -.046 -.559
** .571** .397** .339* .614** .552** 1
**. Correlation is significant at the 0.01 level (2-tailed).
*. Correlation is significant at the 0.05 level (2-tailed).
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Appendix 4.1: 24hr Recall Interview Assessment Measure
Participant Number: 
Interviewer:
Dates/Times of Attempted Interviews:   
Date/Time of Interview:  
Problems with meter or other self-care equipment:  
Describe what you did yesterday from the time you got up until the time you went to bed.
Yesterday morning, did you:
eat a meal?
 No  
 Yes (1)
do a glucose test?
 No  
 Yes (2) 
take insulin?
 No  
 Yes (3) How many minutes before or after eating?  (4)
take the correct amount considering your glucose level and number of carb units?
 No  
 Yes (5) 
In the middle of the day yesterday, did you:
eat a meal?
 No  
 Yes (1)
362
do a glucose test?
 No  
 Yes (2)
take insulin?
 No  
 Yes (3) How many minutes before or after eating?   (4)
take the correct amount considering your glucose level and number of carb units?
 No  
 Yes (5)
Last night, did you:
eat a meal?
 No  
 Yes (1)
do a glucose test?
 No  
 Yes (2)
take insulin?
 No  
 Yes (3) How many minutes before or after eating?   (4)
take the correct amount considering your glucose level and number of carb units?
 No  
 Yes (5)
Before bedtime last night, did you:
eat anything containing carbohydrates?
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 No  
 Yes (1)
do a glucose test?
 No  
 Yes (2)
take insulin?
 No  
 Yes (3)
364
Appendix 4.2: Evaluating Statistical difference and Equivalence Using 
Inferential Confidence Intervals for Dependent Samples (Tryon, 2001; Tryon & 
Lewis, 2008, 2009)
Statistical Difference 
The standard formula for the confidence interval (CI) of a mean is
Where 
= mean
 = standard error of mean 
S = standard deviation 

/
= the upper 100(1−α/2) percentile of the t distribution with v degrees of 
freedom and α significance 
n = sample size 
Non-overlapping CIs for a pair of means ( and ) are sufficient but not 
necessary to determine a significant difference between the means. Tryon (2001)
developed the concept of inferential CIs which modify the standard CIs such that a 
non-overlap of the inferential CIs equates to statistical difference as in a standard t-
test.
A modified inferential CI about each mean,  and  is constructed using a 
standard t test and a reduction factor E. The reduction factor (E) is the ratio of the 
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standard error of the difference between two group means (  and  ) to the sum of 
the standard errors of both group means: 
 =  

 + 
The term  is the estimated standard error for the difference between the group 
means. For dependent samples this is given by 
Where  is the correlation coefficient between the two samples.  
The level of statistical significance can be set, for example, at 5% level of 
statistical significance for 95% confidence and therefore a critical t value can be 
calculated. The inferential CI is then constructed using a proportionately reduced 
critical t value. So, the inferential CI for a mean , , is calculated from 




Statistical difference is said to exist between two groups if the two inferential 
CIs do not overlap; the upper limit of the lesser mean (e.g.,   ) is less than the lower 
limit of the greater mean (e.g.,   ). The probability value associated with this 
statistical difference is p < .05 because the critical value for the 5% significance level 
(95% confidence level) was the initial t value.
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Statistical Equivalence 
Statistical equivalence is when the maximum probable difference estimate 
(i.e., the upper modified CI limit of the greater mean minus the lower modified CI 
limit of the lesser mean) or eRg fits within an inconsequential difference between the 
two CIs. The inconsequential difference can be based on a delta (∆) bound of the 
maximum difference that can be dismissed on substantive ground. Figure A.1 
illustrates the statistical equivalence concept.  
Figure A.1 This figure graphically defines the equivalence range (eRg) as the larger of two 
differences between the endpoints of two ICIs designated by the heavy lines. Delta is a value 
that, on substantive grounds, is agreed to be an inconsequential amount. Statistical 
equivalence occurs when eRg ≤ ∆. The light lines designate the upper and lower limits of 
standard 95% confidence intervals. Source of figure and description is Tryon and Lewis 
(2008, p. 275).
If  >  , then eRg1 > eRg2, so statistical equivalence occurs if and only if:
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Appendix 4.3: Computing the Low Blood Glucose Index (LBGI), High Blood 
Glucose Index, (HBGI) and, Average Daily Risk Range (ADRR). 
The SMOBG data can be analysed using the risk analysis approach, which 
include the following steps: symmetrise the blood glucose (BG) measurement scale to 
correct an inherited asymmetry of the hypoglycaemic versus hyperglycaemic ranges; 
use a BG risk function to measure the risk associated with a certain BG level; and 
employ the SMOBG-based risk metrics to interpret the risk analysis results (Cobelli et 
al., 2009; Kovatchev et al., 1997; Kovatchev et al., 2000; Kovatchev et al., 2006).
Symmetrisation of the BG Measurement Scale 
The BG scale is not symmetric because it has a numerically wider 
hyperglycaemic range (10 < BG < 33.3mmol/L) compared to the hypoglycaemic 
range (1.1 < BG < 3.9mmol/L), and the euglycaemic range (3.9-10mmol/L) is not 
located at the centre of the data range. The scale asymmetry creates computational 
issues and analytical challenges; a symmetrisation of the BG scale resolves these 
issues. 
The symmetrisation can be achieved as follows: transform the hyperglycaemic 
range to have a narrower interval, the hypoglycaemic range to have a wider interval, 
transfer the target range to a central location around zero, and transform the whole 
range to have a zero centre. The zero centre is mapped to the BG reading 
6.25mmol/L, which is in the middle of the recommended clinical clustering of the BG 
values range (i.e., 6-6.5 mmol/L). These transformations yield a transformed BG scale 
that has its whole range and target range symmetric around zero. More formally, let 
f(BG) be a continuous function defined on the BG range [1.1, 33.3]  such as 
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f(BG,α, β) = [(ln (BG ))α − β ],  α, β > 0; Where α = 1.084, β = 5.381, and γ = 1.509. 
Briefly, the derivation of this equation was based on an expected logarithmic 
presentation of the concentration of sugar in the blood (BG levels); solving for the 
fixed parameters involved selecting convenient values for the minimal and maximal 
of the transformed range (i.e., −√ 10 and √ 10 respectively).  The detailed derivation of 
this equation is presented in the original articles; it important to note that these 
parameters are sample independent (Kovatchev et al., 1997; Kovatchev et al., 2000). 
The BG Risk Function 
The transformed BG values using f(BG) can be converted into a risk range 
using a risk function, r(BG). This function represents the risk associated with certain 
BG values. The r(BG) assigns a numerical weight (0 to 100) and sign (+ or −) 
depending on the BG value. In other words, the function progressively allocates a 
numerical weight that depends on the extent of the deviation from the centre zero (i.e., 
from the optimal target value: 6.25 mmol/L, which has an r(BG) of 0). This feature 
accounts for the severity of the deviation from the centre and offers equal emphasis on 
the ranges of hypoglycaemia and hyperglycaemia. This risk function is used to 
compute the SMBG risk metrics (presented shortly).  
The r(BG) is computed by superimposing a quadratic function over the 
transformed BG scale: r(BG)=10.f(BG)2 (Kovatchev et al., 2000). The left branch of 
the quadratic function parabola identifies the risk of hypoglycaemia, while the right 
branch identifies the risk of hyperglycaemia. Based on that, we define the low and the 
high BG Indices as follows: 
Let x1, x2, ... xn be a series of n BG readings, and let
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rl(BG)=r(BG)  if f(BG)<0  and 0 otherwise;
rh(BG)=r(BG)  if f(BG)>0 and 0 otherwise. 
The SMOBG Risk Metrics 




The LBGI and the HBGI measure the risk associated with hypoglycaemia and 
hyperglycaemia, respectively. An increase in the LBGI score indicates an expected 
increase in the frequency and/or extent of hypoglycaemic episodes, and increase in 
HBGI score also indicates an expected increase in the frequency and/or extent of 
hyperglycaemic episodes (Kovatchev et al., 2002; Kovatchev et al., 2000). These two 
measures are specifically sensitive to measuring their end of the glycaemia range, and 
their computations are independent of each other.
A measure of combined high and low BG (i.e., overall glucose variability) can 
be computed based on r(BG). This is the Average Daily Risk Range (ADRR) 
(Kovatchev et al., 2006). This is calculated as follows. Let x1
i, x2
i,. . . xn
i be a series of 
ni SMBG readings taken on day i, i =1,2,. . . ,M. It is required that 14< M <30 and n1,
































Appendix 4.4: Self-monitoring of Blood Glucose Charts
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Figure A.2. SMOBG during baseline (BL), intervention (I), and follow-up (Wk = week; M= month).
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